

8EHQ-0800-373

AR226-0957

RDT-5

Draft Report

Confidential CBI

ORIGINAL

26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic
Acid Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys

2000 DEC -7 AM 7:22

RECEIVED
OPT NCIC

EPA-OTS



000811794U

00 AUG 21 AM 10:55

RECEIVED
AM 10:55

PREPARED FOR:
3M

COVANCE STUDY NUMBER:
6329-223

VOLUME
I of II

002636

UNAUDITED DRAFT
April 12, 2000

Sponsor:

3M
St. Paul, Minnesota

FINAL REPORT

Study Title:

26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid
Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys

Author:

Peter J. Thomford, PhD

Study Completion Date:

To be determined

Testing Facility:

Covance Laboratories Inc.
3301 Kinsman Boulevard
Madison, Wisconsin 53704-2595

Laboratory Study Identification:

Covance 6329-223

Sponsor Study Identification:

3M Study No. T-6295.7

Volume I of II

Page 1 of 821

002637

COMPLIANCE STATEMENT

26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid
Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys

All aspects of this study were in accordance with the Environmental Protection Agency
Good Laboratory Practice Standards, 40 CFR 792.

Peter J. Thomford, PhD
Study Director
Covance Laboratories Inc.

Date

Andrew M. Seacat, PhD
Study Monitor
3M

Date

STUDY IDENTIFICATION

26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys

Test Material	Perfluorooctane Sulfonic Acid Potassium Salt (PFOS; T-6295)
Sponsor	3M Toxicology Services Building 220-2E-02, 3M Center St. Paul, Minnesota 55144-1000
Study Monitor	Andrew M. Seacat, PhD 3M 651.575.3161
Alternate Study Monitor	Marvin T. Case, DVM, PhD 3M Toxicology Services 651.733.5180
Study Location	Covance Laboratories Inc. 3301 Kinsman Boulevard Madison, Wisconsin 53704-2595
Study Director	Peter J. Thomford, PhD Covance Laboratories Inc. PO Box 7545 Madison, Wisconsin 53707-7545 608.241.7207
Study Timetable	
Study Initiation Date	August 20, 1998
In-Life (Experimental) Start Date	August 26, 1998
In-Life Termination Date	March 7, 2000
Experimental Termination Date	To be determined

KEY PERSONNEL

26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys

Study Director	Peter J. Thomford, PhD
Study Toxicologist	Dale Aldridge, BS
Study Coordinator	Elizabeth A. Disch, BA
Manager, Large Animal Toxicology	Sharon Dunn, LATG, AT
Supervisor, Dose Formulation	Dixie Bushee, BS, LATG
Associate Director, Laboratory Animal Medicine	Donna J. Clemons, DVM, MS Diplomate, ACLAM
Clinical Pathologist	Robert L. Hall, DVM, PhD Diplomate, ACVP (Clinical Pathology)
Supervisor, Clinical Pathology	Ronald Markevitch, BS, MT (ASCP)
Anatomic Pathologist	Robert A. Leedle, DVM, PhD Diplomate, ACVP
Supervisor, Anatomic Pathology	Laurie J. Schuller, BA, LAT
Supervisor, Anatomic Pathology	Kimberly W. Durland, BS, HT
Consultant	Stephen I. Bistner, DVM Diplomate, ACVO Veterinary Ophthalmologist

CONTENTS

VOLUME I OF II

	Page
ABSTRACT.....	9
PURPOSE.....	12
REGULATORY COMPLIANCE.....	12
TEST MATERIAL, VEHICLE, AND SOLVENT.....	12
Test Material	12
Vehicle	12
Solvent	13
Gelatin Capsules.....	13
Reserve (Archive) Samples.....	13
Disposition	13
TEST ANIMALS AND HUSBANDRY	13
Animals.....	13
Identification	14
Justification	14
Husbandry	14
Acclimation.....	15
PROCEDURES.....	15
Group Designations and Dosage Levels.....	15
Dosing Procedures.....	16
Dose Analyses.....	17
Observation of Animals	17
Clinical Pathology	18
Blood Hormone Determination.....	19
Serum PFOS Level Determination.....	19
Additional Serum Collection	20
Urine and Feces PFOS Level Determination.....	20
Additional Fecal Samples	20
Interim Liver Biopsy Samples	20
Terminal Liver Biopsy Samples.....	21
Anatomic Pathology - Terminal Sacrifice	21
Anatomic Pathology - Recovery Sacrifice.....	24
Statistical Analyses.....	25
Record Retention.....	25

CONTENTS (Continued)

VOLUME I OF II

	Page
RESULTS AND DISCUSSION	26
Observation of Animals	26
Clinical Pathology	28
Palmitoyl CoA Oxidase Determination	28
Blood Hormone Determination	28
Anatomic Pathology	29
CONCLUSION	30
SIGNATURES	31
REFERENCES	32
OPHTHALMOLOGY REPORT	33
PATHOLOGY REPORT	34
COMMENTS ON THE DATA	41
CODES, ABBREVIATIONS, AND UNITS	43
General Codes and Abbreviations	44
Codes for Clinical Pathology	45
Abbreviations and Units for Clinical Hematology	48
Abbreviations and Units for Clinical Chemistry	50
Abbreviations and Units for Clinical Urinalysis	52
Codes for Anatomic Pathology	53
FIGURES	
1 Mean Body Weight Data - Treatment	55
2 Mean Body Weight Data - Recovery	56
TABLES	
1 Summary of Clinical Observations - Treatment	57
2 Summary of Clinical Observations - Recovery (Days 186 through 365)	61
3 Summary of Clinical Observations - Recovery (Days 366 through 561)	62
4 Summary of Ophthalmic Observations - Treatment	64
5 Summary of Ophthalmic Observations - Recovery	66
6 Summary of Body Weight Data (kg) - Treatment	67
7 Summary of Body Weight Data (kg) - Recovery	72
8 Summary of Clinical Hematology Data - Day -27	80
9 Summary of Clinical Hematology Data - Day 37	84
10 Summary of Clinical Hematology Data - Day 62	88
11 Summary of Clinical Hematology Data - Day 91	92

CONTENTS (Continued)

VOLUME I OF II

Page

TABLES

12 Summary of Clinical Hematology Data - Day 153	96
13 Summary of Clinical Hematology Data - Day 182	100
14 Summary of Clinical Hematology Data - Day 217	104
15 Summary of Clinical Hematology Data - Day 245	108
16 Summary of Clinical Hematology Data - Day 274	112
17 Summary of Clinical Hematology Data - Day 322	116
18 Summary of Clinical Hematology Data - Day 364	120
19 Summary of Clinical Hematology Data - Day 456	124
20 Summary of Clinical Hematology Data - Day 546	128
21 Summary of Clinical Chemistry Data - Day -27	132
22 Summary of Clinical Chemistry Data - Day 37	138
23 Summary of Clinical Chemistry Data - Day 62	144
24 Summary of Clinical Chemistry Data - Day 91	150
25 Summary of Clinical Chemistry Data - Day 153	156
26 Summary of Clinical Chemistry Data - Day 182	162
27 Summary of Clinical Chemistry Data - Day 217	168
28 Summary of Clinical Chemistry Data - Day 245	174
29 Summary of Clinical Chemistry Data - Day 274	180
30 Summary of Clinical Chemistry Data - Day 322	186
31 Summary of Clinical Chemistry Data - Day 364	192
32 Summary of Clinical Chemistry Data - Day 456	198
33 Summary of Clinical Chemistry Data - Day 546	204
34 Summary of Clinical Urinalysis Data - Day -27	210
35 Summary of Clinical Urinalysis Data - Day 37	212
36 Summary of Clinical Urinalysis Data - Day 62	214
37 Summary of Clinical Urinalysis Data - Day 91	216
38 Summary of Clinical Urinalysis Data - Day 153	218
39 Summary of Clinical Urinalysis Data - Day 182	220
40 Summary of Clinical Urinalysis Data - Day 217	222
41 Summary of Clinical Urinalysis Data - Day 245	224
42 Summary of Clinical Urinalysis Data - Day 274	226
43 Summary of Clinical Urinalysis Data - Day 322	228
44 Summary of Clinical Urinalysis Data - Day 364	230
45 Summary of Clinical Urinalysis Data - Day 456	232
46 Summary of Clinical Urinalysis Data - Day 546	234
47 Summary of Palmitoyl CoA Oxidase Determinations.....	236
48 Summary of Organ Weight Data.....	238

CONTENTS (Continued)

VOLUME I OF II

Page

TABLES

49 Incidence of Macroscopic Observations - Terminal Sacrifice	268
50 Incidence of Macroscopic Observations - Recovery Sacrifice	271
51 Incidence of Microscopic Observations - Terminal Sacrifice	272
52 Incidence of Microscopic Observations - Recovery Sacrifice	282

APPENDIX 1	283
Protocol Deviations	284
Protocol	288
Protocol Amendment No. 1	306
Protocol Amendment No. 2	315
Protocol Amendment No. 3	323

APPENDIX 2	329
Individual Animal Fate Data	330
Individual Clinical Observations	332
Individual Ophthalmic Observations	474

APPENDIX 3	489
Individual Body Weight Data (kg)	490

VOLUME II OF II

APPENDIX 4	504
Individual Clinical Hematology Data	505
Individual Clinical Chemistry Data	565
Individual Clinical Urinalysis Data	637

APPENDIX 5	685
Individual Palmitoyl CoA Oxidase Determinations	686
Individual Anatomic Pathology Data	690

APPENDIX 6	769
Summary and Individual Blood Hormone Determination	770

APPENDIX 7	808
Cell Proliferation Report	809

ABSTRACT

The purpose of this study was to assess the effect of the test material, Perfluorooctane Sulfonic Acid Potassium Salt [PFOS; T-6295 (hereafter referred to as PFOS)] on critical enzyme levels, hormones, and other selected biochemical parameters when administered daily by oral capsule to cynomolgus monkeys for at least 26 weeks. The treatment period was followed by an approximate 52-week recovery period.

Male and female cynomolgus monkeys were assigned to four groups (six animals/sex in Groups 1, 3, and 4; four animals/sex in Group 2). Each group received dose preparations containing the vehicle, lactose, or 0.03, 0.15, or 0.75 mg of PFOS/kg of body weight/day (mg/kg/day). Two animals/group in Groups 1, 3, and 4 were in a recovery period and were not treated for at least 52 weeks following the 26 week treatment period.

Food was provided *ad libitum*, except when animals were fasted. Water was provided *ad libitum*. The animals were observed twice daily (a.m. and p.m.) for mortality and moribundity. At least once daily, animals were examined for abnormalities and signs of toxicity, and food consumption was assessed qualitatively. Ophthalmic examinations were done before initiation of treatment and during Weeks 26 and 52. Body weight data were recorded weekly before initiation of treatment, on Days -1 and 1, and weekly thereafter. Blood and urine samples were collected for clinical hematology, clinical chemistry, and urinalysis tests before initiation of treatment and at specified intervals during treatment and recovery. Blood was also collected for blood hormone and PFOS level determinations before, during, and after treatment at specified intervals. Feces and liver samples were also collected at specified intervals. On Day 155 (Week 23), one male given 0.75 mg/kg/day died, and on Day 179 (Week 26), one male given 0.75 mg/kg/day was sacrificed due to poor health. On Days 184 and 185 (Week 27), four animals/sex/group (Groups 1 through 3) and four females and two males (Group 4) were anesthetized, weighed, exsanguinated, and necropsied. At necropsy at the scheduled and unscheduled sacrifices, a serum sample was collected, macroscopic observations were recorded, selected organs were weighed, and selected tissues were collected and preserved. Microscopic examinations were done on tissues from each animal in the control and high-dose groups and selected tissues from animals in the low- and mid-dose groups. Tissues were also collected for palmitoyl CoA oxidase determination, cell proliferation evaluation, PFOS determination, and electron microscopy. Additionally, the bile was collected from the gallbladder, and the gallbladder was preserved. At the recovery sacrifice on Day 549, the remaining Group 4

animals were anesthetized, weighed, exsanguinated, and necropsied. Macroscopic observations were recorded and specified tissues and serum were collected. Remaining animals in Groups 1 and 3 were donated or transferred to a follow-up study, Covance 6329-268.

At all dose levels, clinical observations, ophthalmic observations, and palmitoyl CoA oxidase determinations do not appear to be affected by treatment with PFOS.

Two males given 0.75 mg/kg/day died during treatment. These deaths were preceded by some adverse clinical observations (constricted pupil, pale gums, abnormal feces, excessive salivation, labored respiration, dehydrated appearance, hypoactive, ataxic, recumbent, low food consumption) and appeared to be related to the administration of PFOS. When compared with animals given the control material, covariate adjusted mean body weights (CAM) for males given 0.75 mg/kg/day were slightly lower beginning at Week 21, and for females given 0.75 mg/kg/day CAM body weights were, in general, significantly lower beginning at Week 11. Similar decreases were not seen in the other treated groups; therefore, this finding is likely test material-related. Test material-related effects on body weights were not apparent during recovery. Low food consumption was noted sporadically for animals in the groups given the control material and 0.03 mg/kg/day throughout treatment. The incidence of low food consumption was generally higher in the groups given 0.15 or 0.75 mg/kg/day as compared to animals given the control material and appeared to be test material-related. During recovery, effects on food consumption were reversed.

Estradiol values were generally lower on Days 62, 91, and 182 in males given 0.75 mg/kg/day, although because of the variation in the data only the Day 182 value was significant. Estrone values were generally higher in all of the treated females on Days 37, 62, and 91, although because of the variation in the data none of these values were significantly different, and this difference was not apparent on Day 182. Triiodothyronine values were notably lower in both males and females given 0.15 and 0.75 mg/kg/day on Days 91 and 182. With the single exception of males given 0.15 mg/kg/day on Day 91, all values were significantly lower. During recovery were occasional instances in which the hormone values in treated groups differed slightly from those of controls, but those differences were not consistent over time or between sexes, were not clearly dose-related, and did not appear to be clearly related to the administration of the test material. Apparent differences in the sexual maturity of both males and females used in this study complicates the interpretation of the hormone data.

The only clinical pathology parameters considered related to the test material were lower total cholesterol for animals given 0.75 mg/kg/day and lower high density lipoprotein cholesterol for animals given 0.15 or 0.75 mg/kg/day. These effects were reversed within the first 5 and 9 weeks of recovery, respectively.

At the terminal sacrifice, increased liver weights, macroscopic observations of mottled liver, hepatocellular hypertrophy, and hepatocellular vacuolation in animals given 0.75 mg/kg/day were considered related to PFOS treatment. However, the microscopic examination liver biopsies taken during recovery did not indicate any test material-related findings and none of the macroscopic observations made at the recovery sacrifice were considered test material-related. There were no microscopic findings in the liver from the animals in the high-dose recovery group. This indicates that the hepatic test material-related effects were reversible.

Treatment with PFOS by oral capsule for at least 26 weeks is generally well-tolerated in male and female cynomolgus monkeys at doses up to 0.15 mg/kg/day. Clinical and pathological findings considered to be associated with the treatment of PFOS after at least 26 weeks of treatment were found to be reversible during a 52-week recovery period. Based on the data presented in this report, the no-observable-effect level is 0.03 mg/kg/day. Dose analyses (provided by the Sponsor) and electron microscopy results (provided by PAI) are forthcoming.

PURPOSE

The purpose of this study was to assess the effect of the test material on critical enzyme levels, hormones, and other selected biochemical parameters when administered daily by capsule to cynomolgus monkeys for at least 26 weeks. The treatment period was followed by an approximate 52-week recovery period.

REGULATORY COMPLIANCE

All aspects of this study were done in accordance with the Environmental Protection Agency Good Laboratory Practice Standards, 40 CFR 792.

TEST MATERIAL, VEHICLE, AND SOLVENT

Test Material

The test material, Perfluorooctane Sulfonic Acid Potassium Salt (PFOS; T-6295), Lot No. 217, is a white to off-white powder. It was received at Covance on September 4, 1997. The test material was stored at room temperature.

Information on synthesis methods, stability, purity, composition, or other characteristics that define the test material is on file with the Sponsor.

Vehicle

The vehicle was lactose (Spectrum, New Brunswick, New Jersey), Lot No. NN0192 (expiration date February 13, 1999). It was received at Covance on March 30, 1998.

The vehicle was stored at room temperature.

Information on synthesis methods, purity, stability, composition, or other characteristics that define the vehicle is on file with the manufacturer.

Solvent

The solvent was acetone (Spectrum, Gardena, California), Lot No. LH0253, (expiration date June 2000). It was received at Covance on June 23, 1997. The solvent was stored at room temperature.

Information on synthesis methods, composition, or other characteristics that define the solvent is on file with the manufacturer.

Gelatin Capsules

Gelatin capsules, Size Nos. 2 (Lot No. 122932, expiration date June 12, 2003) and 4 (Lot No. 544043, expiration date August 1, 2002) were manufactured by Torpac Inc., (Fairfield, New Jersey). Lot No. 122932 was received at Covance on June 12, 1998, and Lot No. 544043 was received on September 1 and November 11, 1998. The capsules were stored at room temperature. A copy of the Certificate of Analysis provided by the manufacturer is maintained in the data.

Reserve (Archive) Samples

A reserve sample (1 g) of each lot of the test material, vehicle, and each test material/lactose dilution was taken and stored at room temperature. These samples were transferred to the Sponsor after completion of the treatment phase (see Protocol Deviations).

Disposition

Remaining test material will be retained at Covance for use in possible future studies.

TEST ANIMALS AND HUSBANDRY

Animals

Young adult to adult cynomolgus monkeys were obtained from Covance Research Products Inc. (Denver, Pennsylvania) on June 30, 1998. The animals weighed 2.4 to 4.4 kg at initiation of treatment.

Identification

Each animal was assigned a permanent number upon arrival and identified with a collar tag before initiation of treatment. All data for an animal are recorded under this number.

Justification

PFOS is a known hepatic peroxisome proliferator (PP) in the rat. When exposed to a PP, nonhuman primates (such as the cynomolgus monkey) respond similarly to humans (i.e., low to no hepatic response) and therefore are an appropriate human surrogate species.

Husbandry

Animal Rooms 251 and 259 were used for this study. Environmental controls for the animal rooms were set to maintain 18 to 29°C, a relative humidity of 30 to 70%, and a 12-hour light/12-hour dark cycle. Variations from these conditions are documented in the data and are considered to have had no effect on the outcome of the study.

The animals were housed individually in suspended, stainless-steel cages.

Certified primate diet (#8726C, Harlan Teklad) was provided once or twice daily, unless otherwise specified. The lot numbers are recorded in the data. The diet is routinely analyzed by the manufacturer for nutritional components and environmental contaminants. Results of specified nutrient and contaminant analyses are on file with Covance-Madison. Fruits or additional supplements were provided, but did not require analysis.

Water was provided *ad libitum*. Samples of the water are analyzed for specified microorganisms and environmental contaminants. The results are on file with Covance-Madison.

There were no known contaminants in the diet or water at levels that would have interfered with this study.

Acclimation

Twenty-four males and 24 females were received on June 30, 1998, and acclimated in Animal Room 251 for 57 days before initiation of treatment. In general, animals in this shipment appeared healthy. During acclimation, the animals were examined for abnormalities indicative of health problems. In addition, three tuberculosis tests, a physical examination, and a fecal flotation for parasites were performed on each animal.

PROCEDURES

This study was conducted in accordance with the Protocol dated August 20, 1998, and Protocol Amendment Nos. 1, 2, and 3. The protocol, protocol amendments, and protocol deviations are in Appendix 1.

Group Designations and Dosage Levels

Selection of animals for the study was based on data collected during acclimation. Animals were assigned to treatment groups using a computerized blocking procedure designed to achieve body weight balance with respect to treatment group.

Group	Dose Level (mg/kg/day) ^a	Total Material Dose Level (mg/kg/day) ^b	Number of Animals	
			Males	Females
1	0 ^a	30 ^a	6 ^d	6 ^d
2	0.03	15 ^b	4	4
3	0.15	6 ^c	6 ^d	6 ^d
4	0.75	30 ^c	6 ^d	6 ^d

a The control group (Group 1) received the equivalent amount of lactose in gelatin capsules as the total material administered to Group 4.

b The low-dose (Group 2) received the test material diluted with lactose (1:499, w:w).

c The mid-dose (Group 3) and high-dose (Group 4) groups received the test material diluted with lactose (1:39, w:w).

d Two animals in Groups 1, 3, and 4 designated as recovery animals were treated for at least 26 weeks, then treatment was discontinued, and the animals were observed for reversibility, persistence, or delayed occurrence of toxic effects for at least 52 weeks posttreatment.

Dosing Procedures

Vehicle. Dose levels were based on the vehicle as supplied for Group 1. For Group 1 dose preparations, the specified amount of lactose was weighed, transferred into gelatin capsules, and the top and bottom halves of each capsule were joined. Capsules were prepared at least once weekly.

Test Material. The test material/lactose preparations for Groups 2 through 4 were diluted once before initiation of treatment; capsules were prepared at least once weekly.

A specified amount of test material was weighed, placed into a labeled mixing container, and the appropriate volume of acetone was added. After stirring manually until the test material was dissolved, the required amount of lactose was weighed and transferred to the container. The components were mixed thoroughly using a spatula. The prepared test material dilution was stirred periodically while allowed to stand exposed to the air until the acetone had evaporated. Preparations were diluted to facilitate capsule preparation.

Samples of the finished mixture for dose analyses were taken directly from the container.

The dose preparations were stored at room temperature between capsule preparations. The appropriate amount of prepared test material was weighed and transferred into Size 2 (Days 1 through 8) or 4 (Days 9 through 184) gelatin capsules and the top and bottom halves of each capsule were joined. Size 4 capsules were used instead of Size 2 to better facilitate dose administration. Individual daily doses were based on the most recently recorded body weight, with the exception of doses given on days when body weight measurements were performed; on those days, the previous body weight was used.

All capsule preparations were stored at room temperature until used for dosing.

Method of Administration. Gelatin capsules were used to facilitate comparison with data from previous toxicology studies that used the oral route. Also, oral is the most likely route of exposure in humans. Partial or intact capsules were noted in the vomitus of several animals on occasion; however, this is not considered to have adversely affected the results of the study.

The dose preparations were administered orally in gelatin capsules once daily 7 days/week for at least 26 weeks (see Protocol Deviations for exceptions).

002652

Dose Analyses

Homogeneity and stability analyses were the responsibility of the Sponsor.

Samples (approximately 1 g each) were taken from the top, middle, and bottom of the test material/lactose preparations on Day -15 for homogeneity analysis. Samples collected from the middle of the preparations were also designated for prestudy stability analysis. A set of samples (approximately 1 g each) were taken from the low- and high-dose test material/lactose preparations at the end of the treatment phase for test material content analysis.

All samples were stored at room temperature until sent under ambient conditions to the Sponsor for analysis. Results of dose analyses will be provided for inclusion in the final report.

Observation of Animals

Clinical Observations. The animals were observed twice daily (a.m. and p.m.) for mortality and moribundity. Animals were also observed at least once daily (a.m.) for signs of poor health or abnormal behavior, and food consumption was assessed qualitatively; only abnormal findings were recorded. Once weekly and on the day of scheduled sacrifice, each animal was observed; abnormal findings or an indication of normal was recorded (see Protocol Deviations for exceptions). Additionally, postdose observations were recorded during treatment approximately 30 to 90 minutes after the last dose administration; only abnormal findings were recorded.

Ophthalmology. Ophthalmic examinations were done on each animal before initiation of treatment, before the scheduled terminal sacrifice during Week 26, and during Week 52 (see Protocol Deviations). The pupils were dilated with 1% Mydrinacil® and the anterior portion of the eye, optic media, and ocular fundus were examined with an indirect ophthalmoscope by a board-certified ophthalmologist.

Body Weights. Individual body weight data were recorded weekly before initiation of treatment, on Day -1, on the first day of treatment, and weekly thereafter. Body weights were also recorded for animals sacrificed at unscheduled intervals.

Clinical Pathology

Blood and urine samples were collected from each animal once before initiation of treatment (Day -27); on Days 37, 62, 91, 153, and 182 of treatment; and on Days 245, 271, 274, 322, 364, 456, and 546 during recovery (see Protocol Deviations). Animals were fasted overnight, and urine was collected overnight on wet ice before blood sampling; water was provided *ad libitum*. Blood was collected from the femoral vein. Potassium EDTA was the anticoagulant used for hematology tests; no anticoagulant was used for the chemistry tests. Blood samples were collected from the animal that was sacrificed at an unscheduled interval. Animals were bled in sequential order on Days 37, 62, and 91 and in random order at all other scheduled collections; this is not expected to have an impact on the clinical pathology results. The following were evaluated (see Protocol Deviations for exceptions).

Hematology

red blood cell (erythrocyte) count	differential blood cell count
hemoglobin	segmented neutrophil count
hematocrit	lymphocyte count
mean corpuscular volume	monocyte count
mean corpuscular hemoglobin	eosinophil count
mean corpuscular hemoglobin concentration	basophil count
platelet count	blood cell morphology
white blood cell (leukocyte) count	reticulocyte count

Clinical Chemistry

glucose	sorbitol dehydrogenase
urea nitrogen	creatine kinase
creatinine	calcium
total protein	inorganic phosphorus
albumin	sodium
globulin	potassium
total bilirubin	chloride
cholesterol	bile acids
triglycerides	amylase
alanine aminotransferase	lipase
alkaline phosphatase	pancreatic-specific amylase
aspartate aminotransferase	high density lipoprotein (HDL)
gamma glutamyltransferase	(effective with collection on Day 153)

Urinalysis

volume (approximately 16 hours)	bilirubin
specific gravity	blood
pH	urobilinogen
protein	microscopic examination of sediment
glucose	appearance
ketones	

Blood Hormone Determination

Blood samples (approximately 5 mL) were collected from each animal three times before initiation of treatment (Days -50, -40, and -27); on Days 37, 62, 91, and 182 of treatment; and on Days 217, 245, 274, 322, 364, 458, and 549 during recovery. Animals were fasted overnight. Blood was collected from a femoral vein without using an anticoagulant. Samples were allowed to clot and centrifuged within 1 hour after collection; serum was harvested. The serum was divided into two approximately equal aliquots and stored in a freezer, set to maintain -60 to -80°C, until packed on dry ice and shipped to Ani Lytics Inc. for analysis of cortisol, testosterone, estradiol, estrone, estriol, thyroid stimulating hormone, total triiodothyronine, and total thyroxine. Beginning with the collection on Day 322 the samples were also analyzed for free triiodothyronine and free thyroxine.

Serum PFOS Level Determination

Blood samples (approximately 2 mL) were collected from each animal once before initiation of treatment (Day -27); during Weeks 1 (Day 7), 2, 4, 6, 8, 12, 16, 20, 24, and 26, and 27 (Day 183) of treatment; and during Weeks 27 (Days 184, 185, and 187), 28 (Day 190), 29 (Day 198), 30 (Day 204), 31 (Day 211), 35, 39, 43, 47, 51, 53, 57, 61, 65, 69, 73, 77, and 79 (see Protocol Deviations). Animals were fasted overnight and water was provided *ad libitum*. Blood was collected from a femoral vein without using an anticoagulant. Samples were centrifuged within 1 hour after collection and serum was harvested. Serum samples were stored in a freezer, set to maintain -60 to -80°C, until packed on dry ice and shipped to the Sponsor for analysis. Results will be reported separately.

Additional Serum Collection

At the scheduled terminal necropsy and the necropsy of Animal No. I05506 (Group 4 male), blood samples (approximately 20 mL) were collected from the vena cava at the time of exsanguination. Samples were collected without using an anticoagulant and centrifuged within 1 hour of collection. Serum was harvested and stored in a freezer, set to maintain -60 to -80°C, until packed on dry ice and shipped to the Sponsor for possible future analysis.

An aliquot (0.8 ml) of the additional serum collection samples collected from all animals from Groups 1, 2, 3, and 4 sacrificed at the terminal necropsy were sent on dry ice by the Sponsor to AniLytics for total triiodothyronine, total thyroxin, free triiodothyronine, and free thyroxin determinations.

Urine and Feces PFOS Level Determination

Urine [at least 2 mL (see Protocol Deviations)] and feces (at least 5 g) were collected overnight on the first day of recovery (Day 184) and on Days 189, 216, 275, 321, and 366 during recovery. In addition, a 24-hour sample of urine and feces was collected before the completion of 52 weeks of recovery. Except for the first day of recovery, animals were not fasted. Samples were stored in a freezer set to maintain -10 to -30°C, until they were packed on dry ice and shipped to the Sponsor. The samples will be analyzed for PFOS. Results will be reported separately.

Additional Fecal Samples

During Week 23, a fresh fecal sample (up to 5 g) was collected from all animals in the control and high-dose groups. Samples were collected in white polypropylene containers after pans were cleaned in the morning to ensure that the fecal samples were not more than 6 hours old (see Protocol Deviations). Samples were packed on dry ice and shipped to the Mayo Clinic for analysis.

Interim Liver Biopsy Samples

A sample of liver (approximately 1 to 2 g) was collected by biopsy from animals in Group 4 only during recovery [Week 57 (Day 393), on the same day as the serum PFOS blood collection]. This sample was divided into four portions as follows.

One subsample was preserved in 10% neutral-buffered formalin, embedded in paraffin, sectioned, stained with hematoxylin and eosin (duplicate slides were prepared), and examined microscopically.

The second subsample was flash-frozen in liquid nitrogen and stored in a freezer, set to maintain -60 to -80°C, until shipped to the Sponsor for analysis (see Protocol Deviations). Results will be reported separately.

The third subsample was processed to block stage for electron microscopic evaluation. The tissue blocks and a hematoxylin and eosin-stained slide for light microscopy were transferred to PAI. Tissues will be processed and evaluated by electron microscopy by PAI. A report will be provided by PAI for inclusion in the final report.

The fourth subsample was flash-frozen in liquid nitrogen and stored in a freezer, set to maintain -60 to -80°C, until transferred to the Sponsor for possible future analysis.

Terminal Liver Biopsy Samples

A sample of liver (approximately 1 g) was collected by biopsy from all animals in Group 3 during recovery [Week 80 (Day 554), one week after the serum PFOS blood collection (see Protocol Deviations)]. This sample was flash-frozen in liquid nitrogen and stored in a freezer, set to maintain -60 to -80°C, until shipped to the Sponsor for analysis. Results will be reported separately.

Anatomic Pathology - Terminal Sacrifice

Necropsy. A necropsy was done on Animal No. I05509 (Group 4 male) that died on Day 155 (Week 23) and Animal No. I05506 (Group 4 male) that was sacrificed in a moribund condition on Day 179 (Week 26). During Week 27 (Days 184 and 185) four animals/sex/group (Groups 1 through 3) and four females and two males (Group 4) were fasted overnight, anesthetized with ketamine and xylazine, weighed, bled for required tests, exsanguinated, and necropsied. Animals were necropsied in random order.

The necropsy included a macroscopic examination of the external surface of the body; all orifices; the cranial cavity; the external surface of the brain; the nasal cavity and paranasal sinuses; cervical tissues and organs; and the thoracic, abdominal, and pelvic cavities and viscera.

Organ Weights. At scheduled and unscheduled sacrifices, the following organs (when present) were weighed; paired organs were weighed separately.

adrenal (2)	ovary (2)
brain	pancreas
epididymis (2)	testis (2)
kidney (2)	thyroid (2) with parathyroid
liver	

Organ-to-body weight percentages and organ-to-brain weight ratios were calculated.

Palmitoyl CoA Oxidase Determinations. Representative samples of the right lateral lobe of liver were collected from each animal at the scheduled sacrifice, weighed, flash-frozen in liquid nitrogen, and stored in a freezer, set to maintain -60 to -80°C, until analyzed for palmitoyl CoA oxidase activity.

Cell Proliferation Evaluation. Representative samples of the left lateral lobe of the liver, left and right testes, and pancreas were collected and preserved in zinc formalin. A second set of tissues (representative samples of the left lateral lobe of the liver, left and right testes, and pancreas) preserved in formalin without zinc were also prepared. After fixation, samples were embedded in paraffin and shipped to Pathology Associates International (PAI) for proliferation cell nuclear antigen (PCNA) evaluation, including the examination of slides stained with hematoxylin and eosin (see Protocol Deviations). Results were provided by PAI for inclusion in the final report (Appendix 7).

Liver PFOS Determination. A section of liver (approximately 20 g) was collected from each animal at the scheduled sacrifice, weighed, flash-frozen in liquid nitrogen, and stored in a freezer, set to maintain -60 to -80°C, until shipped with plasma samples to the Sponsor. Results will be reported separately.

Gallbladder and Bile Collection. At the scheduled terminal sacrifice for each animal, bile was collected from the gallbladder, measured, transferred into a cryovial, and flash-frozen in liquid nitrogen. The gallbladder, once emptied, was weighed, and a section (approximately 4 to 5 mm) from the mid-portion was collected. The remaining gallbladder was placed in a cryovial and flash-frozen in liquid nitrogen. The bile and gallbladder samples were stored on dry ice until transferred to a freezer set to maintain

-60 to -80°C. Samples were packed on dry ice and shipped to the Sponsor for possible future analysis.

Tissue Preservation. The following tissues (when present) or representative samples were collected and preserved in 10% neutral-buffered formalin, unless otherwise specified (see Protocol Deviations).

adrenal (2)	ovary (2)
aorta	pancreas
brain	pituitary
cecum	prostate
cervix	rectum
colon	salivary gland [mandibular (2)]
duodenum	sciatic nerve
epididymis (2)	seminal vesicle (2)
esophagus	skeletal muscle (thigh)
eyes [(2) preserved in Davidson's fixative for all sacrificed animals]	skin
femur with bone marrow (articular surface of the distal end)	spinal cord (cervical, thoracic, and lumbar)
gallbladder	spleen
heart	sternum with bone marrow
ileum	stomach
jejunum	testis [(2) preserved in Bouin's solution for all sacrificed animals]
kidney (2)	thymus
lesions	thyroid (2) with parathyroid
liver	trachea
lung	urinary bladder
mammary gland	uterus
mesenteric lymph node	vagina

Histopathology. Tissues (as appropriate) were embedded in paraffin, sectioned, stained with hematoxylin and eosin, and examined microscopically from each animal in the control and high-dose groups (see Protocol Deviations for exceptions). In addition, liver and thymus for all animals in the low- and mid-dose groups and spinal cord gray matter from females in the low- and mid-dose groups were embedded in paraffin, sectioned, stained with hematoxylin and eosin, and examined microscopically. Other tissues, as appropriate, will be retained for possible future examination.

Bone marrow smears from the sternum of each animal at scheduled and unscheduled sacrifices were prepared, stained with Wright's stain, and retained for possible examination.

Electron Microscopy. A sample of the liver was collected from each animal at the scheduled terminal sacrifice. Tissues were processed into blocks and, along with a hematoxylin and eosin-stained slide, were shipped to PAI for analysis. Results will be provided for inclusion in the final report.

Anatomic Pathology - Recovery Sacrifice

Termination. Remaining animals in Group 1 were donated on Day 549 and remaining animals in Group 3 were transferred to Covance 6329-268 on Day 560. On Day 549, remaining animals in Group 4 were fasted overnight, anesthetized with ketamine and xylazine, weighed, exsanguinated, and necropsied.

The necropsy of the animals in Group 4 included a macroscopic examination of the external surface of the body; all orifices; the cranial cavity; the external surface of the brain; the nasal cavity and paranasal sinuses; cervical tissues and organs; and the thoracic, abdominal, and pelvic cavities and viscera.

Liver Samples. Samples of liver were collected from animals in Group 4 as follows.

One sample was preserved in 10% neutral-buffered formalin, embedded in paraffin, sectioned, stained with hematoxylin and eosin (duplicate slides were prepared), and examined microscopically.

The second sample was flash-frozen in liquid nitrogen and stored in a freezer, set to maintain -60 to -80°C, until shipped to the Sponsor for analysis. Results will be reported separately.

The third sample was processed to block stage for electron microscopic evaluation. The tissue blocks and a hematoxylin and eosin-stained slide for light microscopy were transferred to Pathology Associates International (PAI). Tissues will be processed and evaluated by electron microscopy by PAI. A report will be provided by PAI for inclusion in the final report.

Additional Tissue and Serum Samples. Samples of lung, kidney, spleen, thyroid, brain, abdominal fat, heart, (approximately 3 g each), and bile and serum (each as much as possible) were collected. These samples were flash-frozen in liquid nitrogen and stored in a freezer, set to maintain -60 to -80°C, until shipped to the Sponsor for possible future analysis.

Statistical Analyses

Levene's test (Levene, 1960) was done to test for variance homogeneity. In the case of heterogeneity of variance at $p \leq 0.05$, transformations were used to stabilize the variance. Comparison tests took variance heterogeneity into consideration.

One-way analysis of variance [ANOVA (Winer, 1971a)] was used (if applicable) to analyze initial body weights, organ weights, palmitoyl CoA oxidase activities, continuous clinical pathology values, and blood hormone determinations. If the ANOVA was significant, Dunnett's t-test (Dunnett, 1964) was used for control versus treated group comparisons.

One-way analysis of covariance [ANCOVA (Winer, 1971b)] was used to analyze body weights, with initial body weights as the covariate. If the ANCOVA was significant, covariate-adjusted means were used for control versus treated group comparisons.

Group comparisons (Groups 2 through 4 versus Group 1) were evaluated at the 5.0%, two-tailed probability level. Only data collected on or after the first day of treatment were analyzed statistically. Statistical analyses were not performed on data collected during recovery.

Record Retention

All raw data, documentation, records, protocol, and specimens generated as a result of this study will be archived in the storage facilities of Covance-Madison for a period of 1 year. One year after the submission of the final report, the Sponsor will determine the final disposition of the materials. All raw data stored on magnetic media and the protocol, study correspondence, and an original copy of the final report will be retained by Covance-Madison.

Within 1 year after submission of the final report, all of the aforementioned materials from the Sponsor's designees (Ani Lytics Inc., 3M E. T. & S, Mayo Clinic, and Pathology Associates International) will be sent to the Sponsor (Andrew Seacat, PhD, 3M) by the Sponsor's designees.

RESULTS AND DISCUSSION

Observation of Animals

Clinical Observations. Clinical observations are summarized in Tables 1, 2, and 3; individual data are presented in Appendix 2. Individual animal fate data are also presented in Appendix 2.

Animal Nos. I05506 and I05509 given 0.75 mg/kg/day (Group 4 males) did not survive to the scheduled terminal sacrifice. All other animals survived to the scheduled study termination. No clinical observations noted in the animals that survived to the terminal sacrifice or recovery were attributable to the administration of PFOS.

Animal No. I05509 (Group 4 male) died after dosing on Day 155 (Week 23). On Day 154 (Week 22) observations of constricted pupil in both eyes and pale gums were noted. Observations noted on Day 155 prior to dosing included few, mucoid, liquid, and black-colored feces and low food consumption. Approximately 15 minutes after dosing, the animal was observed as hypoactive with labored respiration and pale gums. This animal also appeared dehydrated and was cold to the touch. These observations persisted until approximately 30 minutes postdose when the animal was also noted as recumbent. Shortly thereafter, the animal died during an examination by a laboratory animal veterinarian. An enlarged liver was detected by palpation. The cause of death was determined to be pulmonary necrosis with severe acute inflammation.

On Day 179 (Week 26), Animal No. I05506 (Group 4 male) was sacrificed in a moribund condition. Low food consumption was noted on Day 178 (Week 26) and at the a.m. observation interval on Day 179. Approximately 5 to 10 minutes postdose on Day 179, the animal had excessive salivation, labored respiration, and hypoactive and ataxic behavior. With the exception of excessive salivation, these findings continued to be observed approximately 3 hours postdose. The cause of the moribund condition was not determined.

Two additional animals had noteworthy observations during treatment. One female in the group given the control material, Animal No. I05529, was examined by a laboratory animal veterinarian on Day 5 (Week 1) due to observations of dehydration, thin appearance, clear oral and nasal discharge, excessive salivation, and audible respiration. This animal was diagnosed with pneumonia and treated with Lactated Ringer's solution and antibiotics. This animal had recovered by Day 14 (Week 2). Animal No. I05534 (Group 4 female) was diagnosed with a tapeworm infection during Week 23 and was treated with praziquantel. Neither infection was test material-related.

Clinical observations during recovery were typical of laboratory primates.

Ophthalmology. Ophthalmic observations are summarized in Table 4; individual data are presented in Appendix 2.

There were no ophthalmic observations at the Week 26 or Week 52 examinations that were test material-related. Animal No. I05529 (Group 1 female) was noted as having increased myelination of the right optic nerve at the baseline and Week 52 ophthalmic examinations. Because this is a permanent, congenital condition, it was noted at the baseline and recovery examinations only and is not related to treatment with PFOS.

Body Weights. Body weight data are illustrated in Figures 1 and 2 and summarized in Tables 5 and 6; individual data are presented in Appendix 3.

Covariate-adjusted mean (CAM) body weights were slightly lower in males given 0.75 mg/kg/day when compared with males given the control material beginning at Week 21; the difference was significant at Weeks 23 and 27. In females given 0.75 mg/kg/day, CAM body weights were significantly lower at Weeks 11 through 16, 19 through 23, and 25 through 27 when compared with females given the control material. These decreases were likely test material-related.

Differences in body weights were not apparent during the recovery period.

Food Consumption. Food consumption data are summarized in Tables 1, 2, and 3 (Summary of Clinical Observations); individual data are included in the individual clinical observations in Appendix 2.

Low food consumption was noted sporadically for animals in the groups given the control material and 0.03 mg/kg/day. The incidence of low food consumption was generally higher in the groups given 0.15 and 0.75 mg/kg/day as compared to animals given the control material and appeared to be test material-related. During recovery, instances of low food consumption were sporadic and were similar for animals in the control and treated groups.

Clinical Pathology

Hematology, clinical chemistry, and urinalysis data are summarized in Tables 7 through 45; individual data are presented in Appendix 4.

Administration of PFOS was associated with moderately to markedly lower total cholesterol for males and females given 0.75 mg/kg/day and high density lipoprotein cholesterol for males and females given 0.15 or 0.75 mg/kg/day. During the treatment period, the effect on total cholesterol became progressively worse over time. The effect on cholesterol was reversed within 5 weeks of the end of treatment, and the effect on high density lipoprotein cholesterol was reversed within 9 weeks of the end of treatment. Of uncertain relationship to administration of PFOS was lower total bilirubin concentration for males given 0.75 mg/kg/day and higher serum bile acid concentration for males given 0.75 mg/kg/day. These potential effects of the test material were very mild, and neither was considered adverse.

Palmitoyl CoA Oxidase Determination

Palmitoyl CoA oxidase determinations are summarized in Table 46; individual data are presented in Appendix 5.

Results of palmitoyl CoA oxidase determinations were not considered to be related to the test material.

Blood Hormone Determination

Summary and Individual Blood Hormone Data are presented in Appendix 6.

Estradiol values were generally lower on Days 62, 91, and 182 in males given 0.75 mg/kg/day, although because of the variation in the data only the Day 182 value was significant. Estrone values were generally higher in all of the treated females on Days 37, 62, and 91, although because of the variation in the data none of these values were significantly different, and this difference was not apparent on Day 182.

Triiodothyronine values were notably lower on Days 91 and 182 in both males and females given 0.15 or 0.75 mg/kg/day. With the single exception on Day 91 of males given 0.15 mg/kg/day, all values were significantly lower. There were several other instances in which the hormone values in treated groups differed from those of controls, but these differences were not consistent over time or between sexes, were not clearly dose-related, and did not appear to be related to the administration of the test material.

During recovery were occasional instances in which the hormone values in treated groups differed slightly from those of controls, but those differences were not consistent over time or between sexes, were not clearly dose-related, and did not appear to be clearly related to the administration of the test material.

Apparent differences in the sexual maturity of both males and females used in this study complicates the interpretation of the hormone data.

Anatomic Pathology

Terminal body weights, absolute organ weights, organ-to-body weight percentages, and organ-to-brain weight ratios are summarized in Table 47; incidences of macroscopic and microscopic observations are summarized in Tables 48 through 51. Individual data are presented in Appendix 5.

Two of four males receiving 0.75 mg/kg/day (high dose) did not survive to the scheduled terminal sacrifice at Week 27. At the terminal sacrifice, females in the group receiving 0.75 mg/kg/day had increased absolute liver weight, liver-to-body weight percentages, and liver-to-brain weight ratios. In males, liver-to-body weight percentages were increased in the high-dose group compared to the control group. Absolute and relative liver weight increases were regarded as test material-related. Among the macroscopic observations, only "mottled" liver was considered test material-related. "Mottled" livers were observed in the two high-dose males and in one high-dose female. Of the two males not surviving until the scheduled terminal sacrifice, one had "mottled" and "large" liver.

Microscopic examination of animals sacrificed at Week 27 and of the two males sacrificed at an unscheduled interval yielded test material-related observations in the liver. In three of four high-dose males there was hepatocellular hypertrophy, occurring either centrilobularly or without regard to location within hepatic lobules. Hypertrophy, as described in the males, was observed in all high-dose females. The microscopic observations of hepatocellular hypertrophy were reflected in higher liver weights in the high-dose females. Hypertrophy was regarded as test material-dependent in high-dose animals.

Centrilobular or diffuse hepatocellular vacuolation was also test material-dependent in high-dose animals, occurring in two of four females and two of four males. Multifocal hepatic vacuoles were not regarded as test material-dependent because they were found in one of four low-dose males, and in a control and a low-dose female.

Microscopic examination of liver taken at biopsy on Week 57 from the high-dose animal did not have any test material-related findings.

At the recovery sacrifice, one of two males and one of two females did not have macroscopic observations. The observations in the other animals were of adhesions on the lungs or liver and nodules in the thoracic cavity. None of these observations was considered test material-related. Only livers were examined microscopically, and no test material-related observations were made. The hepatic vacuolation observed in terminal sacrifice and unscheduled death animals was not present, indicating that the hepatic test material-related effects were reversible.

CONCLUSION

Treatment with PFOS by oral capsule for at least 26 weeks is generally well-tolerated in male and female cynomolgus monkeys at doses up to 0.15 mg/kg/day. Clinical and pathological findings considered to be associated with the treatment of PFOS after at least 26 weeks of treatment were found to be reversible during a 52-week recovery period. Based on the data presented in this report, the no-observable-adverse-effect level is 0.15 mg/kg/day. Dose analyses (provided by the Sponsor) and electron microscopy results (provided by PAI) are forthcoming.

SIGNATURES

Elizabeth A. Disch, BA
Study Coordinator
Covance Laboratories Inc.

Date

Peter J. Thomford, PhD
Study Director
Covance Laboratories Inc.

Date

REFERENCES

Dunnett, C. W., "New Tables for Multiple Comparisons with a Control," Biometrics, 20:482-491 (1964).

Levene, H., "Robust Tests for Equality of Variances," Contributions to Probability and Statistics, (eds.) I. Olkin et al., Ch. 25, pp. 278-292, Stanford University Press: Stanford, California (1960).

Winer, B. J., "Design and Analysis of Single-Factor Experiments," Statistical Principles in Experimental Design, Second Ed., Ch. 3, pp. 149-260, McGraw-Hill: New York, New York (1971a).

Winer, B. J., "Analysis of Covariance," Statistical Principles in Experimental Design, Second Ed., Ch. 10, pp. 752-812, McGraw-Hill: New York, New York (1971b).

OPHTHALMOLOGY REPORT

Ophthalmic examinations were done before initiation of treatment and during Weeks 26 and 52. There were no ophthalmic observations at the Week 26 or Week 52 examinations that were test material-related. Animal No. I05529 (Group 1 female) was noted as having increased myelination of the right optic nerve at the baseline and Week 52 ophthalmic examinations. Because this is a permanent, congenital condition, it was noted at the baseline and recovery examinations only and is not related to treatment with PFOS. There were no test material-related observations at any of the examinations.

Stephen I. Bistner, DVM
Diplomate, ACVO
Veterinary Ophthalmologist

Date

PATHOLOGY REPORT

SUMMARY

The purpose of the study was to assess the effect of the test material, Perfluorooctane Sulfonic Acid Potassium Salt (PFOS), on critical enzyme levels, hormones, and other selected biochemical parameters when administered daily by capsule to cynomolgus monkeys for at least 26 weeks. The test material was administered at dose levels of 0.03, 0.15, and 0.75 mg/kg/day. One male given 0.75 mg/kg/day died on Day 155 after dose administration and one male given 0.75 mg/kg/day was sacrificed on Day 179 due to poor health.

Administration of PFOS was associated with moderately to markedly lower total cholesterol for males and females given 0.75 mg/kg/day and high density lipoprotein cholesterol for males and females given 0.15 or 0.75 mg/kg/day. During the treatment period, the effect on total cholesterol became progressively worse over time. The effect on cholesterol was reversed within 5 weeks of the end of treatment, and the effect on high density lipoprotein cholesterol was reversed within 9 weeks of the end of treatment. Of uncertain relationship to administration of PFOS was lower total bilirubin concentration for males given 0.75 mg/kg/day and higher serum bile acid concentration for males given 0.75 mg/kg/day. These potential effects of the test material were very mild, and neither was considered adverse.

Two of four males receiving 0.75 mg/kg/day did not survive to the scheduled terminal sacrifice at Week 27. At the terminal sacrifice, females in the group receiving 0.75 mg/kg/day had increased absolute liver weight, liver-to-body weight percentages, and liver-to-brain weight ratios. In males, liver-to-body weight percentages were increased in the high-dose group compared to controls. These absolute and relative liver weight increases were regarded as test material-related. Among the macroscopic observations, only "mottled" liver was considered test material-related. "Mottled" livers were observed in the two high-dose males and in one high-dose female. Of the two males not surviving until the scheduled terminal sacrifice, one had "mottled" and "large" liver.

Microscopic examination of animals sacrificed at Week 27 and the two unscheduled sacrifice males yielded test material-related observations in the liver. In three of four high-dose males there was hepatocellular hypertrophy, occurring either centrilobular or

without regard to location within hepatic lobules. Hypertrophy, as described in the males, was also observed in four of four high-dose females. The microscopic observations of hepatocellular hypertrophy were reflected in higher liver weights in the high-dose females. Hypertrophy was regarded as test material-dependent in high-dose animals.

Centrilobular or diffuse hepatocellular vacuolation was also test material-dependent in high-dose animals, occurring in two of four females and two of four males. Multifocal hepatic vacuoles were not regarded as test material-dependent because they were found in one of four low-dose males, and in a control and a low-dose female.

Microscopic examination of liver taken at biopsy on Week 57 from the high-dose animal did not have any test material-related findings.

For the recovery sacrifice at Week 79, only high-dose animals were necropsied. One of two males and one of two females did not have macroscopic observations. The observations in the other animals were of adhesions on the lungs or liver and nodules in the thoracic cavity. None of these observations was considered test material-related. Only livers were examined microscopically. No test material-related observations were made. The hepatic vacuolation observed in terminal sacrifice and unscheduled death animals was not present, indicating that the hepatic test material-related effects were reversible.

METHODS

Four groups of male and female cynomolgus monkeys were administered the test material daily by capsule at a dose level of 0 (control group; received capsules containing lactose), 0.03, 0.15, or 0.75 mg/kg of body weight/day (mg/kg/day). There were six animals/sex in the control group and the groups given 0.15 or 0.75 mg/kg/day; two animals/sex in these groups were designated as recovery animals to be observed for approximately 26 weeks posttreatment. The recovery period was later extended an additional 26 weeks. There were four animals/sex in the group given 0.03 mg/kg/day. One male given 0.75 mg/kg/day died on Day 155 following dose administration, and one male given 0.75 mg/kg/day was sacrificed on Day 179 due to poor health.

Blood and urine were collected for hematology, clinical chemistry, and urinalysis tests once before initiation of treatment (Week -4), on Days 37, 62, 91, 153, and 182 and on Days 217, 245, 364, 456, and 546 (recovery animals). High density lipoprotein cholesterol was not measured at the clinical pathology intervals before Day 153.

The terminal sacrifice and necropsy occurred on Days 184/185; macroscopic observations were recorded, organ weights were obtained, and tissues were placed in fixative as specified by the protocol. Samples of the right lateral lobe of the liver from each animal were frozen for analysis of palmitoyl CoA oxidase activity. Sections of liver from each animal were processed to block for electron microscopy and shipped to the Sponsor's designee for ultrastructural evaluation. Samples of liver from each animal were frozen and shipped to the Sponsor for PFOS determination. The gallbladders and bile from each animal were collected, frozen, and shipped to the Sponsor. Samples of pancreas, left and right testes, and the left lateral lobe of the liver were preserved for cell proliferation evaluation by the Sponsor's designee using proliferation cell nuclear antigen. Light microscopic examinations were done on collected tissues from control animals and animals given 0.75 mg/kg/day. In addition, liver and thymus from all animals given 0.03 or 0.15 mg/kg/day and spinal cord gray matter from females given 0.03 or 0.15 mg/kg/day were examined by light microscopy.

During Week 57, liver biopsies were performed on the recovery animals that had been given 0.75 mg/kg/day. The tissue was divided into four samples. Three of the samples were used for light microscopic examination, ultrastructural examination by the Sponsor's designee, and PFOS analysis by the Sponsor, respectively. The fourth sample was frozen and shipped to the Sponsor for possible analysis. At the end of the recovery period (Week 79), the control animals were returned to the Covance stock colony, the animals that had been given 0.15 mg/kg/day were transferred to a subsequent study for the Sponsor (Covance 6329-268) following liver biopsy for PFOS analysis by the Sponsor, and the animals that had been given 0.75 mg/kg/day were sacrificed and necropsied. At this recovery necropsy, macroscopic observations were recorded, and three samples of liver were collected for light microscopic examination, ultrastructural examination by the Sponsor's designee, and PFOS analysis by the Sponsor, respectively.

Statistically significant differences cited in the Results and Discussion are based on comparisons between the control and treated groups.

RESULTS AND DISCUSSION

Mortality

Two of four males receiving 0.75 mg/kg/day (high dose) of the test material did not survive to the scheduled terminal sacrifice at Week 27. One was found dead on Day 155. The other was sacrificed on Day 179 due to poor health. The cause of death in the animal found dead was judged to be pulmonary necrosis with severe acute inflammation. Microscopically, the pulmonary lesion appeared to be an acute exacerbation of a chronic lesion. The cause of death in the moribund animal was not determined. All other animals survived to their scheduled sacrifices.

Clinical Pathology

Week -4. Results of clinical pathology tests indicated no obvious group or individual health abnormalities. Several animals, however, had mildly elevated alanine aminotransferase activities at Week -4. These animals were primarily females and were dispersed among all of the groups. By Day 37, their alanine aminotransferase activities were no longer elevated. The transient increase in this liver enzyme was considered likely due to subclinical infection with Hepatitis A virus, a common infection in cynomolgus monkeys, and did not negatively impact evaluation of the test material.

Days 37, 62, 91, 153, and 182. Although there were several statistically significant or otherwise notable differences for clinical pathology test results between the control and treated animals, most of the differences were inconsistent over time or similar to differences present before initiation of treatment (i.e., Week -4). The only differences considered to represent effects of the test material were lower total cholesterol for males and females given 0.75 mg/kg/day and lower high density lipoprotein cholesterol for males and females given 0.15 or 0.75 mg/kg/day. The effect on total cholesterol became progressively worse over time. At Day 182, the mean total cholesterol concentrations for the males and females given 0.75 mg/kg/day were approximately 68% and 49% lower, respectively, than those for the control males and females. The effect on high density lipoprotein cholesterol, measured only at Days 153 and 182, was proportionately greater than that for total cholesterol. At Day 182, the mean high density lipoprotein cholesterol concentrations for the males and females given 0.75 mg/kg/day were approximately 79% and 62% lower, respectively, than those for the control males and females.

Of uncertain relationship to administration of PFOS was lower total bilirubin concentration for males given 0.75 mg/kg/day (statistically lower on Days 91, 153, and 182) and higher serum bile acid concentration for males given 0.75 mg/kg/day (statistically higher on Day 182 only). These potential effects of the test material were very mild, and neither was considered adverse.

Statistically significant differences for other test results were considered incidental and unrelated to administration of the test material. These differences were inconsistent over time or were similar to differences that existed before the initiation of treatment.

Unscheduled sacrifice Animal No. I05506, a male given 0.75 mg/kg/day, was sacrificed on Day 179. The most notable findings for this animal were a moderate neutrophilic leukocytosis, mildly increased serum bile acid and globulin concentrations, and moderately to markedly decreased total cholesterol and high density lipoprotein cholesterol.

Days 217, 245, 364, 456, and 546 (Recovery animals). The effect on cholesterol was reversed by Day 217, and the effect on high density lipoprotein cholesterol was reversed by Day 245. There were no other findings considered to represent persistent or delayed occurrence of toxic effects.

Anatomic Pathology

Organ Weights. At the terminal sacrifice (Week 27) females in the group receiving 0.75 mg/kg/day (high-dose) had increased absolute liver weight, liver-to-body weight percentages, and liver-to-brain weight ratios. This increase was regarded as test material-related. In females the absolute pancreas weights were higher in animals receiving 0.03 mg/kg/day (low-dose) than in those receiving 0 mg/kg/day (control). Increased pancreatic weights were not regarded as test material-related.

In males, liver-to-body weight percentages were increased in the high-dose group compared to controls. The increase was regarded as test material-related. Left adrenal-to-body weight percentages were also increased in high dose males compared to controls. The significance of the increase left adrenal weight percentage was not known.

Organ weights were not taken at the recovery sacrifice at Week 79.

Macroscopic Observations. Twenty one of 30 animals at the terminal sacrifice had at least one macroscopic observation. One of the observations was obesity; it was not regarded as pathologic. Thus, 20 animals had macroscopic observations. Of all the macroscopic observations, only "mottled" liver was considered test material-related. "Mottled" liver was observed in the two high-dose males and in one high-dose female. The other observations included adhesions and dark or red foci in any of several organs. Among high-dose females, each had at least one observation of a dark or red focus. In addition, adrenal cortices of the two high-dose males and two of four high dose females were recorded as dark. In one high-dose female (Animal No. I05540), the red focus in the lung correlated microscopically with hemorrhage. There were no microscopic correlates for the other observations. Hence, dark or red foci were considered too non-specific to be considered test material-related. Additionally, dark and red foci were observed in animals in other dose groups. Dark adrenal cortices did not have a microscopic correlate; they, too, were not considered test material-related.

Of the two males not surviving until the scheduled terminal sacrifice, one did not have any macroscopic observations. The other (Animal No. I05509) had several observations. Of these observations, those in the liver were considered test material-related. The liver observations were "mottled" and "large".

For the recovery sacrifice at Week 79, only high dose animals were necropsied. One of 2 males and one of two females did not have macroscopic observations. The observations in the other animals were of adhesions on the lungs or liver and nodules in the thoracic cavity. None of these observations was considered test material-related.

Microscopic Observations. At the terminal sacrifice, all tissues from the control and high dose groups were examined. All tissues were examined on the two high-dose males not surviving until the terminal sacrifice; the microscopic data were grouped with that of the terminal sacrifice animals. Liver, thymus, and spinal cord were examined from animals in the low and intermediate dose groups. In three of four high-dose males there was hepatocellular hypertrophy, occurring either centrilobullary or without regard to location within hepatic lobules. Hypertrophy, as described in the males, was observed in four of four high-dose females. The microscopic observations of hepatocellular hypertrophy were reflected in higher liver weights in the high-dose females. Hypertrophy was regarded as test material-dependent in high dose animals.

Centrilobular or diffuse hepatocellular vacuolation was also test material-dependent in high-dose animals, occurring in two of four females and two of four males. Multifocal hepatic vacuoles were not regarded as test material-dependent. Multifocal hepatic vacuoles were found in one of four low dose males, and in a control and a low-dose female.

Two other observations were suggestive of possible test material effects upon examination of only control and high-dose animals. When tissues were examined from the low and intermediate dose groups as well, test material-dependency was not supported. In females, thymic atrophy was more pronounced in dosed animals than in controls. However, there is no clear dose-dependent pattern and thus, thymic atrophy cannot be considered test material-dependent. Intraneuronal pigment was observed in the spinal cord gray matter of two of four high dose, four of four mid-dose, three of four low-dose and one of four control females. And thus, spinal cord pigment was considered unrelated to the test material.

Microscopic examination of liver taken at biopsy on Week 57 from the high-dose animal did not have any test material related findings.

At the recovery sacrifice, livers were examined from high-dose animals. No test material-related observations were made. The hepatic vacuolation observed in terminal sacrifice and unscheduled death animals was not present, indicating that the hepatic test material-related effects were reversible.

In those animals from which all tissues were examined, the width of the femoral growth plates were assessed as a general indication of the maturity of the animals. Based on this indicator, males were less mature than females.

Robert L. Hall, DVM, PhD
Diplomate, ACVP
(Clinical Pathology)

Date

Robert A. Leedle, DVM, PhD
Diplomate, ACVP

Date

COMMENTS ON THE DATA

Various models of calculators, computers, and computer programs were used to analyze data in this study. Because different models round off or truncate numbers differently, values in some tables (e.g., means, standard deviations, or individual values) may differ slightly from those in other tables, from individually calculated data, or from statistical analysis data. Neither the integrity nor the interpretation of the data was affected by these differences.

Some tabular data were compiled using Excel® Version 7.0 software.

The units for the dose levels on the data collection system (PTS) summary tables are mg/kg/day.

The number of animals listed in the heading of the summary table for clinical observations reflects the number of animals assigned to each group at the start of the study.

The summary table for clinical observations indicates the number of animals for which a condition was observed without regard to the specific nature, severity, reversibility, number of incidences/animal, or the length of time the condition persisted.

Only observations other than normal are indicated on the summary of clinical observations table.

The specific details for comments in the individual clinical observations tables that are indicated with a "C" can be found at the end of each group for each sex.

The day of initiation of treatment is "Day 1, Week 1." Body weight data are entered at the start of a study week (e.g., a body weight recorded on Day 1 is considered a Week 1 body weight, a body weight recorded on Day 8 is considered a Week 2 body weight).

Differences in the population size (N) on the summary tables for clinical and anatomic pathology are explained on the individual data tables.

Results of clinical pathology samples collected for animals sacrificed at an unscheduled interval appear on the individual clinical pathology tables for the next scheduled interval. These results are not on the summary tables and are not included in the statistical analyses.

Statistical analyses were not done when there were two or fewer values for a parameter.

COMMENTS ON THE DATA (continued)

Bile volume is located on the individual anatomic pathology table under the heading of "absolute organ weight (grams)". The value listed for bile is not a weight and is designated with a unit of mL.

Some clinical observations discussed in the report were documented on the Request for Veterinary Services form and will be archived with the raw data, but they do not appear on the individual clinical observations tables.

CODES, ABBREVIATIONS, AND UNITS

General Codes and Abbreviations

Codes for Clinical Pathology

Abbreviations and Units for Clinical Hematology

Abbreviations and Units for Clinical Chemistry

Abbreviations and Units for Clinical Urinalysis

Codes for Anatomic Pathology

Note: The following lists of codes, abbreviations, and units are used by Covance. Some, but not necessarily all, of this information may be needed for this report.

General Codes and Abbreviations

WK	Week
N	Number of measurements in a group
Mean; MEAN	Arithmetic mean
CAM	Covariate-adjusted mean
SD; S.D.; STAND DEV;	Standard deviation
STANDARD DEV; sd	
*	Group mean is significantly different from the mean of the control group (Group 1) at $p \leq 0.05$
-; NA	No value; not applicable; not present
P	Present
C	Comment found at the end of each group for each sex
UNSCHED	Unscheduled
DISPATCH	Observations transferred from the in-life module of the data collection system to the necropsy module for reference during necropsy. Observations are duplicates of the last in-life observations.
TBW	Terminal body weight
#	Number
VET EXAM	Veterinary examination
AM OBS	Observations recorded during the daily, morning observation interval.
30-90 OB	Observations recorded during the 30 to 90 minute postdose observation interval.

Codes for Clinical Pathology

GENERAL CODES

NS	No sample
QS/QNS	Quantity not sufficient
NR	No repeat (sample volume not sufficient for repeat analysis)
FS	Fibrin strands
SC	Sample clotted
SH	Slightly hemolyzed
H	Hemolyzed
SL	Slightly lipemic
L	Lipemic
SI	Slightly icteric
I	Icteric
NF	Animal not fasted
U	Unscheduled/moribund bleed
DT/DOT	Animal died on test
DB	Died during bleeding
TJ	Technician judgment to repeat test
TE	Technical error (instrument or technician error that results in unacceptable data, e.g., unacceptable instrument output, sample spilled, entry of invalid data)
RE	Recording error (recorded incorrect data, e.g., wrong number, spelling error, incorrect date)
EE	Entry error (incorrect keyboard entry)
SE	Sampling error
PC	Platelets clumped
PD	Platelets decreased
PI	Platelets increased
PL	Platelets large
PA	Platelets appear adequate
CO	Color interferes with test
HB	Heinz bodies observed
PLASMO	Plasmodium
NO AGG	No aggregation
FR	Fractious
UTD	Unable to determine
NO COAG	No coagulation

Codes for Clinical Pathology (Continued)

RESULTS NOT INCLUDED IN STATISTICAL ANALYSES

Hemolyzed clinical chemistry or coagulation samples
 Samples from animals at unscheduled intervals
 Prothrombin times (PT) greater than 50 seconds
 Activated partial thromboplastin times (PTT) greater than 110 seconds
 Bleed times (BLETIME) greater than 30 minutes

CODES FOR BLOOD CELL MORPHOLOGY

The following scale was used to measure the degree of anisocytosis (ANISO), poikilocytosis (POIK), polychromasia (POLY), hypochromasia (HYPO), and toxic neutrophils (TOXNEUT):

Scale	Degree	Presence
-	Normal for the species	Not present
1	Slight	Rare
2	Moderate	Few
3	Marked	Moderate
4	Not applicable	Many

URINE APPEARANCE

Color			Clarity	Miscellaneous
A Pale	E Amber	I Black	J Clear	M Debris
B Straw	F Brown	P Blue/green	K Hazy	O Feces
C Yellow	G Red	Q Blue	L Cloudy	
D Dark yellow	H Green	R Orange		

Codes for Clinical Pathology (Continued)

URINE CHEMISTRY MULTISTIX® STRIP

Urine Glucose		Urine Ketone		Urine Blood	
-	Negative	-	Negative	-	Negative
+	100 mg/dL	+	5 mg/dL	+	Small
++	250 mg/dL	++	15 mg/dL	++	Moderate
+++	500 mg/dL	+++	40 mg/dL	+++	Large
++++	1,000 mg/dL	++++	80 mg/dL		
+++++	≥2,000 mg/dL	+++++	160 mg/dL		

Urine Urobilinogen		Urine Bilirubin	
-	0.2 mg/dL	-	Negative
+	1 mg/dL	+	Small
++	2 mg/dL	++	Moderate
+++	4 mg/dL	+++	Large
++++	8 mg/dL		

(1 mg = approximately 1 Ehrlich unit)

URINE SEDIMENT

Cells, Crystals, Casts, and Comments		Bacteria
A Amorphous urates	Q Sperm	0 Not present
B Amorphous phosphates	R Fecal contamination	1 Few
C Uric acid	S Pinworm ova found	2 Moderate
D Triple phosphates	T Pinworm larvae found	3 Many
E Calcium oxalate	U Parasite ova found	
F Calcium carbonate		
G Granular casts	0	
H Hyaline casts	1 Not present	
I Cellular casts	2 1-5 per field	
J Waxy casts	3 6-10 per field	
K Unknown crystal	4 11-20 per field	
P Mucous threads	>20 per field	

Abbreviations and Units for Clinical Hematology

Test	Abbreviation (Units)
Red blood cell count	RBC (E6/UL or $\times 10^6/\mu\text{L}$)
Hemoglobin	HGB (G/DL)
Hematocrit	HCT (%)
Mean corpuscular volume	MCV (FL)
Mean corpuscular hemoglobin	MCH (PG)
Mean corpuscular hemoglobin concentration	MCHC (%)
Platelet count	PLT (E3/UL or $\times 10^3/\mu\text{L}$)
Mean platelet volume	MPV (FL)
Reticulocyte count	RETIC (%)
Absolute reticulocyte count	RETIC (E3/UL or $\times 10^3/\mu\text{L}$)
Heinz body count	HEINZ (%)
Erythrocyte sedimentation rate	ESR (MM/HR)
Prothrombin time	PT (SEC)
Activated partial thromboplastin time	PTT (SEC)
Thrombin time	TT (SEC)
Activated coagulation time	ACT (SEC)
Fibrinogen	FBR (MG/DL)
Fibrin/fibrinogen degradation products	FDP (UG/ML)
Platelet aggregation	
Collagen	PAGG/COL (%)
Adenosine diphosphate	PAGG/ADP (%)
Alpha 2-antiplasmin	ANTIPLAS (%)
Bleeding time	BLE TIME (SEC)
Methemoglobin	METHGB (%)
Plasma hemoglobin	PLA HGB (MG/DL)
Myeloid/erythroid ratio	M/E RATIO
Estimated myeloid/erythroid ratio	EST M/E RATIO
White blood cell count	WBC (E3/UL or $\times 10^3/\mu\text{L}$)
Differential blood cell count	
Nucleated red blood cell count	NRBC (/100 WBC)
Corrected white blood cell count	COR WBC (E3/UL or $\times 10^3/\mu\text{L}$)
Segmented neutrophil count	N-SEG (E3/UL or $\times 10^3/\mu\text{L}$) and %
Band neutrophil count	N-BAND (E3/UL or $\times 10^3/\mu\text{L}$) and %
Lymphocyte count	LYMPH (E3/UL or $\times 10^3/\mu\text{L}$) and %
Monocyte count	MONO (E3/UL or $\times 10^3/\mu\text{L}$) and %
Eosinophil count	EOSIN (E3/UL or $\times 10^3/\mu\text{L}$) and %
Basophil count	BASO (E3/UL or $\times 10^3/\mu\text{L}$) and %
Anisocytosis	ANISO (-,1,2,3)
Polychromasia	POLY (-,1,2,3)
Poikilocytosis	POIK (-,1,2,3)

Abbreviations and Units for Clinical Hematology (Continued)

Test	Abbreviation (Units)
Hypochromasia	HYPO (-,1,2,3)
Howell-Jolly bodies	HJBODY (-,1,2,3,4)
Basophilic stippling	BASTIP (-,1,2,3)
Toxic neutrophils	TOXNEUT (-,1,2,3,4)
Atypical lymphocytes	ATYPLYM (-,1,2,3,4)
Aqueous white blood cell count (right eye)	R EYE (WBC/UL)
Aqueous white blood cell count (left eye)	L EYE (WBC/UL)

Abbreviations and Units for Clinical Chemistry

Test	Abbreviation (Units)
Glucose	GLU (MG/DL)
Urea nitrogen	UN (MG/DL)
Urea	UREA (MG/DL)
Creatinine	CREAT (MG/DL)
Total protein	T PRO (G/DL)
Albumin	ALB (G/DL)
Globulin	GLOB (G/DL)
Albumin/globulin ratio	A/G RATIO
Total bilirubin	T BILI (MG/DL)
Direct bilirubin	D BILI (MG/DL)
Indirect bilirubin	I BILI (MG/DL)
Cholesterol	CHOL (MG/DL)
Triglyceride	TRIG (MG/DL)
Urea nitrogen/creatinine ratio	UN/CREAT (RATIO)
Total lipids	T LIPIDS (MG/DL)
Phospholipids	P LIPIDS (MG/DL)
High-density lipoprotein cholesterol	HDL (MG/DL)
Low-density lipoprotein cholesterol	LDL (MG/DL)
Uric acid	UA (MG/DL)
Aspartate aminotransferase	AST/SGOT (IU/L)
Alanine aminotransferase	ALT/SGPT (IU/L)
Alkaline phosphatase	ALK PHOS (IU/L)
Gamma glutamyl transferase	GGT (IU/L)
Sorbitol dehydrogenase	SDH (IU/L)
Lactate dehydrogenase	LDH (IU/L)
Creatine kinase	CK (IU/L)
Amylase	AMYLASE (IU/L)
Lipase	LIPASE (IU/L)
Palmitoyl CoA oxidase	PCOAO (IU/G)
Calcium	CA (MG/DL)
Ionized calcium	ION CA (MG/DL)
Inorganic phosphorus	I PHOS (MG/DL)
Sodium	NA (MMOL/L)
Potassium	K (MMOL/L)
Chloride	CL (MMOL/L)
Magnesium	MG (MEQ/L or MG/DL)
Zinc	ZN (MG/L or PPM)
Strontium	SR (MG/L or PPM)
Iron	FE (UG/DL)

Abbreviations and Units for Clinical Chemistry (Continued)

Test	Abbreviation (Units)
Excess iron	EX FE (UG/DL)
Total iron binding capacity	TIBC (UG/DL)
Unbound iron binding capacity	UIBC (UG/DL)
Percent iron saturation	FE %SAT (%)
Plasma cholinesterase	CHEP (MU/ML)
Red blood cell cholinesterase	CHER (MU/ML)
Brain cholinesterase	CHEB (MU/ML)
Caudate putamen	CAUD PUT (UMOL/G)
Hippocampus	HIPPOCAM (UMOL/G)
Frontal cortex	F CORTEX (UMOL/G)
Cerebellum	CEREBELL (UMOL/G)
Bicarbonate	BICARB (MMOL/L)
Serum hemoglobin	SER HGB (MG/DL)
Serum bile acids	SBA (UMOL/L or MG/DL)
Fecal bile acids	FBA (UG/ML)
Average fecal weight	FCC WGT (G)
Fecal bile acids (calculation)	FBA (MG/Day)
Osmolality	OSMO (MOSM/KG)
Electrophoresis	
Albumin	E ALB (G/DL)
Alpha-1-globulin	E A-1 (G/DL)
Alpha-2-globulin	E A-2 (G/DL)
Beta globulin	E BETA (G/DL)
Gamma globulin	E GAMMA (G/DL)
High-density lipoprotein	E-HDL (%)
Low-density lipoprotein	E-LDL (%)
Very-low-density lipoprotein	E-VLDL (%)
Insulin	INSULIN (UU/ML)
Adrenocorticotrophic hormone	ACTH (PG/ML)
Cortisol	CORTISOL (UG/ML)
Glucagon	GLUCAGON (PG/ML)
Triiodothyronine	T3 (NG/DL)
Thyroxine	T4 (UG/DL)
Creatine kinase isoenzymes	
BB	CK-BB (U/L)
MB	CK-MB (U/L)
MM	CK-MM (U/L)

Abbreviations and Units for Clinical Urinalysis

Test	Abbreviation (Units)
Urine volume	U VOL (ML)
8 hour urine volume	8 HR VOL (ML)
Specific gravity	SP GR
Urine osmolality	U OSMO (MOSM/KG)
Quantitative urinary/cerebrospinal fluid protein	QUAN PRO (MG/DL)
Urine protein excretion	PRO EXC (MG)
Urine chemistry Multistix® strip	
Urine pH	U PH
Urine protein	U PRO (MG/DL)
Urine glucose	U GLU
Urine ketones	U KET
Urine bilirubin	U BILI
Urine blood	U BLOOD
Urine urobilinogen	UROBILI
Urine reducing substances	U RE SUB
Microscopic examination of urine sediment	
Red blood cells per high-power field	RBC (PER HPF)
White blood cells per high-power field	WBC (PER HPF)
Epithelial cells per high-power field	EPITH (PER HPF)
Bacteria per high-power field	BACT (PER HPF)
Casts per low-power field	CASTS (PER LPF)
Crystals per low-power field	CRYSTALS (PER LPF1 or PER LPF2)
Urine appearance	URINE APP1 or URINE APP2
Comments	COMMENTS

Miscellaneous Codes and Abbreviations for Clinical Pathology

Fecal occult blood	Not applicable
Fecal parasite detection	Not applicable
Hemolytic potential	Not applicable

Codes for Anatomic Pathology

Code	Definition
-------------	-------------------

ANIMAL DEATH CODES

T	Terminal sacrifice
U	Recovery sacrifice
D	Found dead
M	Moribund
P/O	Donated
6	Transferred to Covance 6329-268

MACROSCOPIC CODES

EX	Indicates that organ weight is excluded from calculations
NOT TAKEN	Organ weight not taken; explanation given in necropsy notes
MISSING	Organ missing or lost
UNSUITABLE	Organ technically unsuitable for weighing
AUTOLYTIC	Organ autolyzed and could not be weighed
EXCLUDE	Weight was taken, but was excluded from all calculations

MICROSCOPIC CODES

Codes Prefacing Neoplastic Findings

B-	Primary, benign neoplasm
M-	Primary, malignant neoplasm
N-	Metastatic neoplasm
I-	Locally invasive neoplasm
X-	Other neoplasm

Distribution of Findings

Focal
Diffuse
Multifocal

Codes for Anatomic Pathology (Continued)

Code	Definition
Grades for Severity or Amount	
1	Minimal - the least amount of change that can be observed with the light microscope
2	Slight - less than average amount of change, but readily discernible as abnormal
3	Moderate - the average amount of change that is expected for a lesion
4	Moderately severe (marked) - a marked amount of change with possible loss of function of the affected cells or organs
5	Severe - a great amount of change with probable loss of function of the affected cell or organs and frequently involves large areas of the organ

Other Microscopic Codes

TL	Total
P	Finding present
-	Finding not present

TISSUE ABBREVIATIONS

Abbreviation	Definition
LF	Left
RT	Right
LN	Lymph node
GL	Gland
STOMACH, GL	Glandular stomach
STOMACH, NONGL	Nonglandular
SALIV GL, MANDIB	Mandibular salivary gland
LN, ANT MES/PANC	Anterior mesenteric/pancreatic lymph node
AUDITORY SEB GL	Auditory sebaceous gland
LACRIMAL GLAND, EX	Exorbital lacrimal gland
HEMATO NEOPLASIA	Hematopoietic neoplasia
LACRIMAL GL, INT	Internal lacrimal gland
CAVITY, ABDOM	Abdominal cavity
SALIV GL, PAROTID	Parotid salivary gland
LN, TRACHEOBRON	Tracheobronchial lymph node
THYROID/PARA	Thyroid with parathyroid

002690

Figure 1
Mean Body Weight Data (kg) - Males

Covance 6329-223
3M T-6295.7




Figure 2
Mean Body Weight Data (kg) - Females

Covance 6329-223
3M T-6295.7




Table 1

Summary of Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 1

DAYS 1-185		NUMBER OF ANIMALS AFFECTED								
		SEX:	MALE				FEMALE			
CATEGORY	GROUP:	1	2	3	4	1	2	3	4	
KEYWORD	DOSE:	0	0.03	0.15	0.75	0	0.03	0.15	0.75	
QUALIFIER	NUMBER:	6	4	6	6	6	4	6	6	

*** TOP OF LIST ***										

APPEARANCE										
APPEARS DEHYDRATED		0	0	0	1	1	0	0	0	
RECUMBENT		0	0	0	1	0	0	0	0	
BEHAVIOR										
ATAXIC		0	0	0	1	0	0	0	0	
HYPOACTIVE		0	0	0	2	1	0	0	0	
DISCHARGE										
NASAL										
CLEAR		0	0	0	0	1	0	0	0	
ORAL		0	0	0	0	1	0	0	0	
CLOUDY		0	0	0	0	1	0	0	0	
VOMITUS		0	0	0	0	1	0	0	0	
WHITE IN COLOR		0	0	0	0	0	1	0	0	
CONTAINING FOOD		1	1	3	1	2	0	2	1	
INTACT CAPSULE		0	0	0	0	1	0	0	2	
PARTIAL CAPSULE		0	1	0	3	3	0	0	3	
EXCESSIVE SALIVATION		0	0	0	1	1	0	0	0	
APPEARS TO BE MENSTRUATING		0	0	0	0	4	4	2	4	
DISCHARGE UNKNOWN SOURCE										
FOUND IN PAN										
RED IN COLOR		1	0	0	0	1	0	0	0	

Table 1

Summary of Clinical Observations
Treatment

PAGE: 2

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

DAYS 1-185		NUMBER OF ANIMALS AFFECTED								
		SEX:	MALE				FEMALE			
CATEGORY	KEYWORD	GROUP:	1	2	3	4	1	2	3	4
	QUALIFIER	DOSE:	0	0.03	0.15	0.75	0	0.03	0.15	0.75
		NUMBER:	6	4	6	6	6	4	6	6

EXCRETION										
	DISCOLORED FECES									
	BLACK IN COLOR		0	0	0	1	0	0	0	0
	RED IN COLOR		0	0	0	0	1	0	0	3
	YELLOW IN COLOR		0	0	0	0	0	0	0	1
	DISCOLORED URINE									
	GREEN IN COLOR		0	0	0	0	0	0	0	1
	RED IN COLOR		0	0	1	0	0	0	0	0
	FEW FECES		0	0	0	2	0	2	3	5
	LIQUID FECES		1	1	0	1	2	0	0	2
	MUCOID FECES		0	0	0	2	1	0	0	2
	NO FECES		0	0	0	2	0	1	1	1
	NON-FORMED FECES		3	2	1	1	2	1	0	2
	SMALL FECES		0	0	0	0	0	0	0	1
EYES										
	CONSTRICTED PUPIL									
	EYES		0	0	0	1	0	0	0	0
RESPIRATION										
	LABORED		0	0	0	2	0	0	0	0
SKIN & PELAGE										
	ALOPECIA									
	DORSAL		0	0	0	0	0	0	0	1
	DORSAL-THORACIC		0	0	0	0	0	0	0	1

Table 1

Summary of Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 3

DAYS 1-185

NUMBER OF ANIMALS AFFECTED

CATEGORY KEYWORD QUALIFIER	SEX: -----MALE-----				-----FEMALE-----			
	GROUP: 1	2	3	4	1	2	3	4
	DOSE: 0	0.03	0.15	0.75	0	0.03	0.15	0.75
NUMBER:	6	4	6	6	6	4	6	6

SKIN & PELAGE

ALOPECIA

DORSAL-THORACIC-LEFT

FEET

HEAD-ENTIRE

HEAD-CRANIAL

HEAD-MAXILLARY-LEFT

HEAD-MAXILLARY-RIGHT

LIMB-HIND-LEFT

LIMBS-ALL

LIMBS-FRONT

LIMBS-HIND

TAIL

BROKEN SKIN

HAND-LEFT

DIGIT(S)-FRONT-LEFT

HEAD-CRANIAL

HEAD-MAXILLARY-LEFT

HEAD-MAXILLARY-RIGHT

MOUTH

PERI-ORBITAL-LEFT

PERI-ORBITAL-RIGHT

TAIL

TAIL-DISTAL

COLD TO TOUCH

BODY-ENTIRE

0	0	0	0	0	0	0	0	1
0	0	0	0	0	1	0	0	0
0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	2
0	0	0	0	0	0	0	0	1
0	0	0	0	0	1	0	0	0
0	0	0	0	0	1	0	0	1
0	0	0	0	0	1	0	0	0
0	0	0	0	0	0	1	0	0
0	0	0	0	0	0	1	0	0
0	0	0	0	0	1	0	0	0
0	0	0	0	0	1	1	0	1
0	1	0	0	0	0	2	1	0
1	0	1	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0
0	0	0	1	0	0	0	0	0

Table 1

Summary of Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 4

DAYS 1-185

NUMBER OF ANIMALS AFFECTED

CATEGORY KEYWORD QUALIFIER	SEX:	MALE				FEMALE			
	GROUP:	1	2	3	4	1	2	3	4
	DOSE:	0	0.03	0.15	0.75	0	0.03	0.15	0.75
NUMBER:	6	4	6	6	6	4	6	6	

SKIN & PELAGE									
PALE SKIN									
HEAD-ENTIRE									
GUMS		0	0	0	0	0	0	0	1
RED SKIN		0	0	0	1	0	0	0	0
LIMB-FRONT-RIGHT									
SCAB(S)		0	0	0	0	1	0	0	0
HEAD-MAXILLARY-LEFT		0	0	0	0	0	1	0	0
LIMB-FRONT-LEFT		0	0	0	0	1	0	0	0
LIMB-FRONT-RIGHT		0	0	0	0	1	0	0	0
BRUISED SKIN		0	0	0	0	1	0	0	0
PERI-ORBITAL-LEFT		0	0	0	0	0	0	0	1
QUALITATIVE FOOD CONSUMPTION									
LOW									
*** END OF LIST ***		3	3	6	6	5	3	6	6

002696

Table 2

Summary of Clinical Observations
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 1

DAYS 186-365		NUMBER OF ANIMALS AFFECTED							
CATEGORY KEYWORD QUALIFIER	SEX:	MALE				FEMALE			
	GROUP:	1	2	3	4	1	2	3	4
	DOSE:	0	0.03	0.15	0.75	0	0.03	0.15	0.75
	NUMBER:	2	0	2	2	2	0	2	2
*** TOP OF LIST ***									
DISCHARGE									
APPEARS TO BE MENSTRUATING		0	0	0	0	1	0	1	1
EXCRETION									
FEW FECES		0	0	0	0	0	0	1	0
LIQUID FECES		0	0	0	0	1	0	0	0
NON-FORMED FECES		0	0	1	0	0	0	0	1
SKIN & PELAGE									
ALOPECIA									
FEET		0	0	0	0	1	0	0	0
TAIL		0	0	0	0	1	0	0	0
BROKEN SKIN									
DIGIT(S)-FRONT-LEFT		1	0	0	0	0	0	0	0
QUALITATIVE FOOD CONSUMPTION									
LOW		1	0	2	1	2	0	2	2
*** END OF LIST ***									

002697

Table 3

Summary of Clinical Observations
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 1

DAYS 368-558		NUMBER OF ANIMALS AFFECTED								
		SEX:	MALE				FEMALE			
CATEGORY	GROUP:	1	2	3	4	1	2	3	4	
KEYWORD	DOSE:	0	0.03	0.15	0.75	0	0.03	0.15	0.75	
QUALIFIER	NUMBER:	2	0	2	2	2	0	2	2	
*** TOP OF LIST ***										
APPEARANCE										
SWOLLEN										
HEAD-MAXILLARY-RIGHT		0	0	1	0	0	0	0	0	
DISCHARGE										
VOMITUS										
CONTAINING FOOD		1	0	2	0	1	0	1	0	
APPEARS TO BE MENSTRUATING		0	0	0	0	1	0	0	1	
DISCHARGE UNKNOWN SOURCE										
FOUND IN PAN										
RED IN COLOR		0	0	0	0	0	0	1	1	
EXCRETION										
FEW FECES		0	0	1	0	0	0	2	0	
LIQUID FECES		0	0	0	0	1	0	0	1	
NO FECES		0	0	1	0	0	0	2	0	
NON-FORMED FECES		1	0	1	1	1	0	0	1	
SKIN & PELAGE										
ALOPECIA										
LIMB-HIND-RIGHT		0	0	0	0	1	0	0	0	

002698

Covance 6329-223
3M T-6295.7

Table 3

Summary of Clinical Observations
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 2

DAYS 368-558

NUMBER OF ANIMALS AFFECTED

CATEGORY KEYWORD QUALIFIER	SEX:	-----MALE-----				-----FEMALE-----			
	GROUP:	1	2	3	4	1	2	3	4
	DOSE:	0	0.03	0.15	0.75	0	0.03	0.15	0.75
	NUMBER:	2	0	2	2	2	0	2	2

QUALITATIVE FOOD CONSUMPTION

LOW	1	0	2	1	2	0	2	2
NONE	0	0	0	0	0	0	2	0

*** END OF LIST ***

002699

Table 4

Summary of Ophthalmic Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 1

WEEK -4		NUMBER OF ANIMALS AFFECTED							
CATEGORY KEYWORD QUALIFIER	SEX:	MALE				FEMALE			
	GROUP:	1	2	3	4	1	2	3	4
	DOSE:	0	0.03	0.15	0.75	0	0.03	0.15	0.75
	NUMBER:	6	4	6	6	6	4	6	6
*** TOP OF LIST ***									
NO VISIBLE LESIONS									
NO VISIBLE LESIONS									
EYE-LEFT									
EYES									
		0	0	0	0	1	0	0	0
		6	4	6	6	5	4	6	6
MISCELLANEOUS OPHTHALMICS									
INCREASED MYELINATION OF OPTIC NERVE									
EYE-RIGHT									
*** END OF LIST ***									
		0	0	0	0	1	0	0	0

002700

Table 4

Summary of Ophthalmic Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 2

WEEK 26

NUMBER OF ANIMALS AFFECTED

CATEGORY KEYWORD QUALIFIER	SEX:	-----MALE-----				-----FEMALE-----			
	GROUP:	1	2	3	4	1	2	3	4
	DOSE:	0	0.03	0.15	0.75	0	0.03	0.15	0.75
NUMBER:	6	4	6	5	6	4	6	6	

*** TOP OF LIST ***									
NO VISIBLE LESIONS									
NO VISIBLE LESIONS									
EYES									
*** END OF LIST ***		6	4	6	5	6	4	6	6

Table 5

Summary of Ophthalmic Observations
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 3

WEEK 52				NUMBER OF ANIMALS AFFECTED								
				SEX:	MALE				FEMALE			
CATEGORY	GROUP:	1	2	3	4	1	2	3	4			
KEYWORD	DOSE:	0	0.03	0.15	0.75	0	0.03	0.15	0.75			
QUALIFIER	NUMBER:	2	0	2	2	2	0	2	2			

*** TOP OF LIST ***												
NO VISIBLE LESIONS												
NO VISIBLE LESIONS												
EYES												
EYE-LEFT												

002702

Table 6

Summary of Body Weight Data (kg)
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 1

WEEK	SEX: GROUP: DOSE: UNITS:	MALE				FEMALE			
		1	2	3	4	1	2	3	4
		0	0.03	0.15	0.75	0	0.03	0.15	0.75
		MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY
-1 ^a	N	6	4	6	6	6	4	6	6
	MEAN	3.2	3.4	3.0	3.3	2.8	3.0	3.0	2.9
	S.D.	0.43	0.73	0.33	0.59	0.33	0.55	0.38	0.54
-1 ^b	N	6	4	6	6	6	4	6	6
	MEAN	3.3	3.4	3.1	3.4	2.8	3.0	3.0	2.9
	S.D.	0.45	0.65	0.34	0.55	0.29	0.55	0.41	0.52
1	N	6	4	6	6	6	4	6	6
	MEAN	3.3	3.4	3.1	3.4	2.8	3.1	3.0	2.9
	S.D.	0.45	0.70	0.35	0.55	0.29	0.60	0.41	0.52
2	N	6	4	6	6	6	4	6	6
	CAM	3.3	3.2	3.3	3.2	2.9	3.0	3.0	2.9
	MEAN	3.3	3.4	3.1	3.4	2.8	3.1	3.0	2.9
	S.D.	0.44	0.64	0.34	0.62	0.26	0.59	0.43	0.49
3	N	6	4	6	6	6	4	6	6
	CAM	3.3	3.3	3.3	3.3	2.9	3.0	2.9	2.9
	MEAN	3.3	3.4	3.2	3.4	2.8	3.1	3.0	2.9
	S.D.	0.41	0.68	0.32	0.59	0.38	0.59	0.43	0.49
4	N	6	4	6	6	6	4	6	6
	CAM	3.3	3.4	3.4	3.4	3.0	3.0	2.9	2.9
	MEAN	3.3	3.5	3.2	3.5	2.9	3.1	3.0	2.9
	S.D.	0.38	0.64	0.34	0.58	0.34	0.65	0.43	0.52
5	N	6	4	6	6	6	4	6	6
	CAM	3.3	3.4	3.4	3.4	2.9	2.9	2.9	2.8
	MEAN	3.3	3.5	3.2	3.5	2.8	3.1	3.0	2.8
	S.D.	0.39	0.64	0.34	0.60	0.35	0.60	0.44	0.55

a Day -7.
b Day -1.

002703

Table 6

Summary of Body Weight Data (kg)
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 2

WEEK	SEX: GROUP: DOSE: UNITS:	MALE				FEMALE			
		1	2	3	4	1	2	3	4
		0 MG/KG/DAY	0.03 MG/KG/DAY	0.15 MG/KG/DAY	0.75 MG/KG/DAY	0 MG/KG/DAY	0.03 MG/KG/DAY	0.15 MG/KG/DAY	0.75 MG/KG/DAY
6	N	6	4	6	6	6	4	6	6
	CAM	3.3	3.4	3.4	3.4	2.9	3.0	2.9	2.8
	MEAN	3.3	3.5	3.2	3.5	2.8	3.1	3.0	2.8
	S.D.	0.41	0.63	0.34	0.60	0.36	0.57	0.48	0.55
7	N	6	4	6	6	6	4	6	6
	CAM	3.3	3.4	3.4	3.4	3.0	3.0	2.9	2.9
	MEAN	3.3	3.5	3.2	3.5	2.8	3.1	3.0	2.9
	S.D.	0.42	0.64	0.33	0.63	0.38	0.61	0.47	0.48
8	N	6	4	6	6	6	4	6	6
	CAM	3.3	3.4	3.3	3.4	2.9	3.0	2.9	2.9
	MEAN	3.3	3.5	3.2	3.5	2.8	3.1	3.0	2.9
	S.D.	0.39	0.64	0.30	0.65	0.39	0.61	0.47	0.50
9	N	6	4	6	6	6	4	6	6
	CAM	3.4	3.4	3.4	3.5	3.0	3.0	3.0	2.9
	MEAN	3.4	3.6	3.2	3.5	2.9	3.2	3.0	2.9
	S.D.	0.43	0.60	0.29	0.65	0.40	0.66	0.46	0.55
10	N	6	4	6	6	6	4	6	6
	CAM	3.4	3.4	3.3	3.4	3.0	3.0	3.0	2.9
	MEAN	3.4	3.6	3.2	3.5	2.9	3.1	3.0	2.9
	S.D.	0.43	0.60	0.33	0.65	0.36	0.62	0.44	0.55
11	N	6	4	6	6	6	4	6	6
	CAM	3.4	3.5	3.4	3.5	3.0	3.0	3.0	2.8*
	MEAN	3.4	3.7	3.2	3.6	2.9	3.1	3.0	2.8
	S.D.	0.46	0.68	0.33	0.66	0.35	0.60	0.46	0.51
12	N	6	4	6	6	6	4	6	6
	CAM	3.4	3.5	3.4	3.4	3.1	3.0	3.0	2.9*
	MEAN	3.4	3.7	3.2	3.5	3.0	3.2	3.0	2.9
	S.D.	0.47	0.68	0.29	0.65	0.37	0.59	0.48	0.50

Table 6

Summary of Body Weight Data (kg)
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 3

WEEK	SEX: GROUP: DOSE: UNITS:	MALE				FEMALE			
		1	2	3	4	1	2	3	4
		0 MG/KG/DAY	0.03 MG/KG/DAY	0.15 MG/KG/DAY	0.75 MG/KG/DAY	0 MG/KG/DAY	0.03 MG/KG/DAY	0.15 MG/KG/DAY	0.75 MG/KG/DAY
13	N	6	4	6	6	6	4	6	6
	CAM	3.5	3.6	3.4	3.5	3.1	3.1	3.0	2.8*
	MEAN	3.5	3.7	3.3	3.6	3.0	3.2	3.1	2.8
	S.D.	0.46	0.65	0.27	0.66	0.36	0.62	0.47	0.46
14	N	6	4	6	6	6	4	6	6
	CAM	3.5	3.5	3.4	3.4	3.0	3.1	3.0	2.8*
	MEAN	3.5	3.7	3.2	3.5	2.9	3.2	3.1	2.8
	S.D.	0.44	0.57	0.31	0.67	0.37	0.62	0.48	0.44
15	N	6	4	6	6	6	4	6	6
	CAM	3.5	3.6	3.4	3.4	3.0	3.1	3.1	2.8*
	MEAN	3.5	3.7	3.3	3.5	2.9	3.2	3.1	2.8
	S.D.	0.46	0.61	0.30	0.68	0.38	0.63	0.49	0.38
16	N	6	4	6	6	6	4	6	6
	CAM	3.4	3.6	3.4	3.3	3.0	3.1	3.0	2.8*
	MEAN	3.4	3.8	3.3	3.4	2.9	3.2	3.1	2.8
	S.D.	0.48	0.60	0.27	0.71	0.34	0.63	0.45	0.38
17	N	6	4	6	6	6	4	6	6
	CAM	3.5	3.7	3.4	3.4	3.1	3.1	3.1	2.9
	MEAN	3.5	3.8	3.3	3.5	3.0	3.2	3.1	2.9
	S.D.	0.49	0.56	0.26	0.75	0.37	0.70	0.45	0.44
18	N	6	4	6	6	6	4	6	6
	CAM	3.5	3.6	3.4	3.4	3.1	3.1	3.0	2.9
	MEAN	3.5	3.7	3.3	3.5	2.9	3.2	3.1	2.9
	S.D.	0.50	0.56	0.23	0.69	0.38	0.68	0.48	0.45
19	N	6	4	6	6	6	4	6	6
	CAM	3.6	3.7	3.5	3.4	3.1	3.1	3.1	2.9*
	MEAN	3.6	3.8	3.3	3.5	3.0	3.3	3.1	2.9
	S.D.	0.50	0.59	0.19	0.73	0.34	0.66	0.50	0.39

002705

Table 6

Summary of Body Weight Data (kg)
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 4

WEEK	SEX: GROUP: DOSE: UNITS:	MALE				FEMALE			
		1 0	2 0.03	3 0.15	4 0.75	1 0	2 0.03	3 0.15	4 0.75
		MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY
20	N	6	4	6	6	6	4	6	6
	CAM	3.5	3.7	3.5	3.3	3.1	3.1	3.1	2.8*
	MEAN	3.5	3.8	3.3	3.4	3.0	3.2	3.2	2.8
	S.D.	0.53	0.59	0.22	0.73	0.34	0.67	0.48	0.38
21	N	6	4	6	6	6	4	6	6
	CAM	3.6	3.6	3.4	3.2	3.0	3.1	3.0	2.8*
	MEAN	3.6	3.8	3.2	3.3	2.9	3.2	3.0	2.8
	S.D.	0.55	0.64	0.26	0.72	0.34	0.70	0.46	0.33
22	N	6	4	6	6	6	4	6	6
	CAM	3.6	3.7	3.5	3.3	3.1	3.1	3.1	2.8*
	MEAN	3.6	3.8	3.3	3.4	3.0	3.2	3.1	2.8
	S.D.	0.56	0.56	0.25	0.62	0.37	0.68	0.44	0.31
23	N	6	4	6	6	6	4	6	6
	CAM	3.6	3.7	3.5	3.2*	3.0	3.1	3.1	2.8*
	MEAN	3.6	3.8	3.3	3.3	2.9	3.2	3.1	2.8
	S.D.	0.58	0.55	0.25	0.67	0.31	0.68	0.46	0.35
24	N	6	4	6	5	6	4	6	6
	CAM	3.6	3.7	3.5	3.3	3.0	3.1	3.1	2.8
	MEAN	3.6	3.9	3.3	3.4	2.9	3.2	3.1	2.8
	S.D.	0.63	0.60	0.26	0.69	0.32	0.76	0.46	0.32
25	N	6	4	6	5	6	4	6	6
	CAM	3.7	3.8	3.6	3.3	3.1	3.2	3.1	2.8*
	MEAN	3.7	3.9	3.4	3.5	3.0	3.3	3.2	2.8
	S.D.	0.61	0.55	0.20	0.72	0.37	0.76	0.46	0.31
26	N	6	4	6	5	6	4	6	6
	CAM	3.7	3.8	3.5	3.3	3.1	3.1	3.1	2.8*
	MEAN	3.7	3.9	3.3	3.4	3.0	3.2	3.1	2.8
	S.D.	0.67	0.55	0.20	0.73	0.37	0.79	0.46	0.35

002706

Table 6

Summary of Body Weight Data (kg)
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 5

WEEK	SEX: GROUP: DOSE: UNITS:	MALE				FEMALE			
		1	2	3	4	1	2	3	4
		0	0.03	0.15	0.75	0	0.03	0.15	0.75
		MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY
27	N	6	4	6	4	6	4	6	6
	CAM	3.7	3.8	3.5	3.0*	3.1	3.1	3.0	2.8*
	MEAN	3.7	3.9	3.3	3.2	3.0	3.2	3.1	2.8
	S.D.	0.68	0.56	0.26	0.83	0.35	0.72	0.51	0.37

002707

Table 7

Summary of Body Weight Data (kg)
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 1

WEEK	SEX: GROUP: DOSE: UNITS:	MALE			FEMALE		
		1 0 MG/KG/DAY	3 0.15 MG/KG/DAY	4 0.75 MG/KG/DAY	1 0 MG/KG/DAY	3 0.15 MG/KG/DAY	4 0.75 MG/KG/DAY
28	N	2	2	2	2	2	2
	MEAN	3.5	3.1	3.1	2.7	3.3	2.6
	S.D.	0.42	0.21	0.57	0.35	0.71	0.14
29	N	2	2	2	2	2	2
	MEAN	3.6	3.1	3.3	2.7	3.4	2.7
	S.D.	0.42	0.28	0.64	0.42	0.71	0.14
30	N	2	2	2	2	2	2
	MEAN	3.6	3.0	3.3	2.7	3.3	2.7
	S.D.	0.42	0.28	0.57	0.35	0.71	0.14
31	N	2	2	2	2	2	2
	MEAN	3.7	3.1	3.5	2.7	3.4	2.8
	S.D.	0.42	0.35	0.71	0.42	0.78	0.21
32	N	2	2	2	2	2	2
	MEAN	3.8	3.2	3.6	2.8	3.5	2.9
	S.D.	0.42	0.35	0.85	0.35	0.78	0.35
33	N	2	2	2	2	2	2
	MEAN	3.8	3.2	3.7	2.8	3.5	3.0
	S.D.	0.42	0.28	0.78	0.42	0.78	0.28
34	N	2	2	2	2	2	2
	MEAN	3.8	3.2	3.8	2.8	3.4	3.0
	S.D.	0.42	0.21	0.99	0.35	0.85	0.28

Table 7

Summary of Body Weight Data (kg)
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 2

WEEK	SEX: GROUP: DOSE: UNITS:	MALE			FEMALE		
		1 0	3 0.15	4 0.75	1 0	3 0.15	4 0.75
		MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY
35	N	2	2	2	2	2	2
	MEAN	3.8	3.1	3.7	2.8	3.5	3.0
	S.D.	0.35	0.28	0.99	0.35	0.92	0.21
36	N	2	2	2	2	2	2
	MEAN	3.8	3.3	3.9	2.8	3.6	3.1
	S.D.	0.42	0.21	1.06	0.35	0.92	0.35
37	N	2	2	2	2	2	2
	MEAN	3.9	3.2	3.9	2.8	3.6	3.1
	S.D.	0.42	0.28	1.06	0.42	0.78	0.35
38	N	2	2	2	2	2	2
	MEAN	3.9	3.2	3.8	2.8	3.5	3.0
	S.D.	0.42	0.21	0.99	0.35	0.85	0.42
39	N	2	2	2	2	2	2
	MEAN	3.9	3.1	3.7	2.7	3.5	2.9
	S.D.	0.35	0.28	0.99	0.42	0.85	0.35
40	N	2	2	2	2	2	2
	MEAN	3.9	3.1	3.7	2.6	3.4	3.0
	S.D.	0.35	0.28	1.06	0.42	0.85	0.21
41	N	2	2	2	2	2	2
	MEAN	4.0	3.3	3.8	2.8	3.6	3.1
	S.D.	0.42	0.21	0.99	0.42	0.85	0.35

Table 7

Summary of Body Weight Data (kg)
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 3

WEEK	SEX: GROUP: DOSE: UNITS:	MALE			FEMALE		
		1	3	4	1	3	4
		0	0.15	0.75	0	0.15	0.75
		MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY
42	N	2	2	2	2	2	2
	MEAN	4.0	3.2	3.8	2.7	3.6	2.9
	S.D.	0.28	0.21	1.06	0.42	0.78	0.35
43	N	2	2	2	2	2	2
	MEAN	4.0	3.2	3.8	2.7	3.6	3.0
	S.D.	0.28	0.21	0.99	0.42	0.78	0.42
44	N	2	2	2	2	2	2
	MEAN	4.2	3.3	3.8	2.8	3.7	3.1
	S.D.	0.28	0.21	0.92	0.35	0.92	0.35
45	N	2	2	2	2	2	2
	MEAN	4.3	3.3	3.8	2.8	3.7	3.1
	S.D.	0.21	0.28	0.92	0.42	0.78	0.35
46	N	2	2	2	2	2	2
	MEAN	4.4	3.3	4.0	2.8	3.6	3.1
	S.D.	0.21	0.28	0.92	0.42	0.85	0.42
47	N	2	2	2	2	2	2
	MEAN	4.2	3.2	3.8	2.7	3.6	3.1
	S.D.	0.14	0.28	0.85	0.42	0.92	0.49
48	N	2	2	2	2	2	2
	MEAN	4.2	3.2	3.9	2.6	3.6	3.1
	S.D.	0.18	0.25	0.78	0.35	0.94	0.49

002710

Table 7
Summary of Body Weight Data (kg)
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 4

WEEK	SEX: GROUP: DOSE: UNITS:	MALE			FEMALE		
		1 0	3 0.15	4 0.75	1 0	3 0.15	4 0.75
		MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY
49	N	2	2	2	2	2	2
	MEAN	4.3	3.3	4.1	2.8	3.7	3.2
	S.D.	0.21	0.21	0.78	0.35	0.92	0.35
50	N	2	2	2	2	2	2
	MEAN	4.3	3.2	4.0	2.7	3.6	3.1
	S.D.	0.21	0.28	0.71	0.35	0.92	0.35
51	N	2	2	2	2	2	2
	MEAN	4.3	3.3	4.1	2.7	3.7	3.1
	S.D.	0.21	0.21	0.64	0.42	0.92	0.35
52	N	2	2	2	2	2	2
	MEAN	4.4	3.3	4.1	2.7	3.7	3.1
	S.D.	0.21	0.21	0.57	0.28	0.92	0.42
53	N	2	2	2	2	2	2
	MEAN	4.4	3.2	4.1	2.6	3.6	3.1
	S.D.	0.21	0.28	0.49	0.28	0.99	0.49
54	N	2	2	2	2	2	2
	MEAN	4.4	3.3	4.2	2.6	3.6	3.1
	S.D.	0.28	0.21	0.49	0.28	0.92	0.49
55	N	2	2	2	2	2	2
	MEAN	4.5	3.3	4.1	2.7	3.5	3.1
	S.D.	0.28	0.21	0.42	0.35	0.99	0.64

002711

Table 7

Summary of Body Weight Data (kg)
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 5

WEEK	SEX: GROUP: DOSE: UNITS:	MALE			FEMALE		
		1 0 MG/KG/DAY	3 0.15 MG/KG/DAY	4 0.75 MG/KG/DAY	1 0 MG/KG/DAY	3 0.15 MG/KG/DAY	4 0.75 MG/KG/DAY
56	N	2	2	2	2	2	2
	MEAN	4.4	3.3	4.1	2.7	3.6	3.1
	S.D.	0.35	0.14	0.35	0.35	0.92	0.57
57	N	2	2	2	2	2	2
	MEAN	4.4	3.3	4.0	2.6	3.6	3.0
	S.D.	0.35	0.21	0.28	0.35	0.92	0.57
58	N	2	2	2	2	2	2
	MEAN	4.4	3.3	4.1	2.7	3.6	3.0
	S.D.	0.35	0.14	0.35	0.28	0.78	0.57
59	N	2	2	2	2	2	2
	MEAN	4.4	3.3	4.1	2.7	3.5	3.0
	S.D.	0.42	0.14	0.42	0.35	0.71	0.57
60	N	2	2	2	2	2	2
	MEAN	4.6	3.4	4.3	2.8	3.6	3.2
	S.D.	0.49	0.14	0.42	0.35	0.85	0.49
61	N	2	2	2	2	2	2
	MEAN	4.6	3.4	4.3	2.7	3.6	3.2
	S.D.	0.49	0.14	0.42	0.28	0.78	0.49
62	N	2	2	2	2	2	2
	MEAN	4.5	3.5	4.4	2.7	3.6	3.2
	S.D.	0.49	0.21	0.49	0.42	0.78	0.57

002712

Table 7

Summary of Body Weight Data (kg)
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 6

WEEK	SEX: GROUP: DOSE: UNITS:	MALE			FEMALE		
		1	3	4	1	3	4
		0	0.15	0.75	0	0.15	0.75
		MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY
63	N	2	2	2	2	2	2
	MEAN	4.5	3.4	4.4	2.8	3.6	3.2
	S.D.	0.57	0.14	0.42	0.35	0.71	0.57
64	N	2	2	2	2	2	2
	MEAN	4.4	3.4	4.5	2.7	3.6	3.2
	S.D.	0.64	0.14	0.21	0.35	0.78	0.64
65	N	2	2	2	2	2	2
	MEAN	4.4	3.4	4.4	2.7	3.5	3.1
	S.D.	0.57	0.07	0.21	0.35	0.78	0.57
66	N	2	2	2	2	2	2
	MEAN	4.4	3.3	4.3	2.6	3.5	3.1
	S.D.	0.64	0.14	0.28	0.28	0.78	0.57
67	N	2	2	2	2	2	2
	MEAN	4.5	3.4	4.4	2.7	3.6	3.2
	S.D.	0.57	0.14	0.21	0.35	0.71	0.57
68	N	2	2	2	2	2	2
	MEAN	4.6	3.5	4.5	2.7	3.6	3.2
	S.D.	0.57	0.21	0.21	0.35	0.78	0.64
69	N	2	2	2	2	2	2
	MEAN	4.7	3.5	4.5	2.7	3.6	3.2
	S.D.	0.57	0.14	0.28	0.28	0.85	0.71

002713

Table 7

Summary of Body Weight Data (kg)
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 7

WEEK	SEX: GROUP: DOSE: UNITS:	-----MALE-----			-----FEMALE-----		
		1	3	4	1	3	4
		0	0.15	0.75	0	0.15	0.75
		MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY	MG/KG/DAY
70	N	2	2	2	2	2	2
	MEAN	4.6	3.5	4.5	2.7	3.6	3.2
	S.D.	0.57	0.07	0.21	0.35	0.78	0.71
71	N	2	2	2	2	2	2
	MEAN	4.7	3.5	4.4	2.7	3.6	3.2
	S.D.	0.64	0.07	0.28	0.35	0.85	0.71
72	N	2	2	2	2	2	2
	MEAN	4.8	3.6	4.5	2.7	3.7	3.3
	S.D.	0.71	0.07	0.21	0.35	0.78	0.78
73	N	2	2	2	2	2	2
	MEAN	4.7	3.5	4.4	2.7	3.6	3.2
	S.D.	0.71	0.07	0.21	0.35	0.85	0.78
74	N	2	2	2	2	2	2
	MEAN	4.8	3.6	4.5	2.7	3.7	3.3
	S.D.	0.85	0.07	0.21	0.42	0.78	0.78
75	N	2	2	2	2	2	2
	MEAN	4.8	3.6	4.5	2.7	3.7	3.3
	S.D.	0.78	0.07	0.21	0.28	0.78	0.78
76	N	2	2	2	2	2	2
	MEAN	4.8	3.6	4.5	2.7	3.7	3.4
	S.D.	0.85	0.07	0.21	0.28	0.71	0.78

002714

Table 7
Summary of Body Weight Data (kg)
Recovery

PAGE: 8

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

WEEK	SEX: GROUP: DOSE: UNITS:	MALE			FEMALE		
		1 0 MG/KG/DAY	3 0.15 MG/KG/DAY	4 0.75 MG/KG/DAY	1 0 MG/KG/DAY	3 0.15 MG/KG/DAY	4 0.75 MG/KG/DAY
77	N	2	2	2	2	2	2
	MEAN	4.7	3.5	4.4	2.7	3.7	3.3
	S.D.	0.85	0.07	0.14	0.35	0.78	0.78
78	N	2	2	2	2	2	2
	MEAN	4.7	3.5	4.4	2.6	3.5	3.2
	S.D.	0.92	0.07	0.14	0.28	0.85	0.85
79	N	2	2	2	2	2	2
	MEAN	4.7	3.5	4.4	2.7	3.6	3.3
	S.D.	0.92	0.00	0.07	0.35	0.85	0.85
80	N	0	2	0	0	2	0
	MEAN		3.3			3.4	
	S.D.		0.21			0.85	

002715

Table 8
Summary of Clinical Hematology Data

Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		RBC X10 ⁶ /μL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 ³ /μL	RETIC %	RETIC X10 ³ /μL
0	MEAN	6.45	12.2	41.2	63.9	19.0	29.8	530	.3	20
	S.D.	.275	.36	1.30	2.32	.87	.56	125.0	.19	12.6
	N	6	6	6	6	6	6	6	6	6
0.03	MEAN	6.99	12.4	42.9	61.5	17.8	29.0	574	.4	24
	S.D.	.688	.46	2.95	2.51	1.13	1.34	210.3	.24	14.9
	N	4	4	4	4	4	4	4	4	4
0.15	MEAN	6.76	12.6	42.9	63.5	18.7	29.5	493	.5	32
	S.D.	.315	.41	1.88	2.38	.76	.41	109.0	.53	34.5
	N	6	6	6	6	6	6	6	6	6
0.75	MEAN	6.88	12.5	43.1	62.8	18.2	29.0	415	.5	33
	S.D.	.575	.82	2.06	3.44	1.01	.61	202.6	.47	27.8
	N	6	6	6	6	6	6	6	6	6

Table 8
Summary of Clinical Hematology Data

Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	WBC $\times 10^3/\mu\text{L}$	N-SEG $\times 10^3/\mu\text{L}$	LYMPH $\times 10^3/\mu\text{L}$	MONO $\times 10^3/\mu\text{L}$	EOSIN $\times 10^3/\mu\text{L}$	BASO $\times 10^3/\mu\text{L}$	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0											
MEAN	8.6	3.9	4.0	.6	.1	.0	44	47	7	1	0
S.D.	1.76	1.28	.90	.24	.08	.05	8.9	9.2	2.4	.8	.5
N	6	6	6	6	6	6	6	6	6	6	6
0.03											
MEAN	11.0	5.2	4.6	.8	.2	.0	47	43	8	2	0
S.D.	1.00	1.88	1.05	.48	.17	.00	15.2	9.4	4.4	1.3	.0
N	4	4	4	4	4	4	4	4	4	4	4
0.15											
MEAN	11.9	6.6	4.1	.9	.2	.0	54	36	8	2	0
S.D.	1.95	2.42	1.14	.25	.31	.04	13.4	10.9	3.3	2.1	.4
N	6	6	6	6	6	6	6	6	6	6	6
0.75											
MEAN	9.4	3.7	4.3	1.1	.2	.1	39	46	12	2	1
S.D.	2.53	1.40	1.25	.53	.25	.08	10.9	9.5	3.3	3.3	.8
N	6	6	6	6	6	6	6	6	6	6	6

Table 8
Summary of Clinical Hematology Data

Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	RBC X10 ⁶ /μL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 ³ /μL	RETIC %	RETIC X10 ³ /μL	
0	MEAN S.D. N	6.09 .681 6	12.0 .97 6	39.3 3.93 6	64.7 4.51 6	19.7 1.81 6	30.4 .87 6	539 79.5 6	.6 .46 6	35 24.2 6
0.03	MEAN S.D. N	6.31 .522 4	11.5 1.06 4	39.5 3.26 4	62.7 4.49 4	18.3 1.73 4	29.2 .71 4	482 72.4 4	.4 .31 4	27 17.1 4
0.15	MEAN S.D. N	6.54 .320 6	12.0 .49 6	40.1 1.97 6	61.4 2.79 6	18.3 .50 6	29.8 .68 6	481 100.9 6	.4 .26 6	29 16.2 6
0.75	MEAN S.D. N	6.50 .195 6	12.1 .50 6	41.5 1.68 6	63.9 1.14 6	18.7 .50 6	29.2 .52 6	435 108.9 6	.2 .18 6	16 11.4 6

Table 8
Summary of Clinical Hematology Data

Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		WBC X10 ³ /μL	N-SEG X10 ³ /μL	LYMPH X10 ³ /μL	MONO X10 ³ /μL	EOSIN X10 ³ /μL	BASO X10 ³ /μL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
-----		-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----
0												
	MEAN	10.2	4.6	4.5	.8	.3	.0	45	44	7	3	0
	S.D.	2.52	1.14	1.36	.24	.28	.05	8.3	7.6	1.2	2.1	.5
	N	6	6	6	6	6	6	6	6	6	6	6
0.03												
	MEAN	8.7	5.0	2.9	.6	.1	.0	55	35	8	2	0
	S.D.	2.41	2.52	.79	.17	.05	.05	14.3	11.6	2.8	.6	.5
	N	4	4	4	4	4	4	4	4	4	4	4
0.15												
	MEAN	10.1	5.1	3.8	.8	.3	.0	48	40	9	3	0
	S.D.	2.94	2.81	.40	.20	.27	.04	13.0	8.4	3.8	3.0	.4
	N	6	6	6	6	6	6	6	6	6	6	6
0.75												
	MEAN	9.0	4.8	3.2	.8	.1	.0	54	35	9	1	0
	S.D.	3.08	1.70	1.66	.32	.18	.04	10.7	9.7	4.2	1.4	.4
	N	6	6	6	6	6	6	6	6	6	6	6

002719

Table 9
Summary of Clinical Hematology Data

Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	RBC X10 ⁶ /μL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 ³ /μL	RETIC %	RETIC X10 ³ /μL	
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	
0	MEAN S.D. N	6.45 .221 6	12.4 .55 6	40.6 1.44 6	63.0 2.74 6	19.1 .97 6	30.4 .58 6	486 117.8 6	.2 .16 6	14 10.4 6
0.03	MEAN S.D. N	6.86 .501 4	12.5 .38 4	42.4 3.93 4	61.9 4.61 4	18.2 1.17 4	29.5 1.69 4	532 146.1 4	.4 .35 4	29 23.8 4
0.15	MEAN S.D. N	6.66 .385 6	12.5 .27 6	41.2 .76 6	62.0 2.96 6	18.8 1.06 6	30.3 .53 6	476 59.6 6	.4 .14 6	25 10.5 6
0.75	MEAN S.D. N	6.53 .431 6	11.8 .57 6	40.2 1.74 6	61.7 2.63 6	18.1 .85 6	29.4 .57 6	383 164.3 6	.4 .10 6	25 5.9 6

Table 9
Summary of Clinical Hematology Data

Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	WBC X10 ³ /μL	N-SEG X10 ³ /μL	LYMPH X10 ³ /μL	MONO X10 ³ /μL	EOSIN X10 ³ /μL	BASO X10 ³ /μL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0	MEAN S.D. N	7.6 1.98 6	3.9 2.01 6	3.1 .67 6	.5 .31 6	.0 .08 6	50 14.4 6	43 12.8 6	7 3.4 6	1 1.2 6	0 .8 6
0.03	MEAN S.D. N	10.8 1.89 4	6.3 2.40 4	3.7 1.26 4	.5 .17 4	.2 .05 4	58 15.9 4	36 14.2 4	5 1.7 4	2 .5 4	0 .0 4
0.15	MEAN S.D. N	10.0 2.06 6	6.0 2.23 6	3.2 .91 6	.6 .24 6	.2 .32 6	58 12.5 6	33 10.4 6	6 3.6 6	2 2.3 6	0 .4 6
0.75	MEAN S.D. N	10.3 4.16 6	6.6 3.69 6	2.9 .52 6	.6 .18 6	.1 .11 6	62 9.8 6	30 7.5 6	7 2.7 6	1 1.2 6	1 .4 6

Table 9
Summary of Clinical Hematology Data

Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		RBC X10 ⁶ /μL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 ³ /μL	RETIC %	RETIC X10 ³ /μL
0	MEAN	6.41	12.2	40.5	63.1	19.0	30.2	538	.3	22
	S.D.	.351	.69	2.42	2.31	.83	.29	84.2	.16	10.8
	N	6	6	6	6	6	6	6	6	6
0.03	MEAN	6.60	11.8	40.6	61.8	18.1	29.2	417	.3	18
	S.D.	.664	.97	2.92	6.28	1.80	.48	23.6	.28	15.6
	N	4	4	4	4	4	4	4	4	4
0.15	MEAN	6.55	11.8	39.7	60.7	18.1	29.7	431	.3	19
	S.D.	.343	.41	1.06	2.68	.75	.29	85.3	.12	8.0
	N	6	6	6	6	6	6	6	6	6
0.75	MEAN	6.21	11.6	39.1	63.0	18.6	29.6	469	.3	20
	S.D.	.280	.38	1.96	1.48	.44	.89	95.4	.23	13.1
	N	6	6	6	6	6	6	6	6	6

Table 9
Summary of Clinical Hematology Data

Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		WBC X10 ³ /μL	N-SEG X10 ³ /μL	LYMPH X10 ³ /μL	MONO X10 ³ /μL	EOSIN X10 ³ /μL	BASO X10 ³ /μL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%

0												
	MEAN	12.7	7.8	3.6	1.1	.3	.0	59	30	8	2	0
	S.D.	4.75	3.77	1.59	.67	.26	.08	18.2	16.2	2.3	1.7	.5
	N	6	6	6	6	6	6	6	6	6	6	6
0.03												
	MEAN	9.6	5.7	2.8	.8	.2	.0	60	29	8	3	0
	S.D.	2.37	1.90	.82	.24	.17	.05	10.6	6.0	2.1	2.2	1.0
	N	4	4	4	4	4	4	4	4	4	4	4
0.15												
	MEAN	9.1	5.5	2.9	.5	.2	.0	56	35	6	3	0
	S.D.	2.66	2.48	.72	.13	.18	.00	17.0	15.7	1.6	1.2	.0
	N	6	6	6	6	6	6	6	6	6	6	6
0.75												
	MEAN	8.9	5.3	2.9	.6	.1	.0	56	35	7	1	0
	S.D.	2.85	3.19	1.06	.20	.08	.00	15.1	13.7	2.7	1.2	.4
	N	6	6	6	6	6	6	6	6	6	6	6

Table 10
Summary of Clinical Hematology Data

Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		RBC X10 ⁶ /μL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 ³ /μL	RETIC %	RETIC X10 ³ /μL
0	MEAN	6.49	12.5	41.1	63.3	19.2	30.4	522	.3	18
	S.D.	.292	.53	1.78	3.03	.95	.84	126.9	.27	17.3
	N	6	6	6	6	6	6	6	6	6
0.03	MEAN	6.84	12.4	41.4	60.7	18.2	29.9	536	.4	25
	S.D.	.437	.33	1.36	2.92	.91	.62	152.1	.45	29.6
	N	4	4	4	4	4	4	4	4	4
0.15	MEAN	6.60	12.5	40.7	61.7	18.9	30.6	504	.3	21
	S.D.	.315	.52	1.42	2.56	.87	.50	97.3	.25	17.3
	N	6	6	6	6	6	6	6	6	6
0.75	MEAN	6.73	12.3	41.2	61.3	18.3	29.8	437	.3	19
	S.D.	.516	.75	2.31	3.02	.72	.52	217.8	.19	12.6
	N	6	6	6	6	6	6	6	6	6

002724

Table 10
Summary of Clinical Hematology Data

Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	WBC X10 ³ /μL	N-SEG X10 ³ /μL	LYMPH X10 ³ /μL	MONO X10 ³ /μL	EOSIN X10 ³ /μL	BASO X10 ³ /μL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%	
0	MEAN S.D. N	7.3 .81 6	3.0 .68 6	3.5 .87 6	.6 .26 6	.1 .08 6	.0 .05 6	42 10.5 6	48 8.2 6	8 3.2 6	2 .8 6	0 .8 6
0.03	MEAN S.D. N	10.5 1.79 4	6.1 * 1.51 4	3.4 .82 4	.8 .38 4	.2 .05 4	.0 .00 4	58 9.5 4	32 6.5 4	8 3.5 4	2 .5 4	0 .0 4
0.15	MEAN S.D. N	11.8 * 3.02 6	7.0 * 3.16 6	3.9 1.18 6	.7 .40 6	.2 .13 6	.0 .05 6	56 16.3 6	35 14.6 6	7 4.0 6	2 .8 6	0 .4 6
0.75	MEAN S.D. N	9.6 2.97 6	5.3 2.52 6	3.4 .52 6	.6 .23 6	.2 .21 6	.0 .08 6	52 10.0 6	38 11.2 6	6 1.0 6	2 2.1 6	0 .5 6

002725

Table 10
Summary of Clinical Hematology Data

Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		RBC $\times 10^6/\mu\text{L}$	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $\times 10^3/\mu\text{L}$	RETIC %	RETIC $\times 10^3/\mu\text{L}$
0	MEAN	6.23	12.3	40.2	64.9	19.9	30.6	572	.4	27
	S.D.	.766	.66	3.27	4.33	1.87	1.01	74.6	.22	11.2
	N	6	6	6	6	6	6	6	6	6
0.03	MEAN	6.48	12.0	40.2	62.4	18.5	29.7	462	.4	28
	S.D.	.593	.83	2.39	6.25	2.02	.67	83.8	.37	24.1
	N	4	4	4	4	4	4	4	4	4
0.15	MEAN	7.00	12.8	42.3	60.5	18.3	30.3	436	.4	24
	S.D.	1.068	2.17	6.70	2.31	.76	.57	133.5	.28	18.2
	N	6	6	6	6	6	6	6	6	6
0.75	MEAN	6.28	11.8	40.2	64.0	18.9	29.5	504	.3	17
	S.D.	.397	.29	1.96	1.27	.72	.70	148.3	.25	14.9
	N	6	6	6	6	6	6	6	6	6

Table 10
Summary of Clinical Hematology Data

Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		WBC X10 ³ /μL	N-SEG X10 ³ /μL	LYMPH X10 ³ /μL	MONO X10 ³ /μL	EOSIN X10 ³ /μL	BASO X10 ³ /μL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%

0	MEAN	11.1	5.8	4.3	.6	.3	.0	50	40	6	2	0
	S.D.	2.93	3.08	1.73	.48	.18	.08	17.6	15.9	4.6	2.0	.5
	N	6	6	6	6	6	6	6	6	6	6	6
0.03	MEAN	8.7	4.4	3.4	.6	.2	.0	50	40	8	2	0
	S.D.	1.42	1.59	1.16	.13	.17	.06	14.5	14.9	.5	1.7	.6
	N	4	4	4	4	4	4	4	4	4	4	4
0.15	MEAN	8.8	4.3	3.6	.5	.3	.0	48	42	6	3	0
	S.D.	1.78	1.75	.93	.16	.15	.05	13.1	11.2	2.9	1.6	.5
	N	6	6	6	6	6	6	6	6	6	6	6
0.75	MEAN	9.3	5.6	3.0	.6	.1	.0	56	36	7	1	0
	S.D.	4.59	3.89	1.07	.40	.08	.05	13.2	14.2	2.7	1.0	.4
	N	6	6	6	6	6	6	6	6	6	6	6

Table 11
Summary of Clinical Hematology Data

Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		RBC X10 ⁶ /μL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 ³ /μL	RETIC %	RETIC X10 ³ /μL
0	MEAN	6.43	12.4	40.3	62.8	19.3	30.7	490	.3	21
	S.D.	.314	.53	2.17	3.11	1.06	1.00	124.3	.26	16.4
	N	6	6	6	6	6	6	6	6	6
0.03	MEAN	7.00	12.7	42.5	61.0	18.2	29.8	512	.7	47
	S.D.	.628	.55	1.78	3.13	1.02	.43	208.8	.54	33.7
	N	4	4	4	4	4	4	4	4	4
0.15	MEAN	6.50	12.3	40.4	62.1	19.0	30.6	496	.5	33
	S.D.	.295	.16	.93	2.53	.76	.49	82.6	.54	32.0
	N	6	6	6	6	6	6	6	6	6
0.75	MEAN	6.66	12.2	41.0	61.6	18.2	29.6 *	431	.4	26
	S.D.	.488	.81	2.23	2.47	.77	.65	198.6	.19	11.8
	N	6	6	6	6	6	6	6	6	6

002728

Table 11
Summary of Clinical Hematology Data

Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	WBC X10 ³ /μL	N-SEG X10 ³ /μL	LYMPH X10 ³ /μL	MONO X10 ³ /μL	EOSIN X10 ³ /μL	BASO X10 ³ /μL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%	
0	MEAN S.D. N	6.7 1.99 6	2.4 .64 6	3.7 1.24 6	.4 .16 6	.1 .08 6	.0 .04 6	37 4.1 6	55 2.8 6	6 2.1 6	2 1.3 6	0 .5 6
0.03	MEAN S.D. N	8.5 1.60 4	4.4 1.79 4	3.3 .88 4	.6 .00 4	.2 .10 4	.0 .00 4	50 13.9 4	40 * 12.6 4	7 1.0 4	2 1.4 4	0 .0 4
0.15	MEAN S.D. N	10.3 3.21 6	5.7 * 1.85 6	3.7 1.61 6	.6 .27 6	.2 .18 6	.0 .05 6	56 * 9.3 6	36 * 8.4 6	7 2.6 6	2 1.8 6	0 .5 6
0.75	MEAN S.D. N	9.4 2.56 6	5.1 * 2.06 6	3.5 .71 6	.6 .28 6	.2 .16 6	.0 .05 6	52 * 9.8 6	38 * 7.8 6	6 3.2 6	2 1.6 6	0 .5 6

Table 11
Summary of Clinical Hematology Data

Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		RBC X10 ⁶ /μL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 ³ /μL	RETIC %	RETIC X10 ³ /μL
0	MEAN	6.31	12.3	40.3	64.1	19.5	30.4	562	.3	20
	S.D.	.565	.77	2.79	3.90	1.21	.33	83.6	.08	5.7
	N	6	6	6	6	6	6	6	6	6
0.03	MEAN	6.20	11.7	39.2	63.6	19.0	29.9	467	.5	30
	S.D.	.472	.97	2.18	7.19	2.78	1.21	33.4	.13	7.9
	N	4	4	4	4	4	4	4	4	4
0.15	MEAN	6.50	12.0	39.4	60.7	18.6	30.6	442	.2	14
	S.D.	.298	.42	1.44	2.35	.78	.57	78.9	.10	6.6
	N	6	6	6	6	6	6	6	6	6
0.75	MEAN	6.32	11.9	40.3	63.8	18.8	29.4	504	.2	12
	S.D.	.210	.36	1.54	1.37	.51	.54	124.1	.15	9.4
	N	6	6	6	6	6	6	6	6	6

Table 11
Summary of Clinical Hematology Data
Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		WBC X10 ³ /μL	N-SEG X10 ³ /μL	LYMPH X10 ³ /μL	MONO X10 ³ /μL	EOSIN X10 ³ /μL	BASO X10 ³ /μL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0	MEAN	9.4	4.0	4.3	.6	.4	.0	44	46	7	4	0
	S.D.	1.89	1.31	1.59	.10	.27	.04	12.5	10.3	1.0	2.4	.5
	N	6	6	6	6	6	6	6	6	6	6	6
0.03	MEAN	8.7	4.4	3.2	.8	.2	.0	48	39	9	2	0
	S.D.	3.42	2.74	1.22	.41	.10	.10	13.2	11.2	3.9	1.0	1.0
	N	4	4	4	4	4	4	4	4	4	4	4
0.15	MEAN	8.7	4.4	3.4	.6	.2	.0	51	39	7	2	0
	S.D.	1.25	.82	.69	.18	.12	.00	6.4	6.6	1.5	1.0	.4
	N	6	6	6	6	6	6	6	6	6	6	6
0.75	MEAN	8.1	4.6	2.9	.6	.1	.0	56	36	7	2	0
	S.D.	1.91	1.75	1.02	.26	.08	.05	13.1	10.4	3.5	1.2	.5
	N	6	6	6	6	6	6	6	6	6	6	6

002731

Table 12
Summary of Clinical Hematology Data

Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		RBC X10 ⁶ /μL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 ³ /μL	RETIC %	RETIC X10 ³ /μL
0	MEAN	6.68	12.5	40.9	61.4	18.7	30.6	464	.2	17
	S.D.	.421	.54	2.28	2.74	.88	.62	131.6	.26	18.7
	N	6	6	6	6	6	6	6	6	6
0.03	MEAN	7.08	12.6	41.7	59.0	17.8	30.2	483	.2	14
	S.D.	.513	.46	1.91	2.70	.90	.82	167.0	.16	10.7
	N	4	4	4	4	4	4	4	4	4
0.15	MEAN	6.78	12.6	41.3	61.1	18.7	30.6	519	.4	30
	S.D.	.479	.38	1.47	2.82	.95	.40	146.4	.15	9.6
	N	6	6	6	6	6	6	6	6	6
0.75	MEAN	6.65	11.8	40.0	60.3	17.7	29.4 *	398	.6	39
	S.D.	.641	1.04	3.32	2.43	.87	.50	199.1	.48	30.3
	N	6	6	6	6	6	6	6	6	6

002732

Table 12
Summary of Clinical Hematology Data

Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		WBC X10 ³ /μL	N-SEG X10 ³ /μL	LYMPH X10 ³ /μL	MONO X10 ³ /μL	EOSIN X10 ³ /μL	BASO X10 ³ /μL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0	MEAN	7.3	2.7	3.9	.5	.2	.0	35	54	7	2	0
	S.D.	2.62	1.64	.91	.29	.15	.08	8.6	8.3	2.9	2.7	.8
	N	6	6	6	6	6	6	6	6	6	6	6
0.03	MEAN	9.9	5.6	3.5	.6	.2	.0	56	36	6	2	0
	S.D.	1.04	1.70	1.08	.22	.08	.00	15.0	13.5	1.8	1.0	.0
	N	4	4	4	4	4	4	4	4	4	4	4
0.15	MEAN	10.1	5.2	4.0	.7	.3	.0	49	42	7	2	0
	S.D.	2.44	2.81	1.17	.12	.21	.05	18.2	16.4	2.5	2.0	.5
	N	6	6	6	6	6	6	6	6	6	6	6
0.75	MEAN	9.0	4.3	3.6	.8	.2	.0	45	44	9	2	0
	S.D.	2.87	3.02	1.08	.44	.18	.04	16.3	16.1	3.7	1.5	.4
	N	6	6	6	6	6	6	6	6	6	6	6

002733

Table 12
Summary of Clinical Hematology Data

Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		RBC $\times 10^6/\mu\text{L}$	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $\times 10^3/\mu\text{L}$	RETIC %	RETIC $\times 10^3/\mu\text{L}$
0	MEAN	6.60	12.4	40.6	61.7	18.8	30.6	520	.4	24
	S.D.	.559	.85	2.96	2.45	.77	.46	73.1	.31	20.5
	N	6	6	6	6	6	6	6	6	6
0.03	MEAN	6.66	12.0	40.4	61.1	18.1	29.6 *	387	.6	39
	S.D.	.641	.92	2.44	6.52	2.23	.82	52.3	.61	33.6
	N	4	4	4	4	4	4	4	4	4
0.15	MEAN	6.66	12.1	39.9	59.8	18.2	30.4	460	.3	20
	S.D.	.257	.45	1.31	2.12	.64	.18	83.7	.24	16.1
	N	6	6	6	6	6	6	6	6	6
0.75	MEAN	6.33	11.7	39.5	62.4	18.5	29.7 *	492	.2	11
	S.D.	.288	.44	1.98	2.21	.70	.65	144.0	.12	7.9
	N	6	6	6	6	6	6	6	6	6

Table 12
Summary of Clinical Hematology Data

Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		WBC X10 ³ /μL	N-SEG X10 ³ /μL	LYMPH X10 ³ /μL	MONO X10 ³ /μL	EOSIN X10 ³ /μL	BASO X10 ³ /μL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0	MEAN	9.7	4.6	4.1	.8	.2	.0	44	44	9	3	0
	S.D.	2.44	2.98	1.08	.30	.18	.05	18.7	15.9	3.9	2.3	.5
	N	6	6	6	6	6	6	6	6	6	6	6
0.03	MEAN	9.3	5.0	2.9	1.1	.2	.1	50	36	11	2	1
	S.D.	4.49	3.55	.62	1.00	.14	.08	12.6	15.6	3.6	1.4	1.0
	N	4	4	4	4	4	4	4	4	4	4	4
0.15	MEAN	8.1	3.7	3.4	.6	.3	.0	44	44	8	3	0
	S.D.	2.23	1.98	.96	.14	.15	.00	14.5	14.4	2.2	1.9	.5
	N	6	6	6	6	6	6	6	6	6	6	6
0.75	MEAN	9.5	4.4	4.0	.8	.2	.0	46	43	9	2	1
	S.D.	2.99	2.33	2.19	.35	.13	.05	17.4	16.5	4.3	.9	.5
	N	6	6	6	6	6	6	6	6	6	6	6

002735

Covance 6329-223
3M T-6295.7

Table 13
Summary of Clinical Hematology Data

Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

CHLORZEXALONE MONKEYS										
DOSE mg/kg/day		RBC X10 ⁶ /μL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 ³ /μL	RETIC %	RETIC X10 ³ /μL
0	MEAN	6.60	12.5	41.1	62.3	18.9	30.3	467	.2	11
	S.D.	.354	.50	2.07	2.53	.78	.79	90.4	.08	5.8
	N	6	6	6	6	6	6	6	6	6
0.03	MEAN	6.96	12.5	42.1	60.7	18.0	29.6	466	.2	12
	S.D.	.627	.45	1.79	2.81	1.05	.88	183.0	.17	11.8
	N	4	4	4	4	4	4	4	4	4
0.15	MEAN	6.65	12.5	41.0	61.8	18.8	30.4	470	.3	19
	S.D.	.372	.31	1.15	2.76	.80	.30	63.1	.04	3.2
	N	6	6	6	6	6	6	6	6	6
0.75	MEAN	6.32	11.4 *	38.8	61.5	17.9	29.2 *	401	.2	12
	S.D.	.387	.83	2.45	2.72	1.08	.48	228.0	.24	14.6
	N	4	4	4	4	4	4	4	4	4

Table 13
Summary of Clinical Hematology Data

Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		RBC X10 ⁶ /μL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 ³ /μL	RETIC %	RETIC X10 ³ /μL
0	MEAN	6.40	12.1	40.8	63.8	19.0	29.7	484	.4	27
	S.D.	.461	.64	2.67	2.49	.70	.65	100.1	.24	15.1
	N	6	6	6	6	6	6	6	6	6
0.03	MEAN	6.15	11.2	38.3	62.3	18.2	29.3	429	.2	13
	S.D.	.798	1.66	5.67	6.23	2.09	.94	54.7	.13	5.8
	N	4	4	4	4	4	4	4	4	4
0.15	MEAN	6.57	11.9	39.9	60.8	18.2	29.9	412	.2	12
	S.D.	.256	.62	1.78	2.50	.73	.35	74.4	.12	7.5
	N	6	6	6	6	6	6	6	6	6
0.75	MEAN	6.09	11.3	39.2	64.3	18.6	29.0	490	.2	12
	S.D.	.360	.37	2.17	1.46	.71	1.09	166.0	.21	12.7
	N	6	6	6	6	6	6	6	6	6

002737

Table 13
Summary of Clinical Hematology Data

Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		WBC $\times 10^3/\mu\text{L}$	N-SEG $\times 10^3/\mu\text{L}$	LYMPH $\times 10^3/\mu\text{L}$	MONO $\times 10^3/\mu\text{L}$	EOSIN $\times 10^3/\mu\text{L}$	BASO $\times 10^3/\mu\text{L}$	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0	MEAN	10.4	5.0	4.3	.7	.2	.0	46	44	8	3	0
	S.D.	3.59	3.41	1.96	.15	.19	.05	17.5	15.1	3.4	1.8	.5
	N	6	6	6	6	6	6	6	6	6	6	6
0.03	MEAN	8.5	4.3	3.2	.7	.3	.0	50	38	8	3	0
	S.D.	2.05	1.45	.57	.32	.15	.10	9.3	10.1	2.2	1.4	1.0
	N	4	4	4	4	4	4	4	4	4	4	4
0.15	MEAN	9.2	4.5	3.8	.6	.3	.0	48	43	6	3	0
	S.D.	1.61	1.73	.61	.18	.24	.04	13.0	11.7	2.1	2.0	.8
	N	6	6	6	6	6	6	6	6	6	6	6
0.75	MEAN	9.7	4.2	4.6	.7	.2	.1	46	45	8	2	0
	S.D.	2.73	1.10	2.70	.32	.08	.05	14.6	14.8	3.4	.8	.5
	N	6	6	6	6	6	6	6	6	6	6	6

Table 14
Summary of Clinical Hematology Data

Males Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day		RBC $\times 10^6/\mu\text{L}$	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $\times 10^3/\mu\text{L}$	RETIC %	RETIC $\times 10^3/\mu\text{L}$
0	MEAN	6.26	12.0	38.1	60.8	19.1	31.5	483	.4	22
	S.D.	.007	.21	.28	.35	.28	.35	193.7	.07	4.2
	N	2	2	2	2	2	2	2	2	2
0.15	MEAN	6.49	12.7	40.7	62.8	19.6	31.2	488	.3	20
	S.D.	.057	.42	1.27	1.34	.42	.07	118.8	.14	9.2
	N	2	2	2	2	2	2	2	2	2
0.75	MEAN	5.90	11.6	37.8	64.0	19.5	30.6	469	.4	26
	S.D.	.042	.07	.64	.71	.07	.42	22.6	.21	12.0
	N	2	2	2	2	2	2	2	2	2

002739

Table 14
Summary of Clinical Hematology Data

Males Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	WBC X10 ³ /μL	N-SEG X10 ³ /μL	LYMPH X10 ³ /μL	MONO X10 ³ /μL	EOSIN X10 ³ /μL	BASO X10 ³ /μL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%	
0	MEAN S.D. N	7.3 1.70 2	2.4 .14 2	4.0 1.63 2	.6 .14 2	.2 .07 2	.0 .00 2	34 4.9 2	54 9.9 2	9 4.2 2	3 .0 2	1 .0 2
0.15	MEAN S.D. N	11.5 3.82 2	6.2 2.05 2	4.5 2.12 2	.6 .21 2	.3 .14 2	.0 .00 2	53 .0 2	38 5.7 2	6 3.5 2	3 2.8 2	0 .0 2
0.75	MEAN S.D. N	11.8 4.10 2	6.0 2.69 2	4.4 .78 2	.9 .57 2	.4 .07 2	.0 .00 2	50 5.7 2	39 7.1 2	7 2.8 2	4 .0 2	0 .0 2

Table 14
Summary of Clinical Hematology Data
Females Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	RBC X10 ⁶ /μL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 ³ /μL	RETIC %	RETIC X10 ³ /μL	
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	
0	MEAN S.D. N	5.94 .714 2	11.8 1.20 2	36.9 4.81 2	62.0 .64 2	19.8 .35 2	32.0 .99 2	468 111.0 2	.3 .28 2	18 19.1 2
0.15	MEAN S.D. N	6.14 .092 2	11.9 .14 2	37.6 .57 2	61.4 .07 2	19.5 .07 2	31.7 .14 2	408 37.5 2	.4 .21 2	22 13.4 2
0.75	MEAN S.D. N	6.42 .417 2	12.0 .28 2	40.2 2.90 2	62.6 .57 2	18.7 .71 2	29.8 1.34 2	444 160.5 2	.5 .28 2	32 20.5 2

Table 14
Summary of Clinical Hematology Data
Females Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	WBC X10 ³ /μL	N-SEG X10 ³ /μL	LYMPH X10 ³ /μL	MONO X10 ³ /μL	EOSIN X10 ³ /μL	BASO X10 ³ /μL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0											
MEAN	8.2	4.6	2.8	.6	.1	.0	55	36	8	2	0
S.D.	2.76	2.12	.35	.28	.00	.00	7.1	7.8	.7	.7	.0
N	2	2	2	2	2	2	2	2	2	2	2
0.15											
MEAN	7.6	2.6	4.0	.6	.4	.0	34	53	8	4	1
S.D.	1.06	1.20	.35	.14	.21	.07	10.6	11.3	2.8	2.1	.0
N	2	2	2	2	2	2	2	2	2	2	2
0.75											
MEAN	9.3	2.6	5.8	.6	.2	.0	28	64	6	3	0
S.D.	2.26	.64	1.20	.35	.07	.07	.7	2.1	2.8	1.4	.7
N	2	2	2	2	2	2	2	2	2	2	2

Table 15
Summary of Clinical Hematology Data

Males Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day		RBC $\times 10^6/\mu\text{L}$	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $\times 10^3/\mu\text{L}$	RETIC %	RETIC $\times 10^3/\mu\text{L}$
0	MEAN	6.52	12.6	39.2	60.2	19.4	32.1	556	.2	13
	S.D.	.332	.57	1.91	.07	.07	.00	181.7	.14	8.5
	N	2	2	2	2	2	2	2	2	2
0.15	MEAN	6.78	13.3	42.2	62.1	19.6	31.6	493	.2	10
	S.D.	.049	.00	.49	1.13	.28	.21	36.8	.07	4.9
	N	2	2	2	2	2	2	2	2	2
0.75	MEAN	6.20	11.9	39.5	63.7	19.2	30.1	532	.6	36
	S.D.	.191	.71	.64	.99	.49	1.27	43.1	.28	16.3
	N	2	2	2	2	2	2	2	2	2

Covance 6329-223
3M T-6295.7

Table 15
Summary of Clinical Hematology Data

Males Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	WBC X10 ³ /μL	N-SEG X10 ³ /μL	LYMPH X10 ³ /μL	MONO X10 ³ /μL	EOSIN X10 ³ /μL	BASO X10 ³ /μL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%	
0	MEAN S.D. N	10.0 2.90 2	3.2 .78 2	6.1 2.12 2	.4 .07 2	.3 .00 2	.0 .00 2	32 1.4 2	60 3.5 2	4 .7 2	3 1.4 2	0 .0 2
0.15	MEAN S.D. N	11.4 1.13 2	5.5 .42 2	4.8 1.06 2	.6 .28 2	.4 .07 2	.0 .00 2	48 .7 2	42 4.9 2	6 3.5 2	3 1.4 2	0 .0 2
0.75	MEAN S.D. N	13.4 5.52 2	5.6 2.83 2	6.2 1.77 2	1.0 .64 2	.5 .14 2	.1 .00 2	41 4.2 2	47 5.7 2	8 2.1 2	4 .0 2	1 .0 2

002744

Table 15
Summary of Clinical Hematology Data

Females Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day		RBC X10 ⁶ /μL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 ³ /μL	RETIC %	RETIC X10 ³ /μL
0										
	MEAN	6.22	12.3	38.4	61.6	19.8	32.1	519	.2	16
	S.D.	.735	1.41	4.95	.71	.07	.49	82.0	.07	6.4
	N	2	2	2	2	2	2	2	2	2
0.15										
	MEAN	6.74	12.7	40.7	60.3	18.8	31.2	425	.2	10
	S.D.	.191	.28	.35	1.27	.14	.28	48.1	.07	4.2
	N	2	2	2	2	2	2	2	2	2
0.75										
	MEAN	6.70	12.5	42.0	62.7	18.7	29.8	440	.2	17
	S.D.	.453	.42	2.97	.21	.71	1.20	149.2	.21	15.6
	N	2	2	2	2	2	2	2	2	2

002745

Table 15
Summary of Clinical Hematology Data

Females Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	WBC X10 ³ /μL	N-SEG X10 ³ /μL	LYMPH X10 ³ /μL	MONO X10 ³ /μL	EOSIN X10 ³ /μL	BASO X10 ³ /μL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0											
MEAN	11.4	7.1	3.4	.7	.2	.0	62	30	6	2	0
S.D.	1.56	2.83	.85	.28	.14	.00	16.3	12.0	2.8	1.4	.0
N	2	2	2	2	2	2	2	2	2	2	2
0.15											
MEAN	9.4	3.0	5.0	1.0	.4	.0	28	56	11	4	0
S.D.	2.76	2.97	.49	.00	.28	.07	23.3	21.9	2.8	1.4	.7
N	2	2	2	2	2	2	2	2	2	2	2
0.75											
MEAN	11.0	3.6	6.2	.9	.2	.1	32	56	8	2	1
S.D.	.21	1.34	1.77	.28	.07	.00	12.7	14.8	2.8	1.4	.0
N	2	2	2	2	2	2	2	2	2	2	2

002746

Table 16
Summary of Clinical Hematology Data

Males Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day		RBC $\times 10^6/\mu\text{L}$	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $\times 10^3/\mu\text{L}$	RETIC %	RETIC $\times 10^3/\mu\text{L}$
0	MEAN	6.72	12.6	40.1	59.6	18.8	31.6	504	.2	17
	S.D.	.198	.49	2.12	1.34	.21	.42	228.4	.07	4.2
	N	2	2	2	2	2	2	2	2	2
0.15	MEAN	6.78	13.1	41.8	61.5	19.3	31.4	496	.4	27
	S.D.	.106	.42	2.05	1.98	.28	.49	105.4	.28	19.8
	N	2	2	2	2	2	2	2	2	2
0.75	MEAN	6.45	12.3	41.0	63.6	19.1	29.9	519	.3	19
	S.D.	.495	1.13	2.40	1.13	.21	.92	60.8	.14	7.1
	N	2	2	2	2	2	2	2	2	2

Table 16
Summary of Clinical Hematology Data
Males Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	WBC X10 ³ /μL	N-SEG X10 ³ /μL	LYMPH X10 ³ /μL	MONO X10 ³ /μL	EOSIN X10 ³ /μL	BASO X10 ³ /μL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0											
MEAN	7.3	2.6	3.7	.8	.1	.0	36	51	10	2	1
S.D.	.42	.28	.42	.35	.00	.07	6.4	2.8	4.2	.0	.0
N	2	2	2	2	2	2	2	2	2	2	2
0.15											
MEAN	11.5	6.6	4.1	.4	.2	.0	58	36	4	2	0
S.D.	2.26	2.05	.14	.21	.14	.00	6.4	8.5	1.4	1.4	.0
N	2	2	2	2	2	2	2	2	2	2	2
0.75											
MEAN	11.6	5.0	5.4	.8	.4	.0	40	49	7	2	1
S.D.	6.22	3.54	1.91	.49	.21	.07	9.2	9.9	.0	.7	.0
N	2	2	2	2	2	2	2	2	2	2	2

002748

Table 16
Summary of Clinical Hematology Data
Females Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day		RBC X10 ⁶ /μL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 ³ /μL	RETIC %	RETIC X10 ³ /μL
0	MEAN	6.32	12.3	39.0	61.7	19.5	31.6	510	.4	25
	S.D.	1.082	1.70	7.57	1.41	.71	1.91	135.8	.00	4.2
	N	2	2	2	2	2	2	2	2	2
0.15	MEAN	6.64	12.6	40.1	60.3	18.8	31.2	423	.4	23
	S.D.	.071	.07	.57	.21	.35	.64	5.7	.21	14.1
	N	2	2	2	2	2	2	2	2	2
0.75	MEAN	6.78	12.5	40.8	60.2	18.4	30.5	440	.4	30
	S.D.	.410	.35	1.56	1.34	.64	.35	137.9	.35	21.9
	N	2	2	2	2	2	2	2	2	2

Table 16
Summary of Clinical Hematology Data

Females Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	WBC X10 ³ /μL	N-SEG X10 ³ /μL	LYMPH X10 ³ /μL	MONO X10 ³ /μL	EOSIN X10 ³ /μL	BASO X10 ³ /μL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%	
0	MEAN S.D. N	8.8 1.13 2	5.4 2.40 2	2.8 .99 2	.5 .14 2	.0 .07 2	.0 .00 2	60 19.1 2	33 15.6 2	6 2.8 2	1 1.4 2	0 .7 2
0.15	MEAN S.D. N	7.8 2.26 2	2.9 2.55 2	3.8 .64 2	.6 .07 2	.4 .28 2	.0 .07 2	34 22.6 2	53 22.6 2	8 .7 2	5 1.4 2	1 .0 2
0.75	MEAN S.D. N	9.2 2.26 2	4.4 .92 2	4.1 .85 2	.6 .49 2	.1 .00 2	.0 .07 2	48 2.1 2	44 2.1 2	6 3.5 2	0 .7 2	0 .7 2

Table 17
Summary of Clinical Hematology Data
Males Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day		RBC X10 ⁶ /μL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 ³ /μL	RETIC %	RETIC X10 ³ /μL
0	MEAN	6.72	12.6	40.2	59.8	18.8	31.5	544	.3	20
	S.D.	.078	.35	.57	.07	.28	.42	209.3	.28	19.1
	N	2	2	2	2	2	2	2	2	2
0.15	MEAN	6.80	13.2	41.9	61.5	19.4	31.5	491	.2	10
	S.D.	.127	.57	1.84	1.48	.49	.07	80.6	.07	4.9
	N	2	2	2	2	2	2	2	2	2
0.75	MEAN	6.22	11.8	38.1	61.1	19.0	31.0	572	.6	34
	S.D.	.198	.42	.35	1.34	.07	.71	43.1	.35	21.2
	N	2	2	2	2	2	2	2	2	2

002751

Table 17
Summary of Clinical Hematology Data

Males Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	WBC X10 ³ /μL	N-SEG X10 ³ /μL	LYMPH X10 ³ /μL	MONO X10 ³ /μL	EOSIN X10 ³ /μL	BASO X10 ³ /μL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%	
0	MEAN S.D. N	8.6 1.20 2	4.2 .21 2	3.8 1.06 2	.6 .07 2	.1 .00 2	.0 .00 2	48 4.9 2	42 6.4 2	8 1.4 2	1 .0 2	0 .0 2
0.15	MEAN S.D. N	12.8 1.34 2	8.2 2.05 2	3.7 .99 2	.8 .21 2	.2 .07 2	.0 .00 2	64 9.2 2	30 10.6 2	6 1.4 2	1 .0 2	0 .0 2
0.75	MEAN S.D. N	9.0 3.75 2	4.0 2.55 2	3.9 1.13 2	.8 .07 2	.2 .07 2	.0 .07 2	43 9.9 2	44 6.4 2	10 2.8 2	2 1.4 2	0 .7 2

Table 17
Summary of Clinical Hematology Data

Females Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day		RBC $\times 10^6/\mu\text{L}$	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT $\times 10^3/\mu\text{L}$	RETIC %	RETIC $\times 10^3/\mu\text{L}$
0	MEAN	6.32	12.3	38.4	60.8	19.6	32.1	546	.2	13
	S.D.	.403	.64	2.12	.49	.21	.07	140.0	.14	9.9
	N	2	2	2	2	2	2	2	2	2
0.15	MEAN	6.76	12.5	40.1	59.4	18.4	31.0	472	.4	24
	S.D.	.071	.00	.78	1.77	.21	.64	103.9	.07	4.9
	N	2	2	2	2	2	2	2	2	2
0.75	MEAN	6.50	11.9	39.5	60.8	18.4	30.2	424	.3	20
	S.D.	.431	.42	2.19	.64	.64	.71	155.6	.28	19.8
	N	2	2	2	2	2	2	2	2	2

002753

Table 17
Summary of Clinical Hematology Data

Females Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day		WBC X10 ³ /μL	N-SEG X10 ³ /μL	LYMPH X10 ³ /μL	MONO X10 ³ /μL	EOSIN X10 ³ /μL	BASO X10 ³ /μL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0	MEAN	11.8	7.2	3.2	1.0	.2	.0	59	30	8	2	0
	S.D.	4.38	3.96	.07	.57	.07	.00	11.3	11.3	2.1	1.4	.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.15	MEAN	9.4	4.2	4.2	.6	.4	.0	42	48	7	4	0
	S.D.	2.83	3.18	.42	.21	.28	.00	21.2	19.1	4.2	1.4	.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.75	MEAN	8.9	2.7	5.6	.6	.2	.0	30	62	6	2	0
	S.D.	1.56	.57	.78	.07	.07	.00	1.4	1.4	.7	.7	.0
	N	2	2	2	2	2	2	2	2	2	2	2

002754

Table 18
Summary of Clinical Hematology Data

Males Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day		RBC X10 ⁶ /μL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 ³ /μL	RETIC %	RETIC X10 ³ /μL
0	MEAN	6.53	12.4	39.5	60.5	19.2	31.6	514	.1	6
	S.D.	.042	.07	.07	.49	.21	.07	179.6	.14	9.2
	N	2	2	2	2	2	2	2	2	2
0.15	MEAN	6.72	13.0	41.2	61.3	19.4	31.7	448	.1	7
	S.D.	.283	.64	2.97	1.91	.28	.57	68.6	.14	9.9
	N	2	2	2	2	2	2	2	2	2
0.75	MEAN	6.23	12.2	38.9	62.5	19.5	31.2	508	.8	46
	S.D.	.198	.21	.28	2.40	.28	.85	17.7	1.06	64.3
	N	2	2	2	2	2	2	2	2	2

002755

Table 18
Summary of Clinical Hematology Data

Males Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	WBC X10 ³ /μL	N-SEG X10 ³ /μL	LYMPH X10 ³ /μL	MONO X10 ³ /μL	EOSIN X10 ³ /μL	BASO X10 ³ /μL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%	
0	MEAN S.D. N	10.8 .14 2	6.6 .99 2	3.4 .92 2	.7 .14 2	.0 .07 2	.0 .07 2	61 8.5 2	32 9.2 2	6 .7 2	0 .7 2	0 .7 2
0.15	MEAN S.D. N	12.5 1.84 2	8.2 1.98 2	3.5 .71 2	.8 .49 2	.1 .14 2	.0 .00 2	64 6.4 2	28 10.6 2	6 2.8 2	0 .7 2	0 .0 2
0.75	MEAN S.D. N	12.2 3.96 2	6.4 2.69 2	4.2 .78 2	1.1 .42 2	.4 .07 2	.0 .07 2	52 4.9 2	36 5.7 2	9 .0 2	3 .0 2	0 .7 2

Table 18
Summary of Clinical Hematology Data

Females Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	RBC X10 ⁶ /μL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 ³ /μL	RETIC %	RETIC X10 ³ /μL	
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	
0	MEAN S.D. N	6.28 .453 2	12.4 .78 2	38.1 2.90 2	60.8 .35 2	19.8 .14 2	32.6 .42 2	534 142.8 2	.2 .07 2	10 4.9 2
0.15	MEAN S.D. N	6.77 .113 2	12.6 .14 2	40.8 1.34 2	60.2 .92 2	18.6 .07 2	31.0 .64 2	456 67.9 2	.2 .07 2	10 4.2 2
0.75	MEAN S.D. N	6.54 .028 2	12.2 .07 2	40.1 .57 2	61.3 1.13 2	18.6 .14 2	30.4 .78 2	448 181.7 2	.2 .07 2	10 4.2 2

Table 18
Summary of Clinical Hematology Data

Females Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	WBC X10 ³ /μL	N-SEG X10 ³ /μL	LYMPH X10 ³ /μL	MONO X10 ³ /μL	EOSIN X10 ³ /μL	BASO X10 ³ /μL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%	
0	MEAN S.D. N	7.4 1.48 2	3.4 1.13 2	2.8 .42 2	1.0 .28 2	.2 .14 2	.0 .00 2	46 6.4 2	37 1.4 2	14 6.4 2	3 1.4 2	0 .0 2
0.15	MEAN S.D. N	8.1 .57 2	3.0 .71 2	3.7 .99 2	.9 .42 2	.4 .14 2	.0 .07 2	38 10.6 2	46 9.2 2	11 4.2 2	5 2.8 2	0 .7 2
0.75	MEAN S.D. N	10.8 .78 2	4.7 .57 2	5.2 .21 2	.8 .42 2	.1 .14 2	.0 .00 2	43 1.4 2	48 4.9 2	8 3.5 2	1 1.4 2	0 .0 2

Table 19
Summary of Clinical Hematology Data
Males Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day		RBC X10 ⁶ /μL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 ³ /μL	RETIC %	RETIC X10 ³ /μL
-----		-----	-----	-----	-----	-----	-----	-----	-----	-----
0										
	MEAN	6.63	12.9	40.2	60.7	19.4	32.0	460	.3	20
	S.D.	.269	.57	1.34	.42	.00	.28	174.7	.14	9.9
	N	2	2	2	2	2	2	2	2	2
0.15										
	MEAN	7.16	14.0	45.6	63.7	19.5	30.6	490	.3	22
	S.D.	.049	.21	.99	.92	.14	.21	106.8	.28	20.5
	N	2	2	2	2	2	2	2	2	2
0.75										
	MEAN	6.30	12.6	40.6	64.5	19.9	31.0	510	.7	42
	S.D.	.530	.92	2.69	1.13	.21	.14	92.6	.99	58.7
	N	2	2	2	2	2	2	2	2	2

002759

Table 19
Summary of Clinical Hematology Data

Males Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	WBC X10 ³ /μL	N-SEG X10 ³ /μL	LYMPH X10 ³ /μL	MONO X10 ³ /μL	EOSIN X10 ³ /μL	BASO X10 ³ /μL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%	
0	MEAN S.D. N	11.6 .57 2	6.4 1.48 2	4.4 .78 2	.6 .07 2	.1 .00 2	.0 .07 2	55 9.9 2	38 8.5 2	6 .7 2	1 .0 2	0 .7 2
0.15	MEAN S.D. N	11.6 1.27 2	4.9 1.13 2	5.9 .42 2	.6 .21 2	.2 .00 2	.0 .00 2	42 4.9 2	50 2.1 2	6 2.1 2	2 .7 2	0 .0 2
0.75	MEAN S.D. N	16.6 6.51 2	10.3 3.96 2	4.8 1.77 2	1.2 .64 2	.4 .21 2	.1 .00 2	62 .7 2	28 .7 2	6 .7 2	2 1.4 2	0 .7 2

Table 19
Summary of Clinical Hematology Data

Females Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day		RBC X10 ⁶ /μL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 ³ /μL	RETIC %	RETIC X10 ³ /μL
0	MEAN	6.26	12.4	38.5	61.6	19.8	32.2	494	.5	31
	S.D.	.884	1.56	5.23	.35	.35	.49	122.3	.14	4.2
	N	2	2	2	2	2	2	2	2	2
0.15	MEAN	6.66	12.7	40.8	61.4	19.2	31.2	451	.3	20
	S.D.	.064	.00	.85	.71	.21	.78	14.1	.14	9.2
	N	2	2	2	2	2	2	2	2	2
0.75	MEAN	7.06	13.1	42.9	60.8	18.5	30.6	446	.2	12
	S.D.	.629	.57	3.18	.92	.78	.92	215.7	.21	16.3
	N	2	2	2	2	2	2	2	2	2

Table 19
Summary of Clinical Hematology Data

Females Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	WBC X10 ³ /μL	N-SEG X10 ³ /μL	LYMPH X10 ³ /μL	MONO X10 ³ /μL	EOSIN X10 ³ /μL	BASO X10 ³ /μL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%	
0	MEAN S.D. N	8.8 .78 2	4.4 .14 2	3.4 .64 2	.7 .14 2	.3 .14 2	.0 .00 2	50 6.4 2	38 3.5 2	8 .7 2	3 1.4 2	0 .0 2
0.15	MEAN S.D. N	9.9 1.70 2	3.8 1.70 2	4.6 .07 2	.9 .14 2	.6 .28 2	.0 .00 2	37 11.3 2	48 6.4 2	9 .0 2	6 4.2 2	0 .0 2
0.75	MEAN S.D. N	10.6 .92 2	3.0 .71 2	6.2 1.56 2	1.0 .07 2	.3 .14 2	.2 .07 2	29 9.9 2	58 9.9 2	9 1.4 2	3 1.4 2	2 .7 2

002762

Table 20
Summary of Clinical Hematology Data
Males Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day		RBC X10 ⁶ /μL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 ³ /μL	RETIC %	RETIC X10 ³ /μL
0	MEAN	6.56	12.6	40.7	61.9	19.2	31.0	434	.5	33
	S.D.	.035	.00	1.06	1.27	.07	.71	96.9	.28	18.4
	N	2	2	2	2	2	2	2	2	2
0.15	MEAN	6.90	13.6	43.9	63.6	19.8	31.1	373	.7	48
	S.D.	.141	.21	.42	.71	.00	.28	5.7	.00	.7
	N	2	2	2	2	2	2	2	2	2
0.75	MEAN	6.42	12.6	42.4	66.0	19.6	29.8	520	.6	38
	S.D.	.000	.14	1.56	2.33	.14	.78	59.4	.42	27.6
	N	2	2	2	2	2	2	2	2	2

002763

Covance 6329-223
3M T-6295.7

Table 20
Summary of Clinical Hematology Data

Males Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	WBC X10 ³ /μL	N-SEG X10 ³ /μL	LYMPH X10 ³ /μL	MONO X10 ³ /μL	EOSIN X10 ³ /μL	BASO X10 ³ /μL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%
0	MEAN 8.4 S.D. 1.77 N 2	3.1 1.56 2	4.2 .14 2	.8 .42 2	.1 .00 2	.2 .21 2	36 11.3 2	52 12.0 2	9 2.8 2	1 .0 2	2 2.1 2
0.15	MEAN 10.9 S.D. 3.96 N 2	5.0 1.70 2	4.7 2.12 2	.8 .14 2	.4 .21 2	.1 .00 2	46 1.4 2	42 4.2 2	8 4.2 2	2 .7 2	1 .0 2
0.75	MEAN 16.0 S.D. .35 N 2	9.8 1.48 2	4.4 1.41 2	1.2 .07 2	.2 .21 2	.2 .14 2	62 11.3 2	28 7.8 2	8 .7 2	2 .7 2	2 .7 2

Table 20
Summary of Clinical Hematology Data

Females Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day		RBC X10 ⁶ /μL	HGB G/DL	HCT %	MCV FL	MCH PG	MCHC %	PLT X10 ³ /μL	RETIC %	RETIC X10 ³ /μL

0										
	MEAN	6.02	11.8	37.5	62.5	19.8	31.6	508	.4	26
	S.D.	.700	1.06	4.17	.21	.49	.71	35.4	.21	9.2
	N	2	2	2	2	2	2	2	2	2
0.15										
	MEAN	6.46	12.3	40.2	62.2	19.0	30.6	406	.4	29
	S.D.	.191	.42	1.34	.21	.14	.14	2.1	.21	12.7
	N	2	2	2	2	2	2	2	2	2
0.75										
	MEAN	6.72	12.4	40.8	60.8	18.5	30.4	396	.3	20
	S.D.	.134	.14	.28	1.56	.57	.14	146.4	.14	9.9
	N	2	2	2	2	2	2	2	2	2

002765

Table 20

Summary of Clinical Hematology Data

Females Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day		WBC X10 ³ /μL	N-SEG X10 ³ /μL	LYMPH X10 ³ /μL	MONO X10 ³ /μL	EOSIN X10 ³ /μL	BASO X10 ³ /μL	N-SEG%	LYMPH%	MONO%	EOSIN%	BASO%

0												
	MEAN	11.2	7.0	2.8	1.0	.3	.2	58	28	10	2	1
	S.D.	6.15	4.95	.49	.42	.14	.07	12.0	11.3	.7	.7	.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.15												
	MEAN	11.5	5.4	4.2	1.0	.6	.2	46	37	10	5	2
	S.D.	3.25	2.33	1.20	.07	.21	.00	7.1	.0	2.8	2.8	.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.75												
	MEAN	10.4	3.1	6.4	.5	.2	.2	30	61	5	2	2
	S.D.	.85	.14	.92	.00	.14	.07	3.5	4.2	.0	.7	.7
	N	2	2	2	2	2	2	2	2	2	2	2

002766

Table 21
Summary of Clinical Chemistry Data

Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
-----		-----	-----	-----	-----	-----	-----	-----	-----	-----	-----
0	MEAN	76	20	1.2	9.0	4.9	4.1	.6	9	138	70
	S.D.	12.5	3.8	.10	.32	.21	.26	.45	2.0	33.7	13.3
	N	6	6	6	6	6	6	6	6	6	6
0.03	MEAN	70	20	1.2	9.6	5.2	4.4	.4	9	110	61
	S.D.	8.3	6.2	.17	.58	.46	.48	.18	1.4	20.1	35.0
	N	4	4	4	4	4	4	4	4	4	4
0.15	MEAN	82	21	1.2	9.5	5.1	4.4	.6	10	151	56
	S.D.	30.4	3.3	.22	.44	.34	.26	.37	2.2	26.1	4.9
	N	6	6	6	6	6	6	6	6	6	6
0.75	MEAN	73	20	1.3	9.4	5.2	4.3	.5	9	138	67
	S.D.	15.4	2.0	.11	.38	.28	.37	.29	1.3	29.3	11.0
	N	6	6	6	6	6	6	6	6	6	6

002767

Table 21
Summary of Clinical Chemistry Data

Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L	
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	
0	MEAN S.D. N	56 16.5 6	32 9.7 6	711 252.6 6	134 42.8 6	7 1.9 6	1133 535.3 6	395 93.4 6	55 84.4 6	247 54.0 6
0.03	MEAN S.D. N	44 6.3 4	36 11.2 4	700 265.6 4	141 34.5 4	3 1.0 4	936 709.0 4	476 164.6 4	35 20.6 4	302 107.4 4
0.15	MEAN S.D. N	72 23.5 6	69 35.7 6	770 210.3 6	160 68.4 6	8 5.4 6	1087 322.3 6	386 94.5 6	51 42.4 6	242 62.4 6
0.75	MEAN S.D. N	68 11.7 6	80 54.2 6	840 360.9 6	171 53.3 6	6 1.5 6	1094 497.4 6	529 135.6 6	41 31.8 6	324 72.2 6

Table 21
Summary of Clinical Chemistry Data
Males Day -27
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
-----	-----	-----	-----	-----	-----
0					
MEAN	10.8	6.2	159	5.4	109
S.D.	.60	.84	4.6	.58	2.9
N	6	6	6	6	6
0.03					
MEAN	11.6	6.6	164	5.9	111
S.D.	.53	.44	6.0	.32	2.2
N	4	4	4	4	4
0.15					
MEAN	11.5	7.1	163	6.4	112
S.D.	.62	.99	5.3	.60	2.7
N	6	6	6	6	6
0.75					
MEAN	11.3	6.9	161	5.8	108
S.D.	.54	1.06	4.8	.62	2.9
N	6	6	6	6	6

002769

Table 21

Summary of Clinical Chemistry Data

Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
0	MEAN	76	22	1.2	9.6	4.9	4.7	.5	7	149	73
	S.D.	22.2	1.6	.08	.78	.35	.83	.34	1.9	37.2	32.4
	N	6	6	6	6	6	6	6	6	6	6
0.03	MEAN	73	22	1.2	9.3	4.7	4.6	.5	6	130	62
	S.D.	10.7	1.3	.08	.50	.18	.41	.17	1.7	12.4	7.5
	N	4	4	4	4	4	4	4	4	4	4
0.15	MEAN	76	23	1.1	9.6	4.7	4.9	.6	12	144	58
	S.D.	12.0	3.9	.10	.62	.57	.38	.21	12.1	14.0	11.7
	N	6	6	6	6	6	6	6	6	6	6
0.75	MEAN	78	24	1.2	9.4	4.8	4.6	.6	9	154	61
	S.D.	16.3	3.9	.18	.78	.40	.65	.37	1.4	10.1	16.6
	N	6	6	6	6	6	6	6	6	6	6

002270

Table 21
Summary of Clinical Chemistry Data

Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0	MEAN	64	140	291	123	4	979	374	28	220
	S.D.	6.7	76.9	130.1	54.0	1.6	384.3	121.9	12.5	73.1
	N	6	6	6	6	6	6	6	6	6
0.03	MEAN	54	103	201	94	3	484	378	26	237
	S.D.	10.2	29.4	12.5	48.5	.8	156.7	153.7	15.9	79.9
	N	4	4	4	4	4	4	4	4	4
0.15	MEAN	74	110	257	87	4	844	416	35	244
	S.D.	35.5	41.0	118.5	32.9	2.4	306.4	121.0	21.2	81.3
	N	6	6	6	6	6	6	6	6	6
0.75	MEAN	72	123	310	75	4	1624	384	19	247
	S.D.	15.4	54.2	141.4	24.3	2.0	1251.5	88.6	15.4	54.1
	N	6	6	6	6	6	6	6	6	6

002771

Table 21

Summary of Clinical Chemistry Data

Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
-----	-----	-----	-----	-----	-----
0					
MEAN	11.4	6.2	163	6.2	114
S.D.	1.10	.63	7.1	.96	5.0
N	6	6	6	6	6
0.03					
MEAN	10.9	4.7	163	5.9	115
S.D.	.58	.99	3.4	.70	3.3
N	4	4	4	4	4
0.15					
MEAN	11.0	5.9	162	6.1	115
S.D.	.59	.78	6.1	.63	3.1
N	6	6	6	6	6
0.75					
MEAN	11.3	5.5	163	6.1	114
S.D.	.59	.50	4.9	.80	1.5
N	6	6	6	6	6

002772

Table 22
Summary of Clinical Chemistry Data
Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
-----		-----	-----	-----	-----	-----	-----	-----	-----	-----	-----
0	MEAN	60	20	1.1	8.9	4.7	4.2	.8	9	140	69
	S.D.	5.9	3.3	.12	.56	.13	.49	.43	1.5	22.1	18.7
	N	6	6	6	6	6	6	6	6	6	6
0.03	MEAN	62	18	1.2	9.3	5.0	4.3	.4	8	118	47
	S.D.	8.3	3.9	.18	1.02	.46	.85	.16	1.3	28.4	4.6
	N	4	4	4	4	4	4	4	4	4	4
0.15	MEAN	61	21	1.2	9.2	4.8	4.4	.6	8	146	58
	S.D.	9.8	4.9	.23	.33	.25	.32	.27	.8	21.5	5.3
	N	6	6	6	6	6	6	6	6	6	6
0.75	MEAN	65	21	1.3	9.3	5.1	4.2	.4	7	130	91
	S.D.	7.8	2.3	.12	.37	.36	.40	.17	1.5	18.0	27.3
	N	6	6	6	6	6	6	6	6	6	6

002773

Table 22
Summary of Clinical Chemistry Data

Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L	
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	
0	MEAN S.D. N	45 15.9 6	39 19.5 6	888 339.5 6	134 42.9 6	7 2.6 6	354 461.0 6	374 106.3 6	22 12.5 6	222 58.4 6
0.03	MEAN S.D. N	37 6.3 4	40 13.0 4	876 384.3 4	120 35.4 4	3 1.5 4	191 58.2 4	459 149.3 4	24 13.6 4	282 93.3 4
0.15	MEAN S.D. N	48 15.9 6	50 23.8 6	896 267.3 6	136 57.3 6	5 3.2 6	184 59.7 6	369 78.9 6	40 21.7 6	221 55.5 6
0.75	MEAN S.D. N	43 10.0 6	46 23.0 6	996 417.0 6	142 39.9 6	2 * .4 6	283 149.7 6	522 124.7 6	26 10.9 6	307 55.9 6

002774

Table 22

Summary of Clinical Chemistry Data

Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L

0	MEAN	10.6	6.7	160	5.4	115
	S.D.	.25	.80	3.6	.28	3.4
	N	6	6	6	6	6
0.03	MEAN	11.2	6.9	165	5.8	116
	S.D.	1.12	1.58	10.1	.74	4.2
	N	4	4	4	4	4
0.15	MEAN	11.0	6.8	160	5.6	115
	S.D.	.39	1.00	3.1	.38	.9
	N	6	6	6	6	6
0.75	MEAN	10.9	6.6	162	5.4	114
	S.D.	.43	1.29	3.4	.29	2.7
	N	6	6	6	6	6

002775

Table 22

Summary of Clinical Chemistry Data

Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
-----		-----	-----	-----	-----	-----	-----	-----	-----	-----	-----
0	MEAN	58	22	1.1	9.3	4.4	4.9	.6	8	147	71
	S.D.	14.7	4.4	.16	.71	.26	.80	.34	.5	26.9	25.7
	N	6	6	6	6	6	6	6	6	6	6
0.03	MEAN	67	21	1.1	9.0	4.5	4.5	.5	9	124	64
	S.D.	15.2	3.0	.05	.41	.15	.39	.25	2.5	11.1	12.0
	N	4	4	4	4	4	4	4	4	4	4
0.15	MEAN	60	20	1.0	9.2	4.3	4.9	.6	8	133	57
	S.D.	8.4	3.6	.04	.26	.37	.40	.14	3.2	22.4	11.3
	N	6	6	6	6	6	6	6	6	6	6
0.75	MEAN	70	22	1.1	9.1	4.4	4.7	.4	7	123	66
	S.D.	11.5	5.4	.14	.31	.10	.38	.15	1.2	14.1	23.0
	N	6	6	6	6	6	6	6	6	6	6

002776

Table 22
Summary of Clinical Chemistry Data

Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0	MEAN	44	59	362	102	5	240	339	18	194
	S.D.	12.1	30.2	125.6	42.9	2.4	146.6	89.9	13.2	58.2
	N	6	6	6	6	6	6	6	6	6
0.03	MEAN	49	70	240	88	3	378	384	28	237
	S.D.	15.9	13.3	48.7	54.7	1.3	262.2	110.9	15.2	55.5
	N	4	4	4	4	4	4	4	4	4
0.15	MEAN	36	68	319	76	3	198	414	34	230
	S.D.	6.6	30.9	129.0	20.3	1.5	101.3	115.1	17.4	70.7
	N	6	6	6	6	6	6	6	6	6
0.75	MEAN	36	46	415	58	2 *	331	373	23	230
	S.D.	8.0	7.5	188.9	20.0	.9	242.1	83.3	5.9	66.0
	N	6	6	6	6	6	6	6	6	6

002777

Table 22

Summary of Clinical Chemistry Data

Females Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L

0	MEAN	10.4	5.7	161	5.7	115
	S.D.	.39	.73	4.9	.38	4.4
	N	6	6	6	6	6
0.03	MEAN	10.2	4.2 *	161	5.2	116
	S.D.	.42	.37	5.4	.92	4.3
	N	4	4	4	4	4
0.15	MEAN	9.7	5.1	157	5.2	114
	S.D.	.73	.65	2.5	.39	1.1
	N	6	6	6	6	6
0.75	MEAN	10.4	5.0	160	5.9	116
	S.D.	.25	.48	5.3	.42	3.0
	N	6	6	6	6	6

002778

Table 23
Summary of Clinical Chemistry Data

Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
-----		-----	-----	-----	-----	-----	-----	-----	-----	-----	-----
0											
	MEAN	59	20	1.1	8.6	4.6	4.0	.7	9	153	62
	S.D.	9.1	3.9	.08	.50	.17	.42	.42	1.5	23.0	19.0
	N	6	6	6	6	6	6	6	6	6	6
0.03											
	MEAN	59	20	1.2	9.0	4.7	4.3	.4	10	114 *	60
	S.D.	2.9	3.7	.14	.69	.36	.58	.10	2.2	25.1	14.8
	N	4	4	4	4	4	4	4	4	4	4
0.15											
	MEAN	67	18	1.2	8.8	4.6	4.1	.5	10	144	57
	S.D.	13.3	3.9	.19	.42	.48	.44	.23	1.7	19.7	13.4
	N	6	6	6	6	6	6	6	6	6	6
0.75											
	MEAN	74	19	1.3	8.8	4.8	4.0	.3	10	125	76
	S.D.	10.6	2.6	.12	.41	.53	.59	.06	2.7	20.6	16.6
	N	6	6	6	6	6	6	6	6	6	6

002779

Table 23

Summary of Clinical Chemistry Data

Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0	MEAN	36	34	839	130	7	132	371	22	224
	S.D.	7.9	15.2	321.9	46.2	2.3	27.8	115.8	13.9	64.2
	N	6	6	6	6	6	6	6	6	6
0.03	MEAN	35	35	750	116	4	149	428	21	270
	S.D.	7.2	17.5	369.9	25.0	1.5	47.7	143.3	13.8	92.9
	N	4	4	4	4	4	4	4	4	4
0.15	MEAN	40	37	806	128	5	153	344	20	213
	S.D.	9.4	11.7	237.8	39.4	3.8	19.9	89.3	11.3	61.7
	N	6	6	6	6	6	6	6	6	6
0.75	MEAN	34	43	823	125	3	203 *	499	22	301
	S.D.	6.3	16.2	367.0	29.9	.8	57.2	119.4	13.4	53.4
	N	6	6	6	6	6	6	6	6	6

082200

Table 23

Summary of Clinical Chemistry Data

Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0					
MEAN	10.4	7.1	160	5.4	120
S.D.	.39	.66	2.9	.44	2.5
N	6	6	6	6	6
0.03					
MEAN	10.5	6.8	166	5.6	122
S.D.	.44	.88	12.5	.92	9.3
N	4	4	4	4	4
0.15					
MEAN	10.4	6.6	160	5.4	120
S.D.	.26	1.08	3.5	.50	3.5
N	6	6	6	6	6
0.75					
MEAN	10.5	6.8	159	5.6	120
S.D.	.60	1.31	6.4	.63	2.8
N	6	6	6	6	6

002781

Table 23
Summary of Clinical Chemistry Data

Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	
0	MEAN S.D. N	57 10.2 6	21 3.5 6	1.1 .13 6	9.0 .57 6	4.4 .21 6	4.7 .75 6	.5 .24 6	9 .8 6	155 45.4 6	86 49.4 6
0.03	MEAN S.D. N	66 17.3 4	22 3.4 4	1.1 .05 4	8.8 .44 4	4.3 .10 4	4.5 .46 4	.6 .26 4	10 3.7 4	127 11.2 4	76 21.5 4
0.15	MEAN S.D. N	62 12.6 6	20 2.7 6	1.0 .10 6	9.0 .15 6	4.3 .33 6	4.7 .24 6	.6 .18 6	10 3.2 6	137 19.5 6	64 18.0 6
0.75	MEAN S.D. N	74 7.2 6	20 5.0 6	1.2 .13 6	9.0 .44 6	4.4 .17 6	4.6 .39 6	.4 .10 6	9 1.9 6	127 18.9 6	61 10.5 6

002782

Table 23
Summary of Clinical Chemistry Data
Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0	MEAN	38	53	360	106	4	262	342	14	198
	S.D.	3.4	16.7	152.5	47.7	1.8	123.6	86.9	14.7	55.5
	N	6	6	6	6	6	6	6	6	6
0.03	MEAN	45	77	241	84	4	276	358	19	228
	S.D.	9.9	15.8	45.3	44.5	2.2	67.9	108.3	16.7	55.8
	N	4	4	4	4	4	4	4	4	4
0.15	MEAN	37	60	305	75	4	194	410	28	234
	S.D.	7.8	29.3	134.0	20.8	1.0	76.1	129.7	19.6	82.3
	N	6	6	6	6	6	6	6	6	6
0.75	MEAN	31	42	398	58	2 *	243	385	27	246
	S.D.	7.8	6.2	200.5	20.0	.4	130.1	89.4	9.9	56.7
	N	6	6	6	6	6	6	6	6	6

002783

Table 23

Summary of Clinical Chemistry Data

Females Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
-----	-----	-----	-----	-----	-----
0					
MEAN	10.0	6.0	162	5.8	120
S.D.	.34	.36	6.5	.59	5.1
N	6	6	6	6	6
0.03					
MEAN	9.9	4.6 *	160	5.2	120
S.D.	.22	.30	2.9	.43	2.2
N	4	4	4	4	4
0.15					
MEAN	9.6	5.1 *	160	5.5	123
S.D.	.48	.51	3.6	.60	3.0
N	6	6	6	6	6
0.75					
MEAN	10.2	5.0 *	161	5.8	120
S.D.	.60	.30	3.5	.67	1.8
N	6	6	6	6	6

002784

Table 24
Summary of Clinical Chemistry Data

Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
-----		-----	-----	-----	-----	-----	-----	-----	-----	-----	-----
0	MEAN	60	20	1.1	8.7	4.8	3.9	.7	8	154	68
	S.D.	8.0	4.3	.14	.40	.12	.33	.38	1.2	24.6	20.4
	N	6	6	6	6	6	6	6	6	6	6
0.03	MEAN	64	20	1.3	9.6	5.3 *	4.2	.4	8	126	54
	S.D.	7.6	4.9	.22	.98	.39	.75	.13	.6	14.9	9.8
	N	4	4	4	4	4	4	4	4	4	4
0.15	MEAN	75	19	1.2	9.0	5.0	4.0	.4	9	150	50
	S.D.	18.5	4.6	.16	.19	.14	.21	.22	2.7	18.8	10.4
	N	6	6	6	6	6	6	6	6	6	6
0.75	MEAN	73	19	1.4	9.4	5.2 *	4.2	.3 *	10	112 *	73
	S.D.	19.1	1.3	.19	.36	.31	.35	.05	3.6	27.0	21.0
	N	6	6	6	6	6	6	6	6	6	6

002785

Table 24
Summary of Clinical Chemistry Data

Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0	MEAN	39	35	866	136	7	168	392	33	265
	S.D.	7.7	15.8	296.2	50.1	2.6	32.4	111.8	30.3	71.2
	N	6	6	6	6	6	6	6	6	6
0.03	MEAN	35	60	789	131	4	175	465	48	318
	S.D.	7.0	55.8	401.7	34.5	1.4	42.5	185.6	57.9	125.4
	N	4	4	4	4	4	4	4	4	4
0.15	MEAN	42	45	851	140	6	164	377	27	258
	S.D.	12.2	22.4	265.3	58.6	4.3	36.2	94.9	18.3	70.1
	N	6	6	6	6	6	6	6	6	6
0.75	MEAN	36	44	807	127	2 *	214	468	32	350
	S.D.	6.3	21.0	428.6	27.4	.6	75.7	149.1	17.5	70.4
	N	6	6	6	6	6	6	6	6	6

984200

Table 24

Summary of Clinical Chemistry Data

Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0					
MEAN	10.3	6.8	160	5.1	117
S.D.	.77	.37	7.1	.56	5.3
N	6	6	6	6	6
0.03					
MEAN	10.5	6.7	167	5.7	120
S.D.	.79	.70	4.9	1.04	4.1
N	4	4	4	4	4
0.15					
MEAN	10.6	6.8	161	5.4	118
S.D.	.51	1.05	4.6	.35	7.0
N	6	6	6	6	6
0.75					
MEAN	10.8	6.4	163	5.4	117
S.D.	.41	.94	5.0	.45	4.2
N	6	6	6	6	6

002787

Table 24
Summary of Clinical Chemistry Data

Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL
-----		-----	-----	-----	-----	-----	-----	-----	-----	-----	-----
0	MEAN	66	20	1.2	9.2	4.7	4.6	.4	8	166	67
	S.D.	20.5	2.7	.10	.51	.38	.51	.16	1.5	42.0	10.9
	N	6	6	6	6	6	6	6	6	6	6
0.03	MEAN	68	22	1.1	9.0	4.6	4.4	.5	8	134	61
	S.D.	14.7	3.3	.08	.69	.19	.54	.27	1.4	15.6	14.0
	N	4	4	4	4	4	4	4	4	4	4
0.15	MEAN	60	20	1.0	9.1	4.4	4.6	.4	10	140	56
	S.D.	12.4	4.2	.05	.24	.41	.32	.10	5.8	13.1	18.0
	N	6	6	6	6	6	6	6	6	6	6
0.75	MEAN	79	22	1.2	9.5	4.8	4.7	.3	11	111 *	60
	S.D.	15.5	6.3	.19	.45	.29	.33	.08	7.0	26.6	14.4
	N	6	6	6	6	6	6	6	6	6	6

002788

Table 24
Summary of Clinical Chemistry Data
Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0	MEAN	44	54	329	110	6	786	370	15	236
	S.D.	9.1	17.9	128.7	46.5	2.2	947.2	87.4	17.5	62.7
	N	6	6	6	6	6	6	6	6	6
0.03	MEAN	43	79	233	103	4	220	390	18	269
	S.D.	14.6	26.6	57.5	78.3	4.4	39.4	99.8	10.9	62.5
	N	4	4	4	4	4	4	4	4	4
0.15	MEAN	37	67	324	74	4	209	442	40	282
	S.D.	11.1	42.8	140.3	19.2	2.5	81.8	127.6	46.1	87.7
	N	6	6	6	6	6	6	6	6	6
0.75	MEAN	34	45	388	63	2 *	416	379	19	263
	S.D.	9.8	13.0	150.1	22.3	.5	377.0	96.5	13.6	59.4
	N	6	6	6	6	6	6	6	6	6

002789

Table 24

Summary of Clinical Chemistry Data

Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
-----	-----	-----	-----	-----	-----
0					
MEAN	10.2	5.7	161	5.6	118
S.D.	1.11	.66	5.9	.74	6.1
N	6	6	6	6	6
0.03					
MEAN	10.2	4.2 *	161	5.2	117
S.D.	1.21	.44	7.5	.93	6.8
N	4	4	4	4	4
0.15					
MEAN	10.0	5.2	160	5.7	120
S.D.	.53	.63	3.4	.45	4.2
N	6	6	6	6	6
0.75					
MEAN	10.6	5.1	162	5.8	118
S.D.	.58	.53	4.7	.54	3.9
N	6	6	6	6	6

062200

Table 25
Summary of Clinical Chemistry Data

Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
-----		-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----
0	MEAN	60	20	1.1	8.2	4.8	3.4	.7	10	154	60	69
	S.D.	8.0	3.0	.12	.45	.19	.34	.41	1.5	29.9	18.3	10.6
	N	6	6	6	6	6	6	6	6	6	6	6
0.03	MEAN	61	19	1.2	8.8	5.2	3.6	.4	7	120	60	46 *
	S.D.	4.3	2.2	.19	.83	.24	.66	.08	1.0	16.3	24.9	4.5
	N	4	4	4	4	4	4	4	4	4	4	4
0.15	MEAN	63	22	1.2	8.8	5.0	3.8	.5	10	149	65	55 *
	S.D.	9.4	4.5	.18	.55	.31	.61	.20	2.3	22.8	9.5	12.5
	N	6	6	6	6	6	6	6	6	6	6	6
0.75	MEAN	76	20	1.3	9.0	4.9	4.1	.2 *	14	65 *	60	19 *
	S.D.	17.0	2.2	.20	.23	.48	.43	.05	5.5	20.3	26.3	6.5
	N	6	6	6	6	6	6	6	6	6	6	6

002791

Table 25
Summary of Clinical Chemistry Data

Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0	MEAN	31	43	792	142	3	165	392	23	276
	S.D.	4.9	27.3	305.3	53.1	2.6	28.5	112.8	10.5	74.9
	N	6	6	6	6	6	6	6	6	6
0.03	MEAN	30	36	684	123	2	133	470	41	339
	S.D.	6.3	19.8	348.2	32.2	1.5	42.6	165.2	40.0	123.2
	N	4	4	4	4	4	4	4	4	4
0.15	MEAN	40	55	853	148	4	193	429	166	312
	S.D.	15.7	17.2	207.5	63.8	3.1	38.4	69.9	339.9	67.7
	N	6	6	6	6	6	6	6	6	6
0.75	MEAN	39	52	646	112	2	352 *	517	32	364
	S.D.	8.8	26.6	384.1	36.1	1.2	297.5	124.5	17.2	59.9
	N	6	6	6	6	6	6	6	6	6

002792

Table 25
Summary of Clinical Chemistry Data

Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L

0	MEAN	10.1	6.6	157	5.4	116
	S.D.	.73	.31	6.1	.48	4.1
	N	6	6	6	6	6
0.03	MEAN	10.8	6.3	159	5.5	117
	S.D.	.56	1.09	3.9	.67	4.1
	N	4	4	4	4	4
0.15	MEAN	10.4	6.8	158	5.5	115
	S.D.	.64	1.01	3.2	.43	4.2
	N	6	6	6	6	6
0.75	MEAN	10.8	6.8	158	5.8	113
	S.D.	.76	1.66	7.9	.73	7.8
	N	6	6	6	6	6

002793

Table 25
Summary of Clinical Chemistry Data
Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
0	MEAN	58	20	1.1	8.9	4.7	4.2	.5	9	163	80	59
	S.D.	9.9	4.0	.14	.80	.47	.63	.27	1.3	48.5	47.1	16.8
	N	6	6	6	6	6	6	6	6	6	6	6
0.03	MEAN	64	20	1.1	8.6	4.4	4.2	.5	8	110 *	82	47
	S.D.	12.1	6.0	.17	.25	.40	.29	.34	1.7	22.1	28.5	9.5
	N	4	4	4	4	4	4	4	4	4	4	4
0.15	MEAN	57	22	1.1	8.8	4.5	4.2	.5	10	130	69	41 *
	S.D.	4.9	3.1	.08	.33	.37	.48	.12	3.1	23.2	13.7	9.2
	N	6	6	6	6	6	6	6	6	6	6	6
0.75	MEAN	70	18	1.2	8.9	4.5	4.4	.3	15	91 *	64	23 *
	S.D.	14.6	5.3	.14	.43	.41	.40	.08	13.8	23.1	13.5	4.3
	N	6	6	6	6	6	6	6	6	6	6	6

002794

Table 25
Summary of Clinical Chemistry Data
Females Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0	MEAN	36	77	315	112	2	235	373	18	256
	S.D.	8.2	43.3	143.3	51.2	.8	105.0	74.3	17.7	55.7
	N	6	6	6	6	6	6	6	5	6
0.03	MEAN	38	80	262	108	2	255	378	18	275
	S.D.	16.2	52.8	42.2	97.8	.8	131.7	108.8	13.5	67.7
	N	4	4	4	4	4	4	4	4	4
0.15	MEAN	36	66	308	72	3	242	432	25	293
	S.D.	13.4	34.1	120.9	20.3	2.5	116.5	165.5	15.2	129.4
	N	6	6	6	6	6	6	6	6	6
0.75	MEAN	40	48	336	61	2	695	380	26	281
	S.D.	18.1	10.0	146.9	24.2	2.3	1217.1	104.1	10.9	76.1
	N	6	6	6	6	6	6	6	6	6

002795

Table 25
Summary of Clinical Chemistry Data
Females Day 153
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0					
MEAN	10.2	5.6	158	6.0	119
S.D.	.87	.34	8.5	.81	7.2
N	6	6	6	6	6
0.03					
MEAN	9.8	4.1	155	5.6	116
S.D.	1.04	.84	6.9	.46	6.8
N	4	4	4	4	4
0.15					
MEAN	9.8	5.0	154	5.4	116
S.D.	.42	.96	2.2	.52	3.6
N	6	6	6	6	6
0.75					
MEAN	10.5	4.9 *	158	6.3	116
S.D.	.67	.71	5.0	.75	4.4
N	6	6	6	6	6

002796

Table 26

Summary of Clinical Chemistry Data

Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
0											
MEAN	60	18	1.1	8.2	4.8	3.5	.6	6	152	45	63
S.D.	6.1	3.9	.16	.54	.23	.40	.23	.8	27.5	8.7	11.1
N	6	6	6	6	6	6	6	6	6	6	6
0.03											
MEAN	64	18	1.2	8.8	5.0	3.8	.3 *	5 *	110 *	33	42 *
S.D.	9.1	6.3	.16	.65	.34	.47	.08	.5	17.0	6.6	3.7
N	4	4	4	4	4	4	4	4	4	4	4
0.15											
MEAN	70	17	1.1	8.5	4.9	3.6	.4	6	147	36	48
S.D.	8.3	2.6	.17	.30	.31	.17	.10	1.3	24.0	10.4	14.3
N	6	6	6	6	6	6	6	6	6	6	6
0.75											
MEAN	76	22	1.2	9.0	4.9	4.1	.2 *	18 *	48 *	30	13 *
S.D.	12.6	4.5	.24	.77	.53	.44	.05	8.6	18.8	11.8	5.4
N	4	4	4	4	4	4	4	4	4	4	4

002797

Table 26
Summary of Clinical Chemistry Data

Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0	MEAN	32	39	735	150	6	210	393	29	280
	S.D.	6.2	17.9	318.7	65.6	3.7	158.7	102.8	13.4	68.5
	N	6	6	6	6	6	6	6	6	6
0.03	MEAN	27	29	604	126	4	138	442	24	314
	S.D.	6.2	8.8	353.5	42.6	1.9	58.8	136.5	10.6	96.4
	N	4	4	4	4	4	4	4	4	4
0.15	MEAN	36	47	688	148	6	174	381	30	270
	S.D.	13.3	16.9	178.3	55.8	3.8	101.5	82.3	11.8	59.0
	N	6	6	6	6	6	6	6	6	6
0.75	MEAN	34	47	389	104	3	182	446	36	320
	S.D.	5.3	19.7	155.7	25.3	1.0	64.5	65.3	22.2	25.2
	N	4	4	4	4	4	4	4	4	4

002798

Table 26

Summary of Clinical Chemistry Data

Males Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0					
MEAN	10.2	6.4	154	5.1	111
S.D.	.43	.82	4.8	.23	1.5
N	6	6	6	6	6
0.03					
MEAN	10.0	5.8	156	5.0	109
S.D.	.20	.96	1.5	.32	2.2
N	4	4	4	4	4
0.15					
MEAN	10.1	6.2	154	5.0	110
S.D.	.41	.82	4.7	.25	2.9
N	6	6	6	6	6
0.75					
MEAN	10.3	6.1	153	5.4	106
S.D.	.62	1.22	6.4	.17	5.3
N	4	4	4	4	4

002799

Table 26

Summary of Clinical Chemistry Data

Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
-----		-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----
0	MEAN	58	20	1.1	8.9	4.7	4.2	.4	6	160	56	56
	S.D.	15.2	3.7	.18	.66	.42	.55	.25	.6	46.5	13.3	16.0
	N	6	6	6	6	6	6	6	6	6	6	6
0.03	MEAN	54	20	1.0	8.6	4.4	4.2	.5	5	122	49	42
	S.D.	7.8	3.4	.17	.76	.47	.38	.24	1.5	21.6	14.7	9.1
	N	4	4	4	4	4	4	4	4	4	4	4
0.15	MEAN	64	19	1.0	8.9	4.5	4.4	.4	8	129	49	36 *
	S.D.	9.0	3.1	.09	.47	.35	.67	.08	2.0	22.3	15.8	12.1
	N	6	6	6	6	6	6	6	6	6	6	6
0.75	MEAN	73	20	1.2	9.2	4.6	4.7	.2	7	82 *	53	21 *
	S.D.	11.0	4.7	.16	.37	.31	.63	.08	3.4	14.7	15.8	7.2
	N	6	6	6	6	6	6	6	6	6	6	6

Table 26
Summary of Clinical Chemistry Data

Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0	MEAN	41	87	283	114	5	212	378	32	258
	S.D.	25.0	85.9	137.1	53.3	3.1	123.4	84.6	37.1	64.1
	N	6	6	6	6	6	6	6	6	6
0.03	MEAN	42	72	239	111	6	823	358	19	260
	S.D.	14.6	26.3	39.7	99.5	6.0	1281.8	100.7	15.0	64.4
	N	4	4	4	4	4	4	4	4	4
0.15	MEAN	37	53	254	71	7	182	439	33	294
	S.D.	13.0	36.1	85.3	19.7	5.2	84.7	140.9	21.6	111.7
	N	6	6	6	6	6	6	6	6	6
0.75	MEAN	33	44	316	64	3	284	375	31	273
	S.D.	6.2	9.9	172.4	22.7	1.5	119.3	64.9	21.2	43.1
	N	6	6	6	6	6	6	6	6	6

002801

Table 26

Summary of Clinical Chemistry Data

Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
-----	-----	-----	-----	-----	-----
0					
MEAN	10.2	5.3	156	5.3	111
S.D.	.68	.84	6.8	.56	5.0
N	6	6	6	6	6
0.03					
MEAN	9.6	4.4	152	4.8	109
S.D.	.84	.39	7.2	.94	3.6
N	4	4	4	4	4
0.15					
MEAN	9.8	4.8	154	5.0	110
S.D.	.16	1.10	3.3	.37	1.8
N	6	6	6	6	6
0.75					
MEAN	10.3	5.2	156	5.4	110
S.D.	.69	.76	4.9	.82	3.1
N	6	6	6	6	6

002802

Table 27

Summary of Clinical Chemistry Data

Males Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL	
0	MEAN	57	16	1.0	8.0	4.6	3.4	.5	12	132	44	58
	S.D.	2.8	4.9	.07	.21	.07	.14	.14	1.4	28.3	.7	12.7
	N	2	2	2	2	2	2	2	2	2	2	2
0.15	MEAN	70	17	.9	9.0	5.1	3.9	.6	16	158	39	61
	S.D.	12.0	.0	.14	.42	.00	.42	.21	.0	37.5	2.8	19.8
	N	2	2	2	2	2	2	2	2	2	2	2
0.75	MEAN	73	14	1.0	8.7	4.6	4.2	.6	14	137	69	28
	S.D.	4.2	2.1	.07	.00	.35	.35	.00	3.5	4.2	32.5	7.8
	N	2	2	2	2	2	2	2	2	2	2	2

002803

Table 27

Summary of Clinical Chemistry Data

Males Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0	MEAN	22	26	932	150	4	139	338	36	250
	S.D.	3.5	3.5	316.1	123.7	.7	77.8	87.7	7.8	58.7
	N	2	2	2	2	2	2	2	2	2
0.15	MEAN	37	44	793	138	12	162	454	46	288
	S.D.	8.5	2.1	175.4	68.6	1.4	21.9	42.4	2.1	62.2
	N	2	2	2	2	2	2	2	2	2
0.75	MEAN	32	48	518	143	2	200	505	38	346
	S.D.	4.9	28.3	27.6	22.6	.7	32.5	53.7	21.2	23.3
	N	2	2	2	2	2	2	2	2	2

002804

Table 27
Summary of Clinical Chemistry Data
Males Day 217
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0					
MEAN	10.0	6.3	152	5.0	111
S.D.	.57	1.13	2.8	.49	1.4
N	2	2	2	2	2
0.15					
MEAN	11.0	6.6	155	5.3	108
S.D.	.78	.00	1.4	.28	2.8
N	2	2	2	2	2
0.75					
MEAN	10.8	6.2	159	5.4	111
S.D.	.21	1.13	2.8	.07	1.4
N	2	2	2	2	2

002805

Covance 6329-223
3M T-6295.7

Table 27

Summary of Clinical Chemistry Data

Females Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
-----		-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----
0	MEAN	59	16	.8	8.6	4.6	4.0	.4	14	119	72	54
	S.D.	11.3	4.9	.14	.42	.21	.21	.42	1.4	46.7	50.2	29.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.15	MEAN	76	18	1.0	8.7	4.0	4.6	.6	14	145	56	44
	S.D.	.7	2.1	.00	.14	.07	.21	.00	.7	4.2	4.9	24.7
	N	2	2	2	2	2	2	2	2	2	2	2
0.75	MEAN	75	23	1.0	9.3	4.6	4.7	.6	19	133	78	34
	S.D.	9.9	2.8	.21	.42	.57	.14	.07	7.1	2.8	21.9	12.0
	N	2	2	2	2	2	2	2	2	2	2	2

903200

Table 27
Summary of Clinical Chemistry Data
Females Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0	MEAN	34	103	184	61	4	137	343	13	244
	S.D.	.7	24.0	33.2	28.3	.7	28.3	48.1	18.4	17.7
	N	2	2	2	2	2	2	2	2	2
0.15	MEAN	26	48	182	70	4	657	486	32	350
	S.D.	9.9	7.8	97.6	2.1	4.2	763.7	244.0	21.9	163.3
	N	2	2	2	2	2	2	2	2	2
0.75	MEAN	23	50	220	94	4	165	345	38	256
	S.D.	.0	16.3	29.0	37.5	2.1	29.7	69.3	4.2	47.4
	N	2	2	2	2	2	2	2	2	2

002807

Table 27

Summary of Clinical Chemistry Data

Females Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
-----	-----	-----	-----	-----	-----
0					
MEAN	9.8	4.8	148	5.4	108
S.D.	.14	1.56	4.9	.64	6.4
N	2	2	2	2	2
0.15					
MEAN	9.8	5.5	152	5.5	110
S.D.	.14	.28	3.5	.00	2.1
N	2	2	2	2	2
0.75					
MEAN	10.3	5.8	152	5.0	110
S.D.	.14	.64	.0	.21	2.1
N	2	2	2	2	2

002808

Table 28
Summary of Clinical Chemistry Data

Males Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL	
0	MEAN S.D. N	101 21.2 2	16 1.4 2	1.1 .14 2	8.7 .14 2	4.8 .07 2	3.8 .07 2	.4 .07 2	8 .7 2	134 29.0 2	33 7.1 2	77 5.7 2
0.15	MEAN S.D. N	81 2.8 2	17 .0 2	1.1 .14 2	9.0 .14 2	5.2 .07 2	3.8 .07 2	.6 .28 2	8 4.2 2	160 46.0 2	48 5.7 2	84 26.9 2
0.75	MEAN S.D. N	72 16.3 2	17 1.4 2	1.0 .00 2	8.8 .35 2	4.6 .35 2	4.2 .00 2	.4 .00 2	11 5.7 2	136 4.9 2	64 10.6 2	52 2.1 2

002809

Table 28
Summary of Clinical Chemistry Data
Males Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0	MEAN	27	28	900	144	4	177	358	42	270
	S.D.	4.2	.7	334.5	107.5	2.8	45.3	72.1	13.4	50.9
	N	2	2	2	2	2	2	2	2	2
0.15	MEAN	34	40	838	142	4	156	462	37	297
	S.D.	21.2	.0	62.9	62.2	3.5	46.0	57.3	21.2	79.2
	N	2	2	2	2	2	2	2	2	2
0.75	MEAN	46	53	680	166	4	257	544	32	372
	S.D.	4.9	28.3	78.5	14.1	3.5	111.7	118.8	21.9	54.4
	N	2	2	2	2	2	2	2	2	2

002810

Table 28
Summary of Clinical Chemistry Data

Males Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0	MEAN 10.2	6.6	154	5.0	117
	S.D. .35	.64	3.5	.00	.0
	N 2	2	2	2	2
0.15	MEAN 10.9	6.6	160	5.2	117
	S.D. .57	.21	.7	.07	1.4
	N 2	2	2	2	2
0.75	MEAN 10.8	7.0	162	5.2	116
	S.D. .64	1.13	3.5	.28	2.8
	N 2	2	2	2	2

002811

Table 28
Summary of Clinical Chemistry Data

Females Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
-----		-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----
0												
	MEAN	58	18	1.0	9.0	4.6	4.4	.6	9	131	57	70
	S.D.	14.1	3.5	.35	.64	.14	.49	.35	1.4	52.3	5.7	25.5
	N	2	2	2	2	2	2	2	2	2	2	2
0.15												
	MEAN	87	20	1.0	9.0	4.1	4.9	.4	11	150	71	72
	S.D.	5.7	1.4	.14	.28	.14	.14	.14	1.4	17.7	1.4	27.6
	N	2	2	2	2	2	2	2	2	2	2	2
0.75												
	MEAN	92	22	1.2	9.4	4.7	4.7	.2	15	149	95	64
	S.D.	.7	.0	.07	.57	.42	.14	.07	5.7	2.8	48.1	13.4
	N	2	2	2	2	2	2	2	2	2	2	2

002812

Table 28
Summary of Clinical Chemistry Data
Females Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0	MEAN	36	116	182	58	2	168	329	10	242
	S.D.	9.2	59.4	30.4	20.5	.7	50.9	48.1	14.8	27.6
	N	2	2	2	2	2	2	2	2	2
0.15	MEAN	30	66	188	80	3	392	482	34	346
	S.D.	9.2	7.1	105.4	4.2	2.8	384.0	242.5	17.7	157.7
	N	2	2	2	2	2	2	2	2	2
0.75	MEAN	25	40	236	98	2	148	331	66	250
	S.D.	4.2	1.4	17.7	33.2	.7	27.6	76.4	66.5	54.4
	N	2	2	2	2	2	2	2	2	2

002813

Table 28
Summary of Clinical Chemistry Data

Females Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0					
MEAN	9.7	4.6	150	4.6	114
S.D.	.14	.28	4.2	.21	4.9
N	2	2	2	2	2
0.15					
MEAN	9.8	5.4	152	5.4	118
S.D.	.49	.28	4.9	.71	2.1
N	2	2	2	2	2
0.75					
MEAN	10.6	5.4	160	5.5	120
S.D.	.57	.71	7.8	.99	6.4
N	2	2	2	2	2

002814

Table 29
Summary of Clinical Chemistry Data

Males Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL	
0	MEAN S.D. N	67 18.4 2	16 3.5 2	1.2 .14 2	8.5 .42 2	4.7 .14 2	3.8 .28 2	.4 .42 2	2 .7 2	130 26.2 2	36 15.6 2	64 14.8 2
0.15	MEAN S.D. N	74 2.8 2	19 1.4 2	1.0 .14 2	8.8 .21 2	5.0 .21 2	3.8 .00 2	.4 .14 2	9 2.8 2	168 50.2 2	48 13.4 2	76 26.2 2
0.75	MEAN S.D. N	70 9.2 2	18 3.5 2	1.2 .21 2	8.8 .07 2	4.8 .42 2	4.0 .35 2	.3 .14 2	8 3.5 2	139 5.7 2	74 23.3 2	40 7.1 2

002815

Table 29
Summary of Clinical Chemistry Data

Males Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0	MEAN	28	35	842	124	7	176	318	36	239
	S.D.	12.7	5.7	409.4	90.5	4.2	35.4	71.4	7.1	53.7
	N	2	2	2	2	2	2	2	2	2
0.15	MEAN	26	39	850	146	4	141	444	39	285
	S.D.	6.4	4.2	105.4	70.0	2.8	22.6	43.1	2.8	75.0
	N	2	2	2	2	2	2	2	2	2
0.75	MEAN	38	54	689	164	4	230	512	35	354
	S.D.	3.5	21.2	186.7	7.8	.7	89.8	84.1	24.0	32.5
	N	2	2	2	2	2	2	2	2	2

002816

Table 29
Summary of Clinical Chemistry Data

Males Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
-----	-----	-----	-----	-----	-----
0					
MEAN	10.2	6.0	154	5.8	116
S.D.	.21	1.13	4.9	.21	.7
N	2	2	2	2	2
0.15					
MEAN	11.2	6.4	159	5.6	118
S.D.	1.20	.21	7.1	.35	6.4
N	2	2	2	2	2
0.75					
MEAN	11.2	6.4	160	5.6	114
S.D.	.57	.92	3.5	.35	2.1
N	2	2	2	2	2

002817

Covance 6329-223
3M T-6295.7

Table 29
Summary of Clinical Chemistry Data

Females Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL	
0	MEAN S.D. N	56 15.6 2	20 4.9 2	.8 .00 2	8.7 .85 2	4.4 .28 2	4.3 .57 2	.6 .57 2	8 2.1 2	129 58.0 2	48 7.8 2	62 26.2 2
0.15	MEAN S.D. N	74 4.9 2	21 2.8 2	.9 .14 2	8.9 .28 2	4.0 .00 2	4.9 .28 2	.4 .21 2	5 .0 2	144 6.4 2	59 11.3 2	52 22.6 2
0.75	MEAN S.D. N	92 3.5 2	23 4.2 2	1.0 .14 2	9.0 .35 2	4.4 .42 2	4.6 .07 2	.1 .00 2	6 2.1 2	144 .7 2	70 31.8 2	56 4.2 2

002818

Table 29
Summary of Clinical Chemistry Data

Females Day 274

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0									
MEAN	40	104	163	58	3	301	309	9	225
S.D.	9.9	34.6	35.4	17.7	1.4	189.5	26.9	12.7	9.9
N	2	2	2	2	2	2	2	2	2
0.15									
MEAN	37	58	172	76	9	1214	468	74	340
S.D.	14.1	2.1	94.0	.7	7.1	1557.8	256.0	33.9	177.5
N	2	2	2	2	2	2	2	2	2
0.75									
MEAN	29	44	226	87	5	142	316	32	236
S.D.	18.4	10.6	25.5	29.7	1.4	31.8	113.8	2.1	83.4
N	2	2	2	2	2	2	2	2	2

002819

Table 29
Summary of Clinical Chemistry Data
Females Day 274
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0					
MEAN	9.8	4.4	150	5.0	110
S.D.	.78	.28	7.8	.92	4.9
N	2	2	2	2	2
0.15					
MEAN	9.5	5.2	150	4.8	111
S.D.	.00	.07	2.8	.92	5.7
N	2	2	2	2	2
0.75					
MEAN	10.4	5.2	156	6.0	119
S.D.	.00	.85	2.1	.07	2.8
N	2	2	2	2	2

002820

Table 30
Summary of Clinical Chemistry Data

Males Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
0	MEAN	71	18	1.2	8.6	4.8	3.8	.4	6	134	52	69
	S.D.	4.2	2.1	.07	.07	.14	.07	.57	.7	34.6	21.9	17.0
	N	2	2	2	2	2	2	2	2	2	2	2
0.15	MEAN	62	28	1.4	8.7	5.1	3.6	.7	7	163	61	72
	S.D.	23.3	2.8	.21	.42	.14	.28	.71	1.4	65.1	18.4	26.2
	N	2	2	2	2	2	2	2	2	2	2	2
0.75	MEAN	66	18	1.4	8.6	4.7	3.8	.4	8	136	90	39
	S.D.	14.8	.7	.35	.49	.42	.07	.28	2.1	.7	51.6	7.1
	N	2	2	2	2	2	2	2	2	2	2	2

002821

Table 30
Summary of Clinical Chemistry Data
Males Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0	MEAN	38	38	772	124	4	966	487	94	366
	S.D.	5.7	6.4	386.8	105.4	1.4	149.2	35.4	5.7	19.8
	N	2	2	2	2	2	2	2	2	2
0.15	MEAN	53	68	882	140	6	570	1297	710	962
	S.D.	9.9	7.1	159.1	68.6	.0	77.1	454.0	227.7	326.7
	N	2	2	2	2	2	2	2	2	2
0.75	MEAN	61	76	708	157	2	1048	625	30	442
	S.D.	21.2	23.3	191.6	1.4	1.4	368.4	144.2	7.8	85.6
	N	2	2	2	2	2	2	2	2	2

002822

Table 30
Summary of Clinical Chemistry Data
Males Day 322
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0					
MEAN	10.4	5.4	150	5.0	106
S.D.	.49	.57	3.5	.14	.7
N	2	2	2	2	2
0.15					
MEAN	11.0	5.8	154	5.0	106
S.D.	.92	.64	.0	.07	2.8
N	2	2	2	2	2
0.75					
MEAN	10.6	5.8	154	5.4	108
S.D.	.92	1.13	4.9	.35	.0
N	2	2	2	2	2

002823

Covance 6329-223
3M T-6295.7

Table 30

Summary of Clinical Chemistry Data

Females Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL	
0	MEAN S.D. N	54 14.1 2	15 1.4 2	1.2 .21 2	8.4 .07 2	4.4 .07 2	4.1 .14 2	.5 .57 2	10 4.9 2	118 41.7 2	42 8.5 2	58 23.3 2
0.15	MEAN S.D. N	64 7.8 2	28 .7 2	1.3 .14 2	8.8 .78 2	3.9 .14 2	4.8 .64 2	.5 .00 2	8 3.5 2	148 9.2 2	86 23.3 2	60 19.8 2
0.75	MEAN S.D. N	85 1.4 2	18 9.2 2	1.5 .14 2	8.7 .64 2	4.3 .42 2	4.4 .21 2	.0 .07 2	6 2.1 2	129 14.1 2	74 9.2 2	60 .0 2

002824

Table 30
Summary of Clinical Chemistry Data
Females Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0	MEAN	56	87	156	60	4	1118	366	0	268
	S.D.	14.1	14.1	18.4	30.4	2.1	132.9	33.9	.0	12.0
	N	2	2	2	2	2	2	2	2	2
0.15	MEAN	48	78	160	73	6	1058	554	73	406
	S.D.	17.0	9.9	64.3	8.5	3.5	644.2	237.6	14.1	166.9
	N	2	2	2	2	2	2	2	2	2
0.75	MEAN	44	112	235	80	2	1065	449	64	338
	S.D.	2.1	60.1	21.2	35.4	.7	574.2	1.4	43.1	1.4
	N	2	2	2	2	2	2	2	2	2

002825

Table 30
Summary of Clinical Chemistry Data
Females Day 322
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
-----	-----	-----	-----	-----	-----
0					
MEAN	9.7	4.7	147	5.0	104
S.D.	.14	.42	1.4	.21	4.9
N	2	2	2	2	2
0.15					
MEAN	9.8	5.2	151	5.2	108
S.D.	.57	.49	4.2	.07	1.4
N	2	2	2	2	2
0.75					
MEAN	10.3	4.2	156	5.5	110
S.D.	.00	.21	2.8	.42	1.4
N	2	2	2	2	2

002826

Table 31
Summary of Clinical Chemistry Data

Males Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
0											
MEAN	72	20	1.3	8.9	5.2	3.8	.5	6	126	40	61
S.D.	2.1	4.9	.00	.00	.21	.21	.28	.7	30.4	7.8	14.1
N	2	2	2	2	2	2	2	2	2	2	2
0.15											
MEAN	74	26	1.2	8.6	5.2	3.4	.8	6	166	48	74
S.D.	2.1	3.5	.07	.64	.35	.28	.42	.7	55.9	21.9	27.6
N	2	2	2	2	2	2	2	2	2	2	2
0.75											
MEAN	70	18	1.2	8.4	4.8	3.6	.4	4	119	51	38
S.D.	9.2	1.4	.14	.14	.35	.21	.21	2.1	4.2	21.2	4.9
N	2	2	2	2	2	2	2	2	2	2	2

002827

Table 31
Summary of Clinical Chemistry Data

Males Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0									
MEAN	50	42	714	138	6	2137	376	38	272
S.D.	4.9	4.9	461.7	119.5	3.5	19.8	17.7	.7	36.8
N	2	2	2	2	2	2	2	2	2
0.15									
MEAN	60	66	820	143	8	1495	1294	579	958
S.D.	6.4	4.9	134.4	63.6	.7	356.4	489.3	302.6	351.4
N	2	2	2	2	2	2	2	2	2
0.75									
MEAN	60	66	622	155	4	1310	516	33	358
S.D.	2.8	25.5	202.2	1.4	2.8	980.8	142.1	2.8	79.2
N	2	2	2	2	2	2	2	2	2

002828

Table 31
Summary of Clinical Chemistry Data

Males Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0					
MEAN	10.6	4.7	156	5.4	111
S.D.	.49	.71	2.1	.14	.0
N	2	2	2	2	2
0.15					
MEAN	10.9	5.6	155	5.4	111
S.D.	1.41	.14	7.1	.49	2.8
N	2	2	2	2	2
0.75					
MEAN	10.6	4.9	154	5.4	110
S.D.	.49	.42	2.1	.64	3.5
N	2	2	2	2	2

002829

Table 31

Summary of Clinical Chemistry Data

Females Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
0	MEAN	55	20	1.0	9.0	4.7	4.2	.8	6	137	49	60
	S.D.	1.4	2.1	.14	.07	.00	.07	.49	.7	35.4	9.9	27.6
	N	2	2	2	2	2	2	2	2	2	2	2
0.15	MEAN	73	24	1.0	8.7	3.9	4.8	.8	6	137	54	54
	S.D.	9.9	2.8	.07	.57	.14	.42	.07	.0	1.4	16.3	24.7
	N	2	2	2	2	2	2	2	2	2	2	2
0.75	MEAN	88	23	1.2	8.7	4.4	4.2	.4	9	142	75	60
	S.D.	4.2	2.8	.07	.78	.64	.14	.07	5.7	14.8	28.3	7.8
	N	2	2	2	2	2	2	2	2	2	2	2

002830

Table 31
Summary of Clinical Chemistry Data

Females Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0	MEAN	86	202	162	77	6	2408	398	16	300
	S.D.	34.6	135.1	7.1	45.3	1.4	806.1	85.6	23.3	50.2
	N	2	2	2	2	2	2	2	2	2
0.15	MEAN	50	78	148	79	12	871	467	47	345
	S.D.	17.7	24.0	55.9	1.4	4.9	195.2	230.5	7.1	161.2
	N	2	2	2	2	2	2	2	2	2
0.75	MEAN	56	80	228	86	4	1797	479	47	370
	S.D.	15.6	3.5	21.2	43.1	1.4	786.3	67.9	.0	58.7
	N	2	2	2	2	2	2	2	2	2

002831

Table 31
Summary of Clinical Chemistry Data
Females Day 364
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day		CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0	MEAN	9.9	4.9	148	5.0	106
	S.D.	.28	.99	4.9	.92	4.2
	N	2	2	2	2	2
0.15	MEAN	9.4	4.8	148	5.4	110
	S.D.	.64	.07	3.5	.71	2.1
	N	2	2	2	2	2
0.75	MEAN	10.2	4.4	155	5.4	112
	S.D.	.35	.21	2.8	.21	1.4
	N	2	2	2	2	2

002832

Table 32
Summary of Clinical Chemistry Data

Males Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
0											
MEAN	74	14	1.2	8.7	5.0	3.6	.6	3	132	32	58
S.D.	8.5	2.8	.00	.28	.21	.07	.35	.0	14.1	.7	3.5
N	2	2	2	2	2	2	2	2	2	2	2
0.15											
MEAN	91	16	1.2	9.1	5.4	3.6	.4	6	178	41	80
S.D.	4.2	1.4	.07	.28	.07	.35	.21	.7	54.4	2.8	36.1
N	2	2	2	2	2	2	2	2	2	2	2
0.75											
MEAN	70	14	1.2	8.9	5.0	4.0	.6	4	118	59	35
S.D.	7.8	.7	.21	.57	.64	.07	.35	.7	5.7	31.1	12.7
N	2	2	2	2	2	2	2	2	2	2	2

002833

Table 32
Summary of Clinical Chemistry Data

Males Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0	MEAN	24	24	620	124	6	102	298	16	233
	S.D.	7.1	3.5	320.3	91.9	5.7	34.6	30.4	7.1	18.4
	N	2	2	2	2	2	2	2	2	2
0.15	MEAN	25	46	871	150	2	141	450	16	294
	S.D.	5.7	7	141.4	68.6	7	31.1	52.3	2.1	83.4
	N	2	2	2	2	2	2	2	2	2
0.75	MEAN	34	41	418	138	0	202	422	16	294
	S.D.	4.9	12.7	55.9	13.4	7	32.5	82.0	4.9	44.5
	N	2	2	2	2	2	2	2	2	2

002834

Covance 6329-223
3M T-6295.7

Table 32
Summary of Clinical Chemistry Data
Males Day 456
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
-----	-----	-----	-----	-----	-----
0					
MEAN	10.2	6.0	153	5.4	111
S.D.	.21	.49	4.2	.42	2.8
N	2	2	2	2	2
0.15					
MEAN	11.8	6.9	164	6.0	116
S.D.	1.20	.42	4.2	.49	3.5
N	2	2	2	2	2
0.75					
MEAN	10.6	5.3	155	5.0	111
S.D.	.78	1.98	4.2	.57	2.8
N	2	2	2	2	2

002835

Table 32
Summary of Clinical Chemistry Data
Females Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
0											
MEAN	64	17	1.0	8.5	4.6	3.9	.6	6	120	56	50
S.D.	21.9	.0	.07	.28	.00	.28	.49	2.1	30.4	5.7	23.3
N	2	2	2	2	2	2	2	2	2	2	2
0.15											
MEAN	78	17	1.0	8.7	4.1	4.6	.6	5	144	71	47
S.D.	.7	1.4	.07	.42	.00	.42	.07	1.4	.0	17.0	15.6
N	2	2	2	2	2	2	2	2	2	2	2
0.75											
MEAN	100	19	1.0	8.7	4.5	4.2	.2	4	138	78	64
S.D.	2.1	2.8	.07	.64	.57	.07	.07	1.4	1.4	50.9	12.0
N	2	2	2	2	2	2	2	2	2	2	2

002836

Table 32
Summary of Clinical Chemistry Data
Females Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0	MEAN	43	134	156	72	4	222	268	10	204
	S.D.	18.4	69.3	24.7	33.2	2.1	31.1	34.6	2.1	17.0
	N	2	2	2	2	2	2	2	2	2
0.15	MEAN	32	50	140	78	7	183	339	13	250
	S.D.	10.6	22.6	65.1	3.5	4.2	100.4	137.2	2.8	87.0
	N	2	2	2	2	2	2	2	2	2
0.75	MEAN	25	54	232	94	2	124	296	18	230
	S.D.	.0	14.8	22.6	43.1	2.1	14.1	89.8	7.1	66.5
	N	2	2	2	2	2	2	2	2	2

002837

Table 32
Summary of Clinical Chemistry Data
Females Day 456
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
-----	-----	-----	-----	-----	-----
0					
MEAN	9.9	5.2	148	5.0	108
S.D.	.42	.35	5.7	.14	3.5
N	2	2	2	2	2
0.15					
MEAN	9.8	5.2	152	5.6	112
S.D.	.42	.21	1.4	.35	.7
N	2	2	2	2	2
0.75					
MEAN	10.4	5.4	154	6.2	116
S.D.	.14	.35	.7	.85	2.8
N	2	2	2	2	2

002838

Table 33
Summary of Clinical Chemistry Data

Males Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day		GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL
-----		-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----
0												
	MEAN	82	16	1.2	8.8	4.7	4.1	.4	6	134	31	70
	S.D.	4.9	2.8	.07	.14	.14	.00	.21	.7	21.9	1.4	9.9
	N	2	2	2	2	2	2	2	2	2	2	2
0.15												
	MEAN	79	19	1.2	8.8	5.1	3.7	.4	4	166	36	92
	S.D.	2.8	.0	.07	.28	.28	.00	.21	1.4	48.1	6.4	31.8
	N	2	2	2	2	2	2	2	2	2	2	2
0.75												
	MEAN	79	16	1.4	9.4	5.1	4.3	.6	7	138	44	57
	S.D.	5.7	.0	.00	.14	.14	.28	.35	4.2	9.2	10.6	14.1
	N	2	2	2	2	2	2	2	2	2	2	2

002839

Table 33
Summary of Clinical Chemistry Data

Males Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0									
MEAN	24	25	505	116	10	111	262	14	202
S.D.	6.4	7.1	277.2	94.8	12.7	46.7	4.2	4.9	1.4
N	2	2	2	2	2	2	2	2	2
0.15									
MEAN	30	34	754	136	3	171	402	12	264
S.D.	.7	2.1	130.1	60.1	2.8	58.0	62.9	.7	81.3
N	2	2	2	2	2	2	2	2	2
0.75									
MEAN	36	40	404	148	0	165	440	16	297
S.D.	12.7	3.5	88.4	1.4	.0	.0	111.0	7.8	52.3
N	2	2	2	2	2	2	2	2	2

002840

Table 33
Summary of Clinical Chemistry Data
Males Day 546
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day		CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0	MEAN	10.6	6.6	160	6.0	116
	S.D.	.21	.07	3.5	.57	6.4
	N	2	2	2	2	2
0.15	MEAN	11.2	7.0	166	6.4	120
	S.D.	.28	.92	3.5	.78	3.5
	N	2	2	2	2	2
0.75	MEAN	11.9	5.8	172	6.1	118
	S.D.	.14	.57	3.5	.14	3.5
	N	2	2	2	2	2

Table 33

Summary of Clinical Chemistry Data

Females Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	GLU MG/DL	UN MG/DL	CREAT MG/DL	T PRO G/DL	ALB G/DL	GLOB G/DL	T BILI MG/DL	SBA UMOL/L	CHOL MG/DL	TRIG MG/DL	HDL MG/DL	
0	MEAN S.D. N	60 9.9 2	16 .7 2	1.0 .07 2	8.5 .42 2	4.4 .00 2	4.1 .42 2	.6 .35 2	6 .7 2	124 39.6 2	53 2.8 2	64 27.6 2
0.15	MEAN S.D. N	72 2.1 2	18 1.4 2	1.0 .21 2	8.4 .21 2	3.8 .21 2	4.6 .00 2	.6 .07 2	5 .0 2	138 12.7 2	60 19.1 2	62 34.6 2
0.75	MEAN S.D. N	96 4.9 2	19 .0 2	1.2 .00 2	8.4 .78 2	4.3 .42 2	4.2 .35 2	.3 .00 2	5 1.4 2	146 1.4 2	76 50.9 2	74 7.8 2

002842

Table 33
Summary of Clinical Chemistry Data

Females Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day		AST/SGOT IU/L	ALT/SGPT IU/L	ALK PHOS IU/L	GGT IU/L	SDH IU/L	CK IU/L	AMYLASE IU/L	LIPASE IU/L	P AMYL U/L
0	MEAN	42	120	151	69	0	154	280	12	212
	S.D.	16.3	100.4	28.3	33.9	.0	87.0	50.2	.7	28.3
	N	2	2	2	2	2	2	2	2	2
0.15	MEAN	26	34	146	79	2	94	353	11	261
	S.D.	.7	4.2	70.0	4.2	.7	20.5	142.8	4.2	93.3
	N	2	2	2	2	2	2	2	2	2
0.75	MEAN	28	59	213	89	2	130	311	15	240
	S.D.	12.0	28.3	38.2	39.6	2.1	47.4	86.3	4.2	64.3
	N	2	2	2	2	2	2	2	2	2

002843

Table 33

Summary of Clinical Chemistry Data

Females Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	CA MG/DL	I PHOS MG/DL	NA MMOL/L	K MMOL/L	CL MMOL/L
0					
MEAN	10.1	5.4	151	5.2	110
S.D.	.00	.28	1.4	.14	2.1
N	2	2	2	2	2
0.15					
MEAN	10.0	5.2	156	5.8	114
S.D.	.28	.35	1.4	.49	3.5
N	2	2	2	2	2
0.75					
MEAN	10.5	5.6	162	6.2	120
S.D.	.28	.35	4.2	.78	6.4
N	2	2	2	2	2

002844

Table 34

Summary of Clinical Urinalysis Data

Males Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	U VOL ML	SP GR	U PH
-----	-----	-----	-----
0			
MEAN	41.5	1.026	7.3
S.D.	17.76	.0050	.75
N	6	6	6
0.03			
MEAN	52.5	1.021	7.4
S.D.	10.15	.0021	.48
N	4	4	4
0.15			
MEAN	97.8	1.019	7.1
S.D.	71.41	.0078	.20
N	6	6	6
0.75			
MEAN	83.5	1.018	7.2
S.D.	46.63	.0066	.26
N	6	6	6

002845

Table 34

Summary of Clinical Urinalysis Data

Females Day -27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	U VOL ML	SP GR	U PH
-----	-----	-----	-----
0			
MEAN	90.7	1.018	7.3
S.D.	75.84	.0060	.41
N	6	6	6
0.03			
MEAN	92.5	1.019	7.1
S.D.	88.38	.0082	.25
N	4	4	4
0.15			
MEAN	71.8	1.021	7.8
S.D.	33.80	.0052	.42
N	6	6	6
0.75			
MEAN	88.0	1.020	7.3
S.D.	78.91	.0068	.41
N	6	6	6

002846

Table 35

Summary of Clinical Urinalysis Data

Males Day 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	U VOL ML	SP GR	U PH
-----	-----	-----	-----
0			
MEAN	50.2	1.018	7.5
S.D.	13.75	.0071	.45
N	6	6	6
0.03			
MEAN	72.5	1.021	7.5
S.D.	29.73	.0048	.41
N	4	4	4
0.15			
MEAN	94.3	1.019	7.2
S.D.	105.16	.0092	.27
N	6	6	6
0.75			
MEAN	79.0	1.018	7.3
S.D.	42.12	.0082	.75
N	6	6	6

002847

Table 35
Summary of Clinical Urinalysis Data
Females Day 37
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	U VOL ML	SP GR	U PH

0			
MEAN	118.5	1.014	8.0
S.D.	218.53	.0103	.32
N	6	6	6
0.03			
MEAN	86.8	1.018	7.8
S.D.	56.91	.0056	.29
N	4	4	4
0.15			
MEAN	83.7	1.017	7.5
S.D.	53.05	.0076	.32
N	6	6	6
0.75			
MEAN	100.2	1.022	7.8
S.D.	155.27	.0094	.61
N	6	6	6

002848

Table 36
Summary of Clinical Urinalysis Data

Males Day 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	U VOL ML	SP GR	U PH

0			
MEAN	77.5	1.018	8.0
S.D.	50.66	.0054	.32
N	6	6	6
0.03			
MEAN	62.2	1.018	8.0
S.D.	34.86	.0076	.41
N	4	4	4
0.15			
MEAN	94.5	1.015	7.8
S.D.	59.43	.0095	.42
N	6	6	6
0.75			
MEAN	68.0	1.017	7.9
S.D.	26.39	.0051	.38
N	6	6	6

002849

Table 36
Summary of Clinical Urinalysis Data
Females Day 62
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	U VOL ML	SP GR	U PH

0			
MEAN	74.3	1.019	8.2
S.D.	61.32	.0076	.26
N	6	6	6
0.03			
MEAN	53.5	1.020	7.6
S.D.	32.58	.0056	.48
N	4	4	4
0.15			
MEAN	62.3	1.020	7.8
S.D.	28.86	.0061	.26
N	6	6	6
0.75			
MEAN	81.0	1.017	7.6 *
S.D.	51.27	.0091	.38
N	6	6	6

002850

Table 37
Summary of Clinical Urinalysis Data

Males Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	U VOL ML	SP GR	U PH
-----	-----	-----	-----
0			
MEAN	47.5	1.024	7.5
S.D.	7.31	.0046	.77
N	6	6	6
0.03			
MEAN	65.8	1.018	7.8
S.D.	40.43	.0062	.29
N	4	4	4
0.15			
MEAN	101.2	1.014 *	7.4
S.D.	73.16	.0061	.49
N	6	6	6
0.75			
MEAN	54.0	1.020	7.2
S.D.	19.47	.0066	.88
N	6	6	6

002851

Table 37

Summary of Clinical Urinalysis Data

Females Day 91

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	U VOL ML	SP GR	U PH

0			
MEAN	93.3	1.015	8.0
S.D.	68.15	.0053	.00
N	6	6	6
0.03			
MEAN	64.8	1.018	7.4
S.D.	30.02	.0034	.48
N	4	4	4
0.15			
MEAN	63.2	1.018	7.5
S.D.	22.56	.0073	.63
N	6	6	6
0.75			
MEAN	120.5	1.017	7.8
S.D.	125.14	.0096	.42
N	6	6	6

002852

Table 38

Summary of Clinical Urinalysis Data

Males Day 153

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	U VOL ML	SP GR	U PH

0			
MEAN	131.3	1.013	7.1
S.D.	110.42	.0072	.49
N	6	6	6
0.03			
MEAN	55.0	1.020	7.4
S.D.	21.32	.0052	.48
N	4	4	4
0.15			
MEAN	137.8	1.011	7.1
S.D.	114.54	.0062	.20
N	6	6	6
0.75			
MEAN	180.0	1.011	7.1
S.D.	136.48	.0082	.58
N	6	6	6

002853

Table 38
Summary of Clinical Urinalysis Data
Females Day 153
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	U VOL ML	SP GR	U PH
0			
MEAN	85.2	1.016	7.5
S.D.	53.91	.0084	.32
N	6	6	6
0.03			
MEAN	60.5	1.016	7.0
S.D.	36.93	.0029	.41
N	4	4	4
0.15			
MEAN	40.7	1.022	7.1
S.D.	11.15	.0040	.20
N	6	6	6
0.75			
MEAN	89.0	1.017	7.1
S.D.	93.46	.0085	.66
N	6	6	6

002854

Table 39
Summary of Clinical Urinalysis Data
Males Day 182
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	U VOL ML	SP GR	U PH

0			
MEAN	116.2	1.014	7.9
S.D.	79.33	.0072	.20
N	6	6	6
0.03			
MEAN	75.5	1.017	7.9
S.D.	26.20	.0022	.25
N	4	4	4
0.15			
MEAN	122.3	1.013	7.5
S.D.	125.43	.0053	1.00
N	6	6	6
0.75			
MEAN	121.0	1.013	7.2
S.D.	108.83	.0059	.65
N	4	4	4

002855

Table 39

Summary of Clinical Urinalysis Data

Females Day 182

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day	U VOL ML	SP GR	U PH
-----	-----	-----	-----
0			
MEAN	85.7	1.016	8.1
S.D.	40.59	.0050	.20
N	6	6	6
0.03			
MEAN	76.2	1.016	7.6
S.D.	31.48	.0054	.48
N	4	4	4
0.15			
MEAN	73.3	1.017	7.9
S.D.	25.33	.0055	.20
N	6	6	6
0.75			
MEAN	131.8	1.014	7.8
S.D.	156.54	.0058	.26
N	6	6	6

002856

Table 40
Summary of Clinical Urinalysis Data
Males Day 217
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	U VOL ML	SP GR	U PH
-----	-----	-----	-----
0			
MEAN	179.5	1.010	7.2
S.D.	24.75	.0000	.35
N	2	2	2
0.15			
MEAN	239.5	1.007	7.5
S.D.	79.90	.0028	.00
N	2	2	2
0.75			
MEAN	87.5	1.013	7.0
S.D.	36.06	.0028	.71
N	2	2	2

002857

Table 40

Summary of Clinical Urinalysis Data

Females Day 217

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day		U VOL ML	SP GR	U PH

0				
	MEAN	143.0	1.014	7.8
	S.D.	77.78	.0078	.35
	N	2	2	2
0.15				
	MEAN	121.0	1.015	7.2
	S.D.	80.61	.0000	.35
	N	2	2	2
0.75				
	MEAN	89.0	1.015	7.5
	S.D.	36.77	.0000	.71
	N	2	2	2

002858

Table 41

Summary of Clinical Urinalysis Data

Males Day 245

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	U VOL ML	SP GR	U PH
-----	-----	-----	-----
0			
MEAN	195.5	1.009	7.8
S.D.	9.19	.0014	.35
N	2	2	2
0.15			
MEAN	196.0	1.010	7.5
S.D.	132.94	.0064	.00
N	2	2	2
0.75			
MEAN	83.0	1.017	7.8
S.D.	29.70	.0042	.35
N	2	2	2

002859

Table 41
Summary of Clinical Urinalysis Data
Females Day 245
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	U VOL ML	SP GR	U PH
-----	-----	-----	-----
0			
MEAN	117.0	1.018	8.0
S.D.	100.41	.0113	.00
N	2	2	2
0.15			
MEAN	131.5	1.016	7.2
S.D.	62.93	.0021	.35
N	2	2	2
0.75			
MEAN	91.5	1.016	7.8
S.D.	48.79	.0035	.35
N	2	2	2

002860

Table 42
Summary of Clinical Urinalysis Data
Males Day 274
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	U VOL ML	SP GR	U PH

0			
MEAN	284.0	1.004	6.8
S.D.	50.91	.0007	.35
N	2	2	2
0.15			
MEAN	234.0	1.007	7.2
S.D.	169.71	.0042	.35
N	2	2	2
0.75			
MEAN	67.5	1.018	7.0
S.D.	50.20	.0106	.71
N	2	2	2

002861

Table 42
Summary of Clinical Urinalysis Data
Females Day 274
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	U VOL ML	SP GR	U PH

0			
MEAN	141.5	1.006	7.8
S.D.	33.23	.0014	.35
N	2	2	2
0.15			
MEAN	63.5	1.020	7.5
S.D.	37.48	.0050	.00
N	2	2	2
0.75			
MEAN	64.5	1.010	7.2
S.D.	58.69	.0007	1.06
N	2	2	2

002862

Table 43

Summary of Clinical Urinalysis Data

Males Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	U VOL ML	SP GR	U PH

0			
MEAN	296.0	1.008	6.8
S.D.	254.56	.0092	.35
N	2	2	2
0.15			
MEAN	99.5	1.016	6.5
S.D.	94.05	.0099	.71
N	2	2	2
0.75			
MEAN	47.5	1.020	6.0
S.D.	4.95	.0092	.00
N	2	2	2

002863

Table 43

Summary of Clinical Urinalysis Data

Females Day 322

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day		U VOL ML	SP GR	U PH

0				
	MEAN	220.5	1.006	8.0
	S.D.	188.80	.0050	.00
	N	2	2	2
0.15				
	MEAN	59.0	1.018	6.5
	S.D.	24.04	.0042	.71
	N	2	2	2
0.75				
	MEAN	92.0	1.014	6.8
	S.D.	29.70	.0035	.35
	N	2	2	2

002864

Table 44

Summary of Clinical Urinalysis Data

Males Day 364

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day		U VOL ML	SP GR	U PH
0				
	MEAN	206.5	1.017	7.8
	S.D.	81.32	.0028	.35
	N	2	2	2
0.15				
	MEAN	74.5	1.018	7.5
	S.D.	10.61	.0000	.71
	N	2	2	2
0.75				
	MEAN	90.0	1.018	6.8
	S.D.	14.14	.0050	1.06
	N	2	2	2

002865

Table 44
Summary of Clinical Urinalysis Data
Females Day 364
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	U VOL ML	SP GR	U PH

0			
MEAN	158.0	1.011	8.0
S.D.	11.31	.0000	.00
N	2	2	2
0.15			
MEAN	68.5	1.021	7.0
S.D.	13.44	.0014	.00
N	2	2	2
0.75			
MEAN	76.0	1.018	7.0
S.D.	46.67	.0007	.71
N	2	2	2

002866

Table 45
Summary of Clinical Urinalysis Data
Males Day 456
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	U VOL ML	SP GR	U PH
-----	-----	-----	-----
0			
MEAN	185.0	1.010	8.0
S.D.	120.21	.0028	.00
N	2	2	2
0.15			
MEAN	182.0	1.008	8.0
S.D.	147.08	.0050	.00
N	2	2	2
0.75			
MEAN	84.0	1.012	8.0
S.D.	8.49	.0050	.00
N	2	2	2

002867

Table 45

Summary of Clinical Urinalysis Data

Females Day 456

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	U VOL ML	SP GR	U PH
-----	-----	-----	-----
0			
MEAN	214.0	1.009	8.0
S.D.	164.05	.0057	.00
N	2	2	2
0.15			
MEAN	145.0	1.011	7.8
S.D.	74.95	.0042	.35
N	2	2	2
0.75			
MEAN	118.0	1.005	8.0
S.D.	82.02	.0042	.00
N	2	2	2

002868

Table 46
Summary of Clinical Urinalysis Data
Males Day 546
26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	U VOL ML	SP GR	U PH

0			
MEAN	430.0	1.005	8.0
S.D.	70.71	.0000	.00
N	2	2	2
0.15			
MEAN	300.0	1.006	7.8
S.D.	148.49	.0028	.35
N	2	2	2
0.75			
MEAN	222.5	1.010	8.0
S.D.	173.24	.0071	.00
N	2	2	2

002869

Table 46

Summary of Clinical Urinalysis Data

Females Day 546

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS

DOSE mg/kg/day	U VOL ML	SP GR	U PH
-----	-----	-----	-----
0			
MEAN	132.5	1.011	8.0
S.D.	38.89	.0057	.00
N	2	2	2
0.15			
MEAN	67.5	1.018	8.0
S.D.	24.75	.0014	.00
N	2	2	2
0.75			
MEAN	99.0	1.014	8.0
S.D.	80.61	.0050	.00
N	2	2	2

002870

Table 47

Summary of Palmitoyl CoA Oxidase Determinations

Terminal Sacrifice

Males

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		PCOAO IU/G
-----		-----
0	MEAN	5
	S.D.	1.5
	N	4
0.03	MEAN	5
	S.D.	1.0
	N	4
0.15	MEAN	6
	S.D.	.6
	N	4
0.75	MEAN	7
	S.D.	1.4
	N	2

002871

Table 47
Summary of Palmitoyl CoA Oxidase Determinations
Terminal Sacrifice
Females

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID
POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS

DOSE mg/kg/day		PCOAO IU/G
-----		-----
0	MEAN	4
	S.D.	.8
	N	4
0.03	MEAN	4
	S.D.	1.3
	N	4
0.15	MEAN	6
	S.D.	1.0
	N	4
0.75	MEAN	6 *
	S.D.	.8
	N	4

002872

TABLE 48
Summary of Organ Weight Data
Terminal Sacrifice

Covance 6329-223
3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 1

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

LEFT ADRENAL

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO
M	1					F	1				
	NUMBER IN GROUP:	4	4	4	4		NUMBER IN GROUP:	4	4	4	4
	MEAN:	3540.0	0.2858	0.0083	0.0045		MEAN:	2821.3	0.2933	0.0103	0.0052
	STANDARD DEV:	765.9	0.0195	0.0012	0.0002		STANDARD DEV:	304.9	0.0650	0.0016	0.0014
M	2					F	2				
	NUMBER IN GROUP:	4	4	4	4		NUMBER IN GROUP:	4	4	4	4
	MEAN:	3631.3	0.3105	0.0087	0.0051		MEAN:	2988.8	0.3815	0.0132	0.0063
	STANDARD DEV:	524.0	0.0367	0.0015	0.0008		STANDARD DEV:	723.4	0.0508	0.0033	0.0010
M	3					F	3				
	NUMBER IN GROUP:	4	4	4	4		NUMBER IN GROUP:	4	4	4	4
	MEAN:	3190.0	0.2692	0.0084	0.0043		MEAN:	2768.8	0.3400	0.0122	0.0058
	STANDARD DEV:	199.8	0.0298	0.0006	0.0003		STANDARD DEV:	335.9	0.0589	0.0012	0.0010

002873

TABLE 48
Summary of Organ Weight Data
Terminal Sacrifice

Covance 6329-223
3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 2

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

LEFT ADRENAL

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO
M	4					F	4				
NUMBER IN GROUP:		2	2	2	2	NUMBER IN GROUP:		4	4	4	4
MEAN:		3077.5	0.3665	0.0120*	0.0055	MEAN:		2653.8	0.3468	0.0134	0.0061
STANDARD DEV:		1120.8	0.1237	0.0003	0.0012	STANDARD DEV:		403.1	0.0265	0.0029	0.0004

002874

TABLE 48
Summary of Organ Weight Data
Terminal Sacrifice

Covance 6329-223
3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 3

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

RIGHT ADRENAL

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO
M	1					F	1				
	NUMBER IN GROUP:	4	4	4	4		NUMBER IN GROUP:	4	4	4	4
	MEAN:	3540.0	0.2093	0.0059	0.0033		MEAN:	2821.3	0.2178	0.0076	0.0039
	STANDARD DEV:	765.9	0.0503	0.0011	0.0008		STANDARD DEV:	304.9	0.0772	0.0021	0.0016
M	2					F	2				
	NUMBER IN GROUP:	4	4	4	4		NUMBER IN GROUP:	4	4	4	4
	MEAN:	3631.3	0.2240	0.0063	0.0036		MEAN:	2988.8	0.2768	0.0095	0.0046
	STANDARD DEV:	524.0	0.0243	0.0012	0.0005		STANDARD DEV:	723.4	0.0356	0.0020	0.0005
M	3					F	3				
	NUMBER IN GROUP:	4	4	4	4		NUMBER IN GROUP:	4	4	4	4
	MEAN:	3190.0	0.2135	0.0067	0.0033		MEAN:	2768.8	0.2425	0.0088	0.0042
	STANDARD DEV:	199.8	0.0484	0.0014	0.0006		STANDARD DEV:	335.9	0.0377	0.0008	0.0006

002875

TABLE 48
Summary of Organ Weight Data
Terminal Sacrifice

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 4

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

RIGHT ADRENAL

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO
M	4					F	4				
NUMBER IN GROUP:		2	2	2	2	NUMBER IN GROUP:		4	4	4	4
MEAN:		3077.5	0.2725	0.0090	0.0041	MEAN:		2653.8	0.2535	0.0098	0.0044
STANDARD DEV:		1120.8	0.0686	0.0011	0.0006	STANDARD DEV:		403.1	0.0306	0.0025	0.0004

002876

TABLE 48

Covance 6329-223
3M T-6295.7

Summary of Organ Weight Data

Terminal Sacrifice

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 5

TABLE INCLUDES:

SEX=ALL; GROUP=ALL; WEEKS=ALL
DEATH=T; SUBSET=ALL

BRAIN

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO
M	1					F	1				
		4	4	4	4			4	4	4	4
NUMBER IN GROUP:		3540.0	63.1425	1.8330	1.0000	NUMBER IN GROUP:		2821.3	56.6408	2.0307	1.0000
MEAN:		765.9	1.1363	0.3051	0.0000	MEAN:		304.9	4.1710	0.3056	0.0000
STANDARD DEV:						STANDARD DEV:					
M	2					F	2				
		4	4	4	4			4	4	4	4
NUMBER IN GROUP:		3631.3	61.7943	1.7415	1.0000	NUMBER IN GROUP:		2988.8	60.6083	2.1053	1.0000
MEAN:		524.0	5.5692	0.3701	0.0000	MEAN:		723.4	2.6726	0.4471	0.0000
STANDARD DEV:						STANDARD DEV:					
M	3					F	3				
		4	4	4	4			4	4	4	4
NUMBER IN GROUP:		3190.0	63.3520	1.9873	1.0000	NUMBER IN GROUP:		2768.8	58.3910	2.1321	1.0000
MEAN:		199.8	5.3720	0.1406	0.0000	MEAN:		335.9	3.2163	0.2735	0.0000
STANDARD DEV:						STANDARD DEV:					

002877

TABLE 48
Summary of Organ Weight Data
Terminal Sacrifice

Covance 6329-223
3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 6

TABLE INCLUDES:
SEX=ALL; GROUP=ALL; WEEKS=ALL
DEATH=T; SUBSET=ALL

BRAIN

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO
M	4					F	4				
NUMBER IN GROUP:		2	2	2	2	NUMBER IN GROUP:		4	4	4	4
MEAN:		3077.5	66.2635	2.2566	1.0000	MEAN:		2653.8	57.0957	2.1883	1.0000
STANDARD DEV:		1120.8	7.8154	0.5678	0.0000	STANDARD DEV:		403.1	2.2179	0.3459	0.0000

002878

TABLE 48
Summary of Organ Weight Data
Terminal Sacrifice

Covance 6329-223
3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 7

TABLE INCLUDES:
SEX=ALL; GROUP=ALL; WEEKS=ALL
DEATH=T; SUBSET=ALL

LF EPIDIDYMIS

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO
M	1					F	1				
		4	4	4	4			4			
	NUMBER IN GROUP:	3540.0	1.1407	0.0314	0.0180		NUMBER IN GROUP:	2821.3			
	MEAN:	765.9	0.5031	0.0076	0.0076		MEAN:	304.9			
	STANDARD DEV:						STANDARD DEV:				
M	2					F	2				
		4	4	4	4			4			
	NUMBER IN GROUP:	3631.3	1.4208	0.0371	0.0243		NUMBER IN GROUP:	2988.8			
	MEAN:	524.0	0.9897	0.0196	0.0197		MEAN:	723.4			
	STANDARD DEV:						STANDARD DEV:				
M	3					F	3				
		4	4	4	4			4			
	NUMBER IN GROUP:	3190.0	0.9760	0.0306	0.0155		NUMBER IN GROUP:	2768.8			
	MEAN:	199.8	0.0910	0.0027	0.0025		MEAN:	335.9			
	STANDARD DEV:						STANDARD DEV:				

002879

TABLE 48
Summary of Organ Weight Data
Terminal Sacrifice

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 8

TABLE INCLUDES:
SEX=ALL; GROUP=ALL; WEEKS=ALL
DEATH=T; SUBSET=ALL

LF EPIDIDYMIS

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO
M	4					F	4				
NUMBER IN GROUP:		2	2	2	2	NUMBER IN GROUP:		4			
MEAN:		3077.5	1.3095	0.0387	0.0189	MEAN:		2653.8			
STANDARD DEV:		1120.8	1.0812	0.0210	0.0141	STANDARD DEV:		403.1			

002880

TABLE 48
Summary of Organ Weight Data
Terminal Sacrifice

PAGE: 9

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

TABLE INCLUDES:
SEX=ALL; GROUP=ALL; WEEKS=ALL
DEATH=T; SUBSET=ALL

SEX=ALL; GROUP=ALL; WEEKS=ALL
DEATH=T; SUBSET=ALL

RT EPIDIDYMIS

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M	1				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3540.0	1.2160	0.0340	0.0192
STANDARD DEV:		765.9	0.4066	0.0063	0.0061
M	2				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3631.3	1.3563	0.0353	0.0232
STANDARD DEV:		524.0	0.9663	0.0191	0.0192
M	3				
NUMBER IN GROUP:		4	4	4	4
MEAN:		3190.0	1.0213	0.0322	0.0163
STANDARD DEV:		199.8	0.0786	0.0039	0.0025

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
F	1				
NUMBER IN GROUP:		4			
MEAN:		2821.3			
STANDARD DEV:		304.9			
F	2				
NUMBER IN GROUP:		4			
MEAN:		2988.8			
STANDARD DEV:		723.4			
F	3				
NUMBER IN GROUP:		4			
MEAN:		2768.8			
STANDARD DEV:		335.9			

002881

TABLE 48
Summary of Organ Weight Data
Terminal Sacrifice

Covance 6329-223
3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 10

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

RT EPIDIDYMIS

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO
M	4					F	4				
NUMBER IN GROUP:		2	2	2	2	NUMBER IN GROUP:		4			
MEAN:		3077.5	1.3805	0.0396	0.0198	MEAN:		2653.8			
STANDARD DEV:		1120.8	1.3371	0.0290	0.0178	STANDARD DEV:		403.1			

002882

TABLE 48
Summary of Organ Weight Data
Terminal Sacrifice

Covance 6329-223
3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 11

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

LF KIDNEY

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO
M	1					F	1				
		4	4	4	4			4	4	4	4
	NUMBER IN GROUP:	3540.0	6.2305	0.1780	0.0985		NUMBER IN GROUP:	2821.3	5.5023	0.1943	0.0978
	MEAN:	765.9	0.8729	0.0147	0.0120		MEAN:	304.9	0.9665	0.0191	0.0214
	STANDARD DEV:						STANDARD DEV:				
M	2					F	2				
		4	4	4	4			4	4	4	4
	NUMBER IN GROUP:	3631.3	6.6015	0.1838	0.1078		NUMBER IN GROUP:	2988.8	5.8693	0.1993	0.0972
	MEAN:	524.0	0.4812	0.0231	0.0163		MEAN:	723.4	0.9019	0.0191	0.0166
	STANDARD DEV:						STANDARD DEV:				
M	3					F	3				
		4	4	4	4			4	4	4	4
	NUMBER IN GROUP:	3190.0	5.8875	0.1844	0.0936		NUMBER IN GROUP:	2768.8	5.5955	0.2033	0.0960
	MEAN:	199.8	0.6683	0.0157	0.0150		MEAN:	335.9	0.4375	0.0174	0.0090
	STANDARD DEV:						STANDARD DEV:				

002883

TABLE 48
Summary of Organ Weight Data
Terminal Sacrifice

PAGE: 12

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

TABLE INCLUDES:

SEX=ALL; GROUP=ALL; WEEKS=ALL
DEATH=T; SUBSET=ALL

LF KIDNEY

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO
M	4					F	4				
NUMBER IN GROUP:		2	2	2	2	NUMBER IN GROUP:		4	4	4	4
MEAN:		3077.5	5.5310	0.1837	0.0828	MEAN:		2653.8	5.7638	0.2190	0.1007
STANDARD DEV:		1120.8	1.3916	0.0217	0.0112	STANDARD DEV:		403.1	0.9586	0.0364	0.0138

002884

TABLE 48

Covance 6329-223
3M T-6295.7

Summary of Organ Weight Data

Terminal Sacrifice

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 13

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

RT KIDNEY

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO
M	1					F	1				
	NUMBER IN GROUP:	4	4	4	4		NUMBER IN GROUP:	4	4	4	4
	MEAN:	3540.0	6.0052	0.1712	0.0949		MEAN:	2821.3	5.2995	0.1876	0.0941
	STANDARD DEV:	765.9	0.9353	0.0127	0.0130		STANDARD DEV:	304.9	0.7814	0.0168	0.0173
M	2					F	2				
	NUMBER IN GROUP:	4	4	4	4		NUMBER IN GROUP:	4	4	4	4
	MEAN:	3631.3	6.7495	0.1875	0.1104		MEAN:	2988.8	5.7718	0.1966	0.0956
	STANDARD DEV:	524.0	0.6929	0.0228	0.0206		STANDARD DEV:	723.4	0.8467	0.0260	0.0163
M	3					F	3				
	NUMBER IN GROUP:	4	4	4	4		NUMBER IN GROUP:	4	4	4	4
	MEAN:	3190.0	5.7358	0.1795	0.0910		MEAN:	2768.8	5.4028	0.1965	0.0926
	STANDARD DEV:	199.8	0.6730	0.0140	0.0131		STANDARD DEV:	335.9	0.4663	0.0210	0.0067

002885

TABLE 48

Covance 6329-223
3M T-6295.7

Summary of Organ Weight Data

Terminal Sacrifice

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 14

TABLE INCLUDES:

SEX=ALL; GROUP=ALL; WEEKS=ALL
DEATH=T; SUBSET=ALL

RT KIDNEY

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO
M	4					F	4				
NUMBER IN GROUP:		2	2	2	2	NUMBER IN GROUP:		4	4	4	4
MEAN:		3077.5	5.4045	0.1801	0.0810	MEAN:		2653.8	5.7878	0.2191	0.1011
STANDARD DEV:		1120.8	1.2594	0.0247	0.0095	STANDARD DEV:		403.1	1.1793	0.0375	0.0181

989220

TABLE 48

Covance 6329-223
3M T-6295.7

Summary of Organ Weight Data

Terminal Sacrifice

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 15

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

LIVER

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO
M	1					F	1				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4	4	4	4
MEAN:		3540.0	54.9200	1.5733	0.8689	MEAN:		2821.3	51.0925	1.8015	0.9104
STANDARD DEV:		765.9	8.1496	0.2144	0.1203	STANDARD DEV:		304.9	9.4330	0.1518	0.2199
M	2					F	2				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4	4	4	4
MEAN:		3631.3	62.0868	1.7413	1.0090	MEAN:		2988.8	56.8278	1.9074	0.9392
STANDARD DEV:		524.0	5.2757	0.3311	0.0994	STANDARD DEV:		723.4	12.5811	0.0398	0.2089
M	3					F	3				
NUMBER IN GROUP:		4	4	4	4	NUMBER IN GROUP:		4	4	4	4
MEAN:		3190.0	57.3325	1.7955	0.9059	MEAN:		2768.8	57.0393	2.0747	0.9783
STANDARD DEV:		199.8	5.5102	0.0901	0.0581	STANDARD DEV:		335.9	3.1240	0.1801	0.0629

002887

TABLE 48

Covance 6329-223
3M T-6295.7

Summary of Organ Weight Data

Terminal Sacrifice

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 16

TABLE INCLUDES:
SEX=ALL; GROUP=ALL; WEEKS=ALL
DEATH=T; SUBSET=ALL

LIVER

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO
M	4					F	4				
NUMBER IN GROUP:		2	2	2	2	NUMBER IN GROUP:		4	4	4	4
MEAN:		3077.5	85.2815	2.7247*	1.2616	MEAN:		2653.8	75.2997*	2.8466*	1.3189*
STANDARD DEV:		1120.8	38.3782	0.2548	0.4304	STANDARD DEV:		403.1	13.3835	0.3447	0.2262

002888

TABLE 48
Summary of Organ Weight Data
Terminal Sacrifice

PAGE: 17

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

TABLE INCLUDES:
SEX=ALL; GROUP=ALL; WEEKS=ALL
DEATH=T; SUBSET=ALL

LF OVARY

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M	1					F	1				
		NUMBER IN GROUP:	4					NUMBER IN GROUP:	4		
		MEAN:	3540.0					MEAN:	2821.3	0.1688	0.0059
		STANDARD DEV:	765.9					STANDARD DEV:	304.9	0.0679	0.0022
M	2					F	2				
		NUMBER IN GROUP:	4					NUMBER IN GROUP:	4		
		MEAN:	3631.3					MEAN:	2988.8	0.1723	0.0056
		STANDARD DEV:	524.0					STANDARD DEV:	723.4	0.0729	0.0011
M	3					F	3				
		NUMBER IN GROUP:	4					NUMBER IN GROUP:	4		
		MEAN:	3190.0					MEAN:	2768.8	0.1873	0.0067
		STANDARD DEV:	199.8					STANDARD DEV:	335.9	0.0847	0.0028

002889

TABLE 48

Covance 6329-223
3M T-6295.7

Summary of Organ Weight Data

Terminal Sacrifice

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 18

TABLE INCLUDES:

SEX=ALL; GROUP=ALL; WEEKS=ALL
DEATH=T; SUBSET=ALL

LF OVARY

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO
M	4					F	4				
NUMBER IN GROUP:		2				NUMBER IN GROUP:		4	4	4	4
MEAN:		3077.5				MEAN:		2653.8	0.1590	0.0063	0.0028
STANDARD DEV:		1120.8				STANDARD DEV:		403.1	0.0563	0.0031	0.0009

002890

TABLE 48

Covance 6329-223
3M T-6295.7

Summary of Organ Weight Data

Terminal Sacrifice

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 19

TABLE INCLUDES:

SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

RT OVARY

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO
M	1				
		NUMBER IN GROUP:	4		
		MEAN:	3540.0		
		STANDARD DEV:	765.9		
M	2				
		NUMBER IN GROUP:	4		
		MEAN:	3631.3		
		STANDARD DEV:	524.0		
M	3				
		NUMBER IN GROUP:	4		
		MEAN:	3190.0		
		STANDARD DEV:	199.8		

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO
F	1				
		NUMBER IN GROUP:	4		
		MEAN:	2821.3	0.1423	0.0050
		STANDARD DEV:	304.9	0.0491	0.0012
F	2				
		NUMBER IN GROUP:	4		
		MEAN:	2988.8	0.1788	0.0061
		STANDARD DEV:	723.4	0.0453	0.0014
F	3				
		NUMBER IN GROUP:	4		
		MEAN:	2768.8	0.1367	0.0049
		STANDARD DEV:	335.9	0.0353	0.0010

002891

TABLE 48

Covance 6329-223
3M T-6295.7

Summary of Organ Weight Data

Terminal Sacrifice

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 20

TABLE INCLUDES:

SEX=ALL; GROUP=ALL; WEEKS=ALL
DEATH=T; SUBSET=ALL

RT OVARY

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO
M	4					F	4				
NUMBER IN GROUP:		2				NUMBER IN GROUP:		4	4	4	4
MEAN:		3077.5				MEAN:		2653.8	0.1498	0.0058	0.0026
STANDARD DEV:		1120.8				STANDARD DEV:		403.1	0.0169	0.0015	0.0003

002892

TABLE 48
Summary of Organ Weight Data
Terminal Sacrifice

PAGE: 21

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

LF TESTIS

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO
M	1					F	1				
		NUMBER IN GROUP:	4	4	4			NUMBER IN GROUP:	4		
		MEAN:	3540.0	6.9795	0.1918			MEAN:	2821.3		
		STANDARD DEV:	765.9	3.7391	0.0803			STANDARD DEV:	304.9		
M	2					F	2				
		NUMBER IN GROUP:	4	4	4			NUMBER IN GROUP:	4		
		MEAN:	3631.3	7.8848	0.2009			MEAN:	2988.8		
		STANDARD DEV:	524.0	7.4545	0.1587			STANDARD DEV:	723.4		
M	3					F	3				
		NUMBER IN GROUP:	4	4	4			NUMBER IN GROUP:	4		
		MEAN:	3190.0	5.0977	0.1600			MEAN:	2768.8		
		STANDARD DEV:	199.8	0.6925	0.0215			STANDARD DEV:	335.9		

002893

TABLE 48
Summary of Organ Weight Data
Terminal Sacrifice

Covance 6329-223
3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 22

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

LF TESTIS

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO
M	4					F	4				
NUMBER IN GROUP:		2	2	2	2	NUMBER IN GROUP:		4			
MEAN:		3077.5	7.0340	0.1946	0.0998	MEAN:		2653.8			
STANDARD DEV:		1120.8	7.9238	0.1866	0.1078	STANDARD DEV:		403.1			

002894

TABLE 48

Covance 6329-223
3M T-6295.7

Summary of Organ Weight Data

Terminal Sacrifice

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 23

TABLE INCLUDES:

SEX=ALL; GROUP=ALL; WEEKS=ALL
DEATH=T; SUBSET=ALL

RT TESTIS

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO
M	1					F	1				
	NUMBER IN GROUP:	4	4	4	4		NUMBER IN GROUP:	4			
	MEAN:	3540.0	6.7453	0.1868	0.1064		MEAN:	2821.3			
	STANDARD DEV:	765.9	3.3813	0.0764	0.0518		STANDARD DEV:	304.9			
M	2					F	2				
	NUMBER IN GROUP:	4	4	4	4		NUMBER IN GROUP:	4			
	MEAN:	3631.3	8.1230	0.2089	0.1403		MEAN:	2988.8			
	STANDARD DEV:	524.0	7.2175	0.1504	0.1403		STANDARD DEV:	723.4			
M	3					F	3				
	NUMBER IN GROUP:	4	4	4	4		NUMBER IN GROUP:	4			
	MEAN:	3190.0	5.0045	0.1568	0.0798		MEAN:	2768.8			
	STANDARD DEV:	199.8	0.7091	0.0194	0.0163		STANDARD DEV:	335.9			

TABLE 48
Summary of Organ Weight Data
Terminal Sacrifice

PAGE: 24

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

RT TESTIS

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO
M	4					F	4				
NUMBER IN GROUP:		2	2	2	2	NUMBER IN GROUP:		4			
MEAN:		3077.5	6.9155	0.1906	0.0980	MEAN:		2653.8			
STANDARD DEV:		1120.8	7.8977	0.1872	0.1076	STANDARD DEV:		403.1			

002896

TABLE 48
Summary of Organ Weight Data
Terminal Sacrifice

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

TABLE INCLUDES:
SEX=ALL; GROUP=ALL; WEEKS=ALL
DEATH=T; SUBSET=ALL

PANCREAS

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO
M	1					F	1				
	NUMBER IN GROUP:	4	4	4	4		NUMBER IN GROUP:	4	4	4	4
	MEAN:	3540.0	5.4570	0.1576	0.0863		MEAN:	2821.3	4.4270	0.1571	0.0787
	STANDARD DEV:	765.9	0.8021	0.0319	0.0119		STANDARD DEV:	304.9	0.4797	0.0097	0.0125
M	2					F	2				
	NUMBER IN GROUP:	4	4	4	4		NUMBER IN GROUP:	4	4	4	4
	MEAN:	3631.3	4.8133	0.1309	0.0799		MEAN:	2988.8	5.9108*	0.2030	0.0982
	STANDARD DEV:	524.0	1.3674	0.0234	0.0298		STANDARD DEV:	723.4	1.0351	0.0437	0.0216
M	3					F	3				
	NUMBER IN GROUP:	4	4	4	4		NUMBER IN GROUP:	4	4	4	4
	MEAN:	3190.0	4.3790	0.1365	0.0687		MEAN:	2768.8	4.6248	0.1678	0.0792
	STANDARD DEV:	199.8	1.1403	0.0294	0.0138		STANDARD DEV:	335.9	0.4099	0.0126	0.0059

002897

TABLE 48
Summary of Organ Weight Data
Terminal Sacrifice

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 26

TABLE INCLUDES:
SEX=ALL; GROUP=ALL; WEEKS=ALL
DEATH=T; SUBSET=ALL

PANCREAS

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO
M	4					F	4				
NUMBER IN GROUP:		2	2	2	2	NUMBER IN GROUP:		4	4	4	4
MEAN:		3077.5	4.1355	0.1341	0.0615	MEAN:		2653.8	4.3725	0.1659	0.0768
STANDARD DEV:		1120.8	1.5450	0.0014	0.0161	STANDARD DEV:		403.1	0.4273	0.0119	0.0089

868200

TABLE 48
Summary of Organ Weight Data
Terminal Sacrifice

PAGE: 27

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

TABLE INCLUDES:
SEX=ALL; GROUP=ALL; WEEKS=ALL
DEATH=T; SUBSET=ALL

LF THYROID/PARA

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO-BODY WT (%)	ORGAN-TO-BRAIN WT RATIO
M	1					F	1				
	NUMBER IN GROUP:	4	4	4	4		NUMBER IN GROUP:	4	4	4	4
	MEAN:	3540.0	0.1675	0.0047	0.0026		MEAN:	2821.3	0.2567	0.0088	0.0047
	STANDARD DEV:	765.9	0.0479	0.0004	0.0007		STANDARD DEV:	304.9	0.1415	0.0037	0.0029
M	2					F	2				
	NUMBER IN GROUP:	4	4	4	4		NUMBER IN GROUP:	4	4	4	4
	MEAN:	3631.3	0.2750	0.0074	0.0046		MEAN:	2988.8	0.2138	0.0071	0.0035
	STANDARD DEV:	524.0	0.1374	0.0028	0.0027		STANDARD DEV:	723.4	0.0751	0.0013	0.0012
M	3					F	3				
	NUMBER IN GROUP:	4	4	4	4		NUMBER IN GROUP:	4	4	4	4
	MEAN:	3190.0	0.2075	0.0064	0.0032		MEAN:	2768.8	0.1542	0.0057	0.0027
	STANDARD DEV:	199.8	0.0792	0.0022	0.0011		STANDARD DEV:	335.9	0.0382	0.0018	0.0007

002839

TABLE 48
Summary of Organ Weight Data
Terminal Sacrifice

Covance 6329-223
3M T-6295.7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 28

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

LF THYROID/PARA

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO
M	4					F	4				
NUMBER IN GROUP:		2	2	2	2	NUMBER IN GROUP:		4	4	4	4
MEAN:		3077.5	0.2020	0.0063	0.0030	MEAN:		2653.8	0.1872	0.0071	0.0033
STANDARD DEV:		1120.8	0.1174	0.0015	0.0014	STANDARD DEV:		403.1	0.0463	0.0017	0.0008

002900

TABLE 48
Summary of Organ Weight Data
Terminal Sacrifice

PAGE: 29

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

TABLE INCLUDES:
SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;SUBSET=ALL

RT THYROID/PARA

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO
M	1					F	1				
	NUMBER IN GROUP:	4	4	4	4		NUMBER IN GROUP:	4	4	4	4
	MEAN:	3540.0	0.1690	0.0046	0.0027		MEAN:	2821.3	0.2455	0.0084	0.0044
	STANDARD DEV:	765.9	0.0711	0.0009	0.0011		STANDARD DEV:	304.9	0.1300	0.0034	0.0027
M	2					F	2				
	NUMBER IN GROUP:	4	4	4	4		NUMBER IN GROUP:	4	4	4	4
	MEAN:	3631.3	0.2632	0.0070	0.0045		MEAN:	2988.8	0.2350	0.0078	0.0039
	STANDARD DEV:	524.0	0.1614	0.0035	0.0031		STANDARD DEV:	723.4	0.0815	0.0016	0.0013
M	3					F	3				
	NUMBER IN GROUP:	4	4	4	4		NUMBER IN GROUP:	4	4	4	4
	MEAN:	3190.0	0.2575	0.0080	0.0040		MEAN:	2768.8	0.1332	0.0048	0.0023
	STANDARD DEV:	199.8	0.1150	0.0032	0.0016		STANDARD DEV:	335.9	0.0279	0.0007	0.0005

002901

TABLE 48
Summary of Organ Weight Data
Terminal Sacrifice

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 30

TABLE INCLUDES:
SEX=ALL; GROUP=ALL; WEEKS=ALL
DEATH=T; SUBSET=ALL

RT THYROID/PARA

SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO	SEX	DOSE GROUP	TERMINAL BODY WT (g)	ORGAN WEIGHT (g)	ORGAN-TO- BODY WT (%)	ORGAN-TO- BRAIN WT RATIO
M	4					F	4				
NUMBER IN GROUP:		2	2	2	2	NUMBER IN GROUP:		4	4	4	4
MEAN:		3077.5	0.2360	0.0072	0.0034	MEAN:		2653.8	0.1945	0.0073	0.0034
STANDARD DEV:		1120.8	0.1556	0.0024	0.0019	STANDARD DEV:		403.1	0.0633	0.0019	0.0011

002902

TABLE 49
Incidence of Macroscopic Observations
Terminal Sacrifice

PAGE: 1

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

--- N U M B E R - O F - A N I M A L S - A F F E C T E D ---											
TABLE INCLUDES:		SEX: -----MALE-----				-----FEMALE-----					
SEX=ALL;GROUP=ALL;WEEKS=ALL		GROUP: -1- -2- -3- -4-				-1- -2- -3- -4-					
DEATH=T;SUBSET=ALL		NUMBER: 4 4 4 2				4 4 4 4					
ORGAN AND KEYWORD(S) OR PHRASE		--- --				--- --					
** TOP OF LIST **		NUMBER EXAMINED:		4	4	4	2	4	4	4	4
GENERAL COMMENT (GC)		NOT REMARKABLE:		0	0	0	0	0	0	0	0
BONE MARROW SMEAR TAKEN				4	4	4	2	4	4	4	4
EYES - DAVIDSONS				4	4	4	2	4	4	4	4
NO MACROSCOPIC LESIONS				2	2	3	0	1	0	1	0
ANIMAL OBESE				0	0	0	0	0	1	0	0
LUNG (LU)		NUMBER EXAMINED:		4	4	4	2	4	4	4	4
		NOT REMARKABLE:		3	3	3	2	2	1	1	0
ADHESION(S)				0	1	1	0	2	3	1	0
RED FOCUS(I)/AREA(S)				1	0	0	0	0	0	1	2
DARK FOCUS(I)/AREA(S)				0	0	0	0	0	2	1	2
LIGHT FOCUS(I)/AREA(S)				0	0	0	0	0	0	0	1
LIVER (LI)		NUMBER EXAMINED:		4	4	4	2	4	4	4	4
		NOT REMARKABLE:		4	4	4	0	3	3	4	3
MOTTLED				0	0	0	2	0	0	0	1
ADHESION(S)				0	0	0	0	0	1	0	0
LIGHT FOCUS(I)/AREA(S)				0	0	0	0	1	0	0	0
SPLEEN (SP)		NUMBER EXAMINED:		4	4	4	2	4	4	4	4
		NOT REMARKABLE:		3	3	4	2	4	4	3	4
LARGE				1	1	0	0	0	0	0	0
** CONTINUED ON NEXT PAGE **											

002903

TABLE 49
Incidence of Macroscopic Observations
Terminal Sacrifice

Covance 6329-223
3M T-6295.7

PAGE: 2

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

		--- N U M B E R - O F - A N I M A L S - A F F E C T E D ---							
		SEX: -----MALE-----				-----FEMALE-----			
		GROUP: -1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
		NUMBER: 4	4	4	2	4	4	4	4
ORGAN AND KEYWORD(S) OR PHRASE		---	---	---	---	---	---	---	---
TABLE INCLUDES: SEX=ALL;GROUP=ALL;WEEKS=ALL DEATH=T;SUBSET=ALL									
** FROM PREVIOUS PAGE **									
SPLEEN (SP)	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	3	3	4	2	4	4	3	4
		0	0	0	0	0	0	1	0
LIGHT FOCUS(I)/AREA(S)									
LN, MESENTERIC (MS)	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	4	4	4	1	4	4	4	4
		0	0	0	1	0	0	0	0
DIFFUSELY RED									
ADRENAL, CORTEX (AC)	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	4	4	4	0	4	4	4	2
		0	0	0	2	0	0	0	2
DIFFUSELY DARK									
STOMACH, GL (ST)	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	4	4	4	2	3	4	4	4
		0	0	0	0	1	0	0	0
RED FOCUS(I)/AREA(S)									
CECUM (CE)	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	4	4	4	2	4	4	2	3
		0	0	0	0	0	0	2	0
RED FOCUS(I)/AREA(S)		0	0	0	0	0	0	0	1
DARK FOCUS(I)/AREA(S)									

002904

TABLE 49
Incidence of Macroscopic Observations
Terminal Sacrifice

Covance 6329-223
3M T-6295.7

PAGE: 3

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

		--- NUMBER - OF - ANIMALS - AFFECTED ---							
		SEX: -----MALE-----				-----FEMALE-----			
		GROUP: -1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
		NUMBER:	4	4	4	2	4	4	4
ORGAN AND KEYWORD(S) OR PHRASE			--	--	--	--	--	--	--
COLON (CO)	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	4	4	4	2	4	4	4	3
		0	0	0	0	0	0	0	1
DARK FOCUS(I)/AREA(S)									
SKIN (SK)	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	3	4	4	2	4	4	4	2
		1	0	0	0	0	0	0	0
ABRASION(S)/ULCERATION(S)		0	0	0	0	0	0	0	1
ALOPECIA-DIFFUSE		0	0	0	0	0	0	0	1
ALOPECIA-FOCAL									
TESTIS (TE)	NUMBER EXAMINED:	4	4	4	2	0	0	0	0
	NOT REMARKABLE:	4	3	4	2	0	0	0	0
		0	1	0	0	0	0	0	0
LARGE									
ADIPOSE TISSUE (AT)	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	4	4	3	2	4	4	4	3
		0	0	1	0	0	0	0	1
RAISED FOCUS(I)/AREA(S)									
** END OF LIST **									

002905

TABLE 50
Incidence of Macroscopic Observations
Recovery Sacrifice

Covance 6329-223
3M T-6295.7

PAGE: 1

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

		--- N U M B E R - O F - A N I M A L S - A F F E C T E D ---	
		SEX: MALE	FEMALE
		GROUP: -4-	-4-
		NUMBER: 2	2
ORGAN AND KEYWORD(S) OR PHRASE		---	---
TABLE INCLUDES: SEX=ALL; GROUP=4; WEEKS=ALL DEATH=U; SUBSET=ALL			
** TOP OF LIST **			
GENERAL COMMENT (GC)	NUMBER EXAMINED:	2	2
	NOT REMARKABLE:	1	1
NO MACROSCOPIC LESIONS		1	1
LUNG (LU)	NUMBER EXAMINED:	2	2
	NOT REMARKABLE:	1	2
ADHESION(S)		1	0
LIVER (LI)	NUMBER EXAMINED:	2	2
	NOT REMARKABLE:	2	1
ADHESION(S)		0	1
CAVITY, THORACIC (TA)	NUMBER EXAMINED:	2	2
	NOT REMARKABLE:	1	2
MODULE(S)		1	0
** END OF LIST **			

002906

TABLE 51
Incidence of Microscopic Observations
Terminal Sacrifice

Covance 6329-223
3M T-6295.7

PAGE: 1

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

		--- N U M B E R - O F - A N I M A L S - A F F E C T E D ---							
		SEX: -----MALE-----				-----FEMALE-----			
		GROUP: -1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
		NUMBER:	4	4	4	2	4	4	4
ORGAN AND FINDING DESCRIPTION			---	---	---	---	---	---	---
** TOP OF LIST **									
BONE, FEMUR (FE)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	0	0	0	0	3	0	0	3
		4	0	0	2	1	0	0	1
--GROWTH PLATE OPEN									
MARROW, FEMUR (FM)	NUMBER EXAMINED:	1	0	0	0	2	0	0	1
	NOT REMARKABLE:	1	0	0	0	2	0	0	1
MARROW, STERNUM (SE)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	3	0	0	4
		0	0	0	0	1	0	0	0
--HYPOCELLULAR, MARROW									
BONE, STERNUM (SB)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	4	0	0	4
EYE (EY)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	4	0	0	4
BRAIN (BR)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	2	0	0	0	1	0	0	1
--INFILTRATE, LYMPHOHISTIOCYTIC, PERIVASCULAR			0	0	0	1	0	0	0
--INFILTRATE, MACROPHAGES, PIGMENTED, PERIVASCULAR			2	0	0	2	3	0	0
--INFLAMMATION, LYMPHOHISTIOCYTIC			0	0	0	0	0	0	1

002907

TABLE 51

Covance 6329-223
3M T-6295.7

Incidence of Microscopic Observations

Terminal Sacrifice

PAGE: 2

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

TABLE INCLUDES:

SEX=ALL;GROUP=ALL;WEEKS=ALL
DEATH=T;FIND=ALL;SUBSET=ALL

		--- NUMBER - OF - ANIMALS - AFFECTED ---							
		SEX: -----MALE-----				-----FEMALE-----			
		GROUP: -1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
		NUMBER: 4	4	4	2	4	4	4	4
ORGAN AND FINDING DESCRIPTION		---	---	---	---	---	---	---	---
KIDNEY (KD)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	2	0	0	1	2	0	0	2
		2	0	0	1	1	0	0	0
	--INFILTRATE, LYMPHOHISTIOCYTIC	1	0	0	0	1	0	0	0
	--GLOMERULOSCLEROSIS	0	0	0	1	0	0	0	0
LUNG (LU)	--MINERALIZATION, CORTEX	0	0	0	0	0	0	0	2
	--MINERALIZATION, MEDULLA								
	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	0	0	0	2	2	0	0	2
		4	0	0	0	1	0	0	1
HEART (HT)	--HYPERPLASIA, LYMPHOCYTIC, PERIBRONCHIOLAR/PERIVASCULAR	0	0	0	0	2	0	0	0
	--FIBROSIS, PLEURAL/SUBPLEURAL	0	0	0	0	1	0	0	0
	--FIBROSIS, INTERSTITIAL	0	0	0	0	0	0	0	1
	--INFILTRATE, MACROPHAGE, ALVEOLAR	0	0	0	0	0	0	0	1
	--HEMORRHAGE								
LIVER (LI)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	4	0	0	4
		4	4	4	2	4	4	4	4
		0	1	3	0	0	0	1	0
		4	3	1	0	4	4	3	3
	--INFILTRATE, LYMPHOHISTIOCYTIC	1	0	0	0	0	0	0	0
	--GRANULOMA	0	0	0	1	0	0	0	3
	--HYPERTROPHY, HEPATOCELLULAR, CENTRIOBULAR	0	0	1	1	0	0	0	1
	--HYPERTROPHY, HEPATOCELLULAR								

** CONTINUED ON NEXT PAGE **

002908

TABLE 51
Incidence of Microscopic Observations
Terminal Sacrifice

Covance 6329-223
3M T-6295.7

PAGE: 3

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

--- N U M B E R - O F - A N I M A L S - A F F E C T E D ---									
SEX: -----MALE----- FEMALE-----									
GROUP: -1- -2- -3- -4- -1- -2- -3- -4-									
NUMBER: 4 4 4 2 4 4 4 4									

ORGAN AND FINDING DESCRIPTION	NUMBER:	4	4	4	2	4	4	4	4

** FROM PREVIOUS PAGE **	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
LIVER (LI)	NOT REMARKABLE:	0	1	3	0	0	0	1	0
--VACUOLATION, HEPATOCELLULAR, CENTRIOBLULAR		0	0	0	1	0	0	0	1
--VACUOLATION, HEPATOCELLULAR		0	1	0	0	1	1	0	1
--STASIS, BILE		0	1	0	0	0	0	0	0
--DEGENERATION/NECROSIS, HEPATOCELLULAR		0	0	0	0	0	0	1	0
GALLBLADDER (GB)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	3	0	0	1	3	0	0	2
--INFILTRATE, LYMPHOHISTIOCYTIC		1	0	0	1	1	0	0	2
SPLEEN (SP)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	4	0	0	4
THYMUS (TH)	NUMBER EXAMINED:	4	4	4	2	4	4	4	4
	NOT REMARKABLE:	3	1	1	0	4	0	0	1
--CYST		0	1	0	1	0	1	1	2
--ATROPHY		1	2	3	2	0	4	4	3
LN, MESENTERIC (MS)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	2	0	0	1	3	0	0	4
--HEMORRHAGE		1	0	0	1	0	0	0	0
--INFILTRATE, MACROPHAGE, PIGMENTED		1	0	0	0	1	0	0	0

002909

TABLE 51
Incidence of Microscopic Observations
Terminal Sacrifice

Covance 6329-223
3M T-6295.7

PAGE: 4

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

		--- NUMBER - OF - ANIMALS - AFFECTED ---							
		SEX: -----MALE-----				-----FEMALE-----			
		GROUP: -1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
		NUMBER: 4	4	4	2	4	4	4	4
ORGAN AND FINDING DESCRIPTION		---	---	---	---	---	---	---	---
TRACHEA (TR)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	1	0	0	0	2	0	0	0
--INFILTRATE, LYMPHOHISTIOCYTIC		3	0	0	2	2	0	0	4
--INFLAMMATION, ACUTE		0	0	0	1	0	0	0	0
ESOPHAGUS (ES)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	3	0	0	4
--INFILTRATE, LYMPHOHISTIOCYTIC		0	0	0	0	1	0	0	0
THYROID (TY)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	3	0	0	1
--INFILTRATE, LYMPHOHISTIOCYTIC		0	0	0	0	1	0	0	1
--CYST, ULTIMOBRANCHIAL		0	0	0	0	0	0	0	2
PARATHYROID (PT)	NUMBER EXAMINED:	4	0	0	2	3	0	0	4
	NOT REMARKABLE:	3	0	0	2	3	0	0	4
--CYST		1	0	0	0	0	0	0	0
ADRENAL, CORTEX (AC)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	2	0	0	2	3	0	0	3
--HYPERTROPHY, CORTICAL CELL		1	0	0	0	1	0	0	1
--INFILTRATE, LYMPHOHISTIOCYTIC		1	0	0	0	0	0	0	0
--PIGMENT		0	0	0	0	0	0	0	1

002910

TABLE 51
Incidence of Microscopic Observations
Terminal Sacrifice

Covance 6329-223
3M T-6295.7

PAGE: 5

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

		--- N U M B E R - O F - A N I M A L S - A F F E C T E D ---							
		SEX: -----MALE-----				-----FEMALE-----			
		GROUP: -1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
ORGAN AND FINDING DESCRIPTION		NUMBER:	4	4	4	2	4	4	4
			--	--	--	--	--	--	--
ADRENAL, MEDULLA (MA)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	4	0	0	4
AORTA (AO)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	4	0	0	3
--PROLIFERATION, INTIMAL			0	0	0	0	0	0	1
PITUITARY (PI)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	4	0	0	4
SALIV GL, MANDIB (SG)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	0	0	0	1	2	0	0	2
--INFILTRATE, LYMPHOHISTIOCYTIC			4	0	0	1	2	0	2
MUSCLE, SKELETAL (SM)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	3	0	0	2	2	0	0	2
--INFILTRATE, LYMPHOHISTIOCYTIC			1	0	0	0	0	0	1
--DEGENERATION			0	0	0	0	1	0	0
--INFLAMMATION, GRANULOMATOUS			0	0	0	0	1	0	0
--REGENERATION, MYOFIBER			0	0	0	0	1	0	0
--PARASITES, CYST			0	0	0	0	1	0	1

002911

TABLE 51
Incidence of Microscopic Observations
Terminal Sacrifice

Covance 6329-223
3M T-6295.7

PAGE: 6

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

		--- N U M B E R - O F - A N I M A L S - A F F E C T E D ---							
		SEX: -----MALE-----				-----FEMALE-----			
		GROUP: -1- -2- -3- -4-				-1- -2- -3- -4-			
ORGAN AND FINDING DESCRIPTION		NUMBER:	4	4	4	2	4	4	4
			---	---	---	---	---	---	---
SPINAL CORD (SC)	NUMBER EXAMINED:	4	0	0	2	4	4	4	4
	NOT REMARKABLE:	4	0	0	2	3	1	0	2
	--PIGMENT, NEURONAL		0	0	0	0	1	3	4
NERVE, SCIATIC (SN)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	4	0	0	4
STOMACH, GL (ST)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	4	0	0	4
DUODENUM (DU)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	3	0	0	2	2	0	0	1
	--INFILTRATE, MACROPHAGE, PIGMENTED		1	0	0	0	2	0	0
PANCREAS (PA)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	3	0	0	2	4	0	0	4
	--INFILTRATE, LYMPHOHISTIOCYTIC		1	0	0	0	0	0	0
JEJUNUM (JE)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	3	0	0	0	1	0	0	1
	--INFILTRATE, MACROPHAGE, PIGMENTED		1	0	0	2	3	0	0

002912

TABLE 51
Incidence of Microscopic Observations
Terminal Sacrifice

Covance 6329-223
3M T-6295.7

PAGE: 7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

		--- N U M B E R - O F - A N I M A L S - A F F E C T E D ---							
		SEX: -----MALE-----				-----FEMALE-----			
		GROUP: -1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
ORGAN AND FINDING DESCRIPTION		NUMBER:	4	4	4	2	4	4	4
			---	---	---	---	---	---	---
ILEUM (IL)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	2	0	0	1	1	0	0	2
	--INFILTRATE, MACROPHAGE, PIGMENTED	2	0	0	1	3	0	0	2
CECUM (CE)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	3	0	0	2	3	0	0	2
	--INFILTRATE, MACROPHAGE, PIGMENTED	1	0	0	0	1	0	0	1
COLON (CO)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	2	0	0	2	4	0	0	3
	--INFILTRATE, EOSINOPHILIC	1	0	0	0	0	0	0	0
RECTUM (RE)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	4	0	0	2	4	0	0	4
	--PARASITISM	0	0	0	0	0	0	0	1
SKIN (SK)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	3	0	0	2	4	0	0	2
	--HYPERPLASIA, EPIDERMAL (ACANTHOSIS)	1	0	0	0	0	0	0	0
	--INFLAMMATION, CHRONIC-ACTIVE	1	0	0	0	0	0	0	0
	--ULCERATION	1	0	0	0	0	0	0	0
	--HAIR FOLLICLES, DECREASED	0	0	0	0	0	0	0	2

002913

TABLE 51
Incidence of Microscopic Observations
Terminal Sacrifice

Covance 6329-223
3M T-6295.7

PAGE: 8

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

		--- N U M B E R - O F - A N I M A L S - A F F E C T E D ---							
		SEX: -----MALE-----				-----FEMALE-----			
		GROUP: -1-	-2-	-3-	-4-	-1-	-2-	-3-	-4-
ORGAN AND FINDING DESCRIPTION		NUMBER:	4	4	4	2	4	4	4
			--	--	--	--	--	--	--
MAMMARY, FEMALE (MF)	NUMBER EXAMINED:	0	0	0	0	4	0	0	4
	NOT REMARKABLE:	0	0	0	0	2	0	0	4
		0	0	0	0	1	0	0	0
--INFLAMMATION, ACUTE		0	0	0	0	1	0	0	0
--INFILTRATE, LYMPHOHISTIOCYTIC		0	0	0	0	1	0	0	0
MAMMARY, MALE (MM)	NUMBER EXAMINED:	2	0	0	1	0	0	0	0
	NOT REMARKABLE:	2	0	0	1	0	0	0	0
URINARY BLADDER (UB)	NUMBER EXAMINED:	4	0	0	2	4	0	0	4
	NOT REMARKABLE:	3	0	0	2	1	0	0	3
		1	0	0	0	3	0	0	1
--INFILTRATE, LYMPHOHISTIOCYTIC									
UTERUS (UT)	NUMBER EXAMINED:	0	0	0	0	4	0	0	4
	NOT REMARKABLE:	0	0	0	0	2	0	0	3
		0	0	0	0	2	0	0	1
--AMYLOID									
OVARY (OV)	NUMBER EXAMINED:	0	0	0	0	4	0	0	4
	NOT REMARKABLE:	0	0	0	0	3	0	0	2
		0	0	0	0	1	0	0	1
--MINERALIZATION		0	0	0	0	0	0	0	1
--AMYLOID		0	0	0	0	0	0	0	1
--ONE EXAMINED		0	0	0	0	0	0	0	1

002914

TABLE 51
Incidence of Microscopic Observations
Terminal Sacrifice

Covance 6329-223
3M T-6295.7

PAGE: 9

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

--- N U M B E R - O F - A N I M A L S - A F F E C T E D ---									
SEX: -----MALE----- -----FEMALE-----									
GROUP: -1- -2- -3- -4- -1- -2- -3- -4-									
NUMBER: 4 4 4 2 4 4 4 4									

ORGAN AND FINDING DESCRIPTION									
VAGINA (VA)	NUMBER EXAMINED:	0	0	0	0	4	0	0	4
	NOT REMARKABLE:	0	0	0	0	4	0	0	4
CERVIX (CV)	NUMBER EXAMINED:	0	0	0	0	4	0	0	4
	NOT REMARKABLE:	0	0	0	0	4	0	0	4
PROSTATE (PR)	NUMBER EXAMINED:	4	0	0	2	0	0	0	0
	NOT REMARKABLE:	2	0	0	0	0	0	0	0
--INFLAMMATION, LYMPHOHISTIOCYTIC		2	0	0	2	0	0	0	0
SEMINAL VESICLES (SV)	NUMBER EXAMINED:	4	0	0	2	0	0	0	0
	NOT REMARKABLE:	4	0	0	2	0	0	0	0
EPIDIDYMIDES (EP)	NUMBER EXAMINED:	4	0	0	2	0	0	0	0
	NOT REMARKABLE:	3	0	0	1	0	0	0	0
--HYOSPERMIA		1	0	0	1	0	0	0	0
TESTIS (TE)	NUMBER EXAMINED:	4	0	0	2	0	0	0	0
	NOT REMARKABLE:	3	0	0	1	0	0	0	0
--IMMATURE		1	0	0	1	0	0	0	0

002915

TABLE 51
Incidence of Microscopic Observations
Terminal Sacrifice

Covance 6329-223
3M T-6295.7

PAGE: 10

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

--- N U M B E R - O F - A N I M A L S - A F F E C T E D ---									
SEX: -----MALE-----		-----FEMALE-----							
GROUP: -1- -2- -3- -4- -1- -2- -3- -4-									
NUMBER: 4 4 4 2 4 4 4 4									
ORGAN AND FINDING DESCRIPTION									
ADIPOSE TISSUE (AT)		NUMBER EXAMINED:	0	0	0	0	0	0	1
		NOT REMARKABLE:	0	0	0	0	0	0	0
--LYMPHOID TISSUE			0	0	0	0	0	0	1
CAUSE OF DEATH (CD)		NUMBER EXAMINED:	0	0	0	0	0	0	0
		NOT REMARKABLE:	0	0	0	0	0	0	0
LN, TRACHEOBRON (TB)		NUMBER EXAMINED:	0	0	0	0	0	0	0
		NOT REMARKABLE:	0	0	0	0	0	0	0
** END OF LIST **									

002916

TABLE 52
Incidence of Microscopic Observations
Recovery Sacrifice

PAGE: 1

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

		--- N U M B E R - O F - A N I M A L S - A F F E C T E D ---	
		SEX: MALE FEMALE	
		GROUP: -4- -4-	
		NUMBER: 2 2	
ORGAN AND FINDING DESCRIPTION		---	
** TOP OF LIST **			
LIVER, BIOPSY ^a (LI0)		NUMBER EXAMINED:	2 2
		NOT REMARKABLE:	1 2
--PIGMENT, HEPATOCELLULAR			1 0
LIVER (LI)		NUMBER EXAMINED:	2 2
		NOT REMARKABLE:	0 0
--INFILTRATE, LYMPHOHISTIOCYTIC			2 1
--PIGMENT, HEPATOCELLULAR			1 0
--HYPERPLASIA, BILE DUCT			1 0
--INFLAMMATION, EOSINOPHILIC, PERI-BILE DUCT			1 0
--FIBROSIS, CAPSULAR			0 1
** END OF LIST **			

a The liver biopsy was taken during Week 57 of recovery.

APPENDIX 1

Protocol Deviations

Protocol

Protocol Amendment No. 1

Protocol Amendment No. 2

Protocol Amendment No. 3

002918

Protocol Deviations

Protocol. Reserve (Archive) Samples. "These samples will be transferred to the Sponsor after completion of the in-life phase."

Actual Procedure. These samples were shipped to the Sponsor after the dosing phase was completed, which was prior to the end of the in-life phase.

Protocol. Dosing Procedures. Method of Administration. "Orally by gelatin capsules, daily (7 days/week) for at least 26 weeks."

Actual Procedure. On Day 3, Animal Nos. I05520 (Group 1 male) and I05529 (Group 1 female) did not receive a dose administration due to bleeding and irritation in the throat. Dosing was discontinued for Animal No. I05530 (Group 1 female) from Days 10 through 14 due to a sore inside its mouth.

Protocol. Observation of Animals. Clinical Observations. "Once weekly, each animal will be observed; abnormal findings or an indication that the animal was normal will be recorded."

Actual Procedure. During the course of the study, several animals did not have a weekly observation of normal or abnormal recorded on various scheduled days.

Protocol. Observation of Animals. Ophthalmic Examinations. Before initiation of treatment and before each scheduled sacrifice; the anterior portion of the eye, optic media, and ocular fundus will be examined using an indirect ophthalmoscope by a board-certified ophthalmologist.

Actual Procedure. An ophthalmic examination was completed during Week 52 instead of prior to the recovery sacrifice during Week 79.

002919

Protocol Deviations (Continued)

Protocol. Clinical Pathology. Frequency. Scheduled Collections. "Once before initiation of treatment; after at least 30, 60, 90, 150, and 180 days of treatment (before the daily dose); and after at least 30, 60, 90, 135, 180, 274, and 365 days of recovery"

Actual Procedure. On Day 184, urine samples were collected for several animals; however, these samples were not required by the protocol and were discarded.

Protocol. Clinical Pathology. Tests. Hematology. Eleven hematological parameters were to be tested at all intervals.

Actual Procedure. In addition to the required hematology tests at the pretreatment interval, mean platelet volume, red blood cell distribution width, platelet distribution width, and plateletcrit were also inadvertently tested for.

Protocol. Serum PFOS Level Determination. Method of Collection. "Animals will be fasted overnight; blood (approximately 2 mL) will be collected from a femoral vein without an anticoagulant."

Actual Procedure. Animals were not fasted overnight for the scheduled collection on Day 197; however, animals were fasted the following night and collection was done on Day 198.

Protocol. Urine and Feces PFOS Level Determination. Method of Collection. "Animals will not be fasted (except for the first day of recovery); urine (at least 2 mL) and feces (at least 5 g) will be collected overnight."

Actual Procedure. The amount of urine collected was not documented at the time of each collection and therefore cannot be verified.

002920

Protocol Deviations (Continued)

Protocol. Additional Fecal Samples. "The samples will be collected in the early afternoon after pans are cleaned in the morning to ensure that they are no more than 6 hours old."

Actual Procedure. On Day 160, some fecal samples were collected in the late morning rather than the early afternoon.

Protocol. Interim Liver Biopsy Samples. "Kris J. Hansen or her alternate will be notified regarding the shipment of the samples."

Actual Procedure. The phone call made to notify Kris J. Hansen prior to shipment of these samples was not documented and therefore cannot be verified.

Protocol. Terminal Liver Biopsy Samples. "A sample of liver (approximately 1 g) will be collected by biopsy from all animals in Groups 3 during recovery (Week 79, within 1 day of the serum PFOS blood collection)."

Actual Procedure. These samples were collected during Week 80, and were not collected within one day of the serum PFOS blood collection.

Protocol. Postmortem Procedures. Cell Proliferation Evaluation. "After fixation, samples for proliferation cell nuclear antigen (PCNA) evaluation will be embedded in paraffin and shipped to:"

Actual Procedure. PCNA analysis was not done for Animal No. I05509 (Group 4 male).

Protocol. Termination. Postmortem Procedures. Additional Lung Tissue Samples. "At the terminal necropsy, a sample of lung (approximately 5 g) will be collected from an animal in the high-dose group. This sample will be weighed, flash-frozen in liquid nitrogen, and stored in a freezer, set to maintain -60 to -80°C, until shipped. This frozen

Protocol Deviations (Continued)

sample, and a sample of lung (approximately 1 g, stored in formalin) from Animal No. I05509 (Group 4 male, died January 27, 1999) will be sent separately under appropriate conditions (ambient or packed on dry ice) to:

Kris J. Hansen, PhD
3M E. T. & S.
Bldg. 2-3E-09
935 Bush Avenue
St. Paul, Minnesota 55106
Telephone: 651.778.6018
Facsimile: 651.778.6176

Kris J. Hansen or her alternate will be notified regarding the shipment of the samples."

Actual Procedure. This procedure was inadvertently not done at the terminal sacrifice; thus no samples were available for shipment to Kris J. Hansen, PhD.

Protocol. Termination. Postmortem Procedures. Tissue Preservation. "The following tissues (when present) from each animal will be preserved in 10% neutral-buffered formalin, unless otherwise specified, for possible future microscopic examination."

Actual Procedure. Femoral bone marrow from Animal Nos. I05517, I05519, I05527 (Group 1 males), I05507, I05509, I05512 (Group 4 males), I05531, I05535 (Group 1 females), I05536, I05540, and I05551 (Group 4 females); mammary gland from Animal Nos. I05508, I05519 (Group 1 males), and I05512 (Group 4 male); and parathyroid from Animal No. I05544 (Group 1 female) were insufficient. These tissues, therefore, were not examined microscopically. Additionally, one ovary of a possible two was examined from Animal No. I05536 (Group 4 female). Missing tissues are listed with appropriate comments in the pathology data sheets for individual animals. Summary tables do not include them as having been examined.

These deviations are not expected to have affected the results of the study.



Sponsor:

3M
St. Paul, Minnesota

PROTOCOL

Study Title:

26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid
Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys

Date:

August 20, 1998

Performing Laboratory:

Covance Laboratories Inc.
3301 Kinsman Boulevard
Madison, Wisconsin 53704-2595

Laboratory Study Identification:

Proposal No. 90545B

Covance 6329-223

Sponsor Project Identification:

3M Study No. T-6295.7

Study

26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys

Purpose

To assess the effect of the test material on critical enzyme levels, hormones, and other selected biochemical parameters when administered daily by capsule to cynomolgus monkeys for at least 26 weeks

Sponsor

3M
Toxicology Services
Building 220-2E-02, 3M Center
St. Paul, Minnesota 55144-1000

Study Monitor

Andrew M. Seacat, PhD
3M
Telephone No.: 651.575.3161
Facsimile No.: 651.733.1773

Alternate Study Monitor

Marvin T. Case, DVM, PhD
3M Toxicology Services
Telephone No.: 651.733.5180
Facsimile No.: 651.733.1773

Study Location

Covance Laboratories Inc.
3301 Kinsman Boulevard
Madison, Wisconsin 53704-2595

Mailing Address: PO Box 7545
Madison, Wisconsin 53707-7545

Study Director

Peter J. Thomford, PhD
Covance Laboratories Inc.
Telephone No.: 608.241.7207
Facsimile No.: 608.242.2736

Study Toxicologist

Dale Aldridge, BS
Covance Laboratories Inc.

Proposed Study Timetable

Experimental Start Date: August 26, 1998
In-life Start Date: August 26, 1998
In-life Termination Date: To be determined
Audited Draft Report Date: To be determined
Experimental Termination Date: To be determined

Regulatory Compliance

This study will be conducted in compliance with the Environmental Protection Agency Good Laboratory Practice Regulations as set forth in Title 40 of the US Code of Federal Regulations, Part 792, issued November 29, 1983 (effective December 29, 1983), and with any applicable amendments.

Animal Care and Use Statement

All procedures in this protocol are in compliance with the Animal Welfare Act Regulations, 9 CFR 1-4. In the opinion of the Sponsor and study director, the study does not unnecessarily duplicate any previous work.

Quality Assurance

The protocol, study conduct, and final report will be audited by the Covance Quality Assurance Unit (QAU). The proliferation cell nuclear antigen evaluation data and report will be audited by the QAU of Pathology Associates International. The dose analysis and serum and liver PFOS analysis and report will be audited by the QAU of 3M Environmental Laboratories. The blood hormone determinations and report will be audited by the QAU of Ani Lytics Inc.

002925

Test Material

Identification

Perfluorooctane Sulfonic Acid Potassium Salt (PFOS; T-6295)

Lot Number

The lot number will be maintained in the raw data.

Purity

Responsibility of the Sponsor

Stability

Responsibility of the Sponsor

Storage Conditions

At room temperature

Characteristics

Information on synthesis methods, composition, or other characteristics that define the test material is on file with the Sponsor.

Vehicle

Identification

Lactose

Lot Number

The lot number will be maintained in the raw data.

Purity

On file with the manufacturer

Stability

On file with the manufacturer

Storage Conditions

At room temperature

Gelatin Capsules

Capsules (Size No. 2) obtained from Torpac, Inc. (Fairfield, New Jersey); lot number will be supplied by the manufacturer. Gelatin capsules will be stored at room temperature. A copy of the Certificate of Analysis provided by the manufacturer will be maintained in the data.

Reserve (Archive) Samples

A reserve sample of each lot of test material, vehicle, and each test material/lactose dilution (1 g each) will be taken and stored at room temperature. These samples will be transferred to the Sponsor after completion of the in-life phase.

Disposition of Test Material

Any remaining test material will be retained at Covance for use in possible future studies.

Animals

Species

Cynomolgus monkey

Source

Covance Research Products Inc.

Age at Initiation of Treatment

Young adult/adult

Weight at Initiation of Treatment

Approximately 2 to 5 kg

Number and Sex

22 males and 22 females

Identification

Collar tag

Husbandry

Housing

Individual; animals will be housed in suspended, stainless steel cages.

Diet

Certified primate diet (#8726C, Harlan Teklad) once or twice daily. The diet is routinely analyzed by the manufacturer for nutritional components and environmental contaminants. Results of specified nutrient and contaminant analyses are on file at Covance-Madison. Fruit, vegetables, or other supplements may be provided but will not require analysis.

Water

Ad libitum. Samples of the water are routinely analyzed for specified microorganisms and environmental contaminants. The results are on file at Covance-Madison.

Contaminants

There are no known contaminants in the diet or water at levels that might interfere with this study.

Environment

Environmental controls for the animal room will be set to maintain 18 to 29°C, a relative humidity of 30 to 70%, and a 12-hour light/12-hour dark cycle. The dark cycle may be interrupted to accommodate in-life procedures.

Acclimation

Minimum of 4 weeks

Randomization

Animals will be weighed, stratified by body weight, and allocated to the number of blocks equal to the number of animals to be selected for each group. Animals in each block will then be assigned to groups using computer-generated random numbers.

Justification

PFOS is a known hepatic peroxisome proliferator (PP) in the rat. When exposed to PP, nonhuman primates (such as the cynomolgus monkey) respond similarly to humans (i.e., low to no hepatic response) and therefore are an appropriate human surrogate species.

Group Designations and Dosage Levels

Group	Dose Level (mg/kg/day) ^a	Total Material Dose Level (mg/kg/day) ^b	Number of Animals	
			Males	Females
1	0 ^a	30 ^a	6 ^d	6 ^d
2	0.03	15 ^b	4	4
3	0.15	6 ^c	6 ^d	6 ^d
4	0.75	30 ^c	6 ^d	6 ^d

a Dose levels will be provided. The control group (Group 1) will receive an equivalent amount of lactose in gelatin capsules as the total material administered to Group 4.

b The low-dose (Group 2) will receive the test material diluted with lactose (1:499, w:w).

c The mid-dose (Group 3) and high-dose (Group 4) groups will receive the test material diluted with lactose (1:39, w:w).

d Two animals in Groups 1, 3, and 4 designated as recovery animals will be treated for at least 26 weeks, then treatment will be discontinued, and the animals will be observed for reversibility, persistence, or delayed occurrence of toxic effects for at least 13 weeks posttreatment. Based on plasma test material levels and clinical pathology findings, the recovery may be reduced or extended, at the discretion of the study director and after consultation with the Sponsor.

Dosing Procedures

Method of Administration

Orally by gelatin capsules, daily (7 days/week) for at least 26 weeks

Reason for Dosing Route

To compare with data from previous toxicology studies using the oral route, which is the most likely route of exposure

Dose Preparation

Capsules will be prepared at least weekly. The size and number of capsules will depend on the physical characteristics of the test material, the dose level, and the weight of the monkey. Individual daily doses will be based on the most recent individual body weights, with the exception of body weight collection days when the previous body weight will be used. Dose levels will be based on the vehicle as supplied for Group 1.

For the Groups 2 through 4 dose preparations, the test material will be dissolved in acetone and diluted with lactose (1:499, 1:39, and 1:39, w:w, respectively) once before initiation of treatment. Dilution with lactose is necessary to facilitate capsule preparation. All dose preparations will be stored at room temperature until dosed.

Dose Analyses

Dose analyses will be done by the Sponsor.

Homogeneity

Samples (approximately 1 g each) will be collected from the top, middle, and bottom of the test material/lactose preparations for the low- and high-dose groups and analyzed for test material content. All samples will be stored at room temperature until analyzed.

Stability

Homogeneity samples collected from the middle of the preparations will be used for the prestudy stability analysis. One set of samples (approximately 1 g each) will be taken from the low- and high-dose test material/lactose preparations at the end of the in-life phase and analyzed for test material content.

Sample Shipping

Samples will be shipped under ambient conditions to:

Kris J. Hansen, PhD
3M E. T. & S
Bldg. 2-3E-09
935 Bush Avenue
St. Paul, Minnesota 55106
Telephone: 651.778.6018
Facsimile: 651.778.6176

Kris J. Hansen or her alternate will be notified regarding the shipment of the samples. Analysis of for test material content will be done on the samples. Results will be provided for inclusion in the final report.

Observation of Animals

Clinical Observations

Each animal will be observed twice daily (a.m. and p.m.) for mortality and moribundity; findings will be recorded as they are observed.

Each animal will be observed daily and food consumption will be assessed qualitatively; abnormal findings will be recorded. Once weekly, each animal will be observed; abnormal findings, or an indication that the animal is normal will be recorded. During treatment, each animal will be observed for signs of poor health or abnormal behavior approximately 30 to 90 minutes after the last animal on test has been dosed; abnormal findings will be recorded.

Additional findings will be recorded as they are observed.

Body Weights

Weekly before initiation of treatment, on the first day of treatment, and weekly thereafter. An additional body weight will be recorded on Day -1 for the Day 1 dose calculations.

Ophthalmic Examinations

Before initiation of treatment and before each scheduled sacrifice; the anterior portion of the eye, optic media, and ocular fundus will be examined using an indirect ophthalmoscope by a board-certified ophthalmologist.

Clinical Pathology

Frequency

Unscheduled Collections

When possible, blood will be collected for clinical pathology tests from animals sacrificed at unscheduled intervals

Scheduled Collections

Once before initiation of treatment; and (before the daily dose) after at least 30, 60, 90, and 180 days of treatment; and after at least 30, 60, and 90 days of recovery

Method of Collection

Animals will be fasted overnight; blood will be collected from a femoral vein. Anticoagulant will be potassium EDTA for hematology tests. No anticoagulant is required for clinical chemistry tests. Urine will be collected overnight on wet ice;

Tests

Hematology

red blood cell (erythrocyte) count	platelet count
hemoglobin	white blood cell (leukocyte) count
hematocrit	differential blood cell count
mean corpuscular volume	blood cell morphology
mean corpuscular hemoglobin	reticulocyte count
mean corpuscular hemoglobin concentration	

Clinical Chemistry

glucose	aspartate aminotransferase gamma
urea nitrogen	glutamyltransferase
creatinine	sorbitol dehydrogenase
total protein	creatine kinase
albumin	calcium
globulin	inorganic phosphorus
total bilirubin	sodium
direct bilirubin (if total bilirubin is greater than 2.0 mg/dL)	potassium
cholesterol	chloride
triglycerides	bile acids
alanine aminotransferase	amylase
alkaline phosphatase	lipase
	pancreatic-specific amylase

Urinalysis

appearance	glucose
volume (approximately 16 hours)	ketones
specific gravity	bilirubin
pH	blood
protein	microscopic examination of sediment
urobilinogen	

Blood Hormone Determination

Frequency

Three times before initiation of treatment; after at least 30, 60, 90, and 180 days of treatment; and after at least 30, 60, and 90 days of recovery

Number of Animals

All

Method of Collection

Animals will be fasted overnight; blood will be collected from a femoral vein. Approximately 5 mL of blood will be collected without anticoagulant and allowed to clot for serum samples.

Sample Handling

Samples for serum will be centrifuged within 1 hour after collection, and serum will be harvested. Serum will be divided into two approximately equal aliquots and stored in a freezer set to maintain -60 to -80°C until packed on dry ice and shipped to:

Dr. Saroj Das
Ani Lytics Inc.
200 Girard Street, Suite 200
Gaithersburg, Maryland 20877
Telephone No.: 301.921.0168
Facsimile No.: 301.977.0433

Ani Lytics Inc. will be notified regarding shipment of samples.

Tests

Samples will be analyzed by Ani Lytics Inc., for cortisol, testosterone, estradiol, estrone, estriol, thyroid stimulating hormone, triiodothyronine (T3), and thyroxin (T4).

Serum PFOS Level Determination**Frequency**

Before initiation of treatment, and during Weeks 1 (Day 7), 2, 4, 6, 8, 12, 16, 20, 24, 26, 28, 30, 32, 34, and 39.

Number of Animals

All

Method of Collection

Animals will be fasted overnight; blood (approximately 2 mL) will be collected from a femoral vein without an anticoagulant.

Sample Handling

Samples will be centrifuged within 1 hour after collection, and serum will be harvested. Serum samples will be stored in a freezer set to maintain -60 to -80°C.

Sample Shipping

Serum samples will be packed on dry ice and shipped to:

Kris J. Hansen, PhD
3M E. T. & S
Bldg. 2-3E-09
935 Bush Avenue
St. Paul, Minnesota 55106
Telephone: 651.778.6018
Facsimile: 651.778.6176

Kris J. Hansen or her alternate will be notified regarding the shipment of the samples. Analysis of serum for PFOS will be done on the samples. Results will be provided for inclusion in the final report.

Additional Serum Collection

At scheduled and unscheduled necropsies, blood (as much as possible, up to 20 mL) will be collected from the vena cava without an anticoagulant from animals at the time of exsanguination. Samples will be centrifuged within 1 hour after collection, and serum will be harvested. Serum from each animal will be transferred into an appropriate container and stored in a freezer set to maintain -60 to -80°C until shipped to the Sponsor (Kris J. Hansen) for possible future analysis.

Urine and Feces PFOS Level Determination**Frequency**

On the first day of recovery and after at least 6, 30, and 90 days of recovery

Number of Animals

All

Method of Collection

Animals will not be fasted; urine (approximately 2 mL) and feces (approximately 5 grams) will be collected overnight.

002934

Sample Handling

Samples will be stored in a freezer set to maintain -10 to -30°C.

Sample Shipping

Samples will be packed on dry ice and shipped to:

Kris J. Hansen, PhD
3M E. T. & S
Bldg. 2-3E-09
935 Bush Avenue
St. Paul, Minnesota 55106
Telephone: 651.778.6018
Facsimile: 651.778.6176

Kris J. Hansen or her alternate will be notified regarding the shipment of the samples. Analysis of urine and feces for PFOS will be done on the samples. Results will be provided for inclusion in the final report.

Termination

Unscheduled Sacrifices and Deaths

Necropsies will be done. Animals to be sacrificed will be anesthetized with ketamine and xylazine, weighed, bled for required tests, and exsanguinated.

Scheduled Sacrifices

After at least 26 weeks of treatment, four animals/sex/group will be fasted overnight, then anesthetized with ketamine and xylazine, weighed, exsanguinated, and necropsied.

After at least 26 weeks of treatment and at least 13 weeks without treatment, the remaining animals will be fasted overnight, then anesthetized with ketamine and xylazine, weighed, exsanguinated, and necropsied.

Postmortem Procedures

Necropsy

The necropsy will include examination of:

all orifices
cranial cavity
external surface of the brain; the external surface of the spinal cord and cut surfaces of the brain and spinal cord will be examined when tissue trimming is performed.
cervical tissues and organs

thoracic, abdominal, and pelvic cavities and viscera
external surface of the body
nasal cavity and paranasal sinuses

Organ Weights

From each animal at scheduled and unscheduled sacrifices, the following organs (when present) will be weighed; paired organs will be weighed separately:

adrenal (2)	ovary (2)
brain	pancreas
epididymis (2)	testis (2)
kidney (2)	thyroid (2) with parathyroid
liver	

Organ-to-body weight percentages and organ-to-brain weight ratios will be calculated.

Palmitoyl CoA Oxidase Determinations

Representative samples of the right lateral lobe of liver will be collected from each animal at the scheduled sacrifice, weighed, flash-frozen in liquid nitrogen, and stored in a freezer set to maintain -60 to -80°C until analyzed for palmitoyl CoA oxidase activity.

Cell Proliferation Evaluation

Representative samples of the left lateral lobe of the liver, left and right testes, and pancreas will be collected and preserved in zinc formalin.

After fixation, samples for proliferation cell nuclear antigen (PCNA) evaluation will be embedded in paraffin and shipped to:

Sandra R. Eldridge, PhD
Pathology Associates International
15 Worman's Mill Court
Suite I
Frederick, Maryland 21701
Telephone: 301.663.1644 ext. 2036
Facsimile: 301.663.8994

Pathology Associates International will be notified regarding shipment of samples. PCNA evaluation will be done on the samples. Results will be provided for inclusion in the final report.

Liver PFOS Determination

A section (approximately 20 g) of liver will be collected from each animal at the scheduled sacrifice, weighed, flash-frozen in liquid nitrogen, and stored in a freezer set to maintain -60 to -80°C until shipped with plasma samples to 3M (Kris Hansen) for analysis. Results will be provided for inclusion in the final report.

Tissue Preservation

The following tissues (when present) from each animal will be preserved in 10% neutral-buffered formalin, unless otherwise specified, for possible future microscopic examination:

adrenal (2)	mesenteric lymph node
aorta	pancreas
brain	pituitary
cecum	prostate
cervix	rectum
colon	salivary gland [mandibular (2)]
duodenum	sciatic nerve
epididymis (2)	seminal vesicle (2)
esophagus	skeletal muscle (thigh)
eye [(2) to be preserved in Davidson's fixative for sacrificed animals only]	skin
femur with bone marrow (articular surface of the distal end)	spinal cord (cervical, thoracic, and lumbar)
gallbladder	spleen
heart	sternum with bone marrow
ileum	stomach
jejunum	testis [(2) to be preserved in Bouins' solution for sacrificed animals only]
kidney (2)	thymus
lesions	thyroid (2) with parathyroid
liver	trachea
lung	urinary bladder
mammary gland	uterus
ovary (2)	vagina

Bone Marrow Smear

From the sternum of each animal at unscheduled and scheduled sacrifices (made and held for possible future examination).

Histopathology

Tissues from each animal in the control and high-dose groups will be embedded in paraffin, sectioned, stained with hematoxylin and eosin, and examined microscopically. Tissues from all other animals will be retained for possible future examination.

Reports

Letter Report

A letter report will be prepared following the terminal sacrifice.

Final Report

A draft report that includes the following information will be prepared and submitted:

Experimental Design and Methods

Results

- mortality
- clinical observations
- body weights
- food consumption
- ophthalmic examinations
- clinical pathology results
- palmitoyl CoA oxidase activities
- hormone analyses (provided by Ani Lytics)
- serum, urine, feces, and liver PFOS levels (provided by 3M)
- cell proliferation evaluations (provided by Pathology Associates International)
- dose analyses (provided by 3M)
- organ weights
- organ-to-body weight percentages
- organ-to-brain weight ratios
- macroscopic observations
- microscopic observations

Statistical Evaluation

Levene's test will be done to test for variance homogeneity. In the case of heterogeneity of variance at $p \leq 0.05$, transformations will be used to stabilize the variance. Comparison tests will take variance heterogeneity into consideration.

One-way analysis of variance (ANOVA) will be used (if applicable) to analyze initial body weights, palmitoyl CoA oxidase activities, and continuous clinical pathology values. If the ANOVA is significant, Dunnett's t-test will be used for control versus treated group comparisons.

One-way analysis of covariance (ANCOVA) will be used to analyze body weights, with initial body weights as the covariate. If the ANCOVA is significant, covariate-adjusted means will be used for control versus treated group comparisons.

Group comparisons (Groups 2 through 4 versus Group 1) will be evaluated at the 5.0% two-tailed probability level. Only data collected on or after the first day of treatment will be analyzed statistically.

At the end of 1 year after issuance of the audited draft report, if no requested revisions or instructions to finalize have been communicated by the Sponsor, then the audited draft report will be considered 'final' and issued as the final report, signed by the study director, and submitted to the Sponsor.


Any modifications or changes to the audited draft report requested 1 year after issuance will be performed at additional cost to the Sponsor.

Record Retention


All raw data, documentation, records, protocol, specimens, and final report generated as a result of this study generated by Covance will be archived in the storage facilities of Covance for a period of 1 year following submission of the final report to the Sponsor. One year after submission of the final report, all of the aforementioned materials will be sent to the Sponsor, and a return fee will be charged. The Sponsor may elect to have the materials retained in the Covance archives for an additional period of time, and Covance will charge a storage fee. If the Sponsor chooses to have Covance dispose of the materials, a disposal fee will be charged. All raw data stored on magnetic media will be retained by Covance.


Within 1 year after submission of the final report, all of the aforementioned materials from the Sponsor's designees (Ani Lytics Inc., 3M E. T. & S, and Pathology Associates International) will be sent to the Sponsor (Andrew Seacat, PhD, 3M) by the Sponsor's designees.


PROTOCOL APPROVAL



Andrew M. Seacat, PhD
Study Monitor
3M


Date


Peter J. Thomford, PhD
Study Director
Covance Laboratories Inc.


Date

002940

PROTOCOL AMENDMENT NO. 1

Covance 6329-223
3M T-6295.7

**26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid
Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys**

Sponsor:	3M, St. Paul, Minnesota
Study Monitor:	Andrew M. Seacat, PhD
Testing Facility:	Covance Laboratories Inc., Madison, Wisconsin
Study Director:	Peter J. Thomford, PhD

This amendment modifies the following portions of the protocol.

Effective August 20, 1998

1. **Page 4, Vehicle, Storage Conditions.** To include the solvent used to dissolve the test material before mixing with the lactose, add the following after this section.

Solvent

Identification

Acetone

Lot Numbers

The lot numbers will be maintained in the raw data.

Purity

On file with the manufacturer

Stability

On file with the manufacturer

Storage Conditions

At room temperature

002941

Characteristics

Information on synthesis methods, composition, or other characteristics that define the solvent is on file with the manufacturer.

2. **Page 7, Group Designations and Dosage Levels, Footnote a, Sentence 1.** To correct an error, delete this sentence.

Effective September 2, 1998

3. **Page 5, Gelatin Capsules, Sentence 1.** To change the size of the gelatin capsules, delete this sentence and replace with the following.

Capsules (Size Nos. 2 or 4) obtained from Torpac, Inc. (Fairfield, New Jersey); lot number will be supplied by the manufacturer.

Effective December 15, 1998

4. **Page 14, Postmortem Procedures, Cell Proliferation Evaluation, Paragraph 3, Sentence 2.** To include evaluation of slides stained with hematoxylin and eosin in the PCNA evaluation, delete this sentence and replace with the following.

PCNA evaluation (including examination of slides stained with hematoxylin and eosin) will be done on the samples.

Effective January 21, 1999

5. **Page 10, Clinical Pathology, Tests, Clinical Chemistry.** To include an additional clinical chemistry test, add the following.

High density lipoprotein (HDL)

Effective January 21 and 28 and February 2, 1999

6. **Page 12, Urine and Feces PFOS Level Determination, Sample Shipping.** At the request of the Sponsor to collect additional fecal samples (effective January 21, 1999) and to clarify the sample collection requirements (effective January 28 and February 2, 1999), add the following after this section.

002942

Additional Fecal Samples

During Week 23, a fresh fecal sample of at least 5 g, if possible, will be collected from 6 males and 6 females each in the control and high-dose groups, survival permitting. The samples will be collected in the early afternoon after pans are cleaned in the morning to ensure that they are no more than 6 hours old. The samples will be collected in white polypropylene containers and sent on dry ice to:

Joe McConnell
Porphyrins and Nutritional Chemistry Group
Mayo Clinic
200 First Street SW
Rochester, Minnesota 55905
Telephone: 507.284.2150
Lab Telephone: 507.284.3232

Dr. McConnell will be contacted before shipping the samples.

Effective January 21 and February 12 and 16, 1999

7. **Page 9, Clinical Pathology, Frequency, Scheduled Collections.** To reflect the decision of the Sponsor and the Study Director to add a collection interval after 150 days of treatment (effective January 21, 1999), to extend the length of recovery (effective February 12, 1999), and to clarify the collection requirement (effective February 12, 1999), delete the text in this section and replace with the following.

Once before initiation of treatment; and after at least 30, 60, 90, 150, and 180 days of treatment (before the daily dose); and after at least 30, 60, 90, 135, and 180 days of recovery

Effective February 10 and 16, 1999

8. **Page 12, Urine and Feces PFOS Level Determination, Method of Collection.** To modify the amount of sample to be collected (effective February 10, 1999) and to permit collection of samples from fasted animals on the first day of recovery (effective February 16, 1999), delete the text in this section and replace with the following.

Animals will not be fasted (except for the first day of recovery); urine (at least 2 mL) and feces (at least 5 g) will be collected overnight.

Effective February 12, 1999

9. **Page 7, Group Designations and Dosage Levels, Footnote d.** To reflect the decision of the Sponsor and the Study Director to extend the length of recovery, delete the text in this footnote and replace with the following.
- d Two animals in Groups 1, 3, and 4 designated as recovery animals will be treated for at least 26 weeks, then treatment will be discontinued, and the animals will be observed for reversibility, persistence, or delayed occurrence of toxic effects for at least 26 weeks posttreatment.

Effective February 12 and 15, 1999

10. **Page 11, Serum PFOS Level Determination, Frequency.** To reflect the decision of the Sponsor and the Study Director to extend the length of recovery (effective February 12, 1999) and to revise the requirements for these collections during recovery (effective February 15, 1999), delete the text in this section and replace with the following.
- Before initiation of treatment; during Weeks 1 (Day 7), 2, 4, 6, 8, 12, 16, 20, 24, 26, and 27 (Day 183) during treatment; and during Weeks 27 (Days 184, 185, and 187), 28 (Day 190), 29 (Day 197), 30 (Day 204), 31 (Day 211), 35, 39, 43, 47, 51, and 53.
11. **Page 13, Termination, Scheduled Sacrifices.** To reflect the decision of the Sponsor and the Study Director to extend the length of recovery (effective February 12, 1999) and to prioritize the number of animals designated for recovery (effective February 15, 1999), delete the text in this section and replace with the following.
- After at least 26 weeks of treatment, up to four animals/sex/group will be fasted overnight, then anesthetized with ketamine and xylazine, weighed, exsanguinated, and necropsied.
- After at least 26 weeks of treatment and at least 26 weeks without treatment, two animals/sex/group will be fasted overnight, then anesthetized with ketamine and xylazine, weighed, exsanguinated, and necropsied.

002944

Effective February 12 and 16, 1999

12. **Page 10, Blood Hormone Determination, Frequency.** To reflect the decision of the Sponsor and the Study Director to extend the length of recovery (effective February 12, 1999) and to clarify the requirements (effective February 16, 1999), delete the text in this section and replace with the following.

Three times before initiation of treatment; after at least 30, 60, 90, and 180 days of treatment; and after at least 30, 60, 90, 135, and 180 days of recovery

13. **Page 12, Urine and Feces PFOS Level Determination, Frequency.** To reflect the decision of the Sponsor and the Study Director to extend the length of recovery (effective February 12, 1999) and to clarify the requirements (effective February 16, 1999), delete the text in this section and replace with the following.

On the first day of recovery and after at least 6, 30, 90, 135, and 180 days of recovery

Effective February 15, 17, and 18, 1999

14. **Page 13, Postmortem Procedures.** To facilitate a request by the Sponsor to transfer samples of lung tissue (effective February 15 and 18, 1999) and gallbladder and bile (effective February 17, 1999), add the following.

Additional Lung Tissue Samples

At the terminal necropsy, a sample of lung (approximately 5g) will be collected from an animal in the high-dose group. This sample will be weighed, flash-frozen in liquid nitrogen, and stored in a freezer, set to maintain -60 to -80°C, until shipped. This frozen sample and a sample of lung (approximately 1 g, stored in formalin) from Animal No. I05509 (Group 4 male, died January 27, 1999) will be sent separately under appropriate conditions (ambient or packed on dry ice) to:

Kris J. Hansen, PhD
3M E. T. & S.
Bldg. 2-3E-09
935 Bush Avenue
St. Paul, Minnesota 55106
Telephone: 651.778.6018
Facsimile: 651.778.6176

Kris J. Hansen or her alternate will be notified regarding the shipment of the samples.

Additional Gallbladder and Bile Samples

At the scheduled necropsies, the gallbladder and bile will be collected and stored according to a special collection and fixation procedure. Frozen gallbladder and bile samples will be packed on dry ice and transferred to:

Kris J. Hansen, PhD
3M E. T. & S
Bldg. 2-3E-09
935 Bush Avenue
St. Paul, Minnesota 55106
Telephone: 651.778.6018
Facsimile: 651.778.6176

Kris J. Hansen or her alternate will be notified regarding the shipment of the samples.

Effective February 24 and March 9, 1999

15. **Page 13, Postmortem Procedures.** To facilitate a request by the Sponsor to prepare (effective February 24, 1999) and transfer (effective March 9, 1999) samples of liver for electron microscopy and to prepare and transfer hematoxylin and eosin-stained slides for light microscopy (effective March 9, 1999), add the following.

Electron Microscopy

At the terminal necropsy, samples of liver will be collected and processed to block stage for electron microscopic evaluation. The tissue blocks and a hematoxylin and eosin-stained slide for light microscopy will be transferred to:

Sharon Ambrose
Division Director
Pathology Associates International
4915 D. Prospectus Drive
Durham, North Carolina 27713
Telephone: 919.544.5257
Facsimile: 919.544.3218

002946

Tissues will be processed and evaluated by electron microscopy by Pathology Associates International (PAI). A report will be provided by PAI for inclusion in the final report. PAI is responsible for the quality assurance auditing and maintenance of any raw data or specimens produced by PAI.

Sharon Ambrose or her alternate will be notified regarding the shipment of the samples.

Effective April 22, 1999

16. **Page 16, Reports, Statistical Evaluation, Paragraph 2, Sentence 1.** To add statistical analysis of organ weight and hormone values, delete this sentence and replace with the following.

One-way analysis of variance (ANOVA) will be used (if applicable) to analyze initial body weights, palmitoyl CoA oxidase activities, continuous clinical pathology values, hormone values, and organ weight data.

Effective April 26, 1999

17. **Page 14, Postmortem Procedures, Cell Proliferation Evaluation, Paragraph 1.** To add a second set of tissues for cell proliferation evaluation, add the following to this paragraph.

A second set of tissues (representative samples of the left lateral lobe of the liver, left and right testes, and pancreas) preserved in formalin without zinc will also be prepared.

Effective April 28, 1999

18. **Page 8, Dose Analyses, Stability, Sentence 2.** To change the schedule for the return of the samples, delete this sentence and replace with the following.

One set of samples (approximately 1 g each) will be taken from the low- and high-dose test material/lactose preparations at the end of the treatment phase and will be analyzed for test material content.

Effective May 6, 1999

19. **Page 16, Reports, Letter Report.** To change the letter report to an interim report, delete the text in this section and replace with the following.

Interim Report

An interim report, including all items from the final report as appropriate, will be prepared following the terminal sacrifice.

Effective May 17, 1999

20. **Page 16, Postmortem Procedures, Histopathology, Sentence 2.** To include target organs for animals in the low- and mid-dose groups, delete this sentence and replace with the following.

In addition, liver and thymus for all animals in the low- and mid-dose groups and spinal cord gray matter from females in the low- and mid-dose groups will be embedded in paraffin, sectioned, stained with hematoxylin and eosin, and examined microscopically. Other tissues, as appropriate, will be retained for possible future examination.

Effective May 18, 1999

21. **Page 3, Proposed Study Timetable.** To include proposed dates for in-life termination, the unaudited draft interim report, and the audited draft report, delete the text in this section and replace with the following.

Experimental Start Date: August 26, 1998

In-life Start Date: August 26, 1998

In-life Termination Date: August 27, 1999

Unaudited Draft Interim Report Date: May 11, 1999

Audited Draft Report Date: December 28, 1999

Experimental Termination Date: To be determined

002948

AMENDMENT APPROVAL

Andrew M. Seacat

Andrew M. Seacat, PhD
Study Monitor
3M

6/10/99

Date

Peter J. Thornford

Peter J. Thornford, PhD
Study Director
Covance Laboratories Inc.

03 June 1999

Date

PROTOCOL AMENDMENT NO. 2

Covance 6329-223
3M T-6295.7

**26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid
Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys**

Sponsor:	3M, St. Paul, Minnesota
Study Monitor:	Andrew M. Seacat, PhD
Testing Facility:	Covance Laboratories Inc., Madison, Wisconsin
Study Director:	Peter J. Thomford, PhD

This amendment modifies the following portions of the protocol.

Effective February 19, 1999

1. **Page 9, Observation of Animals, Clinical Observations, Paragraph 2, Sentence 2.** To add an observation on the day of scheduled sacrifice, delete this sentence and replace with the following.

Once weekly and on the day of scheduled sacrifice, each animal will be observed; abnormal findings or an indication that the animal is normal will be recorded.

Effective June 11, 1999

2. **Page 11, Blood Hormone Determination, Tests.** To add free triiodothyronine (T3) and free thyroxine (T4) tests, delete the text in this section and replace with the following.

Samples will be analyzed by Ani Lytics Inc. for cortisol, testosterone, estradiol, estrone, estriol, thyroid stimulating hormone, total and free triiodothyronine (T3), and total and free thyroxine (T4).

3. **Page 16, Reports, Final Report, Statistical Evaluation.** To add repeated measure statistical analysis of cholesterol and total and free triiodothyronine (T3), add the following to the end of the section.

Cholesterol and total and free triiodothyronine (T3) will be analyzed by repeated measures analysis of covariance (ANCOVA) procedure with average pretreatment measurements for the parameters as covariates. Treatment effects under ANOVA or ANCOVA procedures will be evaluated at $p = 0.05$ level. All post-hoc control-versus-treated-group mean comparisons (including values during recovery) will be conducted using Dunnett's many-on-one t procedure.

Analyses will be carried out with SAS procedure PROC MIXED or BMDP, or both.

Effective August 24, 1999

4. **Page 7, Group Designations and Dosage Levels, Footnote d.** To reflect the decision of the Sponsor and the Study Director to extend the length of recovery, delete the text in this footnote and replace with the following.

d Two animals in Groups 1, 3, and 4 designated as recovery animals will be treated for at least 26 weeks, then treatment will be discontinued, and the animals will be observed for reversibility, persistence, or delayed occurrence of toxic effects for at least 52 weeks posttreatment.

5. **Page 9, Clinical Pathology, Frequency, Scheduled Collections.** To reflect the decision of the Sponsor and the Study Director to extend the length of recovery, delete the text in this section and replace with the following.

Once before initiation of treatment; after at least 30, 60, 90, 150, and 180 days of treatment (before the daily dose); and after at least 30, 60, 90, 135, 180, 274, and 365 days of recovery

6. **Page 10, Blood Hormone Determination, Frequency.** To reflect the decision of the Sponsor and the Study Director to extend the length of recovery, delete the text in this section and replace with the following.

Three times before initiation of treatment; after at least 30, 60, 90, and 180 days of treatment; and after at least 30, 60, 90, 135, 180, 274, and 365 days of recovery

002951

7. **Page 11, Serum PFOS Level Determination, Frequency.** To reflect the decision of the Sponsor and the Study Director to extend the length of recovery, delete the text in this section and replace with the following.

Before initiation of treatment; during Weeks 1 (Day 7), 2, 4, 6, 8, 12, 16, 20, 24, 26, and 27 (Day 183) during treatment; and during Weeks 27 (Days 184, 185, and 187), 28 (Day 190), 29 (Day 197), 30 (Day 204), 31 (Day 211), 35, 39, 43, 47, 51, 53, 57, 61, 65, 69, 73, 77, and 79

Effective August 24, 1999, and January 12 and 21, 2000

8. **Page 13, Termination, Scheduled Sacrifices.** To reflect the decision of the Sponsor and the Study Director to extend the length of recovery (effective August 24, 1999), to reflect the decision of the Sponsor to cancel the recovery necropsy (effective January 12, 2000), and to subsequently clarify the requirement (effective January 21, 2000), delete the text in this section and replace with the following.

After at least 26 weeks of treatment, up to four animals/sex/group will be fasted overnight, then anesthetized with ketamine and xylazine, weighed, exsanguinated, and necropsied.

After at least 26 weeks of treatment and at least 52 weeks without treatment, the remaining animals will be removed from the study as follows.

Two animals/sex in Group 1 will be returned to the Covance stock.

Two animals/sex in Group 3 will be transferred to a subsequent study (Covance 6329-268).

Two animals/sex in Group 4 will be fasted overnight, then anesthetized with ketamine and xylazine, weighed, exsanguinated, and necropsied.

Effective August 24 and September 22, 1999

9. **Page 12, Additional Fecal Samples.** At the request of the Sponsor to collect liver samples by biopsy (effective August 24, 1999) and to modify the procedures (effective September 22, 1999), add the following after this section.

002952

Interim Liver Biopsy Samples

A sample of liver (approximately 1 to 2 g) will be collected by biopsy from animals in Group 4 only during recovery (Week 57, within 1 day of the serum PFOS blood collection). This sample will be divided into four portions as follows.

One subsample will be preserved in 10% neutral-buffered formalin, embedded in paraffin, sectioned, stained with hematoxylin and eosin (duplicate slides will be prepared), and examined microscopically.

The second subsample will be flash-frozen in liquid nitrogen, and stored in a freezer, set to maintain -60 to -80°C, until shipped for analysis to:

Kris J. Hansen, PhD
3M E. T. & S.
Bldg. 2-3E-09
935 Bush Avenue
St. Paul, Minnesota 55106
Telephone No.: 651.778.6018
Facsimile No.: 651.778.6176

Kris J. Hansen or her alternate will be notified regarding the shipment of the samples. Results will be provided for inclusion in the final report.

The third subsample will be processed to block stage for electron microscopic evaluation. The tissue blocks and a hematoxylin and eosin-stained slide for light microscopy will be transferred to:

Sharon Ambrose
Division Director
Pathology Associates International
4915 D. Prospectus Drive
Durham, North Carolina 27713
Telephone No.: 919.544.5257
Facsimile No.: 919.544.3218

Tissues will be processed and evaluated by electron microscopy by Pathology Associates International (PAI). A report will be provided by PAI for inclusion in the final report. Sharon Ambrose or her alternate will be notified regarding the shipment of the samples.

The fourth subsample will be flash-frozen in liquid nitrogen and stored in a freezer, set to maintain -60 to -80°C, and transferred to the Sponsor for possible future analysis.

Effective January 12 and 21, 2000

10. **Page 12, Interim Liver Biopsy Samples.** At the request of the Sponsor to collect liver samples by biopsy, then terminate the study and transfer the animals to a subsequent study (effective January 12, 2000) and to modify the requirement (effective January 21, 2000), add the following after this section.

Terminal Liver Biopsy Samples

A sample of liver (approximately 1 g) will be collected by biopsy from all animals in Groups 3 during recovery (Week 79, within 1 day of the serum PFOS blood collection). This sample will be flash-frozen in liquid nitrogen and stored in a freezer, set to maintain -60 to -80°C, until shipped for analysis to:

Kris J. Hansen, PhD
3M E. T. & S.
Bldg. 2-3E-09
935 Bush Avenue
St. Paul, Minnesota 55106
Telephone No.: 651.778.6018
Facsimile No.: 651.778.6176

Kris J. Hansen or her alternate will be notified regarding the shipment of the samples. Results will be provided for inclusion in the final report.

Effective January 21, 2000

11. **Page 12, Additional Serum Collection.** To reflect the decision of the Sponsor to analyze additional serum samples for specified thyroid hormones, add following to the end of this section.

An aliquot (0.8 ml) of the additional serum collection samples collected from all animals from Groups 1, 2, 3 and 4 sacrificed at the terminal necropsy will be sent on dry ice by the Sponsor to Dr. Saroj Das, Ani Lytics, for free T3, free T4, total T3, and total T4 determinations.

12. **Page 12, Urine and Feces PFOS Level Determination, Frequency.** To reflect the decision of the Sponsor to collect a 24-hour urine and fecal sample after one year of recovery, delete the text in this section and replace with the following.

On the first day of recovery and after at least 6, 30, 90, 135, and 180 days of recovery. In addition, a 24-hour sample of urine and feces will be collected before the completion of 52 weeks of recovery.

13. **Page 16, Postmortem Procedures, Histopathology.** To define the postmortem procedures for recovery animals in the high-dose group, add the following after this section.

Postmortem Procedures for Recovery Animals in the High-Dose Group
At necropsy of the recovery animals in the high-dose group, procedures (including organ weights and collection of tissues for histopathological examination) described previously are not required. The following procedures will be done.

Necropsy

The necropsy will include examination of:

all orifices
cranial cavity
external surface of the brain; the external surface of the spinal cord and cut
surfaces of the brain and spinal cord will be examined when tissue trimming
is performed
cervical tissues and organs
thoracic, abdominal, and pelvic cavities and viscera
external surface of the body
nasal cavity and paranasal sinuses

Liver Samples

A sample of liver (approximately 1 to 2 g) will be collected. This sample will be divided into three portions as follows.

One subsample will be preserved in 10% neutral-buffered formalin, embedded in paraffin, sectioned, stained with hematoxylin and eosin (duplicate slides will be prepared), and examined microscopically.

The second subsample will be flash-frozen in liquid nitrogen and stored in a freezer, set to maintain -60 to -80°C, until shipped for analysis to:

Kris J. Hansen, PhD
3M E. T. & S.
Bldg. 2-3E-09
935 Bush Avenue
St. Paul, Minnesota 55106
Telephone No.: 651.778.6018
Facsimile No.: 651.778.6176

Kris J. Hansen or her alternate will be notified regarding the shipment of the samples. Results will be provided for inclusion in the final report.

The third subsample will be processed to block stage for electron microscopic evaluation. The tissue blocks and a hematoxylin and eosin-stained slide for light microscopy will be transferred to:

Sharon Ambrose
Division Director
Pathology Associates International
4915 D. Prospectus Drive
Durham, North Carolina 27713
Telephone No.: 919.544.5257
Facsimile No.: 919.544.3218

Tissues will be processed and evaluated by electron microscopy by Pathology Associates International (PAI). A report will be provided by PAI for inclusion in the final report. Sharon Ambrose or her alternate will be notified regarding the shipment of the samples.

Additional Tissue and Serum Samples

Samples of lung, kidney, spleen, thyroid, brain, abdominal fat, heart, bile, (approximately 3 g each), and serum (as much as possible) will be collected. These samples will be flash-frozen in liquid nitrogen and stored in a freezer, set to maintain -60 to -80°C, until shipped for possible future analysis to:

Kris J. Hansen, PhD
3M E. T. & S.
Bldg. 2-3E-09
935 Bush Avenue
St. Paul, Minnesota 55106
Telephone No.: 651.778.6018
Facsimile No.: 651.778.6176


Kris J. Hansen or her alternate will be notified regarding the shipment of the samples.

Effective February 11 and 15, 2000

14. **Page 3, Proposed Study Timetable.** To change proposed dates for in-life termination (effective February 11, 2000) and the audited draft report (effective February 15, 2000), delete the text in this section and replace with the following.

Experimental Start Date: August 26, 1998
In-life Start Date: August 26, 1998
In-life Termination Date: March 7, 2000
Unaudited Draft Interim Report Date: May 11, 1999
Audited Draft Report Date: May 29, 2000
Experimental Termination Date: To be determined


AMENDMENT APPROVAL



Andrew M. Seacat, PhD
Study Monitor
3M

3/30/2000

Date



Peter J. Thomford, PhD
Study Director
Covance Laboratories Inc.

16 Feb 2000

Date

DRAFT

PROTOCOL AMENDMENT NO. 3

Covance 6329-223
3M T-6295.7

26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys

Sponsor:	3M, St. Paul, Minnesota
Study Monitor:	Andrew M. Seacat, PhD
Testing Facility:	Covance Laboratories Inc., Madison, Wisconsin
Study Director:	Peter J. Thomford, PhD

This amendment modifies the following portions of the protocol.

Effective August 20, 1998

1. **Page 16, Reports, Final Report, Statistical Evaluation, Paragraph 4.** To correct an omission, add the following to the end of the section.

Data collected during recovery will not be analyzed statistically due to the small sample size.

Effective January 21, 2000

2. **Protocol Amendment No. 2, Item 13.** To correct a typographical error, change the font to bold on the following heading.

Postmortem Procedures for Recovery Animals in the High-Dose Group

Effective February 18, 2000

3. **Page 12, Serum PFOS Level Determinations, Sample Shipping, Paragraph 3, Sentence 3.** To indicate that the results of the Sponsor's analysis of serum samples for PFOS will be reported separately, delete this sentence and replace with the following.

Results will be reported separately.

4. **Page 12, Interim Liver Biopsy Samples, Paragraph 3, Sentence 2.** To indicate that the results of the Sponsor's analysis of the interim liver biopsy samples will be reported separately, delete this sentence and replace with the following.

Results will be reported separately.

5. **Page 12, Terminal Liver Biopsy Samples, Paragraph 2, Sentence 2.** To indicate that the results of the Sponsor's analysis of the terminal liver biopsy samples will be reported separately, delete this sentence and replace with the following.

Results will be reported separately.

6. **Page 15, Postmortem Procedures, Liver PFOS Determinations, Sentence 2.** To indicate that the results of the Sponsor's analysis of the liver samples will be reported separately, delete this sentence and replace with the following.

Results will be reported separately.

7. **Page 16, Reports, Final Report, Statistical Evaluation, Paragraph 4.** To remove repeated measure statistical analysis of cholesterol and total and free triiodothyronine (T3) at the request of the Sponsor, delete the following.

Cholesterol and total and free triiodothyronine (T3) will be analyzed by repeated measures analysis of covariance (ANCOVA) procedure with average pretreatment measurements for the parameters as covariates. Treatment effects under ANOVA or ANCOVA procedures will be evaluated at $p = 0.05$ level. All post-hoc control-versus-treated-group mean comparisons (including values during recovery) will be conducted using Dunnett's many-on-one t procedure.

Analyses will be carried out with SAS procedure PROC MIXED or BMDP, or both.

Effective February 18 and 22, 2000

8. **Page 16, Reports, Final Report, Results.** To indicate that the results of the Sponsor's analysis of the serum and liver samples (effective February 18, 2000) and urine and feces samples (effective February 22, 2000) will be reported separately, delete the following.

serum, urine, feces, and liver PFOS levels (provided by 3M)

9. **Page 16, Postmortem Procedures for Recovery Animals in the High-Dose Group, Liver Samples.** To indicate that the results of the Sponsor's analysis of the liver samples will be reported separately (effective February 18, 2000) and to modify the amount of liver collected at necropsy (effective February 22, 2000), delete the text in this section and replace with the following.

Samples of liver will be collected as follows.

One sample will be preserved in 10% neutral-buffered formalin, embedded in paraffin, sectioned, stained with hematoxylin and eosin (duplicate slides will be prepared), and examined microscopically.

The second sample will be flash-frozen in liquid nitrogen and stored in a freezer, set to maintain -60 to -80°C, until shipped for analysis to:

Kris J. Hansen, PhD
3M E. T. & S.
Bldg. 2-3E-09
935 Bush Avenue
St. Paul, Minnesota 55106
Telephone No.: 651.778.6018
Facsimile No.: 651.778.6176

Kris J. Hansen or her alternate will be notified regarding the shipment of the samples. Results will be reported separately.

The third sample will be processed to block stage for electron microscopic evaluation. The tissue blocks and a hematoxylin and eosin-stained slide for light microscopy will be transferred to:

Sharon Ambrose
Division Director
Pathology Associates International
4915 D. Prospectus Drive
Durham, North Carolina 27713
Telephone No.: 919.544.5257
Facsimile No.: 919.544.3218

Tissues will be processed and evaluated by electron microscopy by Pathology Associates International (PAI). A report will be provided by PAI for inclusion in the final report. Sharon Ambrose or her alternate will be notified regarding the shipment of the samples.

Effective February 22, 2000

10. **Page 13, Urine and Feces PFOS Determination, Sample Shipping, Paragraph 2, Sentence 3.** To indicate that the results of the Sponsor's analysis of the urine and feces samples will be reported separately, delete this sentence and replace with the following.

Results will be reported separately.

11. **Page 16, Postmortem Procedures for Recovery Animals in the High-Dose Group, Additional Tissue and Serum Samples, Paragraph 1.** To modify the amount of tissue collected at necropsy, delete this paragraph and replace with the following.

Samples of lung, kidney, spleen, thyroid, brain, abdominal fat, heart, (approximately 3 g each, if possible), and bile and serum (each as much as possible) will be collected. These samples will be flash-frozen in liquid nitrogen and stored in a freezer, set to maintain -60 to -80°C, until shipped for possible future analysis to:

Kris J. Hansen, PhD
3M E. T. & S.
Bldg. 2-3E-09
935 Bush Avenue
St. Paul, Minnesota 55106
Telephone No.: 651.778.6018
Facsimile No.: 651.778.6176

Kris J. Hansen or her alternate will be notified regarding the shipment of the samples.

Effective April 6, 2000

12. **Page 3, Regulatory Compliance.** To include a compliance exception for the fecal analysis done at the Mayo Clinic, delete the text in this section and replace with the following.

This study will be conducted in compliance with the Environmental Protection Agency Good Laboratory Practice Regulations as set forth in Title 40 of the US Code of Federal Regulations, Part 792, issued November 29, 1983 (effective December 29, 1983), and with any applicable amendments with the following exception. Analysis of fecal samples for urobilinogen at the Mayo Clinic will not be done in compliance with GLPs.

13. **Page 3, Quality Assurance.** To include an exception for the fecal analysis done at the Mayo Clinic, add the following to the end of the section.

Analysis of fecal samples for urobilinogen at the Mayo Clinic will not be done in compliance with GLPs and will not be audited by a Quality Assurance Unit.

14. **Page 12, Additional Fecal Samples.** To clarify analysis and reporting requirements for fecal analysis, add the following to the end of this section.

The samples will be analyzed for urobilinogen using a routine standardized colorimetric assay. The results of these analyses will be provided for inclusion in the final report.

15. **Page 17, Record Retention, Paragraph 2.** To include the record retention requirements for fecal analysis, delete this paragraph and replace with the following.

Within 1 year after submission of the final report, all of the aforementioned materials from the Sponsor's designees (Ani Lytics Inc., 3M E. T. & S, Mayo Clinic, and Pathology Associates International) will be sent to the Sponsor (Andrew Seacat, PhD, 3M) by the Sponsor's designees.

Effective April 7, 2000

16. **Page 2, Purpose.** To modify the purpose of the study, delete the text in this section and replace with the following.

To assess the effect of the test material on critical enzyme levels, hormones, and other selected biochemical parameters when administered daily by capsule to cynomolgus monkeys for at least 26 weeks. The treatment period will be followed by an approximate 52-week recovery period.

002962

AMENDMENT APPROVAL

Andrew M. Seacat, PhD
Study Monitor
3M

Date

Peter J. Thomford, PhD
Study Director
Covance Laboratories Inc.

Date

APPENDIX 2

Individual Animal Fate Data
Individual Clinical Observations
Individual Ophthalmic Observations

APPENDIX 2
Individual Animal Fate Data

Covance 6329-223
3M T-6295.7

PAGE: 1

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DOSE GROUP	SEX	DEATH CODE	TYPE OF DEATH	DESCRIPTION OF DEATH	DATE OF DEATH	DAY OF STUDY	WEEK OF STUDY
I05508	1	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
I05517	1	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
I05519	1	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
I05520	1	MALE	O	UNSCHEDULED	UNSCHEDULED DEATH	02/25/00	549	79
I05526	1	MALE	O	UNSCHEDULED	UNSCHEDULED DEATH	02/25/00	549	79
I05527	1	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
I05514	2	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
I05515	2	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
I05516	2	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
I05521	2	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
I05505	3	MALE	6	SCHEDULED	SIXTH INTERIM SACRIFICE	03/08/00	561	81
I05510	3	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
I05518	3	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
I05523	3	MALE	6	SCHEDULED	SIXTH INTERIM SACRIFICE	03/08/00	561	81
I05524	3	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
I05528	3	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
I05506	4	MALE	M	UNSCHEDULED	UNSCHEDULED DEATH	02/20/99	179	26
I05507	4	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
I05509	4	MALE	D	UNSCHEDULED	UNSCHEDULED DEATH	01/27/99	155	23
I05511	4	MALE	U	SCHEDULED	FIRST POST-RECOV SAC	02/25/00	549	79
I05512	4	MALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
I05522	4	MALE	U	SCHEDULED	FIRST POST-RECOV SAC	02/25/00	549	79
I05529	1	FEMALE	P	UNSCHEDULED	UNSCHEDULED DEATH	02/25/00	549	79
I05530	1	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
I05531	1	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
I05535	1	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
I05544	1	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
I05549	1	FEMALE	P	UNSCHEDULED	UNSCHEDULED DEATH	02/25/00	549	79
I05537	2	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
I05541	2	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
I05547	2	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
I05550	2	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
I05532	3	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
I05538	3	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27

APPENDIX 2
Individual Animal Fate Data

Covance 6329-223
3M T-6295.7

PAGE: 2

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DOSE GROUP	SEX	DEATH CODE	TYPE OF DEATH	DESCRIPTION OF DEATH	DATE OF DEATH	DAY OF STUDY	WEEK OF STUDY
I05539	3	FEMALE	6	SCHEDULED	SIXTH INTERIM SACRIFICE	03/08/00	561	81
I05545	3	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
I05548	3	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
I05552	3	FEMALE	6	SCHEDULED	SIXTH INTERIM SACRIFICE	03/08/00	561	81
I05533	4	FEMALE	U	SCHEDULED	FIRST POST-RECOV SAC	02/25/00	549	79
I05534	4	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
I05536	4	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/25/99	184	27
I05540	4	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27
I05542	4	FEMALE	U	SCHEDULED	FIRST POST-RECOV SAC	02/25/00	549	79
I05551	4	FEMALE	T	SCHEDULED	TERMINAL SACRIFICE	02/26/99	185	27

002966

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 1

ANIMAL DEATH WK OF	CATEGORY	GROUP: M1	DOSE: 0 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP
NUMBER CODE DEATH	KEYWORD			AM OBS UNSCHED 30-90 OB DISPATCH
	QUALIFIER	DAYS 1-185	DAY	
I05508	T	27	NORMAL	
			NO REMARKABLE OBSERVATIONS	
			1	P - - -
			8	P - - -
			15	P - - -
			22	P - - -
			29	P - - -
			36	P - - -
			43	P - - -
			50	P - - -
			57	P - - -
			64	P - - -
			71	P - - -
			78	P - - -
			85	P - - -
			92	P - - -
			99	P - - -
			106	P - - -
			113	P - - -
			120	P - - -
			127	P - - -
			134	P - - -
			141	P - - -
			148	P - - -
			155	P - - -
			162	P - - -
			169	P - - -
			176	P - - -
			183	P - - -
			184	P - - P

002957

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 2

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M1	DOSE: 0 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP	AM OBS	UNSCHED	30-90 OB	DISPATCH
				DAYS 1-185	DAY					
I05517	T	27	NORMAL							
			NO REMARKABLE OBSERVATIONS							
					1	P	-	-	-	
					8	P	-	-	-	
					15	P	-	-	-	
					22	P	-	-	-	
					29	P	-	-	-	
					36	P	-	-	-	
					43	P	-	-	-	
					50	P	-	-	-	
					57	P	-	-	-	
					64	P	-	-	-	
					71	P	-	-	-	
					78	P	-	-	-	
					85	P	-	-	-	
					92	P	-	-	-	
					99	P	-	-	-	
					106	P	-	-	-	
					113	P	-	-	-	
					120	P	-	-	-	
					127	P	-	-	-	
					134	P	-	-	-	
					141	P	-	-	-	
					148	P	-	-	-	
					155	P	-	-	-	
					162	P	-	-	-	
					169	P	-	-	-	
					176	P	-	-	-	
					183	P	-	-	-	
					184	P	-	-	-	P
			QUALITATIVE FOOD CONSUMPTION							
			LOW		102	P	-	-	-	

896200

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 3

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M1	DOSE: 0 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP	AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)												
I05517	T	27	QUALITATIVE FOOD CONSUMPTION LOW				141	P	-	-	-	
							176	P	-	-	-	
							177	P	-	-	-	
							179	P	-	-	-	
I05519	T	27	NORMAL NO REMARKABLE OBSERVATIONS				1	P	-	-	-	
							8	P	-	-	-	
							15	P	-	-	-	
							22	P	-	-	-	
							29	P	-	-	-	
							36	P	-	-	-	
							43	P	-	-	-	
							50	P	-	-	-	
							57	P	-	-	-	
							64	P	-	-	-	
							71	P	-	-	-	
							78	P	-	-	-	
							85	P	-	-	-	
							92	P	-	-	-	
							99	P	-	-	-	
							106	P	-	-	-	
							113	P	-	-	-	
							120	P	-	-	-	
							127	P	-	-	-	
							134	P	-	-	-	
							141	P	-	-	-	
							148	P	-	-	-	
							155	P	-	-	-	
							162	P	-	-	-	
							169	P	-	-	-	

002939

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 4

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M1	DOSE: 0 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP
								AM OBS UNSCHED 30-90 OB DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05519	T	27	NORMAL					
			NO REMARKABLE OBSERVATIONS				176	P - - -
							183	P - - -
							184	P - - P
I05520	O	79	DISCHARGE					
			VOMITUS					
			CONTAINING FOOD				141	P - - -
			EXCRETION					
			LIQUID FECES				29	- - P -
			NON-FORMED FECES				29	P - P -
			NORMAL					
			NO REMARKABLE OBSERVATIONS				1	P - - -
							8	P - - -
							15	P - - -
							22	P - - -
							36	P - - -
							43	P - - -
							50	P - - -
							57	P - - -
							64	P - - -
							71	P - - -
							78	P - - -
							85	P - - -
							92	P - - -
							99	P - - -
							106	P - - -
							113	P - - -
							120	P - - -
							127	P - - -

002970

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 5

ANIMAL DEATH WK OF	CATEGORY	GROUP: M1	DOSE: 0 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH
	QUALIFIER	DAYS 1-185	DAY				
(CONTINUED FROM PREVIOUS PAGE)							
I05520	O	79	NORMAL				
			NO REMARKABLE OBSERVATIONS				
				134	P	-	-
				148	P	-	-
				155	P	-	-
				162	P	-	-
				169	P	-	-
				176	P	-	-
				183	P	-	-
			QUALITATIVE FOOD CONSUMPTION				
			LOW				
				122	P	-	-
I05526	O	79	EXCRETION				
			NON-FORMED FECES				
				179	P	-	-
			NORMAL				
			NO REMARKABLE OBSERVATIONS				
				1	P	-	-
				8	P	-	-
				15	P	-	-
				22	P	-	-
				29	P	-	-
				36	P	-	-
				43	P	-	-
				50	P	-	-
				57	P	-	-
				64	P	-	-
				71	P	-	-
				78	P	-	-
				85	P	-	-
				92	P	-	-
				99	P	-	-
				106	P	-	-

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 6

ANIMAL DEATH WK OF	CATEGORY	GROUP: M1	DOSE: 0 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP
NUMBER CODE DEATH	KEYWORD			AM OBS UNSCHED 30-90 OB DISPATCH
	QUALIFIER	DAYS 1-185	DAY	
(CONTINUED FROM PREVIOUS PAGE)				
I05526	O	79	NORMAL	
			NO REMARKABLE OBSERVATIONS	
			113	P - - -
			120	P - - -
			127	P - - -
			134	P - - -
			141	P - - -
			148	P - - -
			155	P - - -
			162	P - - -
			169	P - - -
			176	P - - -
			183	P - - -
I05527	T	27	DISCHARGE UNKNOWN SOURCE	
			FOUND IN PAN	
			RED IN COLOR	
			144	P - - -
			EXCRETION	
			NON-FORMED FECES	
			2	P - - -
			SKIN & PELAGE	
			BROKEN SKIN	
			HAND-LEFT	
			37	P - - -
			38	P - - -
			39	P - - -
			40	P - - -
			43	P - - -
			168	- - - P
			169	P - - -
			170	- - - P
			176	P - - -
			177	- - - P
			TAIL	

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 7

ANIMAL DEATH WK OF	CATEGORY	GROUP: M1	DOSE: 0 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH
	QUALIFIER	DAYS 1-185	DAY				
=====							
(CONTINUED FROM PREVIOUS PAGE)							
I05527	T	27	SKIN & PELAGE				
			BROKEN SKIN				
			TAIL				
				178	P	-	P
				179	P	-	-
				180	P	-	-
				181	-	-	P
				183	P	-	-
				184	P	-	-
			TAIL-DISTAL	145	-	-	P
			NORMAL				
			NO REMARKABLE OBSERVATIONS				
				1	P	-	-
				8	P	-	-
				15	P	-	-
				22	P	-	-
				29	P	-	-
				36	P	-	-
				50	P	-	-
				57	P	-	-
				64	P	-	-
				71	P	-	-
				78	P	-	-
				85	P	-	-
				92	P	-	-
				99	P	-	-
				106	P	-	-
				113	P	-	-
				120	P	-	-
				127	P	-	-
				134	P	-	-
				141	P	-	-
				148	P	-	-

002973

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 8

ANIMAL DEATH WK OF	CATEGORY	GROUP: M1	DOSE: 0 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH
	QUALIFIER	DAYS 1-185	DAY				
(CONTINUED FROM PREVIOUS PAGE)							
I05527	T	27	NORMAL				
			NO REMARKABLE OBSERVATIONS	155	P	-	-
				162	P	-	-
			QUALITATIVE FOOD CONSUMPTION				
			LOW	43	P	-	-

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 9

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M2	DOSE: 0.03 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP	AM OBS	UNSCHED	30-90 OB	DISPATCH
				DAYS 1-185	DAY					
I05514	T	27	EXCRETION							
			LIQUID FECES		91	P	-	-	-	-
			NON-FORMED FECES		105	-	-	-	P	-
					132	-	-	-	P	-
			NORMAL							
			NO REMARKABLE OBSERVATIONS		1	P	-	-	-	-
					8	P	-	-	-	-
					15	P	-	-	-	-
					22	P	-	-	-	-
					29	P	-	-	-	-
					36	P	-	-	-	-
					43	P	-	-	-	-
					50	P	-	-	-	-
					57	P	-	-	-	-
					64	P	-	-	-	-
					71	P	-	-	-	-
					78	P	-	-	-	-
					85	P	-	-	-	-
					92	P	-	-	-	-
					99	P	-	-	-	-
					106	P	-	-	-	-
					113	P	-	-	-	-
					120	P	-	-	-	-
					127	P	-	-	-	-
					134	P	-	-	-	-
					141	P	-	-	-	-
					148	P	-	-	-	-
					155	P	-	-	-	-
					162	P	-	-	-	-
					169	P	-	-	-	-
					176	P	-	-	-	-

002975

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 10

ANIMAL DEATH WK OF NUMBER CODE DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M2	DOSE: 0.03 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP	AM OBS	UNSCHED	30-90 OB	DISPATCH
		DAYS 1-185	DAY					
(CONTINUED FROM PREVIOUS PAGE)								
I05514	T	27	NORMAL					
			NO REMARKABLE OBSERVATIONS	183	P	-	-	-
				184	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION					
			LOW	102	P	-	-	-
				179	P	-	-	-
I05515	T	27	EXCRETION					
			NON-FORMED FECES	69	-	-	P	-
			NORMAL					
			NO REMARKABLE OBSERVATIONS	1	P	-	-	-
				8	P	-	-	-
				15	P	-	-	-
				22	P	-	-	-
				29	P	-	-	-
				36	P	-	-	-
				43	P	-	-	-
				50	P	-	-	-
				57	P	-	-	-
				64	P	-	-	-
				71	P	-	-	-
				78	P	-	-	-
				85	P	-	-	-
				92	P	-	-	-
				99	P	-	-	-
				106	P	-	-	-
				113	P	-	-	-
				120	P	-	-	-
				127	P	-	-	-
				134	P	-	-	-

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 11

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M2	DOSE: 0.03 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP	AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)												
I05515	T	27	NORMAL									
			NO REMARKABLE OBSERVATIONS				141	P	-	-	-	
							148	P	-	-	-	
							155	P	-	-	-	
							162	P	-	-	-	
							169	P	-	-	-	
							176	P	-	-	-	
							183	P	-	-	-	
							185	P	-	-	-	P
			QUALITATIVE FOOD CONSUMPTION									
			LOW				141	P	-	-	-	
							162	P	-	-	-	
I05516	T	27	DISCHARGE									
			VOMITUS									
			CONTAINING FOOD				179	P	-	-	-	
			PARTIAL CAPSULE				85	-	-	-	P	-
			NORMAL									
			NO REMARKABLE OBSERVATIONS				1	P	-	-	-	
							8	P	-	-	-	
							15	P	-	-	-	
							22	P	-	-	-	
							29	P	-	-	-	
							36	P	-	-	-	
							43	P	-	-	-	
							50	P	-	-	-	
							57	P	-	-	-	
							64	P	-	-	-	
							71	P	-	-	-	
							78	P	-	-	-	

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 12

ANIMAL DEATH WK OF	CATEGORY	GROUP: M2	DOSE: 0.03 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH
	QUALIFIER	DAYS 1-185	DAY				
(CONTINUED FROM PREVIOUS PAGE)							
I05516	T	27	NORMAL				
			NO REMARKABLE OBSERVATIONS				
				85	P	-	-
				92	P	-	-
				99	P	-	-
				106	P	-	-
				113	P	-	-
				120	P	-	-
				127	P	-	-
				134	P	-	-
				141	P	-	-
				148	P	-	-
				155	P	-	-
				162	P	-	-
				169	P	-	-
				176	P	-	-
				183	P	-	-
				185	P	-	P
			QUALITATIVE FOOD CONSUMPTION				
			LOW	179	P	-	-
I05521	T	27	SKIN & PELAGE				
			BROKEN SKIN				
			PERI-ORBITAL-RIGHT	20	P	-	P
			NORMAL				
			NO REMARKABLE OBSERVATIONS				
				1	P	-	-
				8	P	-	-
				15	P	-	-
				22	P	-	-
				29	P	-	-
				36	P	-	-

002979

Covance 6329-223
3M T-6295.7

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 13

ANIMAL DEATH WK OF NUMBER CODE DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M2	DOSE: 0.03 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP
		DAYS 1-185	DAY	AM OBS UNSCHED 30-90 OB DISPATCH
(CONTINUED FROM PREVIOUS PAGE)				
I05521	T 27 NORMAL			
NO REMARKABLE OBSERVATIONS				
		43	P	- - -
		50	P	- - -
		57	P	- - -
		64	P	- - -
		71	P	- - -
		78	P	- - -
		85	P	- - -
		92	P	- - -
		99	P	- - -
		106	P	- - -
		113	P	- - -
		120	P	- - -
		127	P	- - -
		134	P	- - -
		141	P	- - -
		148	P	- - -
		155	P	- - -
		162	P	- - -
		169	P	- - -
		176	P	- - -
		183	P	- - -
		185	P	- - - P

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 14

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M3 DAYS 1-185	DOSE: 0.15 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS UNSCHED 30-90 OB DISPATCH			
I05505	6	81	DISCHARGE VOMITUS CONTAINING FOOD		141	P	-	-	-
			NORMAL NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					29	P	-	-	-
					36	P	-	-	-
					43	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					78	P	-	-	-
					85	P	-	-	-
					92	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					120	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 15

ANIMAL DEATH WK OF	CATEGORY	GROUP: M3	DOSE: 0.15 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH
	QUALIFIER	DAYS 1-185	DAY				
(CONTINUED FROM PREVIOUS PAGE)							
I05505	6	81					
	QUALITATIVE FOOD CONSUMPTION						
	LOW		80	P	-	-	-
			141	P	-	-	-
			180	P	-	-	-
I05510	T	27					
	EXCRETION						
	DISCOLORED URINE						
	RED IN COLOR		97	-	-	P	-
	NORMAL						
	NO REMARKABLE OBSERVATIONS		1	P	-	-	-
			8	P	-	-	-
			15	P	-	-	-
			22	P	-	-	-
			29	P	-	-	-
			36	P	-	-	-
			43	P	-	-	-
			50	P	-	-	-
			57	P	-	-	-
			64	P	-	-	-
			71	P	-	-	-
			78	P	-	-	-
			85	P	-	-	-
			92	P	-	-	-
			99	P	-	-	-
			106	P	-	-	-
			113	P	-	-	-
			120	P	-	-	-
			134	P	-	-	-
			141	P	-	-	-

002981

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 16

ANIMAL DEATH WK OF NUMBER CODE DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M3 DAYS 1-185	DOSE: 0.15 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS UNSCHED 30-90 OB DISPATCH
(CONTINUED FROM PREVIOUS PAGE)				
I05510 T 27	NORMAL			
	NO REMARKABLE OBSERVATIONS		155 P - - -	
			162 P - - -	
			169 P - - -	
			176 P - - -	
			183 P - - -	
			185 P - - P	
	QUALITATIVE FOOD CONSUMPTION LOW			
			67 P - - -	
			73 P - - -	
			109 P - - -	
			127 P - - -	
			141 P - - -	
			142 P - - -	
			148 P - - -	
			154 P - - -	
			180 P - - -	
			183 P - - -	
I05518 T 27	DISCHARGE VOMITUS CONTAINING FOOD			
	NORMAL		179 P - - -	
	NO REMARKABLE OBSERVATIONS			
			1 P - - -	
			8 P - - -	
			15 P - - -	
			22 P - - -	
			29 P - - -	
			36 P - - -	
			43 P - - -	

002982

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 17

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF	CATEGORY	GROUP: M3	DOSE: 0.15 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD QUALIFIER	DAYS 1-185	DAY	AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)							
I05518	T 27	NORMAL					
	NO REMARKABLE OBSERVATIONS		50	P	-	-	-
			57	P	-	-	-
			64	P	-	-	-
			71	P	-	-	-
			78	P	-	-	-
			85	P	-	-	-
			92	P	-	-	-
			99	P	-	-	-
			106	P	-	-	-
			113	P	-	-	-
			120	P	-	-	-
			127	P	-	-	-
			134	P	-	-	-
			141	P	-	-	-
			148	P	-	-	-
			155	P	-	-	-
			162	P	-	-	-
			169	P	-	-	-
			176	P	-	-	-
			183	P	-	-	-
			185	P	-	-	P
	QUALITATIVE FOOD CONSUMPTION						
	LOW		141	P	-	-	-
			179	P	-	-	-

002983

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 18

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M3 DOSE: 0.15 MG/KG/DAY DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
I05523	6	81	SKIN & PELAGE BROKEN SKIN TAIL		149	-	-	P	-
			NORMAL NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					29	P	-	-	-
					36	P	-	-	-
					43	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					78	P	-	-	-
					85	P	-	-	-
					92	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					120	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 19

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF	CATEGORY	GROUP: M3	DOSE: 0.15 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH
	QUALIFIER	DAYS 1-185	DAY				
=====							
(CONTINUED FROM PREVIOUS PAGE)							
I05523	6	81					
	QUALITATIVE FOOD CONSUMPTION						
	LOW		6	P	-	-	-
			141	P	-	-	-
			179	P	-	-	-
I05524	T	27					
	DISCHARGE						
	VOMITUS						
	CONTAINING FOOD		141	P	-	-	-
	EXCRETION						
	NON-FORMED FECES		179	P	-	-	-
			180	P	-	-	-
	NORMAL						
	NO REMARKABLE OBSERVATIONS		1	P	-	-	-
			8	P	-	-	-
			15	P	-	-	-
			22	P	-	-	-
			29	P	-	-	-
			36	P	-	-	-
			50	P	-	-	-
			57	P	-	-	-
			64	P	-	-	-
			71	P	-	-	-
			78	P	-	-	-
			85	P	-	-	-
			92	P	-	-	-
			99	P	-	-	-
			106	P	-	-	-
			113	P	-	-	-

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 20

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M3	DOSE: 0.15 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER	CODE	DEATH	QUALIFIER	DAYS 1-185	DAY	AM OBS	UNSCHED	30-90 OB	DISPATCH
=====									
(CONTINUED FROM PREVIOUS PAGE)									
I05524	T	27	NORMAL						
NO REMARKABLE OBSERVATIONS					120	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-
					185	P	-	-	P
QUALITATIVE FOOD CONSUMPTION									
LOW					43	P	-	-	-
					65	P	-	-	-
					141	P	-	-	-
					179	P	-	-	-
					180	P	-	-	-
I05528	T	27	NORMAL						
NO REMARKABLE OBSERVATIONS					1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					29	P	-	-	-
					36	P	-	-	-
					43	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					85	P	-	-	-

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 21

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF	CATEGORY	GROUP: M3	DOSE: 0.15 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH
	QUALIFIER	DAYS 1-185	DAY				
(CONTINUED FROM PREVIOUS PAGE)							
I05528	T	27	NORMAL				
			NO REMARKABLE OBSERVATIONS				
			92	P	-	-	-
			99	P	-	-	-
			106	P	-	-	-
			120	P	-	-	-
			134	P	-	-	-
			141	P	-	-	-
			148	P	-	-	-
			155	P	-	-	-
			162	P	-	-	-
			169	P	-	-	-
			176	P	-	-	-
			183	P	-	-	-
			185	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION				
			LOW				
			78	P	-	-	-
			113	P	-	-	-
			116	P	-	-	-
			127	P	-	-	-
			134	P	-	-	-
			162	P	-	-	-
			176	P	-	-	-
			179	P	-	-	-

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 22

ANIMAL DEATH WK OF	CATEGORY	GROUP: M4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP						
NUMBER CODE DEATH	KEYWORD			AM OBS	UNCHED	30-90 OB	DISPATCH			
	QUALIFIER	DAYS 1-185	DAY							
=====										
I05506	M	26	BEHAVIOR							
	ATAXIC									
	<UNSPECIFIED>		179	-	P	-	P			
	HYPOACTIVE									
	<UNSPECIFIED>		179	-	P	-	P			
	DISCHARGE									
	EXCESSIVE SALIVATION		179	-	P	-	-			
	RESPIRATION									
	LABORED		179	-	P	-	P			
	NORMAL									
	NO REMARKABLE OBSERVATIONS		1	P	-	-	-			
			8	P	-	-	-			
			15	P	-	-	-			
			22	P	-	-	-			
			29	P	-	-	-			
			36	P	-	-	-			
			43	P	-	-	-			
			50	P	-	-	-			
			57	P	-	-	-			
			64	P	-	-	-			
			71	P	-	-	-			
			78	P	-	-	-			
			85	P	-	-	-			
			92	P	-	-	-			
			99	P	-	-	-			
			106	P	-	-	-			
			113	P	-	-	-			
			120	P	-	-	-			
			127	P	-	-	-			

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 23

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF	CATEGORY	GROUP: M4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH
	QUALIFIER	DAYS 1-185	DAY				
=====							
(CONTINUED FROM PREVIOUS PAGE)							
I05506	M	26	NORMAL				
			NO REMARKABLE OBSERVATIONS				
			134	P	-	-	-
			141	P	-	-	-
			148	P	-	-	-
			155	P	-	-	-
			162	P	-	-	-
			169	P	-	-	-
			176	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION				
			LOW				
			3	P	-	-	-
			141	P	-	-	-
			178	P	-	-	-
			179	P	-	-	-
I05507	T	27	DISCHARGE				
			VOMITUS				
			PARTIAL CAPSULE				
			11	-	-	P	-
			111	-	-	P	-
			178	-	-	P	-
			SKIN & PELAGE				
			BROKEN SKIN				
			DIGIT(S)-FRONT-LEFT				
			97	-	-	P	-
			98	P	-	P	-
			99	P	-	P	-
			100	P	-	-	-
			101	-	-	P	-
			102	P	-	-	-
			104	P	-	P	-
			106	P	-	P	-
			107	P	-	P	-

002989

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 24

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF	CATEGORY	GROUP: M4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH
	QUALIFIER	DAYS 1-185	DAY				
(CONTINUED FROM PREVIOUS PAGE)							
I05507	T	27	SKIN & PELAGE				
			BROKEN SKIN				
			DIGIT(S)-FRONT-LEFT	108	P	-	-
				111	-	-	P
				112	P	-	P
			NORMAL				
			NO REMARKABLE OBSERVATIONS	1	P	-	-
				8	P	-	-
				15	P	-	-
				22	P	-	-
				29	P	-	-
				36	P	-	-
				43	P	-	-
				50	P	-	-
				57	P	-	-
				64	P	-	-
				71	P	-	-
				78	P	-	-
				85	P	-	-
				92	P	-	-
				113	P	-	-
				120	P	-	-
				127	P	-	-
				134	P	-	-
				141	P	-	-
				148	P	-	-
				155	P	-	-
				162	P	-	-
				169	P	-	-
				176	P	-	-
				183	P	-	-

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 25

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF NUMBER CODE DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP	AM OBS	UNSCHED	30-90 OB	DISPATCH
		DAYS 1-185	DAY					
(CONTINUED FROM PREVIOUS PAGE)								
I05507	T	27	NORMAL					
			NO REMARKABLE OBSERVATIONS	184	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION					
			LOW	141	P	-	-	-
I05509	D	23	APPEARANCE					
			APPEARS DEHYDRATED	155	-	P	-	P
			OTHER	155	-	-	-	PC
			BEHAVIOR					
			HYPOACTIVE					
			<UNSPECIFIED>	155	-	P	-	P
			EXCRETION					
			DISCOLORED FECES					
			BLACK IN COLOR	155	P	-	-	-
			FEW FECES	152	P	-	-	-
				155	P	-	-	-
			LIQUID FECES	155	P	-	-	-
			MUCOID FECES	155	P	-	-	-
			NO FECES	154	P	-	-	-
			EYES					
			CONSTRICTED PUPIL					
			EYES	154	-	-	P	-
			RESPIRATION					
			LABORED	155	-	P	-	P

002991

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 26

ANIMAL DEATH WK OF NUMBER CODE DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP				
		DAYS 1-185	DAY	AM OBS	UNSCHED	30-90 OB	DISPATCH	
(CONTINUED FROM PREVIOUS PAGE)								
I05509	D	23						
	SKIN & PELAGE							
	COLD TO TOUCH							
	BODY-ENTIRE		155	-	P	-	P	
	PALE SKIN		154	-	-	P	-	
	GUMS		155	-	P	-	P	
	NORMAL							
	NO REMARKABLE OBSERVATIONS		1	P	-	-	-	
			8	P	-	-	-	
			15	P	-	-	-	
			22	P	-	-	-	
			29	P	-	-	-	
			36	P	-	-	-	
			43	P	-	-	-	
			50	P	-	-	-	
			57	P	-	-	-	
			64	P	-	-	-	
			71	P	-	-	-	
			78	P	-	-	-	
			85	P	-	-	-	
			92	P	-	-	-	
			99	P	-	-	-	
			106	P	-	-	-	
			113	P	-	-	-	
			120	P	-	-	-	
			127	P	-	-	-	
			134	P	-	-	-	
			141	P	-	-	-	
			148	P	-	-	-	

Individual Clinical Observations
Treatment

ANIMAL	DEATH	WK OF	CATEGORY	GROUP: M4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP				
NUMBER	CODE	DEATH	KEYWORD			AM	OBS	UNSCHE	30-90 OB	DISPATCH
			QUALIFIER	DAYS 1-185	DAY					
=====										
(CONTINUED FROM PREVIOUS PAGE)										
I05509	D	23								

002993

PAGE: 28

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY	GROUP: M4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP				
NUMBER	CODE	DEATH	KEYWORD	QUALIFIER	DAYS 1-185	DAY	AM OBS	UNCHED	30-90 OB	DISPATCH
=====										
(CONTINUED FROM PREVIOUS PAGE)										
I05511	U	79	NORMAL							
NO REMARKABLE OBSERVATIONS						127	P	-	-	-
						134	P	-	-	-
						141	P	-	-	-
						148	P	-	-	-
						155	P	-	-	-
						162	P	-	-	-
						169	P	-	-	-
						176	P	-	-	-
						183	P	-	-	-
QUALITATIVE FOOD CONSUMPTION										
LOW						57	P	-	-	-
						60	P	-	-	-
						100	P	-	-	-
						102	P	-	-	-
						141	P	-	-	-
						145	P	-	-	-
						148	P	-	-	-
						154	P	-	-	-
						155	P	-	-	-
						170	P	-	-	-
						171	P	-	-	-
						172	P	-	-	-
						173	P	-	-	-
						174	P	-	-	-
						175	P	-	-	-
						176	P	-	-	-
						177	P	-	-	-
						179	P	-	-	-
						180	P	-	-	-

002994

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 29

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4	DOSE: 0.75 MG/KG/DAY	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP
							AM OBS UNSCHED 30-90 OB DISPATCH
I05512	T	27	DISCHARGE VOMITUS PARTIAL CAPSULE			32 37	- - P - - P
			EXCRETION FEW FECES			100 102 105 106 110 125 126 127 128 129 130 133 134 155 156 157 158 159 161 181 183 184	P - - P - -
			NO FECES			99 131 132	P - - P - - P - -
			NON-FORMED FECES			130	P - -

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 30

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF NUMBER CODE DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
				AM OBS	UNSCHED	30-90 OB	DISPATCH
		DAYS 1-185	DAY				
(CONTINUED FROM PREVIOUS PAGE)							
I05512	T	27	EXCRETION				
			NON-FORMED FECES	133	P	-	-
			NORMAL				
			NO REMARKABLE OBSERVATIONS	1	P	-	-
				8	P	-	-
				15	P	-	-
				22	P	-	-
				29	P	-	-
				36	P	-	-
				43	P	-	-
				50	P	-	-
				57	P	-	-
				64	P	-	-
				71	P	-	-
				78	P	-	-
				85	P	-	-
				92	P	-	-
				113	P	-	-
				120	P	-	-
				141	P	-	-
				148	P	-	-
				162	P	-	-
				169	P	-	-
				176	P	-	-
				184	-	-	P
			QUALITATIVE FOOD CONSUMPTION				
			LOW	17	P	-	-
				98	P	-	-
				99	P	-	-
				100	P	-	-

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 31

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF	CATEGORY	GROUP: M4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH
	QUALIFIER	DAYS 1-185	DAY				
=====							
(CONTINUED FROM PREVIOUS PAGE)							
I05512	T	27	QUALITATIVE FOOD CONSUMPTION				
			LOW				
			102	P	-	-	-
			105	P	-	-	-
			110	P	-	-	-
			116	P	-	-	-
			125	P	-	-	-
			126	P	-	-	-
			127	P	-	-	-
			128	P	-	-	-
			129	P	-	-	-
			130	P	-	-	-
			131	P	-	-	-
			132	P	-	-	-
			133	P	-	-	-
			134	P	-	-	-
			155	P	-	-	-
			156	P	-	-	-
			157	P	-	-	-
			158	P	-	-	-
			159	P	-	-	-
			160	P	-	-	-
			161	P	-	-	-
			162	P	-	-	-
			164	P	-	-	-
			168	P	-	-	-
			174	P	-	-	-
			175	P	-	-	-
			176	P	-	-	-
			178	P	-	-	-
			179	P	-	-	-
			180	P	-	-	-
			181	P	-	-	-

002997

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 32

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4 DAYS 1-185	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)									
I05512	T	27	QUALITATIVE FOOD CONSUMPTION LOW		183	P	-	-	-
I05522	U	79	EXCRETION MUCOID FECES		179	P	-	-	-
			NORMAL NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					29	P	-	-	-
					36	P	-	-	-
					43	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					78	P	-	-	-
					85	P	-	-	-
					92	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					120	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 33

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4	DOSE: 0.75 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP
								AM OBS UNSCHED 30-90 OB DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05522	U	79	NORMAL					
			NO REMARKABLE OBSERVATIONS				176	P - - -
							183	P - - -
			QUALITATIVE FOOD CONSUMPTION					
			LOW				102	P - - -
							180	P - - -

666200

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 34

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL	GROUP	STUDY DAY WK	CATEGORY KEYWORD QUALIFIER	FREE-TEXT COMMENT
I05509	M4	155 23	APPEARANCE OTHER	AFTER DOSING ANIMAL BECAME RECUMBENT. VET [WAS CALLED. ANIMAL DIED PRIOR TO VET EXAM.

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 35

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1 DAYS 1-185	DOSE: 0 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS UNSCHED 30-90 OB DISPATCH			
I05529	P	79	APPEARANCE APPEARS DEHYDRATED		5 6 7	- P P	- - -	P - -	- - -
			BEHAVIOR HYPOACTIVE <UNSPECIFIED>		6 7 8	- P P	- - -	P - P	- - -
			DISCHARGE NASAL CLEAR		5 6 7 8 9	- P P P P	- - - - -	P P - P -	- - - - -
			ORAL CLOUDY		6 7 8	- P P	- - -	P - -	- - -
			EXCESSIVE SALIVATION		5 6 7 8	- P P P	- - - -	P P - -	- - - -
			EXCRETION LIQUID FECES		29 30 38 39	P P P P	- - - -	- - P -	- - - -

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 36

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF	CATEGORY	GROUP: F1	DOSE: 0 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH
	QUALIFIER	DAYS 1-185	DAY				
=====							
(CONTINUED FROM PREVIOUS PAGE)							
I05529	P	79	EXCRETION				
			LIQUID FECES				
			40	-	-	P	-
			41	P	-	-	-
			42	P	-	P	-
			43	P	-	-	-
			44	P	-	-	-
			65	-	-	P	-
			66	P	-	-	-
			67	P	-	-	-
			68	P	-	-	-
			69	P	-	-	-
			70	P	-	-	-
			99	-	-	P	-
			100	P	-	P	-
			101	P	-	-	-
			102	P	-	-	-
			115	-	-	P	-
			71	P	-	-	-
			73	P	-	-	-
			77	P	-	-	-
			103	P	-	-	-
			115	P	-	-	-
			NON-FORMED FECES				
			SKIN & PELAGE				
			ALOPECIA				
			FEET				
			105	P	-	P	-
			106	P	-	P	-
			107	P	-	P	-
			108	P	-	P	-
			109	P	-	P	-
			110	P	-	P	-
			111	P	-	P	-

003002

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 37

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF	CATEGORY	GROUP: F1	DOSE: 0 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP
NUMBER CODE DEATH	KEYWORD			AM OBS UNSCHED 30-90 OB DISPATCH
	QUALIFIER	DAYS 1-185	DAY	
=====				
(CONTINUED FROM PREVIOUS PAGE)				
105529 P 79	SKIN & PELAGE			
	ALOPECIA			
	FEET			
		112	P	- P -
		113	P	- P -
		114	P	- P -
		115	P	- P -
		117	P	- P -
		118	P	- P -
		119	P	- P -
		120	P	- P -
		121	P	- P -
		122	-	- P -
		124	-	- P -
		125	P	- P -
		126	P	- P -
		127	P	- P -
		128	P	- P -
		129	-	- P -
		130	P	- P -
		131	P	- P -
		132	P	- P -
		133	P	- P -
		134	P	- P -
		135	P	- P -
		136	P	- P -
		137	P	- P -
		138	P	- P -
		139	P	- P -
		140	P	- P -
		142	P	- P -
		143	P	- P -
		146	P	- P -

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 38

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF			CATEGORY	GROUP: F1	DOSE: 0 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER	CODE	DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH
			QUALIFIER	DAYS 1-185	DAY				
=====									
(CONTINUED FROM PREVIOUS PAGE)									
I05529	P	79	SKIN & PELAGE						
			ALOPECIA						
			FEET						
					147	P	-	P	-
					148	P	-	-	-
					149	P	-	P	-
					150	P	-	P	-
					151	P	-	P	-
					152	P	-	P	-
					153	P	-	P	-
					154	P	-	-	-
					155	P	-	-	-
					156	P	-	-	-
					157	P	-	P	-
					158	-	-	P	-
					162	P	-	P	-
					163	P	-	P	-
					164	P	-	P	-
					165	P	-	P	-
					166	P	-	P	-
					167	P	-	P	-
					168	P	-	P	-
					169	P	-	P	-
					170	P	-	P	-
					171	P	-	P	-
					172	P	-	P	-
					173	P	-	P	-
					174	P	-	P	-
					175	P	-	P	-
					176	P	-	P	-
					177	P	-	P	-
					178	P	-	P	-
					179	P	-	P	-

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 39

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1	DOSE: 0 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP
								AM OBS UNSCHED 30-90 OB DISPATCH
=====								
(CONTINUED FROM PREVIOUS PAGE)								
I05529	P	79	SKIN & PELAGE					
			ALOPECIA					
			FEET					
						180	P	- P -
						181	-	- P -
						182	P	- P -
						183	P	- P -
						184	P	- - -
						185	P	- - -
			LIMBS-HIND			92	-	- P -
						93	-	- P -
						94	P	- P -
						95	P	- P -
						96	P	- P -
						98	P	- P -
						99	P	- P -
						100	P	- P -
						101	P	- - -
						102	P	- P -
						142	-	- P -
						144	-	- P -
			TAIL			134	P	- P -
						135	P	- P -
						136	P	- P -
						137	P	- P -
						138	P	- - -
						139	P	- P -
						140	P	- P -
						142	P	- P -
						143	P	- P -
						146	P	- P -
						147	P	- P -
						148	P	- - -

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

003006

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 41

ANIMAL DEATH WK OF			CATEGORY	GROUP: F1	DOSE: 0 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER	CODE	DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH
			QUALIFIER	DAYS 1-185	DAY				
=====									
(CONTINUED FROM PREVIOUS PAGE)									
I05529	P	79	SKIN & PELAGE						
			ALOPECIA						
			TAIL						
					182	P	-	P	-
					183	P	-	P	-
					184	P	-	-	-
					185	P	-	-	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					36	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					78	P	-	-	-
					85	P	-	-	-
					92	P	-	-	-
					141	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION						
			LOW		5	P	-	-	-
					8	P	-	-	-
					41	P	-	-	-
					42	P	-	-	-
					69	P	-	-	-
					72	P	-	-	-
					73	P	-	-	-
					75	P	-	-	-
					102	P	-	-	-
					174	P	-	-	-
					179	P	-	-	-

003007

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 42

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1	DOSE: 0 MG/KG/DAY	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP
				DAYS 1-185			AM OBS UNSCHED 30-90 OB DISPATCH
I05530	T	27	DISCHARGE				
			VOMITUS				
			PARTIAL CAPSULE		97	-	P
			APPEARS TO BE MENSTRUATING		39	-	P
					40	P	-
					92	P	-
					176	P	-
					180	P	-
			EXCRETION				
			DISCOLORED FECES				
			RED IN COLOR		28	P	-
			LIQUID FECES		27	P	-
					28	P	-
					29	P	-
					31	-	P
					32	P	-
					33	P	-
					34	P	P
					35	P	-
					36	P	-
					37	P	-
					38	P	P
					39	-	P
					40	P	-
					49	P	-
					50	P	-
					51	P	P
					55	P	-
			MUCOID FECES		28	P	-
			NON-FORMED FECES		12	P	-
					31	P	-

003008

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 43

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1	DOSE: 0 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP	AM OBS	UNSCHED	30-90 OB	DISPATCH
=====												
(CONTINUED FROM PREVIOUS PAGE)												
I05530	T	27	EXCRETION									
			NON-FORMED FECES				41	P	-	-	-	-
							54	P	-	-	-	-
							55	P	-	-	-	-
							57	P	-	-	-	-
			SKIN & PELAGE									
			BROKEN SKIN									
			MOUTH				10	-	-	-	P	-
							12	P	-	-	-	-
							15	P	-	-	-	-
							22	P	-	-	-	-
							23	P	-	-	-	-
							25	P	-	-	P	-
							26	P	-	-	P	-
							27	P	-	-	P	-
							28	P	-	-	P	-
							29	P	-	-	P	-
							30	P	-	-	P	-
							31	P	-	-	P	-
			NORMAL									
			NO REMARKABLE OBSERVATIONS				1	P	-	-	-	-
							8	P	-	-	-	-
							43	P	-	-	-	-
							64	P	-	-	-	-
							71	P	-	-	-	-
							78	P	-	-	-	-
							85	P	-	-	-	-
							99	P	-	-	-	-
							106	P	-	-	-	-
							113	P	-	-	-	-

003009

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 44

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF	CATEGORY	GROUP: F1	DOSE: 0 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH
	QUALIFIER	DAYS 1-185	DAY				
=====							
(CONTINUED FROM PREVIOUS PAGE)							
I05530	T	27	NORMAL				
			NO REMARKABLE OBSERVATIONS				
			120	P	-	-	-
			127	P	-	-	-
			134	P	-	-	-
			141	P	-	-	-
			148	P	-	-	-
			155	P	-	-	-
			162	P	-	-	-
			169	P	-	-	-
			183	P	-	-	-
			184	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION				
			LOW				
			26	P	-	-	-
			27	P	-	-	-
			29	P	-	-	-
			141	P	-	-	-
I05531	T	27	DISCHARGE				
			VOMITUS				
			CONTAINING FOOD				
			179	P	-	-	-
			176	P	-	-	-
			APPEARS TO BE MENSTRUATING				
			NORMAL				
			NO REMARKABLE OBSERVATIONS				
			1	P	-	-	-
			8	P	-	-	-
			15	P	-	-	-
			22	P	-	-	-
			29	P	-	-	-
			36	P	-	-	-
			43	P	-	-	-
			50	P	-	-	-

003010

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 45

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF	CATEGORY	GROUP: F1	DOSE: 0 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP
NUMBER CODE DEATH	KEYWORD			AM OBS UNSCHED 30-90 OB DISPATCH
	QUALIFIER	DAYS 1-185	DAY	
=====				
(CONTINUED FROM PREVIOUS PAGE)				
I05531	T	27	NORMAL	
			NO REMARKABLE OBSERVATIONS	
			57	P - - -
			64	P - - -
			71	P - - -
			78	P - - -
			85	P - - -
			92	P - - -
			99	P - - -
			106	P - - -
			113	P - - -
			120	P - - -
			127	P - - -
			134	P - - -
			141	P - - -
			148	P - - -
			155	P - - -
			162	P - - -
			169	P - - -
			183	P - - -
			185	P - - P
			QUALITATIVE FOOD CONSUMPTION	
			LOW	
			141	P - - -
			179	P - - -

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 46

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1 DAYS 1-185	DOSE: 0 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
I05535	T	27	DISCHARGE APPEARS TO BE MENSTRUATING						
					37	-	-	P	-
					38	P	-	-	-
					108	P	-	P	-
					137	P	-	P	-
					138	P	-	-	-
					166	P	-	P	-
					167	P	-	P	-
			SKIN & PELAGE						
			RED SKIN						
			LIMB-FRONT-RIGHT		22	-	-	P	-
					23	-	-	P	-
					24	P	-	P	-
			SCAB(S)						
			LIMB-FRONT-LEFT		183	P	-	-	-
			LIMB-FRONT-RIGHT		22	-	-	P	-
					23	-	-	P	-
					24	P	-	P	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					29	P	-	-	-
					36	P	-	-	-
					43	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 47

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF NUMBER CODE DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1	DOSE: 0 MG/KG/DAY		'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP
		DAYS 1-185	DAY	AM OBS	UNSCHED 30-90 OB DISPATCH
=====					
(CONTINUED FROM PREVIOUS PAGE)					
I05535	T 27	NORMAL			
		NO REMARKABLE OBSERVATIONS	78	P	-
			85	P	-
			92	P	-
			99	P	-
			106	P	-
			113	P	-
			120	P	-
			127	P	-
			134	P	-
			141	P	-
			148	P	-
			155	P	-
			162	P	-
			169	P	-
			176	P	-
			185	P	-
I05544	T 27	DISCHARGE			
		VOMITUS			
		CONTAINING FOOD	141	P	-
		PARTIAL CAPSULE	29	-	-
			33	-	P
			34	-	P
			66	-	P
			117	-	P
			141	-	P
		DISCHARGE UNKNOWN SOURCE			
		FOUND IN PAN			
		RED IN COLOR	112	P	-

003013

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 48

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF NUMBER CODE DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1	DOSE: 0 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP
		DAYS 1-185	DAY	AM OBS UNSCHED 30-90 OB DISPATCH
(CONTINUED FROM PREVIOUS PAGE)				
I05544 T 27				

NORMAL
NO REMARKABLE OBSERVATIONS

1	P	-	-	-
8	P	-	-	-
15	P	-	-	-
22	P	-	-	-
29	P	-	-	-
50	P	-	-	-
57	P	-	-	-
64	P	-	-	-
71	P	-	-	-
78	P	-	-	-
85	P	-	-	-
92	P	-	-	-
99	P	-	-	-
106	P	-	-	-
113	P	-	-	-
120	P	-	-	-
134	P	-	-	-
148	P	-	-	-
155	P	-	-	-
162	P	-	-	-
169	P	-	-	-
176	P	-	-	-
183	P	-	-	-
184	P	-	-	P

QUALITATIVE FOOD CONSUMPTION
LOW

6	P	-	-	-
36	P	-	-	-
38	P	-	-	-

003014

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 49

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF NUMBER CODE DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1	DOSE: 0 MG/KG/DAY	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNCHED	30-90 OB	DISPATCH
		DAYS 1-185						
(CONTINUED FROM PREVIOUS PAGE)								
I05544	T	27	QUALITATIVE FOOD CONSUMPTION LOW	42 43 127 171 174 176	P P P P P P	- - - - - -	- - - - - -	- - - - - -
I05549	P	79	DISCHARGE VOMITUS INTACT CAPSULE PARTIAL CAPSULE APPEARS TO BE MENSTRUATING	111 97 175	- - P	- - -	P P -	- - -
			SKIN & PELAGE BROKEN SKIN HEAD-CRANIAL PERI-ORBITAL-LEFT	3 7 8 15	- - P P	- - - -	P P P P	- - - -
			NORMAL NO REMARKABLE OBSERVATIONS	1 22 29 36 43 50 57 64 71 78	P P P P P P P P P P	- - - - - - - - - -	- - - - - - - - - -	- - - - - - - - - -

003015

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 50

ANIMAL DEATH WK OF	CATEGORY	GROUP: F1	DOSE: 0 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP
NUMBER CODE DEATH	KEYWORD			AM OBS UNSCHED 30-90 OB DISPATCH
	QUALIFIER	DAYS 1-185	DAY	
=====				
(CONTINUED FROM PREVIOUS PAGE)				
I05549	P	79	NORMAL	
			NO REMARKABLE OBSERVATIONS	
			85	P - - -
			92	P - - -
			99	P - - -
			106	P - - -
			113	P - - -
			120	P - - -
			127	P - - -
			134	P - - -
			141	P - - -
			148	P - - -
			155	P - - -
			162	P - - -
			169	P - - -
			176	P - - -
			183	P - - -
			141	P - - -
			175	P - - -
			QUALITATIVE FOOD CONSUMPTION	
			LOW	

003016

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 51

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F2	DOSE: 0.03 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP	AM OBS	UNSCHED	30-90 OB	DISPATCH
I05537	T	27	DISCHARGE VOMITUS WHITE IN COLOR APPEARS TO BE MENSTRUATING				1 45 46 47 48 49 72 73 74 75 104 105 106 107 168 169	- - - P P - P P P P P P P P P P P	- - - - - - - - - - - - - - - -	- - - - - - - - - - - - - - - -	P P P - - P P P P P P P P P P P	- - - - - - - - - - - - - - - -
			SKIN & PELAGE BROKEN SKIN HEAD-MAXILLARY-RIGHT PERI-ORBITAL-LEFT PERI-ORBITAL-RIGHT				50 52 8 9 10 3 4 6 7	- - P P P P P P -	- - - - - - - - -	- - - - - - - - -	P P P P P P P P	- - - - - - - -

003017

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 52

ANIMAL DEATH WK OF	CATEGORY	GROUP: F2	DOSE: 0.03 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH
	QUALIFIER	DAYS 1-185	DAY				
(CONTINUED FROM PREVIOUS PAGE)							
I05537	T	27					

NORMAL

NO REMARKABLE OBSERVATIONS

1	P	-	-	-
15	P	-	-	-
22	P	-	-	-
29	P	-	-	-
36	P	-	-	-
43	P	-	-	-
50	P	-	-	-
57	P	-	-	-
64	P	-	-	-
71	P	-	-	-
78	P	-	-	-
85	P	-	-	-
92	P	-	-	-
99	P	-	-	-
113	P	-	-	-
120	P	-	-	-
127	P	-	-	-
134	P	-	-	-
141	P	-	-	-
148	P	-	-	-
155	P	-	-	-
162	P	-	-	-
176	P	-	-	-
183	P	-	-	-
184	P	-	-	P

003018

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 53

ANIMAL DEATH WK OF			CATEGORY	GROUP: F2	DOSE: 0.03 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP						
NUMBER	CODE	DEATH	KEYWORD	QUALIFIER	DAYS 1-185	DAY	AM OBS	UNSCHED	30-90 OB	DISPATCH		
=====												
I05541	T	27	DISCHARGE									
			APPEARS TO BE MENSTRUATING			99	-	-	P	-		
						102	P	-	-	-		
						152	-	-	P	-		
						154	-	-	P	-		
			EXCRETION									
			FEW FECES			141	P	-	-	-		
			SKIN & PELAGE									
			BROKEN SKIN									
			PERI-ORBITAL-RIGHT			98	-	-	P	-		
						99	P	-	P	-		
						102	P	-	-	-		
			NORMAL									
			NO REMARKABLE OBSERVATIONS			1	P	-	-	-		
						8	P	-	-	-		
						15	P	-	-	-		
						36	P	-	-	-		
						50	P	-	-	-		
						57	P	-	-	-		
						64	P	-	-	-		
						71	P	-	-	-		
						78	P	-	-	-		
						85	P	-	-	-		
						92	P	-	-	-		
						106	P	-	-	-		
						120	P	-	-	-		
						127	P	-	-	-		
						134	P	-	-	-		
						148	P	-	-	-		

003019

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 54

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F2	DOSE: 0.03 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP	AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)												
I05541	T	27	NORMAL									
			NO REMARKABLE OBSERVATIONS				155	P	-	-	-	-
							162	P	-	-	-	-
							169	P	-	-	-	-
							176	P	-	-	-	-
							183	P	-	-	-	-
							185	P	-	-	-	P
			QUALITATIVE FOOD CONSUMPTION									
			LOW				3	P	-	-	-	-
							22	P	-	-	-	-
							28	P	-	-	-	-
							29	P	-	-	-	-
							43	P	-	-	-	-
							55	P	-	-	-	-
							57	P	-	-	-	-
							76	P	-	-	-	-
							87	P	-	-	-	-
							113	P	-	-	-	-
							140	P	-	-	-	-
							169	P	-	-	-	-
							174	P	-	-	-	-
							179	P	-	-	-	-
I05547	T	27	DISCHARGE									
			APPEARS TO BE MENSTRUATING				129	P	-	-	-	-
							164	-	-	P	-	-
							165	P	-	-	-	-
							167	P	-	-	-	-
			EXCRETION									
			FEW FECES				150	P	-	-	-	-

003020

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 55

ANIMAL DEATH WK OF	CATEGORY	GROUP: F2	DOSE: 0.03 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH
	QUALIFIER	DAYS 1-185	DAY				
=====							
(CONTINUED FROM PREVIOUS PAGE)							
I05547	T	27	EXCRETION				
	FEW FECES		151	P	-	-	-
			152	P	-	-	-
			156	P	-	-	-
	NO FECES		168	P	-	-	-
			154	P	-	-	-
	NON-FORMED FECES		155	P	-	-	-
			178	P	-	-	-
			181	-	-	P	-
	SKIN & PELAGE						
	BROKEN SKIN						
	HEAD-MAXILLARY-LEFT		170	P	-	P	-
			171	P	-	P	-
			172	P	-	P	-
			173	-	-	P	-
			174	P	-	P	-
			175	P	-	-	-
	SCAB(S)						
	HEAD-MAXILLARY-LEFT		176	P	-	-	-
			178	P	-	P	-
	NORMAL						
	NO REMARKABLE OBSERVATIONS		1	P	-	-	-
			8	P	-	-	-
			15	P	-	-	-
			22	P	-	-	-
			29	P	-	-	-
			36	P	-	-	-
			50	P	-	-	-
			57	P	-	-	-
			64	P	-	-	-

003021

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 56

ANIMAL DEATH WK OF	CATEGORY	GROUP: F2	DOSE: 0.03 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH
	QUALIFIER	DAYS 1-185	DAY				
(CONTINUED FROM PREVIOUS PAGE)							
I05547	T	27	NORMAL				
			NO REMARKABLE OBSERVATIONS				
			71	P	-	-	-
			78	P	-	-	-
			85	P	-	-	-
			92	P	-	-	-
			106	P	-	-	-
			113	P	-	-	-
			134	P	-	-	-
			141	P	-	-	-
			148	P	-	-	-
			162	P	-	-	-
			169	P	-	-	-
			183	P	-	-	-
			185	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION				
			LOW				
			17	P	-	-	-
			41	P	-	-	-
			43	P	-	-	-
			55	P	-	-	-
			57	P	-	-	-
			66	P	-	-	-
			99	P	-	-	-
			120	P	-	-	-
			121	P	-	-	-
			127	P	-	-	-
			134	P	-	-	-
			141	P	-	-	-
			148	P	-	-	-
			150	P	-	-	-
			151	P	-	-	-
			152	P	-	-	-

003022

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 57

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF NUMBER CODE DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F2	DOSE: 0.03 MG/KG/DAY	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP	AM OBS	UNSCHED	30-90 OB	DISPATCH
=====									
(CONTINUED FROM PREVIOUS PAGE)									
I05547	T	27	QUALITATIVE FOOD CONSUMPTION LOW	154	P	-	-	-	-
				155	P	-	-	-	-
				156	P	-	-	-	-
				160	P	-	-	-	-
				161	P	-	-	-	-
				162	P	-	-	-	-
				165	P	-	-	-	-
				167	P	-	-	-	-
				168	P	-	-	-	-
				169	P	-	-	-	-
				170	P	-	-	-	-
				171	P	-	-	-	-
				174	P	-	-	-	-
				175	P	-	-	-	-
				179	P	-	-	-	-
				184	P	-	-	-	-
I05550	T	27	DISCHARGE	91	-	-	-	P	-
			APPEARS TO BE MENSTRUATING	92	P	-	-	-	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS	1	P	-	-	-	-
				8	P	-	-	-	-
				15	P	-	-	-	-
				22	P	-	-	-	-
				29	P	-	-	-	-
				36	P	-	-	-	-
				43	P	-	-	-	-
				50	P	-	-	-	-
				57	P	-	-	-	-

003023

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 58

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF	CATEGORY	GROUP: F2	DOSE: 0.03 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH
	QUALIFIER	DAYS 1-185	DAY				
=====							
(CONTINUED FROM PREVIOUS PAGE)							
I05550	T	27	NORMAL				
			NO REMARKABLE OBSERVATIONS				
			64	P	-	-	-
			71	P	-	-	-
			78	P	-	-	-
			85	P	-	-	-
			99	P	-	-	-
			106	P	-	-	-
			113	P	-	-	-
			120	P	-	-	-
			127	P	-	-	-
			134	P	-	-	-
			141	P	-	-	-
			148	P	-	-	-
			155	P	-	-	-
			162	P	-	-	-
			169	P	-	-	-
			176	P	-	-	-
			183	P	-	-	-
			185	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION				
			LOW				
			3	P	-	-	-
			141	P	-	-	-
			179	P	-	-	-

003024

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 59

ANIMAL	DEATH	WK OF	CATEGORY	GROUP: F3	DOSE: 0.15 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER	CODE	DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH
			QUALIFIER	DAYS 1-185	DAY				
=====									
I05532	T	27	SKIN & PELAGE						
			BROKEN SKIN						
			HEAD-CRANIAL		2	P	-	P	-
			PERI-ORBITAL-RIGHT		3	P	-	P	-
					31	-	-	P	-
					32	P	-	P	-
					33	-	-	P	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		1	P	-	-	-
					8	P	-	-	-
					15	P	-	-	-
					22	P	-	-	-
					36	P	-	-	-
					43	P	-	-	-
					50	P	-	-	-
					57	P	-	-	-
					64	P	-	-	-
					71	P	-	-	-
					92	P	-	-	-
					99	P	-	-	-
					106	P	-	-	-
					113	P	-	-	-
					127	P	-	-	-
					134	P	-	-	-
					141	P	-	-	-
					148	P	-	-	-
					155	P	-	-	-
					162	P	-	-	-
					169	P	-	-	-
					176	P	-	-	-
					183	P	-	-	-

003025

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 60

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF	CATEGORY	GROUP: F3	DOSE: 0.15 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH
	QUALIFIER	DAYS 1-185	DAY				
=====							
(CONTINUED FROM PREVIOUS PAGE)							
I05532	T	27	NORMAL				
			NO REMARKABLE OBSERVATIONS	184	P	-	P
			QUALITATIVE FOOD CONSUMPTION				
			LOW	26	P	-	-
				29	P	-	-
				32	P	-	-
				41	P	-	-
				55	P	-	-
				57	P	-	-
				58	P	-	-
				65	P	-	-
				78	P	-	-
				85	P	-	-
				115	P	-	-
				116	P	-	-
				120	P	-	-
				126	P	-	-
				141	P	-	-
				143	P	-	-
				147	P	-	-
				150	P	-	-
				155	P	-	-
				162	P	-	-
				164	P	-	-
				169	P	-	-
				170	P	-	-
				174	P	-	-
				175	P	-	-
				176	P	-	-
				179	P	-	-
				183	P	-	-

003026

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 61

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF	CATEGORY	GROUP: F3	DOSE: 0.15 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP				
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH	
	QUALIFIER	DAYS 1-185	DAY					
=====								
I05538	T	27	DISCHARGE					
			VOMITUS					
			CONTAINING FOOD	141	P	-	-	
				179	P	-	-	
			EXCRETION					
			FEW FECES	43	P	-	-	
			NORMAL					
			NO REMARKABLE OBSERVATIONS	1	P	-	-	
				8	P	-	-	
				15	P	-	-	
				22	P	-	-	
				29	P	-	-	
				36	P	-	-	
				50	P	-	-	
				57	P	-	-	
				64	P	-	-	
				71	P	-	-	
				78	P	-	-	
				85	P	-	-	
				92	P	-	-	
				99	P	-	-	
				106	P	-	-	
				113	P	-	-	
				120	P	-	-	
				127	P	-	-	
				134	P	-	-	
				148	P	-	-	
				155	P	-	-	
				162	P	-	-	
				169	P	-	-	

003027

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 62

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F3	DOSE: 0.15 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP	AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)												
I05538	T	27	NORMAL									
			NO REMARKABLE OBSERVATIONS				176	P	-	-	-	-
							183	P	-	-	-	-
							184	P	-	-	-	P
			QUALITATIVE FOOD CONSUMPTION									
			LOW				27	P	-	-	-	-
							41	P	-	-	-	-
							42	P	-	-	-	-
							43	P	-	-	-	-
							141	P	-	-	-	-
							160	P	-	-	-	-
							167	P	-	-	-	-
							174	P	-	-	-	-
							178	P	-	-	-	-
							179	P	-	-	-	-
I05539	6	81	DISCHARGE									
			APPEARS TO BE MENSTRUATING				71	P	-	-	P	-
			EXCRETION									
			FEW FECES				141	P	-	-	-	-
			NORMAL									
			NO REMARKABLE OBSERVATIONS				1	P	-	-	-	-
							8	P	-	-	-	-
							15	P	-	-	-	-
							22	P	-	-	-	-
							29	P	-	-	-	-
							36	P	-	-	-	-
							43	P	-	-	-	-
							50	P	-	-	-	-

003028

PAGE: 63

ANIMAL DEATH WK OF	CATEGORY	GROUP: F3	DOSE: 0.15 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD			AM OBS	UNCHED	30-90 OB	DISPATCH
	QUALIFIER	DAYS 1-185	DAY				

(CONTINUED FROM PREVIOUS PAGE)
I05539 6 81 NORMAL
NO REMARKABLE OBSERVATIONS

QUALITATIVE FOOD CONSUMPTION
LOW

57	P	-	-
64	P	-	-
78	P	-	-
92	P	-	-
99	P	-	-
106	P	-	-
120	P	-	-
134	P	-	-
148	P	-	-
155	P	-	-
162	P	-	-
169	P	-	-
176	P	-	-
183	P	-	-

17	P	-	-
18	P	-	-
24	P	-	-
57	P	-	-
60	P	-	-
70	P	-	-
85	P	-	-
109	P	-	-
113	P	-	-
116	P	-	-
127	P	-	-
132	P	-	-
133	P	-	-
138	P	-	-
139	P	-	-

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 64

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF	CATEGORY	GROUP: F3	DOSE: 0.15 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP
NUMBER CODE DEATH	KEYWORD			AM OBS UNSCHED 30-90 OB DISPATCH
	QUALIFIER	DAYS 1-185	DAY	
=====				
(CONTINUED FROM PREVIOUS PAGE)				
I05539	6	81	QUALITATIVE FOOD CONSUMPTION	
			LOW	
			150	P - - -
			155	P - - -
			158	P - - -
			159	P - - -
			162	P - - -
			171	P - - -
			174	P - - -
			179	P - - -
I05545	T	27	DISCHARGE	
			APPEARS TO BE MENSTRUATING	
			136	P - P -
			EXCRETION	
			NO FECES	
			51	P - - -
			NORMAL	
			NO REMARKABLE OBSERVATIONS	
			1	P - - -
			8	P - - -
			15	P - - -
			22	P - - -
			29	P - - -
			36	P - - -
			50	P - - -
			57	P - - -
			64	P - - -
			71	P - - -
			85	P - - -
			92	P - - -
			99	P - - -
			106	P - - -
			127	P - - -

003030

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 65

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F3	DOSE: 0.15 MG/KG/DAY	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP	AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)											
I05545	T	27	NORMAL								
			NO REMARKABLE OBSERVATIONS			134	P	-	-	-	
						141	P	-	-	-	
						148	P	-	-	-	
						155	P	-	-	-	
						162	P	-	-	-	
						176	P	-	-	-	
						183	P	-	-	-	
						184	P	-	-	P	
			QUALITATIVE FOOD CONSUMPTION								
			LOW			25	P	-	-	-	
						30	P	-	-	-	
						35	P	-	-	-	
						43	P	-	-	-	
						74	P	-	-	-	
						78	P	-	-	-	
						86	P	-	-	-	
						113	P	-	-	-	
						116	P	-	-	-	
						120	P	-	-	-	
						141	P	-	-	-	
						149	P	-	-	-	
						150	P	-	-	-	
						155	P	-	-	-	
						161	P	-	-	-	
						169	P	-	-	-	
						171	P	-	-	-	
						174	P	-	-	-	
						175	P	-	-	-	
						176	P	-	-	-	
						179	P	-	-	-	

003031

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 66

ANIMAL DEATH WK OF	CATEGORY	GROUP: F3	DOSE: 0.15 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP						
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH			
	QUALIFIER	DAYS 1-185	DAY							
=====										
(CONTINUED FROM PREVIOUS PAGE)										
I05545	T	27	QUALITATIVE FOOD CONSUMPTION							
			LOW	180	P	-	-	-		
				183	P	-	-	-		
I05548	T	27	DISCHARGE							
			VOMITUS							
			CONTAINING FOOD	141	P	-	-	-		
			EXCRETION							
			FEW FECES	178	P	-	-	-		
			NORMAL							
			NO REMARKABLE OBSERVATIONS	1	P	-	-	-		
				8	P	-	-	-		
				15	P	-	-	-		
				22	P	-	-	-		
				29	P	-	-	-		
				36	P	-	-	-		
				43	P	-	-	-		
				50	P	-	-	-		
				57	P	-	-	-		
				64	P	-	-	-		
				71	P	-	-	-		
				78	P	-	-	-		
				85	P	-	-	-		
				92	P	-	-	-		
				99	P	-	-	-		
				106	P	-	-	-		
				113	P	-	-	-		
				120	P	-	-	-		
				127	P	-	-	-		
				134	P	-	-	-		

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 67

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF	CATEGORY	GROUP: F3	DOSE: 0.15 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH
	QUALIFIER	DAYS 1-185	DAY				
(CONTINUED FROM PREVIOUS PAGE)							
I05548	T	27	NORMAL				
			NO REMARKABLE OBSERVATIONS	148	P	-	-
				155	P	-	-
				162	P	-	-
				169	P	-	-
				176	P	-	-
				183	P	-	-
				184	P	-	P
			QUALITATIVE FOOD CONSUMPTION				
			LOW	18	P	-	-
				28	P	-	-
				58	P	-	-
				141	P	-	-
				142	P	-	-
				174	P	-	-
I05552	6	81	NORMAL				
			NO REMARKABLE OBSERVATIONS	1	P	-	-
				8	P	-	-
				15	P	-	-
				22	P	-	-
				29	P	-	-
				36	P	-	-
				43	P	-	-
				50	P	-	-
				57	P	-	-
				64	P	-	-
				71	P	-	-
				78	P	-	-
				85	P	-	-
				92	P	-	-

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 68

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF NUMBER CODE DEATH	CATEGORY KEYWORD	GROUP: F3	DOSE: 0.15 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
				AM OBS	UNSCHED	30-90 OB	DISPATCH
	QUALIFIER	DAYS 1-185	DAY				
(CONTINUED FROM PREVIOUS PAGE)							
I05552	6	81	NORMAL				
			NO REMARKABLE OBSERVATIONS				
			99	P	-	-	-
			106	P	-	-	-
			113	P	-	-	-
			120	P	-	-	-
			127	P	-	-	-
			134	P	-	-	-
			141	P	-	-	-
			148	P	-	-	-
			155	P	-	-	-
			162	P	-	-	-
			169	P	-	-	-
			176	P	-	-	-
			183	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION				
			LOW				
			20	P	-	-	-
			141	P	-	-	-
			156	P	-	-	-

003034

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 69

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4	DOSE: 0.75 MG/KG/DAY	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
							AM OBS	UNSCHED	30-90 OB	DISPATCH
=====										
I05533	U	79	DISCHARGE							
			APPEARS TO BE MENSTRUATING			39	P	-	P	-
						40	P	-	-	-
			SKIN & PELAGE							
			ALOPECIA							
			HEAD-CRANIAL			22	-	-	P	-
						24	-	-	P	-
						27	P	-	P	-
						28	-	-	P	-
						29	P	-	P	-
						30	P	-	P	-
						31	P	-	P	-
						32	P	-	P	-
						33	-	-	P	-
						34	P	-	P	-
						35	P	-	P	-
						36	P	-	P	-
						37	-	-	P	-
						38	P	-	P	-
						39	P	-	P	-
						40	P	-	-	-
						41	P	-	P	-
						42	P	-	P	-
						43	P	-	P	-
						44	-	-	P	-
						45	-	-	P	-
						48	-	-	P	-
						49	-	-	P	-
						50	P	-	P	-
						51	P	-	P	-
						52	P	-	P	-

003035

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 70

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF	CATEGORY	GROUP: F4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH
	QUALIFIER	DAYS 1-185	DAY				
=====							
(CONTINUED FROM PREVIOUS PAGE)							
I05533	U	79	SKIN & PELAGE				
			ALOPECIA				
			HEAD-CRANIAL				
				53	P	-	P
				54	P	-	P
				55	P	-	P
				56	P	-	P
				57	P	-	P
				58	P	-	P
				59	P	-	P
				60	-	-	P
				61	-	-	P
				62	P	-	-
			HEAD-MAXILLARY-LEFT	27	-	-	P
				28	-	-	P
				29	P	-	P
				30	P	-	P
				31	P	-	P
				32	P	-	P
				33	-	-	P
				34	P	-	P
				35	P	-	P
				36	P	-	P
				37	-	-	P
				38	P	-	P
				39	P	-	P
				40	P	-	-
				41	P	-	P
				42	P	-	P
				43	P	-	P
				44	-	-	P
				45	-	-	P
				48	-	-	P

PAGE: 72

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP
				DAYS 1-185	DAY	AM OBS UNSCHED 30-90 OB DISPATCH
=====						
(CONTINUED FROM PREVIOUS PAGE)						
I05533	U	79	SKIN & PELAGE			
			ALOPECIA			
			HEAD-MAXILLARY-RIGHT		42	

NORMAL
NO REMARKABLE OBSERVATIONS

42	P	-	P
43	P	-	P
44	-	-	P
45	-	-	P
48	-	-	P
49	-	-	P
50	P	-	P
51	P	-	P
52	P	-	P
53	P	-	P
54	P	-	P
55	P	-	P
56	P	-	P
57	P	-	P
58	P	-	P
59	P	-	P
60	-	-	P
61	-	-	P
62	P	-	P
63	P	-	P
1	P	-	-
8	P	-	-
15	P	-	-
22	P	-	-
64	P	-	-
71	P	-	-
78	P	-	-
85	P	-	-

890300

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 73

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4	DOSE: 0.75 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP	AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)												
I05533	U	79	NORMAL									
			NO REMARKABLE OBSERVATIONS				92	P	-	-	-	
							99	P	-	-	-	
							106	P	-	-	-	
							113	P	-	-	-	
							120	P	-	-	-	
							127	P	-	-	-	
							134	P	-	-	-	
							141	P	-	-	-	
							148	P	-	-	-	
							155	P	-	-	-	
							162	P	-	-	-	
							169	P	-	-	-	
							176	P	-	-	-	
							183	P	-	-	-	
			QUALITATIVE FOOD CONSUMPTION									
			LOW				141	P	-	-	-	
I05534	T	27	DISCHARGE									
			VOMITUS									
			PARTIAL CAPSULE				6	-	-	P	-	
							10	-	-	P	-	
							72	-	-	P	-	
			APPEARS TO BE MENSTRUATING				59	P	-	-	-	
							98	P	-	-	-	
							133	P	-	-	-	
							134	P	-	-	-	
			EXCRETION									
			DISCOLORED FECES									
			RED IN COLOR				149	P	-	-	-	

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 74

ANIMAL DEATH WK OF	CATEGORY	GROUP: F4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH
	QUALIFIER	DAYS 1-185	DAY				
(CONTINUED FROM PREVIOUS PAGE)							
I05534	T	27	EXCRETION				
			DISCOLORED FECES				
			RED IN COLOR	150	P	-	-
			YELLOW IN COLOR	156	P	-	-
			FEW FECES	102	P	-	-
				105	P	-	-
				107	P	-	-
				109	P	-	-
				113	P	-	-
				127	P	-	-
				163	P	-	-
			LIQUID FECES	92	P	-	-
				93	P	-	-
				136	P	-	-
				137	P	-	-
				138	P	P	-
				139	P	-	-
				141	P	P	-
				142	P	-	-
				143	P	-	-
				144	P	-	-
				156	P	-	-
				185	P	-	-
			MUCOID FECES	150	P	-	-
			NO FECES	49	P	-	-
			NON-FORMED FECES	110	P	-	-
				113	P	-	-
				127	P	-	-
				137	P	-	-
				140	P	-	-
				144	P	-	-
				145	P	-	-

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 75

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF	CATEGORY	GROUP: F4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCHE	30-90 OB	DISPATCH
	QUALIFIER	DAYS 1-185	DAY				
=====							
(CONTINUED FROM PREVIOUS PAGE)							
I05534	T	27	EXCRETION				
			NON-FORMED FECES	146	P	-	-
				147	P	-	-
				148	P	-	-
				149	P	-	-
				150	P	-	-
			SKIN & PELAGE				
			BROKEN SKIN				
			PERI-ORBITAL-LEFT	70	-	-	P
				71	P	-	P
			OTHER	9	PC	-	PC
				10	PC	-	PC
				12	PC	-	-
				15	PC	-	PC
			NORMAL				
			NO REMARKABLE OBSERVATIONS	1	P	-	-
				29	P	-	-
				36	P	-	-
				50	P	-	-
				57	P	-	-
				64	P	-	-
				85	P	-	-
				99	P	-	-
				106	P	-	-
				155	P	-	-
				162	P	-	-
				169	P	-	-
				176	P	-	-
				183	P	-	-
				185	-	-	P

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 76

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF	CATEGORY	GROUP: F4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH
	QUALIFIER	DAYS 1-185	DAY				
(CONTINUED FROM PREVIOUS PAGE)							
I05534	T	27					

QUALITATIVE FOOD CONSUMPTION
LOW

2	P	-	-	-
3	P	-	-	-
8	P	-	-	-
10	P	-	-	-
22	P	-	-	-
24	P	-	-	-
38	P	-	-	-
43	P	-	-	-
49	P	-	-	-
60	P	-	-	-
63	P	-	-	-
66	P	-	-	-
78	P	-	-	-
80	P	-	-	-
81	P	-	-	-
92	P	-	-	-
93	P	-	-	-
98	P	-	-	-
100	P	-	-	-
102	P	-	-	-
105	P	-	-	-
109	P	-	-	-
113	P	-	-	-
116	P	-	-	-
120	P	-	-	-
122	P	-	-	-
125	P	-	-	-
127	P	-	-	-
128	P	-	-	-

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 77

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP	AM OBS	UNSCHED	30-90 OB	DISPATCH
				DAYS 1-185	DAY					
(CONTINUED FROM PREVIOUS PAGE)										
I05534	T	27	QUALITATIVE FOOD CONSUMPTION LOW		129	P	-	-	-	
					133	P	-	-	-	
					134	P	-	-	-	
					137	P	-	-	-	
					138	P	-	-	-	
					141	P	-	-	-	
					148	P	-	-	-	
					149	P	-	-	-	
					150	P	-	-	-	
					154	P	-	-	-	
					155	P	-	-	-	
					156	P	-	-	-	
					157	P	-	-	-	
					162	P	-	-	-	
					164	P	-	-	-	
					167	P	-	-	-	
					170	P	-	-	-	
					174	P	-	-	-	
					175	P	-	-	-	
					176	P	-	-	-	
					180	P	-	-	-	
					184	P	-	-	-	
I05536	T	27	DISCHARGE VOMITUS CONTAINING FOOD PARTIAL CAPSULE		141	P	-	-	-	
					30	-	-	-	P	
			EXCRETION DISCOLORED FECES RED IN COLOR		69	-	-	-	P	

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 78

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF	CATEGORY	GROUP: F4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH
	QUALIFIER	DAYS 1-185	DAY				
(CONTINUED FROM PREVIOUS PAGE)							
I05536	T	27	EXCRETION				
			FEW FECES	88	P	-	-
			LIQUID FECES	88	P	-	-
			NON-FORMED FECES	179	P	-	-
				183	P	-	-
			NORMAL				
			NO REMARKABLE OBSERVATIONS	1	P	-	-
				8	P	-	-
				15	P	-	-
				22	P	-	-
				29	P	-	-
				36	P	-	-
				43	P	-	-
				50	P	-	-
				57	P	-	-
				64	P	-	-
				71	P	-	-
				78	P	-	-
				85	P	-	-
				92	P	-	-
				99	P	-	-
				106	P	-	-
				113	P	-	-
				120	P	-	-
				134	P	-	-
				148	P	-	-
				155	P	-	-
				162	P	-	-
				169	P	-	-
				176	P	-	-
				184	P	-	P

003044

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 79

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4	DOSE: 0.75 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP
								AM OBS UNSCHED 30-90 OB DISPATCH

(CONTINUED FROM PREVIOUS PAGE)

I05536 T 27

QUALITATIVE FOOD CONSUMPTION
LOW

3	P	-	-	-
65	P	-	-	-
72	P	-	-	-
81	P	-	-	-
88	P	-	-	-
114	P	-	-	-
117	P	-	-	-
126	P	-	-	-
127	P	-	-	-
129	P	-	-	-
130	P	-	-	-
141	P	-	-	-
149	P	-	-	-
156	P	-	-	-
157	P	-	-	-
160	P	-	-	-
180	P	-	-	-
181	P	-	-	-

I05540 T 27 DISCHARGE
 VOMITUS
 INTACT CAPSULE

99	-	-	P	-
----	---	---	---	---

EXCRETION
DISCOLORED FECES
RED IN COLOR

27	P	-	P	-
----	---	---	---	---

DISCOLORED URINE
GREEN IN COLOR

28	P	-	P	-
----	---	---	---	---

71	P	-	-	-
----	---	---	---	---

003045

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 80

ANIMAL DEATH WK OF NUMBER CODE DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP	AM OBS	UNSCHED	30-90 OB	DISPATCH
		DAYS 1-185	DAY					
(CONTINUED FROM PREVIOUS PAGE)								
I05540 T 27	EXCRETION							
	DISCOLORED URINE		72	P	-	-	-	-
	GREEN IN COLOR		28	P	-	-	-	-
	FEW FECES		29	P	-	-	-	-
	MUCOID FECES		28	-	-	P	-	-
			29	P	-	-	-	-
	SKIN & PELAGE							
	ALOPECIA							
	DORSAL		1	P	-	-	-	-
			141	-	-	P	-	-
	DORSAL-THORACIC		1	-	-	P	-	-
			2	P	-	P	-	-
			3	-	-	P	-	-
			5	-	-	P	-	-
			6	P	-	P	-	-
			7	P	-	P	-	-
			8	P	-	P	-	-
			9	P	-	P	-	-
			10	P	-	P	-	-
			11	P	-	P	-	-
			12	P	-	P	-	-
			13	P	-	P	-	-
			14	P	-	P	-	-
			15	P	-	P	-	-
			16	P	-	P	-	-
			17	P	-	P	-	-
			18	P	-	P	-	-
			19	P	-	P	-	-
			20	P	-	P	-	-
			21	P	-	P	-	-

003046

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 81

ANIMAL DEATH WK OF	CATEGORY	GROUP: F4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH
	QUALIFIER	DAYS 1-185	DAY				
=====							
(CONTINUED FROM PREVIOUS PAGE)							
I05540	T	27	SKIN & PELAGE				
			ALOPECIA				
			DORSAL-THORACIC				
			22	P	-	P	-
			23	P	-	P	-
			24	P	-	P	-
			25	P	-	P	-
			26	P	-	P	-
			27	P	-	P	-
			28	P	-	P	-
			29	P	-	P	-
			30	P	-	P	-
			31	P	-	P	-
			32	P	-	P	-
			33	P	-	P	-
			34	P	-	P	-
			35	P	-	P	-
			36	P	-	P	-
			37	P	-	P	-
			38	P	-	P	-
			39	P	-	P	-
			40	P	-	P	-
			41	P	-	P	-
			42	P	-	P	-
			43	P	-	P	-
			44	-	-	P	-
			45	-	-	P	-
			46	P	-	P	-
			47	P	-	P	-
			48	-	-	P	-
			49	-	-	P	-
			50	P	-	P	-
			51	P	-	-	-

003047

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 82

ANIMAL DEATH WK OF	CATEGORY	GROUP: F4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH
	QUALIFIER	DAYS 1-185	DAY				
(CONTINUED FROM PREVIOUS PAGE)							
I05540	T	27	SKIN & PELAGE				
			ALOPECIA				
			DORSAL-THORACIC				
			142	P	-	P	-
			143	P	-	P	-
			146	P	-	P	-
			147	P	-	P	-
			148	P	-	P	-
			149	P	-	P	-
			150	P	-	P	-
			151	P	-	P	-
			152	P	-	P	-
			153	P	-	P	-
			154	P	-	P	-
			155	P	-	P	-
			156	P	-	P	-
			157	P	-	P	-
			158	P	-	P	-
			159	P	-	P	-
			160	P	-	P	-
			161	P	-	P	-
			162	P	-	P	-
			163	P	-	P	-
			164	P	-	P	-
			165	P	-	P	-
			166	P	-	P	-
			167	P	-	P	-
			168	P	-	P	-
			169	P	-	P	-
			170	P	-	P	-
			171	P	-	P	-
			172	P	-	P	-
			173	P	-	P	-

003048

PAGE: 83

(CONTINUED FROM PREVIOUS PAGE)

DORSAL-THORACIC

DORSAL-THORACIC-LEFT

174	P	-	P
175	P	-	P
176	P	-	P
177	P	-	P
178	P	-	P
179	P	-	P
180	P	-	P
181	P	-	P
182	P	-	P
183	P	-	P
184	P	-	P
185	P	-	-
57	-	-	P
58	P	-	P
59	P	-	P
60	P	-	P
61	P	-	P
62	P	-	P
63	P	-	P
64	P	-	P
65	P	-	P
66	P	-	P
67	P	-	P
68	P	-	P
69	P	-	P
70	P	-	P
71	P	-	P
72	P	-	P
73	P	-	P
74	P	-	P

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 84

ANIMAL DEATH WK OF	CATEGORY	GROUP: F4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH
	QUALIFIER	DAYS 1-185	DAY				
(CONTINUED FROM PREVIOUS PAGE)							
I05540	T	27	SKIN & PELAGE				
			ALOPECIA				
			DORSAL-THORACIC-LEFT				
			76	P	-	P	-
			77	P	-	P	-
			78	P	-	-	-
			79	P	-	P	-
			80	P	-	P	-
			81	P	-	P	-
			82	P	-	P	-
			83	P	-	P	-
			84	P	-	P	-
			85	P	-	P	-
			86	P	-	P	-
			87	P	-	P	-
			88	P	-	-	-
			89	P	-	P	-
			90	P	-	P	-
			91	P	-	P	-
			92	P	-	P	-
			93	P	-	P	-
			94	P	-	P	-
			95	P	-	P	-
			96	P	-	P	-
			97	P	-	P	-
			98	P	-	P	-
			99	P	-	P	-
			100	P	-	P	-
			101	-	-	P	-
			102	P	-	P	-
			103	P	-	P	-
			104	P	-	P	-
			105	P	-	P	-

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 85

ANIMAL DEATH WK OF CATEGORY GROUP: F4 DOSE: 0.75 MG/KG/DAY 'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP
NUMBER CODE DEATH KEYWORD QUALIFIER DAYS 1-185 DAY AM OBS UNSCHED 30-90 OB DISPATCH
=====

(CONTINUED FROM PREVIOUS PAGE)

I05540 T 27 SKIN & PELAGE
ALOPECIA
DORSAL-THORACIC-LEFT

106	P	-	P	-
107	P	-	P	-
108	P	-	P	-
109	P	-	P	-
110	P	-	P	-
111	P	-	P	-
112	P	-	P	-
113	P	-	P	-
114	P	-	P	-
115	P	-	P	-
117	P	-	P	-
118	P	-	P	-
119	P	-	P	-
120	P	-	P	-
121	P	-	P	-
122	P	-	P	-
123	P	-	P	-
124	P	-	P	-
125	P	-	P	-
126	P	-	P	-
127	P	-	P	-
128	P	-	P	-
129	-	-	P	-
130	-	-	P	-
131	-	-	P	-
132	P	-	P	-
133	P	-	P	-
134	P	-	P	-
135	P	-	P	-
136	P	-	P	-

003051

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 86

ANIMAL DEATH WK OF NUMBER CODE DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
		DAYS 1-185	DAY	AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)							
I05540	T	27	SKIN & PELAGE				
			ALOPECIA				
			DORSAL-THORACIC-LEFT				
				137	P	-	P
				138	P	-	P
				139	P	-	P
				140	P	-	P
			HEAD-ENTIRE	1	P	-	P
				2	P	-	P
				3	-	-	P
				5	-	-	P
				6	P	-	P
				7	P	-	P
				8	P	-	P
				9	P	-	P
				10	P	-	P
				11	P	-	P
				12	P	-	P
				13	P	-	P
				14	P	-	P
				15	P	-	P
				16	P	-	P
				17	P	-	P
				18	P	-	P
				19	P	-	P
				20	P	-	P
				21	P	-	P
				22	P	-	P
				23	P	-	P
				24	P	-	P
				25	P	-	P
				26	P	-	P
				27	P	-	P

003052

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 87

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD	QUALIFIER	GROUP: F4	DOSE: 0.75 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP	AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)													
I05540	T	27	SKIN & PELAGE										
			ALOPECIA										
			HEAD-ENTIRE										
								28	P	-		P	-
								29	P	-		P	-
								30	P	-		P	-
								31	P	-		P	-
								32	P	-		P	-
								33	P	-		P	-
								34	P	-		P	-
								35	P	-		P	-
								36	P	-		P	-
								37	P	-		P	-
								38	P	-		P	-
								39	P	-		P	-
								40	P	-		P	-
								41	P	-		P	-
			LIMB-HIND-LEFT					57	-	-		P	-
								58	P	-		P	-
								59	P	-		P	-
								60	P	-		P	-
								61	P	-		P	-
								62	P	-		P	-
								63	P	-		P	-
								64	P	-		P	-
								65	P	-		P	-
								66	P	-		P	-
								67	P	-		P	-
								68	P	-		P	-
								69	P	-		P	-
								70	P	-		P	-
								71	P	-		P	-
								72	P	-		P	-

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 88

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4	DOSE: 0.75 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP
								AM OBS UNSCHED 30-90 OB DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05540	T	27	SKIN & PELAGE					
			ALOPECIA					
			LIMB-HIND-LEFT					
						73	P	-
						74	P	-
						76	P	-
						77	P	-
						78	P	-
						79	P	-
						80	P	-
						81	P	-
						82	P	-
						83	P	-
						84	P	-
						85	P	-
						86	P	-
						87	P	-
						88	P	-
						89	P	-
						90	P	-
						91	P	-
						92	P	-
						93	P	-
						94	P	-
						95	P	-
						96	P	-
						97	P	-
						98	P	-
						99	P	-
						100	P	-
						101	P	-
						102	P	-
						103	P	-

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 89

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF	CATEGORY	GROUP: F4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH
	QUALIFIER	DAYS 1-185	DAY				
(CONTINUED FROM PREVIOUS PAGE)							
I05540	T	27	SKIN & PELAGE				
			ALOPECIA				
			LIMB-HIND-LEFT	104	P	-	-
			LIMBS-ALL	42	P	-	P
				43	P	-	P
				44	-	-	P
				45	-	-	P
				46	P	-	P
				47	P	-	P
				48	-	-	P
				49	-	-	P
				50	P	-	P
				51	P	-	P
				52	P	-	P
				53	P	-	P
				54	P	-	P
				55	P	-	P
				56	P	-	-
				57	P	-	-
			LIMBS-FRONT	1	P	-	P
				2	P	-	P
				3	-	-	P
				5	-	-	P
				6	P	-	P
				7	P	-	P
				8	P	-	P
				9	P	-	P
				10	P	-	P
				11	P	-	P
				12	P	-	P
				13	P	-	P
				14	P	-	P

Appendix 2

Covance 6329-223
3M T-6295.7Individual Clinical Observations
Treatment

PAGE: 90

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP
				DAYS 1-185	DAY	AM OBS UNSCHED 30-90 OB DISPATCH
(CONTINUED FROM PREVIOUS PAGE)						
I05540	T	27	SKIN & PELAGE			
			ALOPECIA			
			LIMBS-FRONT			
				15	P	- P -
				16	P	- P -
				17	P	- P -
				18	P	- P -
				19	P	- P -
				20	P	- P -
				21	P	- P -
				22	P	- P -
				23	P	- P -
				24	P	- P -
				25	P	- P -
				26	P	- P -
				27	P	- P -
				28	P	- P -
				29	P	- P -
				30	P	- P -
				31	P	- P -
				32	P	- P -
				33	P	- P -
				34	P	- P -
				35	P	- P -
				36	P	- P -
				37	P	- P -
				38	P	- P -
				39	P	- P -
				40	P	- P -
				41	P	- P -
				145	-	- P -
				146	P	- P -
				147	P	- P -
			TAIL			

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 91

ANIMAL DEATH WK OF		CATEGORY	GROUP: F4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP					
NUMBER	CODE	DEATH	KEYWORD	QUALIFIER	DAYS 1-185	DAY	AM OBS	UNSCHED	30-90 OB	DISPATCH
=====										
(CONTINUED FROM PREVIOUS PAGE)										
I05540	T	27	SKIN & PELAGE							
			ALOPECIA							
			TAIL							
					148	P	-	P	-	
					149	P	-	P	-	
					150	P	-	P	-	
					151	P	-	P	-	
					152	P	-	P	-	
					153	P	-	P	-	
					154	P	-	P	-	
					155	P	-	P	-	
					156	P	-	P	-	
					157	P	-	P	-	
					158	P	-	P	-	
					159	P	-	P	-	
					160	P	-	P	-	
					161	P	-	P	-	
					162	P	-	P	-	
					163	P	-	P	-	
					164	P	-	P	-	
					165	P	-	P	-	
					166	P	-	P	-	
					167	P	-	P	-	
					168	P	-	P	-	
					169	P	-	P	-	
					170	P	-	P	-	
					171	P	-	P	-	
					172	P	-	P	-	
					173	P	-	P	-	
					174	P	-	P	-	
					175	P	-	P	-	
					176	P	-	P	-	
					177	P	-	P	-	

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 92

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF NUMBER CODE DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP	AM OBS	UNSCHED	30-90 OB	DISPATCH
		DAYS 1-185	DAY					
=====								
(CONTINUED FROM PREVIOUS PAGE)								
I05540	T	27	SKIN & PELAGE					
			ALOPECIA					
			TAIL					
			178	P	-		P	-
			179	P	-		P	-
			180	P	-		P	-
			181	P	-		P	-
			182	P	-		P	-
			183	P	-		P	-
			184	P	-		P	-
			185	P	-		-	P
			17	P	-		-	-
			20	P	-		-	-
			25	P	-		-	-
			27	P	-		-	-
			69	P	-		-	-
			71	P	-		-	-
			73	P	-		-	-
			74	P	-		-	-
			78	P	-		-	-
			80	P	-		-	-
			85	P	-		-	-
			87	P	-		-	-
			120	P	-		-	-
			132	P	-		-	-
			137	P	-		-	-
			141	P	-		-	-
			155	P	-		-	-
			179	P	-		-	-

QUALITATIVE FOOD CONSUMPTION
LOW

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 93

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP	AM OBS	UNSCHED	30-90 OB	DISPATCH
				DAYS 1-185	DAY					
I05542	U	79	DISCHARGE							
			VOMITUS							
			INTACT CAPSULE		136	P	-	-	P	-
			PARTIAL CAPSULE		65	-	-	-	P	-
					78	-	-	-	P	-
					126	-	-	-	P	-
					131	-	-	-	P	-
			APPEARS TO BE MENSTRUATING		71	P	-	-	P	-
					115	P	-	-	-	-
					161	P	-	-	-	-
			EXCRETION							
			FEW FECES		155	P	-	-	-	-
					161	P	-	-	-	-
					162	P	-	-	-	-
			SKIN & PELAGE							
			PALE SKIN							
			HEAD-ENTIRE		182	-	-	-	P	-
					183	P	-	-	-	-
					184	P	-	-	-	-
			NORMAL							
			NO REMARKABLE OBSERVATIONS		1	P	-	-	-	-
					8	P	-	-	-	-
					15	P	-	-	-	-
					22	P	-	-	-	-
					29	P	-	-	-	-
					50	P	-	-	-	-
					57	P	-	-	-	-
					64	P	-	-	-	-
					85	P	-	-	-	-

003059

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 94

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF	NUMBER CODE	DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP	AM OBS	UNSCHED	30-90 OB	DISPATCH
				DAYS 1-185	DAY					
(CONTINUED FROM PREVIOUS PAGE)										
I05542	U	79	NORMAL							
			NO REMARKABLE OBSERVATIONS							
					99	P	-	-	-	-
					106	P	-	-	-	-
					113	P	-	-	-	-
					120	P	-	-	-	-
					127	P	-	-	-	-
					134	P	-	-	-	-
					141	P	-	-	-	-
					148	P	-	-	-	-
					169	P	-	-	-	-
					176	P	-	-	-	-
			QUALITATIVE FOOD CONSUMPTION							
			LOW							
					14	P	-	-	-	-
					36	P	-	-	-	-
					43	P	-	-	-	-
					49	P	-	-	-	-
					57	P	-	-	-	-
					59	P	-	-	-	-
					60	P	-	-	-	-
					65	P	-	-	-	-
					78	P	-	-	-	-
					92	P	-	-	-	-
					98	P	-	-	-	-
					125	P	-	-	-	-
					134	P	-	-	-	-
					139	P	-	-	-	-
					141	P	-	-	-	-
					142	P	-	-	-	-
					143	P	-	-	-	-
					154	P	-	-	-	-
					155	P	-	-	-	-

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 95

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4	DOSE: 0.75 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP	AM OBS	UNSCHED	30-90 OB	DISPATCH
(CONTINUED FROM PREVIOUS PAGE)												
I05542	U	79	QUALITATIVE FOOD CONSUMPTION LOW				161 162 175	P P P	- - -	- - -	- - -	- - -
I05551	T	27	DISCHARGE APPEARS TO BE MENSTRUATING				43 44 45 73 74 75 76 80 112 113 137 138 139 140 141 166 167 168	- - - P P P P P P P - P P P P P P P	- - - - - - - - - - - - - - - - - -	- - - P P P P P P P P P P P P P P P P	- - - - - - - - - - - - - - - - - -	
			EXCRETION FEW FECES SMALL FECES				161 49	P P	- -	- -	- P	- -
			SKIN & PELAGE ALOPECIA LIMBS-ALL				1	P	-	-	P	-

003061

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 96

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF	CATEGORY	GROUP: F4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH
	QUALIFIER	DAYS 1-185	DAY				
(CONTINUED FROM PREVIOUS PAGE)							
I05551	T	27	SKIN & PELAGE				
			ALOPECIA				
			LIMBS-ALL				
			2	P	-	P	-
			3	-	-	P	-
			4	-	-	P	-
			5	-	-	P	-
			6	P	-	P	-
			7	P	-	P	-
			8	P	-	P	-
			9	P	-	P	-
			10	P	-	P	-
			11	P	-	P	-
			12	P	-	P	-
			13	P	-	P	-
			14	P	-	P	-
			15	P	-	P	-
			16	P	-	P	-
			17	P	-	P	-
			18	P	-	P	-
			19	P	-	P	-
			20	P	-	P	-
			21	P	-	P	-
			22	P	-	P	-
			23	P	-	P	-
			24	P	-	P	-
			25	P	-	P	-
			26	P	-	P	-
			27	P	-	P	-
			28	P	-	P	-
			29	P	-	P	-
			30	P	-	P	-
			31	P	-	P	-

003062

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 97

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4	DOSE: 0.75 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP
								AM OBS UNSCHED 30-90 OB DISPATCH
(CONTINUED FROM PREVIOUS PAGE)								
I05551	T	27	SKIN & PELAGE ALOPECIA LIMBS-ALL					
							32	P - P -
							33	P - P -
							34	P - P -
							35	P - P -
							36	P - P -
							37	P - P -
							38	P - P -
							39	P - P -
							40	P - P -
							41	P - P -
							42	P - P -
							43	P - P -
							44	- - P -
							45	- - P -
							46	P - P -
							47	P - P -
							48	- - P -
							49	P - P -
							50	P - P -
							51	P - P -
							52	P - P -
							53	P - P -
							54	P - P -
							55	P - P -
							56	P - P -
							57	P - P -
							58	P - P -
							59	P - P -
							60	P - P -
							61	P - P -

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 98

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF			CATEGORY	GROUP: F4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER	CODE	DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH
			QUALIFIER	DAYS 1-185	DAY				
=====									
(CONTINUED FROM PREVIOUS PAGE)									
I05551	T	27	SKIN & PELAGE						
			ALOPECIA						
			LIMBS-ALL						
					62	P	-	P	-
					63	P	-	P	-
					64	P	-	P	-
					65	P	-	P	-
					66	P	-	P	-
					67	P	-	P	-
					68	P	-	P	-
					69	P	-	P	-
					70	P	-	P	-
					71	P	-	P	-
					72	P	-	P	-
					73	P	-	P	-
					74	P	-	P	-
					75	P	-	P	-
					76	P	-	P	-
					77	P	-	P	-
					78	P	-	P	-
					79	P	-	P	-
					80	P	-	P	-
					81	P	-	P	-
					82	P	-	P	-
					83	P	-	P	-
					84	P	-	P	-
					85	P	-	P	-
					86	P	-	P	-
					87	P	-	P	-
					88	P	-	P	-
					89	P	-	P	-
					90	P	-	P	-
					91	P	-	P	-

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 99

ANIMAL DEATH WK OF	CATEGORY	GROUP: F4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH
	QUALIFIER	DAYS 1-185	DAY				
=====							
(CONTINUED FROM PREVIOUS PAGE)							
I05551	T	27	SKIN & PELAGE				
			ALOPECIA				
			LIMBS-ALL				
			92	P	-	P	-
			93	P	-	P	-
			94	P	-	P	-
			95	P	-	P	-
			96	P	-	P	-
			97	P	-	P	-
			98	P	-	P	-
			99	P	-	P	-
			100	P	-	P	-
			101	-	-	P	-
			102	P	-	P	-
			103	P	-	P	-
			104	P	-	P	-
			105	P	-	P	-
			106	P	-	P	-
			107	P	-	P	-
			108	P	-	P	-
			109	P	-	P	-
			110	P	-	P	-
			111	P	-	P	-
			112	P	-	P	-
			113	P	-	P	-
			114	P	-	P	-
			115	P	-	P	-
			116	-	-	P	-
			117	P	-	P	-
			118	P	-	P	-
			119	P	-	P	-
			120	P	-	P	-
			121	P	-	P	-

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 100

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF	CATEGORY	GROUP: F4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH
	QUALIFIER	DAYS 1-185	DAY				
=====							
(CONTINUED FROM PREVIOUS PAGE)							
I05551	T	27	SKIN & PELAGE				
			ALOPECIA				
			LIMBS-ALL				
				122	P	-	P
				123	P	-	P
				124	P	-	P
				125	P	-	P
				126	P	-	P
				127	P	-	P
				128	P	-	P
				129	-	-	P
				130	-	-	P
				131	-	-	P
				132	P	-	P
				133	P	-	P
				134	P	-	P
				135	P	-	P
				136	P	-	P
				137	P	-	P
				138	P	-	P
				139	P	-	P
				140	P	-	P
				141	-	-	P
				142	P	-	P
				143	P	-	P
				144	-	-	P
				145	-	-	P
				146	P	-	P
				147	P	-	P
				148	P	-	P
				149	P	-	P
				150	P	-	P
				151	P	-	P

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 101

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4	DOSE: 0.75 MG/KG/DAY	DAYS 1-185	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP
								AM OBS UNSCHED 30-90 OB DISPATCH
=====								
(CONTINUED FROM PREVIOUS PAGE)								
I05551	T	27	SKIN & PELAGE ALOPECIA LIMBS-ALL					
							152	P - P -
							153	P - P -
							154	P - P -
							155	P - P -
							156	P - P -
							157	P - P -
							158	P - P -
							159	P - P -
							160	P - P -
							161	P - P -
							162	P - P -
							163	P - P -
							164	P - P -
							165	P - P -
							166	P - P -
							167	P - P -
							168	P - P -
							169	P - P -
							170	P - P -
							171	P - P -
							172	P - P -
							173	P - P -
							174	P - P -
							175	P - P -
							176	P - P -
							177	P - P -
							178	P - P -
							179	P - P -
							180	P - P -
							181	P - P -

003067

003068

Covance 6329-223
3M T-6295.7

Appendix 2

Individual Clinical Observations
Treatment

PAGE: 102

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF		CATEGORY	GROUP: F4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE	DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH
		QUALIFIER	DAYS 1-185	DAY				
=====								
(CONTINUED FROM PREVIOUS PAGE)								
I05551	T	27	SKIN & PELAGE					
			ALOPECIA					
			LIMBS-ALL					
				182	P	-	P	-
				183	P	-	P	-
				184	P	-	P	-
				185	P	-	-	P
			QUALITATIVE FOOD CONSUMPTION					
			LOW					
				72	P	-	-	-
				85	P	-	-	-
				102	P	-	-	-
				146	P	-	-	-
				162	P	-	-	-

Appendix 2

Individual Clinical Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 103

ANIMAL	GROUP	STUDY DAY WK	CATEGORY KEYWORD QUALIFIER	FREE-TEXT COMMENT
I05534	F4	9 2 TO 15 3	SKIN & PELAGE OTHER	BRUISED SKIN PERI-ORBITAL LEFT EYE.

Appendix 2

Individual Clinical Observations
Recovery (Days 186 through 365)

PAGE: 1

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M1 DOSE: 0 MG/KG/DAY DAYS 186-365	DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS	UNSCHED	30-90 OB	DISPATCH
I05520	O	79	SKIN & PELAGE BROKEN SKIN DIGIT(S)-FRONT-LEFT		361 362	P P	- -	- -	- -
			NORMAL NO REMARKABLE OBSERVATIONS		190 197 204 211 218 225 232 239 246 253 260 267 274 281 288 295 302 309 316 323 330 337 344 351 358 365	P P	- -	- -	- -

003070

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

QUALITATIVE FOOD CONSUMPTION							
LOW				273	P	-	-
I05526	O	79	NORMAL				
			NO REMARKABLE OBSERVATIONS	190	P	-	-
				197	P	-	-
				204	P	-	-
				211	P	-	-
				218	P	-	-
				225	P	-	-
				232	P	-	-
				239	P	-	-
				246	P	-	-
				253	P	-	-
				260	P	-	-
				267	P	-	-
				274	P	-	-
				281	P	-	-
				288	P	-	-
				295	P	-	-
				302	P	-	-
				309	P	-	-
				316	P	-	-
				323	P	-	-
				330	P	-	-
				337	P	-	-
				344	P	-	-
				351	P	-	-
				358	P	-	-
				365	P	-	-

Appendix 2

Individual Clinical Observations
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 3

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M3 DAYS 186-365	DOSE: 0.15 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS UNSCHED 30-90 OB DISPATCH
I05505	6	81	EXCRETION NON-FORMED FECES		191	P - - -
			NORMAL NO REMARKABLE OBSERVATIONS		190	P - -
					197	P - -
					204	P - -
					211	P - -
					218	P - -
					225	P - -
					232	P - -
					239	P - -
					246	P - -
					253	P - -
					260	P - -
					267	P - -
					274	P - -
					281	P - -
					288	P - -
					295	P - -
					302	P - -
					309	P - -
					316	P - -
					323	P - -
					330	P - -
					337	P - -
					344	P - -
					351	P - -
					358	P - -
					365	P - -

Covance 6329-223
3M T-6295.7

Appendix 2

Individual Clinical Observations
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 5

ANIMAL DEATH WK OF	CATEGORY	GROUP: M3	DOSE: 0.15 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP
NUMBER CODE DEATH	KEYWORD			AM OBS UNSCHED 30-90 OB DISPATCH
	QUALIFIER	DAYS 186-365	DAY	
=====				
(CONTINUED FROM PREVIOUS PAGE)				
I05523	6	81		

QUALITATIVE FOOD CONSUMPTION
LOW

247 P - - -

003074

Appendix 2

Individual Clinical Observations
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 6

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4 DAYS 186-365	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
I05511	U	79	NORMAL NO REMARKABLE OBSERVATIONS						
					190	P	-	-	-
					197	P	-	-	-
					204	P	-	-	-
					211	P	-	-	-
					218	P	-	-	-
					225	P	-	-	-
					232	P	-	-	-
					239	P	-	-	-
					246	P	-	-	-
					253	P	-	-	-
					260	P	-	-	-
					267	P	-	-	-
					274	P	-	-	-
					281	P	-	-	-
					288	P	-	-	-
					295	P	-	-	-
					302	P	-	-	-
					309	P	-	-	-
					316	P	-	-	-
					323	P	-	-	-
					330	P	-	-	-
					337	P	-	-	-
					344	P	-	-	-
					351	P	-	-	-
					358	P	-	-	-
					365	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION						
			LOW		255	P	-	-	-

003075

Appendix 2

Individual Clinical Observations
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 7

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP
				DAYS 186-365	DAY	AM OBS UNSCHED 30-90 OB DISPATCH
I05522	U	79	NORMAL			
			NO REMARKABLE OBSERVATIONS			
					190	P - - -
					197	P - - -
					204	P - - -
					211	P - - -
					218	P - - -
					225	P - - -
					232	P - - -
					239	P - - -
					246	P - - -
					253	P - - -
					260	P - - -
					267	P - - -
					274	P - - -
					281	P - - -
					288	P - - -
					295	P - - -
					302	P - - -
					309	P - - -
					316	P - - -
					323	P - - -
					330	P - - -
					337	P - - -
					344	P - - -
					351	P - - -
					358	P - - -
					365	P - - -

003076

Appendix 2

Individual Clinical Observations
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 8

ANIMAL DEATH WK OF		CATEGORY	GROUP: F1	DOSE: 0 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP				
NUMBER	CODE	DEATH	KEYWORD		AM OBS	UNSCHED	30-90 OB	DISPATCH	
		QUALIFIER	DAYS 186-365	DAY					
=====									
I05529	P	79	EXCRETION						
			LIQUID FECES	277	P	-	-	-	
				278	P	-	-	-	
				306	P	-	-	-	
				308	P	-	-	-	
			SKIN & PELAGE						
			ALOPECIA						
			FEET	186	P	-	-	-	
				187	P	-	-	-	
				188	P	-	-	-	
				189	P	-	-	-	
				190	P	-	-	-	
				191	P	-	-	-	
				192	P	-	-	-	
				193	P	-	-	-	
				194	P	-	-	-	
				195	P	-	-	-	
				197	P	-	-	-	
				200	P	-	-	-	
				201	P	-	-	-	
				203	P	-	-	-	
				204	P	-	-	-	
				206	P	-	-	-	
				210	P	-	-	-	
				211	P	-	-	-	
				213	P	-	-	-	
				216	P	-	-	-	
				217	P	-	-	-	
				218	P	-	-	-	
				219	P	-	-	-	
				220	P	-	-	-	

820300

Covance 6329-223
3M T-6295.7

Appendix 2

Individual Clinical Observations
Recovery (Days 186 through 365)

PAGE: 9

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF	CATEGORY	GROUP: F1	DOSE: 0 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP
NUMBER CODE DEATH	KEYWORD			AM OBS UNSCHED 30-90 OB DISPATCH
	QUALIFIER	DAYS 186-365	DAY	
(CONTINUED FROM PREVIOUS PAGE)				
I05529	P 79 SKIN & PELAGE			
	ALOPECIA			
	FEET			
		221	P	- - -
		222	P	- - -
		223	P	- - -
		225	P	- - -
		226	P	- - -
		229	P	- - -
		230	P	- - -
		231	P	- - -
		232	P	- - -
		233	P	- - -
		234	P	- - -
		235	P	- - -
		236	P	- - -
		237	P	- - -
		238	P	- - -
		239	P	- - -
		240	P	- - -
		241	P	- - -
		244	P	- - -
		245	P	- - -
		246	P	- - -
		247	P	- - -
		248	P	- - -
		251	P	- - -
		252	P	- - -
		253	P	- - -
		254	P	- - -
		255	P	- - -
		257	P	- - -
		258	P	- - -

Appendix 2

Individual Clinical Observations
Recovery (Days 186 through 365)

PAGE: 10

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF	CATEGORY	GROUP: F1	DOSE: 0 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP
NUMBER CODE DEATH	KEYWORD			AM OBS UNSCHED 30-90 OB DISPATCH
	QUALIFIER	DAYS 186-365	DAY	
=====				
(CONTINUED FROM PREVIOUS PAGE)				
I05529	P 79 SKIN & PELAGE			
	ALOPECIA			
	FEET			
		259	P	- - -
		260	P	- - -
		261	P	- - -
		263	P	- - -
		264	P	- - -
		265	P	- - -
		266	P	- - -
		267	P	- - -
		268	P	- - -
		269	P	- - -
		272	P	- - -
		273	P	- - -
		274	P	- - -
		275	P	- - -
		276	P	- - -
		277	P	- - -
		278	P	- - -
		279	P	- - -
		280	P	- - -
		281	P	- - -
		288	P	- - -
		289	P	- - -
		294	P	- - -
		295	P	- - -
		298	P	- - -
		301	P	- - -
		302	P	- - -
		305	P	- - -
		306	P	- - -
		308	P	- - -

620300

Appendix 2

Individual Clinical Observations
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 11

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1	DOSE: 0 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP
				DAYS 186-365	DAY	AM OBS UNSCHED 30-90 OB DISPATCH
=====						
(CONTINUED FROM PREVIOUS PAGE)						
I05529	P	79	SKIN & PELAGE			
			ALOPECIA			
			FEET			
				309	P	- - -
				310	P	- - -
				311	P	- - -
				314	P	- - -
				186	P	- - -
				187	P	- - -
				188	P	- - -
				189	P	- - -
				190	P	- - -
				191	P	- - -
				192	P	- - -
				193	P	- - -
				194	P	- - -
				195	P	- - -
				197	P	- - -
				200	P	- - -
				201	P	- - -
				203	P	- - -
				204	P	- - -
				206	P	- - -
				210	P	- - -
				211	P	- - -
				213	P	- - -
				216	P	- - -
				217	P	- - -
				218	P	- - -
				219	P	- - -
				220	P	- - -
				221	P	- - -
				222	P	- - -

445

063030

Appendix 2

Individual Clinical Observations
Recovery (Days 186 through 365)

PAGE: 12

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF			CATEGORY	GROUP: F1	DOSE: 0 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP				
NUMBER	CODE	DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH	
			QUALIFIER	DAYS 186-365	DAY					
=====										
(CONTINUED FROM PREVIOUS PAGE)										
I05529	P	79	SKIN & PELAGE							
			ALOPECIA							
			TAIL							
					223	P	-	-	-	
					225	P	-	-	-	
					226	P	-	-	-	
					229	P	-	-	-	
					230	P	-	-	-	
					231	P	-	-	-	
					232	P	-	-	-	
					233	P	-	-	-	
					234	P	-	-	-	
					235	P	-	-	-	
					236	P	-	-	-	
					237	P	-	-	-	
					238	P	-	-	-	
					239	P	-	-	-	
					240	P	-	-	-	
					241	P	-	-	-	
					244	P	-	-	-	
					245	P	-	-	-	
					246	P	-	-	-	
					247	P	-	-	-	
=====										
			NORMAL							
			NO REMARKABLE OBSERVATIONS							
					316	P	-	-	-	
					323	P	-	-	-	
					330	P	-	-	-	
					337	P	-	-	-	
					344	P	-	-	-	
					351	P	-	-	-	
					358	P	-	-	-	
					365	P	-	-	-	

003031

Appendix 2

Individual Clinical Observations
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 13

ANIMAL DEATH WK OF NUMBER CODE DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1 DAYS 186-365	DOSE: 0 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS UNSCHED 30-90 OB DISPATCH			
=====							
(CONTINUED FROM PREVIOUS PAGE)							
I05529	P	79					
			QUALITATIVE FOOD CONSUMPTION				
			LOW				
			195	P	-	-	-
			210	P	-	-	-
			247	P	-	-	-
			248	P	-	-	-
			260	P	-	-	-
			272	P	-	-	-
			273	P	-	-	-
			294	P	-	-	-
I05549	P	79	DISCHARGE				
			APPEARS TO BE MENSTRUATING				
			261	P	-	-	-
			NORMAL				
			NO REMARKABLE OBSERVATIONS				
			190	P	-	-	-
			197	P	-	-	-
			204	P	-	-	-
			211	P	-	-	-
			218	P	-	-	-
			225	P	-	-	-
			232	P	-	-	-
			239	P	-	-	-
			246	P	-	-	-
			253	P	-	-	-
			260	P	-	-	-
			267	P	-	-	-
			274	P	-	-	-
			281	P	-	-	-
			288	P	-	-	-
			295	P	-	-	-

Appendix 2

Individual Clinical Observations
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 14

ANIMAL DEATH WK OF NUMBER CODE DEATH		CATEGORY KEYWORD QUALIFIER	GROUP: F1	DOSE: 0 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP				
			DAYS 186-365	DAY	AM OBS	UNSCHED	30-90 OB	DISPATCH	
=====									
(CONTINUED FROM PREVIOUS PAGE)									
I05549	P	79	NORMAL						
NO REMARKABLE OBSERVATIONS				302	P	-	-	-	
				309	P	-	-	-	
				316	P	-	-	-	
				323	P	-	-	-	
				330	P	-	-	-	
				337	P	-	-	-	
				344	P	-	-	-	
				351	P	-	-	-	
				358	P	-	-	-	
				365	P	-	-	-	
QUALITATIVE FOOD CONSUMPTION									
LOW				195	P	-	-	-	
				231	P	-	-	-	
				248	P	-	-	-	
				272	P	-	-	-	

003033

Appendix 2

Individual Clinical Observations
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 15

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F3 DAYS 186-365	DOSE: 0.15 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCHED	30-90 OB	DISPATCH
I05539	6	81	DISCHARGE						
			APPEARS TO BE MENSTRUATING		216	P	-	-	-
					217	P	-	-	-
					246	P	-	-	-
					275	P	-	-	-
			EXCRETION						
			FEW FECES		191	P	-	-	-
					195	P	-	-	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		190	P	-	-	-
					197	P	-	-	-
					204	P	-	-	-
					211	P	-	-	-
					218	P	-	-	-
					225	P	-	-	-
					232	P	-	-	-
					239	P	-	-	-
					253	P	-	-	-
					260	P	-	-	-
					267	P	-	-	-
					274	P	-	-	-
					281	P	-	-	-
					288	P	-	-	-
					295	P	-	-	-
					302	P	-	-	-
					309	P	-	-	-
					316	P	-	-	-
					323	P	-	-	-
					330	P	-	-	-
					337	P	-	-	-

003034

Appendix 2

Individual Clinical Observations
Recovery (Days 186 through 365)

PAGE: 16

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF	CATEGORY	GROUP: F3	DOSE: 0.15 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH
	QUALIFIER	DAYS 186-365	DAY				
(CONTINUED FROM PREVIOUS PAGE)							
I05539	6	81	NORMAL				
			NO REMARKABLE OBSERVATIONS				
			344	P	-	-	-
			351	P	-	-	-
			358	P	-	-	-
			365	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION				
			LOW				
			191	P	-	-	-
			195	P	-	-	-
			213	P	-	-	-
			218	P	-	-	-
			251	P	-	-	-
			254	P	-	-	-
			259	P	-	-	-
			269	P	-	-	-
			316	P	-	-	-
			346	P	-	-	-
I05552	6	81	NORMAL				
			NO REMARKABLE OBSERVATIONS				
			190	P	-	-	-
			197	P	-	-	-
			204	P	-	-	-
			211	P	-	-	-
			218	P	-	-	-
			225	P	-	-	-
			232	P	-	-	-
			239	P	-	-	-
			246	P	-	-	-
			253	P	-	-	-
			260	P	-	-	-
			267	P	-	-	-
			274	P	-	-	-

003035

Appendix 2

Individual Clinical Observations
Recovery (Days 186 through 365)

PAGE: 17

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF		CATEGORY	GROUP: F3	DOSE: 0.15 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP					
NUMBER	CODE	DEATH	KEYWORD	QUALIFIER	DAYS 186-365	DAY	AM OBS	UNSCHED	30-90 OB	DISPATCH
=====										
(CONTINUED FROM PREVIOUS PAGE)										
I05552	6	81	NORMAL							
NO REMARKABLE OBSERVATIONS						281	P	-	-	-
						288	P	-	-	-
						295	P	-	-	-
						302	P	-	-	-
						309	P	-	-	-
						316	P	-	-	-
						323	P	-	-	-
						330	P	-	-	-
						337	P	-	-	-
						344	P	-	-	-
						351	P	-	-	-
						358	P	-	-	-
						365	P	-	-	-
QUALITATIVE FOOD CONSUMPTION										
LOW						220	P	-	-	-
						343	P	-	-	-
						344	P	-	-	-
						346	P	-	-	-

Appendix 2

Individual Clinical Observations
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 18

ANIMAL	DEATH	WK OF	CATEGORY	GROUP: F4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER	CODE	DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH
			QUALIFIER	DAYS 186-365	DAY				
=====									
I05533	U	79	EXCRETION						
			NON-FORMED FECES		245	P	-	-	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		190	P	-	-	-
					197	P	-	-	-
					204	P	-	-	-
					211	P	-	-	-
					218	P	-	-	-
					225	P	-	-	-
					232	P	-	-	-
					239	P	-	-	-
					246	P	-	-	-
					253	P	-	-	-
					260	P	-	-	-
					267	P	-	-	-
					274	P	-	-	-
					281	P	-	-	-
					288	P	-	-	-
					295	P	-	-	-
					302	P	-	-	-
					309	P	-	-	-
					316	P	-	-	-
					323	P	-	-	-
					330	P	-	-	-
					337	P	-	-	-
					344	P	-	-	-
					351	P	-	-	-
					358	P	-	-	-
					365	P	-	-	-

003087

PAGE: 19

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD	GROUP	F4	DOSE	0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP
NUMBER	CODE	DEATH	QUALIFIER	DAYS	186-365	DAY		AM OBS UNSCHED 30-90 OB DISPATCH
=====								
(CONTINUED FROM PREVIOUS PAGE)								
I05533	U	79						

003088

Appendix 2

Individual Clinical Observations
Recovery (Days 186 through 365)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 20

ANIMAL DEATH WK OF	CATEGORY	GROUP: F4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCHED	30-90 OB	DISPATCH
	QUALIFIER	DAYS 186-365	DAY				
(CONTINUED FROM PREVIOUS PAGE)							
I05542	U	79	NORMAL				
			NO REMARKABLE OBSERVATIONS				
			344	P	-	-	-
			351	P	-	-	-
			358	P	-	-	-
			365	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION				
			LOW				
			269	P	-	-	-
			273	P	-	-	-
			275	P	-	-	-
			281	P	-	-	-
			302	P	-	-	-
			343	P	-	-	-
			344	P	-	-	-

003089

Appendix 2

Individual Clinical Observations
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 1

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M1 DAYS 368-558	DOSE: 0 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCH	EXTRA	DISPATCH
I05520	O	79	EXCRETION NON-FORMED FECES		533 534	P P	- -	- -	- -
			NORMAL NO REMARKABLE OBSERVATIONS		372 379 386 393 400 407 414 421 428 435 442 449 456 463 470 477 484 491 498 505 512 519 526 540 547	P P	- -	- -	- -

003090

Appendix 2

Covance 6329-223
3M T-6295.7Individual Clinical Observations
Recovery (Days 366 through 561)26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 2

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M1 DAYS 368-558	DOSE: 0 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP AM OBS UNSCH EXTRA DISPATCH
(CONTINUED FROM PREVIOUS PAGE)						
I05520	O	79				
			QUALITATIVE FOOD CONSUMPTION			
			LOW	541	P	- - -
I05526	O	79	DISCHARGE			
			VOMITUS	535	P	- - -
			CONTAINING FOOD	541	P	- - -
			NORMAL			
			NO REMARKABLE OBSERVATIONS	372	P	- - -
				379	P	- - -
				386	P	- - -
				393	P	- - -
				400	P	- - -
				407	P	- - -
				414	P	- - -
				421	P	- - -
				428	P	- - -
				435	P	- - -
				442	P	- - -
				449	P	- - -
				456	P	- - -
				463	P	- - -
				470	P	- - -
				477	P	- - -
				484	P	- - -
				491	P	- - -
				498	P	- - -
				505	P	- - -
				512	P	- - -

Appendix 2

Individual Clinical Observations
Recovery (Days 366 through 561)

PAGE: 3

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF	CATEGORY	GROUP: M1	DOSE: 0 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD QUALIFIER			AM OBS	UNSCH	EXTRA	DISPATCH
		DAYS 368-558	DAY				
(CONTINUED FROM PREVIOUS PAGE)							
I05526	O 79 NORMAL						
	NO REMARKABLE OBSERVATIONS		519	P	-	-	-
			526	P	-	-	-
			533	P	-	-	-
			540	P	-	-	-
			547	P	-	-	-

Appendix 2

Individual Clinical Observations
Recovery (Days 366 through 561)

PAGE: 4

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M3 DAYS 368-558	DOSE: 0.15 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCH	EXTRA	DISPATCH
I05505	6	81	APPEARANCE SWOLLEN	HEAD-MAXILLARY-RIGHT	390	P	-	-	-
					391	P	-	-	-
					393	P	-	-	-
					394	P	-	-	-
					395	P	-	-	-
					397	P	-	-	-
					400	P	-	-	-
			DISCHARGE VOMITUS	CONTAINING FOOD	535	P	-	-	-
			EXCRETION FEW FECES		555	P	-	-	-
			NORMAL NO REMARKABLE OBSERVATIONS		372	P	-	-	-
					379	P	-	-	-
					386	P	-	-	-
					407	P	-	-	-
					414	P	-	-	-
					421	P	-	-	-
					428	P	-	-	-
					435	P	-	-	-
					442	P	-	-	-
					449	P	-	-	-
					456	P	-	-	-
					463	P	-	-	-
					470	P	-	-	-
					477	P	-	-	-

Appendix 2

Individual Clinical Observations
Recovery (Days 366 through 561)

PAGE: 5

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF	CATEGORY	GROUP: M3	DOSE: 0.15 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP				
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCH	EXTRA	DISPATCH	
	QUALIFIER	DAYS 368-558	DAY					
=====								
(CONTINUED FROM PREVIOUS PAGE)								
I05505	6	81	NORMAL					
			NO REMARKABLE OBSERVATIONS	484	P	-	-	
				491	P	-	-	
				498	P	-	-	
				505	P	-	-	
				512	P	-	-	
				519	P	-	-	
				526	P	-	-	
				533	P	-	-	
				540	P	-	-	
				547	P	-	-	
				554	P	-	-	
			QUALITATIVE FOOD CONSUMPTION					
			LOW	375	P	-	-	
				376	P	-	-	
				555	P	-	-	
I05523	6	81	DISCHARGE					
			VOMITUS					
			CONTAINING FOOD	535	P	-	-	
			EXCRETION					
			NO FECES	555	P	-	-	
				556	P	-	-	
			NON-FORMED FECES	557	P	-	-	
			NORMAL					
			NO REMARKABLE OBSERVATIONS	372	P	-	-	
				386	P	-	-	
				393	P	-	-	
				400	P	-	-	

003094

Appendix 2

Individual Clinical Observations
Recovery (Days 366 through 561)

PAGE: 6

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF		CATEGORY	GROUP: M3	DOSE: 0.15 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP					
NUMBER	CODE	DEATH	KEYWORD	QUALIFIER	DAYS 368-558	DAY	AM OBS	UNSCH	EXTRA	DISPATCH
=====										
(CONTINUED FROM PREVIOUS PAGE)										
I05523	6	81	NORMAL							
NO REMARKABLE OBSERVATIONS						407	P	-	-	-
						414	P	-	-	-
						421	P	-	-	-
						428	P	-	-	-
						435	P	-	-	-
						442	P	-	-	-
						449	P	-	-	-
						456	P	-	-	-
						463	P	-	-	-
						470	P	-	-	-
						477	P	-	-	-
						484	P	-	-	-
						491	P	-	-	-
						498	P	-	-	-
						505	P	-	-	-
						512	P	-	-	-
						519	P	-	-	-
						526	P	-	-	-
						533	P	-	-	-
						540	P	-	-	-
						547	P	-	-	-
						554	P	-	-	-
QUALITATIVE FOOD CONSUMPTION										
LOW						375	P	-	-	-
						379	P	-	-	-
						553	P	P	-	-
						555	P	-	-	-
						558	P	-	-	-

003095

Appendix 2

Individual Clinical Observations
Recovery (Days 366 through 561)

PAGE: 7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH		WK OF	CATEGORY	GROUP: M4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP				
NUMBER	CODE	DEATH	KEYWORD			AM	OBS	UNSCH	EXTRA	DISPATCH
			QUALIFIER	DAYS 368-558	DAY					
=====										
I05511	U	79	NORMAL							
			NO REMARKABLE OBSERVATIONS							
					372	P	-	-	-	
					379	P	-	-	-	
					386	P	-	-	-	
					393	P	-	-	-	
					400	P	-	-	-	
					407	P	-	-	-	
					414	P	-	-	-	
					421	P	-	-	-	
					428	P	-	-	-	
					435	P	-	-	-	
					442	P	-	-	-	
					449	P	-	-	-	
					456	P	-	-	-	
					463	P	-	-	-	
					470	P	-	-	-	
					477	P	-	-	-	
					484	P	-	-	-	
					491	P	-	-	-	
					498	P	-	-	-	
					505	P	-	-	-	
					512	P	-	-	-	
					519	P	-	-	-	
					526	P	-	-	-	
					533	P	-	-	-	
					540	P	-	-	-	
					547	P	-	-	-	
					549	P	-	-	-	P

003096

Appendix 2

Individual Clinical Observations
Recovery (Days 366 through 561)

PAGE: 8

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF	CATEGORY	GROUP: M4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCH	EXTRA	DISPATCH
	QUALIFIER	DAYS 368-558	DAY				
=====							
I05522	U	79	EXCRETION				
			NON-FORMED FECES	402	P	-	-
				403	P	-	-
			NORMAL				
			NO REMARKABLE OBSERVATIONS	372	P	-	-
				379	P	-	-
				386	P	-	-
				393	P	-	-
				400	P	-	-
				407	P	-	-
				414	P	-	-
				421	P	-	-
				428	P	-	-
				435	P	-	-
				442	P	-	-
				449	P	-	-
				456	P	-	-
				463	P	-	-
				470	P	-	-
				477	P	-	-
				484	P	-	-
				491	P	-	-
				498	P	-	-
				505	P	-	-
				512	P	-	-
				519	P	-	-
				526	P	-	-
				533	P	-	-
				540	P	-	-
				547	P	-	-
				549	P	-	P

003097

Covance 6329-223
3M T-6295.7

Appendix 2

Individual Clinical Observations
Recovery (Days 366 through 561)

PAGE: 9

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF	CATEGORY	GROUP: M4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP
NUMBER CODE DEATH	KEYWORD			AM OBS UNSCH EXTRA DISPATCH
	QUALIFIER	DAYS 368-558	DAY	
=====				
(CONTINUED FROM PREVIOUS PAGE)				
I05522	U	79		

QUALITATIVE FOOD CONSUMPTION
LOW

394 P - - -

Appendix 2

Individual Clinical Observations
Recovery (Days 366 through 561)

PAGE: 10

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1 DAYS 368-558	DOSE: 0 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCH	EXTRA	DISPATCH
I05529	P	79	EXCRETION						
			LIQUID FECES		489	P	-	-	-
					491	P	-	-	-
					492	P	-	-	-
					493	P	-	-	-
					494	P	-	-	-
			NON-FORMED FECES		496	P	-	-	-
			SKIN & PELAGE						
			ALOPECIA						
			LIMB-HIND-RIGHT		368	P	-	-	-
					369	P	-	-	-
					372	P	-	-	-
					376	P	-	-	-
					377	P	-	-	-
					378	P	-	-	-
					549	P	-	-	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		379	P	-	-	-
					386	P	-	-	-
					393	P	-	-	-
					400	P	-	-	-
					407	P	-	-	-
					414	P	-	-	-
					421	P	-	-	-
					428	P	-	-	-
					435	P	-	-	-
					442	P	-	-	-
					449	P	-	-	-
					456	P	-	-	-
					463	P	-	-	-

003699

Appendix 2

Individual Clinical Observations
Recovery (Days 366 through 561)

PAGE: 11

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL		DEATH	WK OF	CATEGORY	GROUP: F1	DOSE: 0 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER	CODE	DEATH	QUALIFIER	KEYWORD	DAYS 368-558	DAY	AM OBS	UNSCH	EXTRA	DISPATCH
=====										
(CONTINUED FROM PREVIOUS PAGE)										
I05529	P	79	NORMAL							
			NO REMARKABLE OBSERVATIONS			470	P	-	-	-
						477	P	-	-	-
						484	P	-	-	-
						498	P	-	-	-
						505	P	-	-	-
						512	P	-	-	-
						519	P	-	-	-
						526	P	-	-	-
						533	P	-	-	-
						540	P	-	-	-
						547	P	-	-	-
			QUALITATIVE FOOD CONSUMPTION							
			LOW			372	P	-	-	-
						376	P	-	-	-
						452	P	-	-	-
I05549	P	79	DISCHARGE							
			VOMITUS							
			CONTAINING FOOD			535	P	-	-	-
			APPEARS TO BE MENSTRUATING			372	P	-	-	-
						400	P	-	-	-
						456	P	-	-	-
						484	P	-	-	-
						541	P	-	-	-
			NORMAL							
			NO REMARKABLE OBSERVATIONS			379	P	-	-	-
						386	P	-	-	-
						393	P	-	-	-
						407	P	-	-	-

003100

Appendix 2

Individual Clinical Observations
Recovery (Days 366 through 561)

PAGE: 12

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF	CATEGORY	GROUP: F1	DOSE: 0 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCH	EXTRA	DISPATCH
	QUALIFIER	DAYS 368-558	DAY				
=====							
(CONTINUED FROM PREVIOUS PAGE)							
I05549	P	79	NORMAL				
			NO REMARKABLE OBSERVATIONS	414	P	-	-
				421	P	-	-
				428	P	-	-
				435	P	-	-
				442	P	-	-
				449	P	-	-
				463	P	-	-
				470	P	-	-
				477	P	-	-
				491	P	-	-
				498	P	-	-
				505	P	-	-
				512	P	-	-
				519	P	-	-
				526	P	-	-
				533	P	-	-
				540	P	-	-
				547	P	-	-
			QUALITATIVE FOOD CONSUMPTION				
			LOW	372	P	-	-
				452	P	-	-

003101

Appendix 2

Individual Clinical Observations
Recovery (Days 366 through 561)

PAGE: 13

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF			CATEGORY	GROUP: F3	DOSE: 0.15 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER	CODE	DEATH	KEYWORD			AM OBS	UNSCH	EXTRA	DISPATCH
			QUALIFIER	DAYS 368-558	DAY				
=====									
I05539	6	81	DISCHARGE UNKNOWN SOURCE						
			FOUND IN PAN		555	P	-	-	-
			RED IN COLOR		556	P	-	-	-
			EXCRETION						
			FEW FECES		404	P	-	-	-
					558	P	-	-	-
			NO FECES		555	P	-	-	-
					556	P	-	-	-
					557	P	-	-	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		372	P	-	-	-
					379	P	-	-	-
					386	P	-	-	-
					393	P	-	-	-
					400	P	-	-	-
					407	P	-	-	-
					414	P	-	-	-
					421	P	-	-	-
					428	P	-	-	-
					435	P	-	-	-
					442	P	-	-	-
					449	P	-	-	-
					456	P	-	-	-
					463	P	-	-	-
					470	P	-	-	-
					477	P	-	-	-
					484	P	-	-	-
					491	P	-	-	-
					498	P	-	-	-

003102

Appendix 2

Individual Clinical Observations
Recovery (Days 366 through 561)

PAGE: 14

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL		DEATH	WK OF	CATEGORY	GROUP: F3	DOSE: 0.15 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER	CODE	DEATH		KEYWORD			AM OBS	UNSCH	EXTRA	DISPATCH
				QUALIFIER	DAYS 368-558	DAY				
=====										
(CONTINUED FROM PREVIOUS PAGE)										
I05539	6	81		NORMAL						
				NO REMARKABLE OBSERVATIONS		505	P	-	-	-
						512	P	-	-	-
						519	P	-	-	-
						526	P	-	-	-
						533	P	-	-	-
						540	P	-	-	-
						547	P	-	-	-
						554	P	-	-	-
				QUALITATIVE FOOD CONSUMPTION						
				LOW		375	P	-	-	-
						376	P	-	-	-
						399	P	-	-	-
						404	P	-	-	-
						407	P	-	-	-
						553	-	P	-	-
						556	P	-	-	-
						557	P	-	-	-
						558	P	-	-	-
				NONE		555	P	-	-	-
I05552	6	81		DISCHARGE						
				VOMITUS						
				CONTAINING FOOD		535	P	-	-	-
				EXCRETION						
				FEW FECES		555	P	-	-	-
						557	P	-	-	-
						558	P	-	-	-
				NO FECES		556	P	-	-	-

003103

Appendix 2

Individual Clinical Observations
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 15

ANIMAL DEATH WK OF	CATEGORY	GROUP: F3	DOSE: 0.15 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
NUMBER CODE DEATH	KEYWORD			AM OBS	UNSCH	EXTRA	DISPATCH
	QUALIFIER	DAYS 368-558	DAY				
(CONTINUED FROM PREVIOUS PAGE)							
I05552	6	81					

NORMAL

NO REMARKABLE OBSERVATIONS

372	P	-	-	-
379	P	-	-	-
386	P	-	-	-
393	P	-	-	-
400	P	-	-	-
407	P	-	-	-
414	P	-	-	-
421	P	-	-	-
428	P	-	-	-
435	P	-	-	-
442	P	-	-	-
449	P	-	-	-
456	P	-	-	-
463	P	-	-	-
470	P	-	-	-
477	P	-	-	-
484	P	-	-	-
491	P	-	-	-
498	P	-	-	-
505	P	-	-	-
512	P	-	-	-
519	P	-	-	-
526	P	-	-	-
533	P	-	-	-
540	P	-	-	-
547	P	-	-	-
554	P	-	-	-

003104

Appendix 2

Individual Clinical Observations
Recovery (Days 366 through 561)

PAGE: 16

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF NUMBER CODE DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F3	DOSE: 0.15 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP
		DAYS 368-558	DAY	AM OBS UNSCH EXTRA DISPATCH
(CONTINUED FROM PREVIOUS PAGE)				
I05552 6 81				

QUALITATIVE FOOD CONSUMPTION

LOW

372	P	-	-	-
557	P	-	-	-
558	P	-	-	-
555	P	-	-	-
556	P	-	-	-

NONE

Appendix 2

Individual Clinical Observations
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 17

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4 DAYS 368-558	DOSE: 0.75 MG/KG/DAY DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP			
						AM OBS	UNSCH	EXTRA	DISPATCH
I05533	U	79	EXCRETION						
			LIQUID FECES		399	P	-	-	-
					400	P	-	-	-
			NON-FORMED FECES		402	P	-	-	-
			NORMAL						
			NO REMARKABLE OBSERVATIONS		372	P	-	-	-
					379	P	-	-	-
					386	P	-	-	-
					393	P	-	-	-
					407	P	-	-	-
					414	P	-	-	-
					421	P	-	-	-
					428	P	-	-	-
					435	P	-	-	-
					442	P	-	-	-
					449	P	-	-	-
					456	P	-	-	-
					463	P	-	-	-
					470	P	-	-	-
					477	P	-	-	-
					484	P	-	-	-
					491	P	-	-	-
					498	P	-	-	-
					505	P	-	-	-
					512	P	-	-	-
					519	P	-	-	-
					526	P	-	-	-
					533	P	-	-	-
					540	P	-	-	-
					547	P	-	-	-
					549	P	-	-	P

Appendix 2

Individual Clinical Observations
Recovery (Days 366 through 561)

PAGE: 18

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL DEATH WK OF			CATEGORY	GROUP: F4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP				
NUMBER	CODE	DEATH	KEYWORD			AM	OBS	UNSCH	EXTRA	DISPATCH
			QUALIFIER	DAYS 368-558	DAY					
=====										
(CONTINUED FROM PREVIOUS PAGE)										
I05533	U	79								
			QUALITATIVE FOOD CONSUMPTION							
			LOW		394	P	-	-	-	-
I05542	U	79	DISCHARGE							
			APPEARS TO BE MENSTRUATING		496	P	-	-	-	-
			DISCHARGE UNKNOWN SOURCE							
			FOUND IN PAN							
			RED IN COLOR		375	P	-	-	-	-
			NORMAL							
			NO REMARKABLE OBSERVATIONS		372	P	-	-	-	-
					379	P	-	-	-	-
					386	P	-	-	-	-
					393	P	-	-	-	-
					400	P	-	-	-	-
					407	P	-	-	-	-
					414	P	-	-	-	-
					421	P	-	-	-	-
					428	P	-	-	-	-
					435	P	-	-	-	-
					442	P	-	-	-	-
					449	P	-	-	-	-
					456	P	-	-	-	-
					463	P	-	-	-	-
					470	P	-	-	-	-
					477	P	-	-	-	-
					484	P	-	-	-	-
					491	P	-	-	-	-
					498	P	-	-	-	-

Appendix 2

Individual Clinical Observations
Recovery (Days 366 through 561)

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 19

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4	DOSE: 0.75 MG/KG/DAY	'C' - COMMENTS LISTED AT END OF OBSERVATIONS FOR SEX/GROUP	AM OBS	UNSCH	EXTRA	DISPATCH
				DAYS 368-558	DAY					
(CONTINUED FROM PREVIOUS PAGE)										
I05542	U	79	NORMAL							
NO REMARKABLE OBSERVATIONS						505	P	-	-	-
						512	P	-	-	-
						519	P	-	-	-
						526	P	-	-	-
						533	P	-	-	-
						540	P	-	-	-
						547	P	-	-	-
						549	P	-	-	P
QUALITATIVE FOOD CONSUMPTION										
LOW						375	P	-	-	-
						394	P	-	-	-
						395	P	-	-	-

003108

Appendix 2

Individual Ophthalmic Observations
Treatment

PAGE: 1

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M1	DOSE: 0 MG/KG/DAY	WEEKS -4 AND 26 - OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05508	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05517	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05519	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05520	O	79	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05526	O	79	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05527	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26

003109

Appendix 2

Individual Ophthalmic Observations
Treatment

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 2

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M2	DOSE: 0.03 MG/KG/DAY	WEEKS -4 AND 26 - OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05514	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05515	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05516	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05521	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26

Appendix 2

Individual Ophthalmic Observations
Treatment

PAGE: 3

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M3	DOSE: 0.15 MG/KG/DAY WEEKS -4 AND 26 - OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05505	6	81	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES		-4, 26
I05510	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES		-4, 26
I05518	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES		-4, 26
I05523	6	81	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES		-4, 26
I05524	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES		-4, 26
I05528	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES		-4, 26

003111

Appendix 2

Individual Ophthalmic Observations
Treatment

PAGE: 4

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4	DOSE: 0.75 MG/KG/DAY WEEKS -4 AND 26	OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05506	M	26	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05507	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05509	D	23	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4
I05511	U	79	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05512	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05522	U	79	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26

Appendix 2
Individual Ophthalmic Observations
Treatment

PAGE: 5

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1	DOSE: 0 MG/KG/DAY	WEEKS -4 AND 26 - OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05529	P	79	NO VISIBLE LESIONS NO VISIBLE LESIONS EYE-LEFT EYES			-4 26
			MISCELLANEOUS OPHTHALMICS INCREASED MYELINATION OF OPTIC NERVE EYE-RIGHT			-4
I05530	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05531	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05535	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05544	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05549	P	79	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26

003113

Appendix 2
Individual Ophthalmic Observations
Treatment

PAGE: 6

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F2	DOSE: 0.03 MG/KG/DAY WEEKS -4 AND 26	OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05537	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05541	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05547	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05550	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26

Appendix 2

Individual Ophthalmic Observations
Treatment

PAGE: 7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F3	DOSE: 0.15 MG/KG/DAY WEEKS -4 AND 26	OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05532	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05538	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05539	6	81	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05545	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05548	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05552	6	81	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26

003115

Appendix 2
Individual Ophthalmic Observations
Treatment

PAGE: 8

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4	DOSE: 0.75 MG/KG/DAY WEEKS -4 AND 26	OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05533	U	79	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05534	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05536	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05540	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05542	U	79	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26
I05551	T	27	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			-4, 26

003116

Appendix 2

Individual Ophthalmic Observations
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 1

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M1	DOSE: 0 MG/KG/DAY	WEEK 52 - OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05520	O	79	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			52
I05526	O	79	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			52

003117

Appendix 2

Individual Ophthalmic Observations
Recovery

PAGE: 2

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M3	DOSE: 0.15 MG/KG/DAY	WEEK 52 - OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05505	6	81	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			52
I05523	6	81	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			52

003118

Appendix 2

Individual Ophthalmic Observations
Recovery

PAGE: 3

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: M4	DOSE: 0.75 MG/KG/DAY	WEEK 52 - OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05511	U	79	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			52
I05522	U	79	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			52

Appendix 2

Individual Ophthalmic Observations
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 4

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F1	DOSE: 0 MG/KG/DAY	WEEK 52 - OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05529	P	79	NO VISIBLE LESIONS NO VISIBLE LESIONS EYE-LEFT			52
			MISCELLANEOUS OPHTHALMICS OTHER EYE-RIGHT			52C
I05549	P	79	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			52

Appendix 2

Individual Ophthalmic Observations
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 5

ANIMAL	GROUP	STUDY DAY WK	CATEGORY	FREE-TEXT COMMENT
			KEYWORD QUALIFIER	
I05529	F1	363 52	MISCELLANEOUS OPHTHALMICS OTHER EYE-RIGHT	INCREASED MYELINATION OF OPTIC NERVE HEAD THAT MAY BE ASSOCIATED WITH OPTIC NEURITIS. MACULA NORMAL.

003121

Appendix 2

Individual Ophthalmic Observations
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 6

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY	GROUP: F3	DOSE: 0.15 MG/KG/DAY	WEEK 52 - OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
			KEYWORD QUALIFIER			
I05539	6	81	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			52
I05552	6	81	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			52

003122

Appendix 2

Individual Ophthalmic Observations
Recovery

PAGE: 7

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

ANIMAL NUMBER	DEATH CODE	WK OF DEATH	CATEGORY KEYWORD QUALIFIER	GROUP: F4	DOSE: 0.75 MG/KG/DAY	WEEK 52 - OBSERVED DURING THE WEEKS LISTED BELOW; 'C' - COMMENTS LISTED AT END OF OBSERVATIONS
I05533	U	79	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			52
I05542	U	79	NO VISIBLE LESIONS NO VISIBLE LESIONS EYES			52

003123

APPENDIX 3

Individual Body Weight Data (kg)

003124

Appendix 3

Individual Body Weight Data (kg)
Treatment Phase

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 1

ANIMAL NUMBER	WEEK ^a -1	WEEK ^b -1	WEEK 1	WEEK 2	WEEK 3	WEEK 4	WEEK 5	WEEK 6	WEEK 7	WEEK 8
GROUP: MALE 1 - 0 MG/KG/DAY										
I05508	3.0	3.1	3.1	3.1	3.2	3.2	3.2	3.2	3.2	3.2
I05517	3.4	3.4	3.4	3.3	3.2	3.2	3.3	3.3	3.3	3.3
I05519	2.9	3.0	3.0	3.0	3.0	3.1	3.1	3.0	3.0	3.1
I05520	2.9	2.9	2.9	2.9	3.0	3.1	3.0	3.0	2.9	3.0
I05526	3.0	3.0	3.0	3.1	3.2	3.3	3.3	3.3	3.3	3.3
I05527	4.0	4.1	4.1	4.1	4.1	4.1	4.1	4.1	4.1	4.1
GROUP: MALE 2 - 0.03 MG/KG/DAY										
I05514	3.1	3.1	3.1	3.2	3.2	3.3	3.3	3.3	3.3	3.3
I05515	3.3	3.3	3.3	3.2	3.3	3.4	3.4	3.5	3.4	3.4
I05516	2.7	2.8	2.8	2.8	2.8	2.9	2.9	2.9	2.9	2.9
I05521	4.4	4.3	4.4	4.3	4.4	4.4	4.4	4.4	4.4	4.4
GROUP: MALE 3 - 0.15 MG/KG/DAY										
I05505	3.1	3.2	3.2	3.2	3.3	3.3	3.3	3.3	3.3	3.2
I05510	2.9	3.0	2.9	2.9	2.9	3.0	3.0	3.0	3.1	3.1
I05518	3.0	3.1	3.1	3.1	3.1	3.2	3.2	3.2	3.2	3.2
I05523	2.6	2.7	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8
I05524	2.9	2.9	2.9	3.0	3.1	3.1	3.1	3.1	3.1	3.0
I05528	3.6	3.7	3.7	3.7	3.7	3.8	3.8	3.8	3.8	3.7
GROUP: MALE 4 - 0.75 MG/KG/DAY										
I05506	3.3	3.4	3.4	3.4	3.5	3.5	3.6	3.7	3.7	3.7
I05507	4.4	4.4	4.4	4.5	4.5	4.5	4.5	4.5	4.6	4.6
I05509	3.1	3.2	3.2	3.1	3.2	3.2	3.3	3.3	3.2	3.2
I05511	2.8	2.9	2.9	2.9	2.9	2.9	2.8	2.8	2.8	2.8
I05512	2.8	2.9	2.9	2.8	2.9	3.0	3.0	3.0	3.1	3.0
I05522	3.4	3.4	3.4	3.4	3.5	3.6	3.6	3.6	3.6	3.6

a Day -7.
b Day -1.

003125

Appendix 3

Individual Body Weight Data (kg)
Treatment Phase

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 2

ANIMAL NUMBER	WEEK ^a -1	WEEK ^b -1	WEEK 1	WEEK 2	WEEK 3	WEEK 4	WEEK 5	WEEK 6	WEEK 7	WEEK 8
GROUP: FEMALE 1 - 0 MG/KG/DAY										
I05529	2.5	2.5	2.5	2.7	2.3	2.4	2.4	2.4	2.4	2.4
I05530	2.9	2.9	2.9	2.8	2.9	2.9	2.7	2.4	2.4	2.4
I05531	2.6	2.6	2.6	2.6	2.6	2.7	2.6	2.6	2.8	2.8
I05535	3.4	3.3	3.3	3.3	3.4	3.4	3.4	3.4	2.7	2.6
I05544	2.6	2.7	2.7	2.6	2.6	3.4	3.4	3.4	3.5	3.5
I05549	2.9	2.9	2.9	2.9	3.0	3.0	3.0	2.6	2.6	2.6
GROUP: FEMALE 2 - 0.03 MG/KG/DAY										
I05537	3.8	3.8	3.9	3.9	3.9	4.0	3.9	3.9	4.0	4.0
I05541	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.6	2.6	2.6
I05547	2.9	2.9	2.9	3.0	3.0	3.0	3.0	3.0	3.0	3.0
I05550	2.9	2.9	2.9	2.9	2.9	2.8	2.8	2.8	2.9	2.9
GROUP: FEMALE 3 - 0.15 MG/KG/DAY										
I05532	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
I05538	3.2	3.2	3.2	3.1	3.1	3.0	3.0	3.0	3.0	3.0
I05539	3.6	3.7	3.7	3.8	3.8	3.8	3.8	3.9	3.9	3.9
I05545	2.6	2.6	2.6	2.7	2.7	2.7	2.6	2.6	2.6	2.6
I05548	2.8	2.9	2.9	3.0	2.9	3.0	3.0	3.0	3.0	3.0
I05552	2.8	2.8	2.8	2.7	2.7	2.7	2.7	2.7	2.7	2.7
GROUP: FEMALE 4 - 0.75 MG/KG/DAY										
I05533	2.6	2.6	2.6	2.6	2.6	2.6	2.5	2.6	2.6	2.5
I05534	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8
I05536	3.9	3.9	3.9	3.8	3.8	3.9	3.9	3.9	3.8	3.8
I05540	2.9	3.0	3.0	3.1	3.1	2.8	2.6	2.6	2.8	2.9
I05542	2.8	2.9	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8
I05551	2.3	2.4	2.4	2.4	2.4	2.4	2.4	2.3	2.4	2.4

a Day -7.
b Day -1.

003126

Appendix 3

Individual Body Weight Data (kg)
Treatment Phase26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 3

ANIMAL NUMBER	WEEK 9	WEEK 10	WEEK 11	WEEK 12	WEEK 13	WEEK 14	WEEK 15	WEEK 16	WEEK 17	WEEK 18
GROUP: MALE 1 - 0 MG/KG/DAY										
I05508	3.2	3.2	3.2	3.3	3.3	3.3	3.3	3.3	3.4	3.4
I05517	3.4	3.3	3.3	3.3	3.3	3.3	3.3	3.3	3.4	3.4
I05519	3.1	3.1	3.1	3.1	3.2	3.2	3.2	3.1	3.3	3.3
I05520	3.0	3.0	3.1	3.0	3.0	3.1	3.0	3.2	3.3	3.2
I05526	3.4	3.4	3.5	3.5	3.6	3.5	3.0	3.0	3.0	3.0
I05527	4.2	4.2	4.3	4.3	4.3	4.3	4.3	3.6	3.7	3.7
								4.3	4.4	4.4
GROUP: MALE 2 - 0.03 MG/KG/DAY										
I05514	3.3	3.3	3.4	3.4	3.4	3.4	3.5	3.5	3.6	3.5
I05515	3.5	3.5	3.6	3.7	3.7	3.6	3.6	3.7	3.8	3.7
I05516	3.0	3.0	3.0	3.0	3.1	3.2	3.2	3.2	3.3	3.2
I05521	4.4	4.4	4.6	4.6	4.6	4.5	4.6	4.6	4.6	4.5
GROUP: MALE 3 - 0.15 MG/KG/DAY										
I05505	3.3	3.2	3.3	3.3	3.3	3.2	3.3	3.3	3.3	3.3
I05510	3.1	3.1	3.2	3.2	3.3	3.1	3.2	3.2	3.3	3.3
I05518	3.3	3.2	3.2	3.3	3.3	3.2	3.2	3.3	3.3	3.3
I05523	2.8	2.7	2.8	2.8	2.9	2.9	2.9	2.9	3.0	2.9
I05524	3.2	3.0	3.1	3.1	3.1	3.1	3.1	3.1	3.0	3.2
I05528	3.7	3.7	3.8	3.7	3.7	3.8	3.8	3.7	3.7	3.6
GROUP: MALE 4 - 0.75 MG/KG/DAY										
I05506	3.8	3.7	3.9	3.8	3.9	3.8	3.9	3.9	4.0	3.9
I05507	4.7	4.6	4.7	4.7	4.7	4.6	4.6	4.5	4.6	4.5
I05509	3.2	3.2	3.2	3.2	3.2	3.1	3.1	3.0	3.1	3.0
I05511	2.9	2.8	2.9	2.9	2.9	2.9	2.9	2.8	2.7	2.8
I05512	3.1	3.0	3.1	3.1	3.1	2.9	2.9	2.7	2.8	2.8
I05522	3.6	3.6	3.7	3.6	3.7	3.7	3.7	3.6	3.7	3.7

Appendix 3

Individual Body Weight Data (kg)
Treatment Phase

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 4

ANIMAL NUMBER	WEEK 9	WEEK 10	WEEK 11	WEEK 12	WEEK 13	WEEK 14	WEEK 15	WEEK 16	WEEK 17	WEEK 18
GROUP: FEMALE 1 - 0 MG/KG/DAY										
I05529	2.5	2.5	2.5	2.6	2.6	2.6	2.4	2.5	2.5	2.5
I05530	2.9	2.9	3.0	3.1	3.0	3.0	3.0	3.0	3.0	3.0
I05531	2.7	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.8	2.8
I05535	3.6	3.5	3.5	3.6	3.6	3.6	3.5	3.5	3.6	3.6
I05544	2.6	2.7	2.7	2.7	2.8	2.7	2.7	2.8	2.8	2.7
I05549	3.0	3.0	2.9	3.0	3.0	3.0	3.0	3.0	3.1	3.0
GROUP: FEMALE 2 - 0.03 MG/KG/DAY										
I05537	4.1	4.0	4.0	4.0	4.1	4.1	4.1	4.1	4.2	4.2
I05541	2.6	2.6	2.7	2.7	2.7	2.7	2.7	2.7	2.6	2.7
I05547	3.0	3.0	3.0	3.1	3.1	3.1	3.0	3.0	3.0	3.0
I05550	2.9	2.8	2.8	2.8	2.9	2.9	2.9	2.9	2.9	2.9
GROUP: FEMALE 3 - 0.15 MG/KG/DAY										
I05532	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.8
I05538	3.0	3.0	3.2	3.2	3.3	3.2	3.3	3.3	3.4	3.4
I05539	3.9	3.9	3.9	3.9	3.9	4.0	4.0	3.9	3.9	3.9
I05545	2.6	2.7	2.7	2.6	2.6	2.7	2.7	2.7	2.7	2.6
I05548	3.0	3.0	3.0	3.1	3.1	3.1	3.1	3.0	3.1	3.0
I05552	2.8	2.8	2.7	2.7	2.8	2.8	2.8	2.8	2.8	2.8
GROUP: FEMALE 4 - 0.75 MG/KG/DAY										
I05533	2.6	2.6	2.6	2.7	2.7	2.6	2.6	2.6	2.7	2.6
I05534	2.9	2.8	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9
I05536	3.9	3.9	3.8	3.8	3.7	3.6	3.5	3.4	3.7	3.6
I05540	3.1	3.0	2.8	2.8	2.8	2.7	2.9	3.0	3.1	3.1
I05542	2.8	2.7	2.7	2.7	2.7	2.7	2.6	2.6	2.8	2.7
I05551	2.3	2.3	2.3	2.3	2.3	2.3	2.4	2.6	2.4	2.3

003128

Appendix 3

Individual Body Weight Data (kg)
Treatment Phase26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 5

ANIMAL NUMBER	WEEK 19	WEEK 20	WEEK 21	WEEK 22	WEEK 23	WEEK 24	WEEK 25	WEEK 26	WEEK 27
GROUP: MALE 1 - 0 MG/KG/DAY									
I05508	3.4	3.4	3.4	3.4	3.4	3.4	3.6	3.6	3.6
I05517	3.4	3.4	3.3	3.3	3.3	3.4	3.4	3.3	3.3
I05519	3.3	3.2	3.2	3.2	3.3	3.3	3.4	3.4	3.4
I05520	3.1	3.0	3.1	3.1	3.1	3.0	3.2	3.2	3.1
I05526	3.7	3.7	3.7	3.8	3.7	3.7	3.8	3.9	3.8
I05527	4.5	4.5	4.6	4.6	4.7	4.8	4.9	5.0	5.0
GROUP: MALE 2 - 0.03 MG/KG/DAY									
I05514	3.6	3.6	3.6	3.6	3.7	3.7	3.8	3.8	3.8
I05515	3.8	3.8	3.6	3.7	3.7	3.7	3.8	3.8	3.7
I05516	3.2	3.2	3.2	3.3	3.3	3.3	3.4	3.4	3.4
I05521	4.6	4.6	4.7	4.6	4.6	4.7	4.7	4.7	4.7
GROUP: MALE 3 - 0.15 MG/KG/DAY									
I05505	3.3	3.3	3.2	3.3	3.3	3.3	3.4	3.3	3.2
I05510	3.3	3.3	3.2	3.3	3.3	3.4	3.5	3.4	3.4
I05518	3.3	3.3	3.2	3.3	3.3	3.3	3.3	3.4	3.3
I05523	3.0	3.0	2.9	2.9	2.9	2.9	3.1	3.0	2.9
I05524	3.3	3.3	3.2	3.3	3.3	3.3	3.4	3.4	3.3
I05528	3.6	3.7	3.7	3.7	3.7	3.7	3.7	3.6	3.7
GROUP: MALE 4 - 0.75 MG/KG/DAY									
I05506	4.0	4.0	3.9	3.9	3.9	4.0	4.0	3.9	
I05507	4.5	4.4	4.3	4.2	4.2	4.1	4.2	4.2	4.2
I05509	3.0	3.1	2.9	3.0	2.8				
I05511	2.9	2.8	2.6	2.7	2.7	2.8	2.7	2.6	2.5
I05512	2.6	2.5	2.6	2.8	2.7	2.6	2.7	2.7	2.5
I05522	3.7	3.6	3.6	3.6	3.6	3.6	3.7	3.7	3.5

Appendix 3

Individual Body Weight Data (kg)
Treatment Phase

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 6

ANIMAL NUMBER	WEEK 19	WEEK 20	WEEK 21	WEEK 22	WEEK 23	WEEK 24	WEEK 25	WEEK 26	WEEK 27
GROUP: FEMALE 1 - 0 MG/KG/DAY									
I05529	2.5	2.5	2.5	2.5	2.5	2.6	2.5	2.5	2.4
I05530	3.0	3.0	2.9	3.0	3.0	3.0	3.1	3.0	3.0
I05531	2.8	2.8	2.7	2.8	2.7	2.7	2.8	2.8	2.9
I05535	3.5	3.5	3.5	3.6	3.4	3.5	3.6	3.6	3.5
I05544	2.8	2.8	2.8	2.8	2.8	2.8	2.9	2.9	2.9
I05549	3.1	3.1	3.0	3.1	3.0	3.0	3.0	3.1	3.0
GROUP: FEMALE 2 - 0.03 MG/KG/DAY									
I05537	4.2	4.2	4.2	4.2	4.2	4.3	4.4	4.4	4.3
I05541	2.7	2.7	2.6	2.7	2.8	2.7	2.8	2.8	2.8
I05547	3.1	3.0	3.0	2.9	2.8	2.7	2.8	2.7	2.8
I05550	3.0	3.0	2.9	3.0	2.9	3.0	3.1	3.0	3.0
GROUP: FEMALE 3 - 0.15 MG/KG/DAY									
I05532	2.8	2.8	2.7	2.8	2.8	2.8	2.8	2.8	2.7
I05538	3.4	3.4	3.3	3.5	3.5	3.4	3.5	3.4	3.5
I05539	4.0	4.0	3.8	3.8	3.8	3.9	3.9	3.9	3.9
I05545	2.7	2.8	2.6	2.7	2.6	2.7	2.7	2.7	2.7
I05548	3.1	3.1	3.0	3.1	3.1	3.1	3.1	3.1	3.1
I05552	2.8	2.8	2.7	2.8	2.8	2.8	2.9	2.8	2.7
GROUP: FEMALE 4 - 0.75 MG/KG/DAY									
I05533	2.6	2.6	2.6	2.6	2.6	2.7	2.7	2.7	2.5
I05534	2.9	2.8	2.7	2.9	2.8	2.9	2.8	2.7	2.8
I05536	3.5	3.5	3.3	3.3	3.4	3.3	3.3	3.4	3.4
I05540	3.1	3.0	3.0	2.9	2.9	3.0	3.0	3.0	3.0
I05542	2.7	2.7	2.6	2.7	2.6	2.6	2.7	2.6	2.6
I05551	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4

Appendix 3

Individual Body Weight Data (kg)
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 1

ANIMAL NUMBER	WEEK 28	WEEK 29	WEEK 30	WEEK 31	WEEK 32	WEEK 33	WEEK 34	WEEK 35	WEEK 36	WEEK 37
GROUP: MALE 1 - 0 MG/KG/DAY										
I05520	3.2	3.3	3.3	3.4	3.5	3.5	3.5	3.5	3.5	3.6
I05526	3.8	3.9	3.9	4.0	4.1	4.1	4.1	4.0	4.1	4.2
GROUP: MALE 3 - 0.15 MG/KG/DAY										
I05505	3.2	3.3	3.2	3.3	3.4	3.4	3.3	3.3	3.4	3.4
I05523	2.9	2.9	2.8	2.8	2.9	3.0	3.0	2.9	3.1	3.0
GROUP: MALE 4 - 0.75 MG/KG/DAY										
I05511	2.7	2.8	2.9	3.0	3.0	3.1	3.1	3.0	3.1	3.1
I05522	3.5	3.7	3.7	4.0	4.2	4.2	4.5	4.4	4.6	4.6
GROUP: FEMALE 1 - 0 MG/KG/DAY										
I05529	2.4	2.4	2.4	2.4	2.5	2.5	2.5	2.5	2.5	2.5
I05549	2.9	3.0	2.9	3.0	3.0	3.1	3.0	3.0	3.0	3.1
GROUP: FEMALE 3 - 0.15 MG/KG/DAY										
I05539	3.8	3.9	3.8	3.9	4.0	4.0	4.0	4.1	4.2	4.1
I05552	2.8	2.9	2.8	2.8	2.9	2.9	2.8	2.8	2.9	3.0
GROUP: FEMALE 4 - 0.75 MG/KG/DAY										
I05533	2.5	2.6	2.6	2.6	2.7	2.8	2.8	2.8	2.8	2.8
I05542	2.7	2.8	2.8	2.9	3.2	3.2	3.2	3.1	3.3	3.3

003131

Appendix 3

Individual Body Weight Data (kg)
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 2

ANIMAL NUMBER	WEEK 38	WEEK 39	WEEK 40	WEEK 41	WEEK 42	WEEK 43	WEEK 44	WEEK 45	WEEK 46	WEEK 47
GROUP: MALE 1 - 0 MG/KG/DAY										
I05520	3.6	3.6	3.6	3.7	3.8	3.8	4.0	4.1	4.2	4.1
I05526	4.2	4.1	4.1	4.3	4.2	4.2	4.4	4.4	4.5	4.3
GROUP: MALE 3 - 0.15 MG/KG/DAY										
I05505	3.3	3.3	3.3	3.4	3.3	3.3	3.4	3.5	3.5	3.4
I05523	3.0	2.9	2.9	3.1	3.0	3.0	3.1	3.1	3.1	3.0
GROUP: MALE 4 - 0.75 MG/KG/DAY										
I05511	3.1	3.0	2.9	3.1	3.0	3.1	3.2	3.2	3.3	3.2
I05522	4.5	4.4	4.4	4.5	4.5	4.5	4.5	4.5	4.6	4.4
GROUP: FEMALE 1 - 0 MG/KG/DAY										
I05529	2.5	2.4	2.3	2.5	2.4	2.4	2.5	2.5	2.5	2.4
I05549	3.0	3.0	2.9	3.1	3.0	3.0	3.0	3.1	3.1	3.0
GROUP: FEMALE 3 - 0.15 MG/KG/DAY										
I05539	4.1	4.1	4.0	4.2	4.1	4.1	4.3	4.2	4.2	4.2
I05552	2.9	2.9	2.8	3.0	3.0	3.0	3.0	3.1	3.0	2.9
GROUP: FEMALE 4 - 0.75 MG/KG/DAY										
I05533	2.7	2.7	2.8	2.8	2.7	2.7	2.8	2.8	2.8	2.7
I05542	3.3	3.2	3.1	3.3	3.2	3.3	3.3	3.3	3.4	3.4

003132

Appendix 3

Individual Body Weight Data (kg)
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 3

ANIMAL NUMBER	WEEK 48	WEEK 49	WEEK 50	WEEK 51	WEEK 52	WEEK 53	WEEK 54	WEEK 55	WEEK 56	WEEK 57
GROUP: MALE 1 - 0 MG/KG/DAY										
I05520	4.1	4.1	4.1	4.1	4.2	4.2	4.2	4.3	4.2	4.1
I05526	4.3	4.4	4.4	4.4	4.5	4.5	4.6	4.7	4.7	4.6
GROUP: MALE 3 - 0.15 MG/KG/DAY:										
I05505	3.4	3.4	3.4	3.4	3.4	3.4	3.4	3.4	3.4	3.4
I05523	3.0	3.1	3.0	3.1	3.1	3.0	3.1	3.1	3.2	3.1
GROUP: MALE 4 - 0.75 MG/KG/DAY:										
I05511	3.3	3.5	3.5	3.6	3.7	3.7	3.8	3.8	3.9	3.8
I05522	4.4	4.6	4.5	4.5	4.5	4.4	4.5	4.4	4.4	4.2
GROUP: FEMALE 1 - 0 MG/KG/DAY:										
I05529	2.3	2.5	2.4	2.4	2.5	2.4	2.4	2.4	2.4	2.3
I05549	2.8	3.0	2.9	3.0	2.9	2.8	2.8	2.9	2.9	2.8
GROUP: FEMALE 3 - 0.15 MG/KG/DAY:										
I05539	4.3	4.3	4.2	4.3	4.3	4.3	4.2	4.2	4.2	4.2
I05552	2.9	3.0	2.9	3.0	3.0	2.9	2.9	2.8	2.9	2.9
GROUP: FEMALE 4 - 0.75 MG/KG/DAY:										
I05533	2.7	2.9	2.8	2.8	2.8	2.7	2.7	2.6	2.7	2.6
I05542	3.4	3.4	3.3	3.3	3.4	3.4	3.4	3.5	3.5	3.4

003133

Appendix 3

Individual Body Weight Data (kg)
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 4

ANIMAL NUMBER	WEEK 58	WEEK 59	WEEK 60	WEEK 61	WEEK 62	WEEK 63	WEEK 64	WEEK 65	WEEK 66	WEEK 67
GROUP: MALE 1 - 0 MG/KG/DAY										
I05520	4.2	4.1	4.2	4.2	4.1	4.1	4.0	4.0	4.0	4.1
I05526	4.7	4.7	4.9	4.9	4.8	4.9	4.9	4.8	4.9	4.9
GROUP: MALE 3 - 0.15 MG/KG/DAY:										
I05505	3.4	3.4	3.5	3.5	3.6	3.5	3.5	3.4	3.4	3.5
I05523	3.2	3.2	3.3	3.3	3.3	3.3	3.3	3.3	3.2	3.3
GROUP: MALE 4 - 0.75 MG/KG/DAY:										
I05511	3.9	3.8	4.0	4.0	4.0	4.1	4.3	4.2	4.1	4.2
I05522	4.4	4.4	4.6	4.6	4.7	4.7	4.6	4.5	4.5	4.5
GROUP: FEMALE 1 - 0 MG/KG/DAY:										
I05529	2.5	2.4	2.5	2.5	2.4	2.5	2.4	2.4	2.4	2.4
I05549	2.9	2.9	3.0	2.9	3.0	3.0	2.9	2.9	2.8	2.9
GROUP: FEMALE 3 - 0.15 MG/KG/DAY:										
I05539	4.1	4.0	4.2	4.1	4.1	4.1	4.1	4.0	4.0	4.1
I05552	3.0	3.0	3.0	3.0	3.0	3.1	3.0	2.9	2.9	3.1
GROUP: FEMALE 4 - 0.75 MG/KG/DAY:										
I05533	2.6	2.6	2.8	2.8	2.8	2.8	2.7	2.7	2.7	2.8
I05542	3.4	3.4	3.5	3.5	3.6	3.6	3.6	3.5	3.5	3.6

003134

Appendix 3

Individual Body Weight Data (kg)
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 5

ANIMAL NUMBER	WEEK 68	WEEK 69	WEEK 70	WEEK 71	WEEK 72	WEEK 73	WEEK 74	WEEK 75	WEEK 76	WEEK 77
GROUP: MALE 1 - 0 MG/KG/DAY										
I05520	4.2	4.3		4.2	4.3	4.2	4.2	4.2	4.2	4.1
I05526	5.0	5.1	5.0	5.1	5.3	5.2	5.4	5.3	5.4	5.3
GROUP: MALE 3 - 0.15 MG/KG/DAY:										
I05505	3.6	3.6	3.5	3.5	3.6	3.5	3.6	3.6	3.6	3.5
I05523	3.3	3.4	3.4	3.4	3.5	3.4	3.5	3.5	3.5	3.4
GROUP: MALE 4 - 0.75 MG/KG/DAY:										
I05511	4.3	4.3	4.3	4.2	4.3	4.2	4.3	4.3	4.3	4.3
I05522	4.6	4.7	4.6	4.6	4.6	4.5	4.6	4.6	4.6	4.5
GROUP: FEMALE 1 - 0 MG/KG/DAY:										
I05529	2.4	2.5	2.4	2.4	2.4	2.4	2.4	2.5	2.5	2.4
I05549	2.9	2.9	2.9	2.9	2.9	2.9	3.0	2.9	2.9	2.9
GROUP: FEMALE 3 - 0.15 MG/KG/DAY:										
I05539	4.1	4.2	4.1	4.2	4.2	4.2	4.2	4.2	4.2	4.2
I05552	3.0	3.0	3.0	3.0	3.1	3.0	3.1	3.1	3.2	3.1
GROUP: FEMALE 4 - 0.75 MG/KG/DAY:										
I05533	2.7	2.7	2.7	2.7	2.7	2.6	2.7	2.7	2.8	2.7
I05542	3.6	3.7	3.7	3.7	3.8	3.7	3.8	3.8	3.9	3.8

003135

Appendix 3

Individual Body Weight Data (kg)
Recovery

26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC
ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS

PAGE: 6

ANIMAL NUMBER	WEEK 78	WEEK 79	WEEK 80
GROUP: MALE 1 - 0 MG/KG/DAY			
I05520	4.0	4.0	
I05526	5.3	5.3	
GROUP: MALE 3 - 0.15 MG/KG/DAY			
I05505	3.5	3.5	3.5
I05523	3.4	3.5	3.2
GROUP: MALE 4 - 0.75 MG/KG/DAY			
I05511	4.3	4.4	
I05522	4.5	4.5	
GROUP: FEMALE 1 - 0 MG/KG/DAY			
I05529	2.4	2.4	
I05549	2.8	2.9	
GROUP: FEMALE 3 - 0.15 MG/KG/DAY			
I05539	4.1	4.2	4.0
I05552	2.9	3.0	2.8
GROUP: FEMALE 4 - 0.75 MG/KG/DAY			
I05533	2.6	2.7	
I05542	3.8	3.9	

003136

THE AMERICAS
+1.888.COVANCE
2 6 8 2 6 2 3 1

EUROPE
+44 (0)1423.500888

ASIA
+65.5677333

AUSTRALIA
+61.2.8879.2000

E-mail
info@covance.com

Visit the Covance Web Site
www.covance.com

COVANCE LABORATORIES

Madison, WI, USA
888-541-LABS (5227)

Vienna, VA, USA
888-541-LABS (5227)

Harrogate, UK
011 44 1423 5000011

Münster, Germany
011 49 251 785091

COVANCE

THE DEVELOPMENT SERVICES COMPANY

Shaping Solutions

003137

Covance is an independent, publicly held company with headquarters in Princeton, New Jersey, USA. Covance is the marketing name for Covance Inc. and its subsidiaries around the world. The use of "Covance" in this publication refers to one or more of these subsidiaries.

© COPYRIGHT 2000 COVANCE INC.